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Abstract  
 
Behçet’s disease (BD) is a vasculitis of unknown aetiology typified by recurrent oral and 
genital ulcers, skin and ocular lesions. Debilitating manifestations can also affect 
vascular, gastrointestinal and neurological systems. Previous BD investigations showed 
increased circulating neutrophils and neutrophil elastase (NE), a serine protease. NE can 
digest connective tissues compromising their integrity if not regulated. In this study, NE 
and its two main inhibitors, secretory leukocyte protease inhibitor (SLPI) and alpha1-
antitrypsin (α1AT), were investigated to determine if NE dysregulation is triggering oral 
mucosal damage. Findings were compared to healthy controls (HC) and recurrent 
aphthous stomatitis (RAS) patients, a disorder of episodic oral ulceration. 
 
FlowCytoMix
TM
multiplex-assays compared saliva and serum inflammatory cytokines 
measurements where salivary levels reflected disease activity and correlated with 
published serum levels. Salivary NE, SLPI, and α1AT were measured by ELISA. Patients 
with oral ulcers had increased NE. Unexpectedly, BDq (quiescent, without ulceration) 
had increased NE, but SLPI was significantly lower than RASq and HC. RASq NE levels 
were similar to HC. Overall, NE correlated with α1AT levels, but showed an inverse 
relationship with SLPI. Quantitative PCR revealed significantly increased SLPI mRNA 
expression in both BDq and RASq buccal epithelium. High mRNA/low SLPI protein 
expression during ulceration could be explained by deficient translation, blocked ELISA 
antibody binding, or SLPI depletion. Despite high α1AT, all study groups had 
enzymatically active salivary NE which was successfully inhibited by recombinant SLPI.   
Confocal microscopy revealed BD patients’ blood neutrophils readily release neutrophil 
extracellular traps (NETs) in vitro compared to HCs. Antimicrobial NETs have mixed 
granule contents coating decondensed chromatin fibres and are associated with 
autoimmunity. During NET production, our novel observation that intracellular SLPI but 
not α1AT co-localised with NE suggests a regulatory role.  
 
This study supports the theory that a protease-antiprotease imbalance may play a role in 
BD oral and systemic pathology. 
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1. Introduction 
1.1. Oral Ulceration with Non-Systemic Symptoms  
1.1.1. Recurrent Aphthous Stomatitis  
Oral ulceration is one of the most common oral disorders that can affect up to 25% of the 
global population (Scully and Porter, 2008). When oral ulceration occurs intermittently 
throughout a person’s life without any other clinically related symptom, it is deemed 
recurrent aphthous stomatitis (RAS). The term aphthous (plural of aphtha) refers to the 
oral ulcer itself and stomatitis is the mucosal inflammation. The round or oval ulcer(s) are 
often painful and classified as minor (<10 mm diameter) in 80% of RAS cases which heal 
without any scarring. There can be single or multiple shallow ulcers with distinct, regular 
margins and have a grey, white, or yellow pseudomembrane with erythematous halos. 
Minor ulcers usually develop on non-keratinized mucosa such as the buccal and labial 
sites as well as the floor of the mouth and takes up to 2 weeks to resolve. About 10% of 
those with RAS suffer major ulcers (≥10 mm diameter) often lasting ~ 6 weeks typically 
on the throat, soft palate, and/or lips where scarring is more likely to occur. Herpetiform 
ulcers are rare (1-10% of RAS) and show up as widespread crops of 1-100 small 2-3 mm 
oral ulcers which fuse to create an irregular border. Similar to the minor form of 
ulceration, they can last about 7 – 10 days before healing usually without scarring (Natah 
et al., 2004, Scully and Porter, 2008).  
 
Aphthous oral ulcers can also occur in a variety of immune disorders such as 
inflammatory bowel disease which includes Crohn’s disease and ulcerative colitis 
(Fatahzadeh et al., 2009), neutropenia (Boxer and Dale, 2002), or due to 
chemotherapeutics (Scully and Felix, 2005). Therefore, a detailed medical history and 
clinical investigation is necessary especially if the patient has any systemic 
manifestations. Risk factors for developing an oral ulcer include poor oral hygiene, 
consuming spicy or acidic food, vitamin B12 deficiency, trauma, rubbing of prosthetics 
such as dentures, high stress levels, and the menstrual cycle (Talacko et al., 2010, Scully 
and Felix, 2005, Balan et al., 2012). This range of conditions shows that both local and 
systemic factors can influence the development of an ulcer, however the mechanism is 
still unknown. 
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1.1.2. Neutrophils Implicated in RAS 
Primed neutrophil granulocytes of the innate immune system have been implicated in the 
recurrent manifestation of oral ulcers. RAS patients’ neutrophils isolated from whole 
blood have been shown to produce significantly higher reactive oxygen species (ROS) 
levels than healthy controls (HCs). This was found in RAS patients with and without 
ulcers (Lewkowicz et al., 2003). Despite the histological detection of neutrophils at the 
site of an RAS ulcer, it has also been proposed that neutrophils are involved in the 
pathology of RAS due to diminished function. A study by Sistig, et al, demonstrated that 
circulating blood neutrophils from RAS patients with acute ulceration showed decreased 
migration in vitro compared to HCs (Sistig et al., 2001). However in another study by 
Dagalis, et al, there were no differences in RAS neutrophil chemotaxis (Dagalis et al., 
1987). It has also been shown that RAS patients with and without ulcers had significantly 
decreased phagocytosis ability (Sistig et al., 2001). Interestingly, this diminished vital 
function was also true for saliva neutrophils from RAS patients with ulcers compared to 
HCs (Lukac et al., 2003) (Kumar et al., 2010) and individuals with the inflammatory 
condition oral lichen planus (Lukac et al., 2003). This suggests that in RAS patients, once 
neutrophils are recruited to the oral cavity, the cells’ ability to ingest microbes is 
diminished. It is not clear whether salivary neutrophils from RAS patients favour 
extracellular anti-microbial action involving exocytosed granule proteases and ROS 
rather than intracellular microbicidity. There is limited literature of protease involvement 
in RAS ulcers, however, an increased plasma level of the potent neutrophil elastase (NE) 
proteolytic enzyme was measured in children with RAS (Polanska et al, 2006). 
1.1.3. RAS Treatment 
A clinical treatment regime is usually not necessary for minor aphtha, but may be sought 
for more severe major or herpetiform ulcers. Even though minor oral ulcers are fairly 
common, the frequency, size, and location of the ulcers can negatively affect one’s 
quality of life (Mumcu et al., 2007). The main treatment goal is to relieve pain using 
topical anaesthetics therefore products containing lidocaine are frequently used 
(Altenburg et al., 2007). Local antiseptics and anti-inflammatories can be used as well. A 
controlled study showed that out of 54 different agents, Corsodyl
®
 mouthwash containing 
chlorhexidine had the most beneficial effect of relieving oral ulcers (Edres et al., 1997).  
Antibiotics such as tetracycline may also be prescribed. In more severe cases, the topical 
use of steroids may be prescribed but this may increase the risk of Candida albicans 
infection (Vincent and Lilly, 1992). Systemic therapy is an option for severe RAS 
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sufferers but is usually reserved for individuals who also have a systemic inflammatory 
involvement (see Section 1.2.3).   
1.2. Oral Ulceration and Systemic Disease: Behçet’s Disease 
The main investigative patient group in this study have Behçet’s disease (BD) in which 
oral ulcers are a primary feature. BD is a rare, multi-systemic disorder which is thought to 
be partly autoimmune and autoinflammatory in its nature causing lesions on mucosal 
surfaces and the skin as well as affecting the ocular, cardiovascular, neurological, 
gastrointestinal systems and/or joints (Mendes et al., 2009). Skin problems, such as 
erythema nodosum and folliculitis, may also feature. BD patients do not necessarily 
develop all of these systemic symptoms which is partly why BD is so difficult to 
diagnose. Vascular involvement that can lead to thrombosis and aneurysms are the main 
causes of death among BD patients (Kural-Seyahi et al., 2003). The development of 
uveitis can lead to blindness. Neurological maladies of the central nervous system may 
develop such as meningo-encephalitis and neuro-psychiatric symptoms, although 
involvement of the peripheral nerves and muscles is rare (Al-Otaibi et al., 2005). The 
multiple manifestations suffered by individuals with BD can be debilitating.  
 
Oral ulcers are believed to develop as a consequence of the systemic disease. There are 
many aspects of BD that as yet need to be explained such as the causative factors and 
why the illness, in most cases, initially manifests in the oral cavity in the form of 
recurrent ulcers in 86.5-100% of the cases (Al-Otaibi et al., 2005, Mumcu et al., 2009). 
The clinical diagnosis for BD is based upon the collective criteria published in 1990 by 
the International Study Group for Behçet’s Disease in which a patient would present with 
recurrent aphthous oral ulcers at least three times per year (the types described in section 
1.1.1) plus at least two additional symptoms characteristic of the disease, for instance, eye 
lesions, skin lesions, genital ulcers, and/or a positive cutaneous pathergy test (1990). BD 
patients have a higher incidence of major and herpetiform ulcers than RAS (Main and 
Chamberlain, 1992, Oh et al., 2009). A laboratory-based diagnostic test has not yet been 
discovered for BD hence only after extensive investigation, often involving various 
professional disciplines, and excluding differential diagnoses, can a clinician conclude 
that a person has BD.  
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1.2.1. Etiopathogenesis of BD 
Several microbiological entities such as Helicobacter pylori, Streptococcus sanguinis, 
and Herpes simplex virus I have been implicated in the pathogenesis of BD but never 
decisively proven (Avci et al., 1999, Studd et al., 1991, Yokota et al., 1992). BD patients 
have also been described as having hypersensitivity to the presence of microbes 
(Kurauchi et al., 2005).  
 
Hyperfunctional neutrophils are characteristic of BD leading to an overactive neutrophil 
response (Matsumura and Mizushima, 1975) (Sakane et al., 1999). Various neutrophil 
chemotaxis and priming factors are found to be up-regulated in BD such as interleukin 
(IL)-8, tumour necrosis factor alpha (TNF-α), (Mege et al., 1993) and IL-1β (Yosipovitch 
et al., 1995). Furthermore, significantly increased levels of NE in plasma has been 
detected in both quiescent and active symptomatic episodes of BD (Deger et al., 1995).   
 
Other reported findings associated with the immunopathogenesis of the disease are 
inflammatory reactions due to human heat shock protein and the tendency towards a T 
helper (Th)1-type cytokine profile in active BD (Kurokawa et al., 2004). The strongest 
evidence of any genetic risk factor is the existence of human leukocyte antigen (HLA)-
B51 allele on the major histocompatibility complex (MHC) locus, but this genotype is not 
detected in all BD cases (Kurokawa et al., 2004). BD has been deliberated to be a 
hereditary disorder due to its high incidence rate in specific geographical regions and the 
demonstration of affected generations within a family (Fresko et al., 1998). However, a 
genetic cause has not been ascertained. 
1.2.2. Histological Features of Oral Ulcers in BD and RAS 
BD and RAS patients share nearly indistinguishable histological features of oral 
ulceration (Lehner, 1978). Their oral ulcer biopsies are mainly described as non-specific 
ulceration showing a large infiltration of neutrophils, some macrophages, and mast cells 
(Direskeneli, 2006) (Kose et al., 2008) (Natah et al., 2004). Gamma-delta (γδ)-T-cells 
may also be present which are rarely seen in normal oral mucosa (Natah et al., 2000, 
Pepin et al., 1993). Both BD and RAS ulcers are also positive for CD4 and CD8 T cells, 
as well as the Th1-type cytokines IL-12, interferon-gamma (IFN-γ), and TNF-α. 
However, IL-4, a Th2 cytokine, has only been detected in BD ulcers (Dalghous et al., 
2006). Recently, BD oral ulcers were also found to express the pro-apoptotic protein, Bcl-
2, at high levels which could encourage inflammatory cell survival but has also been 
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implicated in the autoimmune disease systemic lupus erythematosus (Kose et al., 2008) 
(Tischner et al., 2010).   
1.2.3. Current Treatments 
BD cannot be “cured” therefore the treatment revolves around controlling the symptoms. 
Oral ulcers are treated similarly to RAS patients which includes topical 
immunosuppressants, ointments and mouthwashes containing anaesthetic, anti-microbial, 
and anti-inflammatory agents. A common recommendation is Betnesol
®
 mouthwash 
containing the moderately potent corticosteroid betamethasone phosphate to control 
inflammation. Steroid-based, antiseptic topical creams are also used for genital ulcers. In 
addition, depending on the organs and areas of the body affected, medication is usually 
necessary if symptoms are more difficult to alleviate. Cholchicine was first suggested by 
Matsumara and Mizushima in 1975 when increased neutrophil chemotaxis was first 
recognised in BD (Matsumura and Mizushima, 1975) and has been affective in the 
treatment of oral, genital, and ocular ulceration (Sander and Randle, 1986). Cholchicine 
acts to reduce neutrophil migration (Roubille et al., 2013). It can be found binding to 
tubulin in blood leukocytes and inhibits microtubule polymerization. Downstream, this 
alteration, reduces the E-selectin ligand distribution on endothelial cells and the 
expression of L-selectin on neutrophils – both of which are necessary as part of the 
neutrophil transendothelial migration from the blood stream to tissues (Witko-Sarsat et 
al., 2000, Cronstein et al., 1995). Cholchicine is also commonly used for rheumatic 
inflammation due to gout (Roubille et al., 2013) and so is prescribed to BD patients with 
arthritic manifestations as well as mucocutaneous disease (Al-Otaibi et al., 2005). 
Thalidomide can also reduce neutrophil chemotaxis, TNF-α production from a variety of 
cells, and the development of new vessels associated with vascular inflammation 
(Altenburg et al., 2007). It has been shown to be effective in reducing severe recurrent 
oral ulceration (Revuz et al., 1990) and orogenital and follicular skin lesions in BD 
(Hamuryudan et al., 1998). However, a major risk factor for female patients who may 
become or are currently pregnant is malformation of the foetus (Altenburg et al., 2007).  
A monoclonal antibody against TNF-α (anti-TNF-α) is a biological agent also known as 
infliximab and is fairly new in its use for BD (Marshall, 2004). It has shown improvement 
of refractory uveoretinitis (Okada et al., 2012), uveitis and extraocular manifestations 
(Accorinti et al., 2007), orogenital ulceration, and gastrointestinal symptoms.  
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Azathioprine, an immunosuppressive drug, has been shown to reduce systemic 
inflammation in all aspects of the disease including uveitis, oral and genital ulcers, and 
arthritis (Yazici et al., 1990, Keogan, 2009). Azathioprine blocks CD28 signalling, a co-
stimulatory molecule on CD4 T cells, resulting in the cell’s apoptosis thus down 
regulating the adaptive immune response (Maltzman and Koretzky, 2003). 
Mycophenolate mofetil is also an immunosuppressive sometimes used in place of 
azathioprine for mucocutaneous (Adler et al., 2001) and neurological BD symptoms 
(Shugaiv et al., 2011). 
Non-steroidal anti-inflammatory drugs (NSAIDs), are useful in cases involving arthritis, 
but have been shown to cause oral ulcers as a side effect (Boulinguez et al., 2000). 
Similarly, the disease-modifying drug methotrexate has also shown a high incidence of 
oral mucosal damage (Kalantzis et al., 2005). Systemic corticosteroids, such as 
prednisolone, can be used for an acute, symptomatic flair involving inflammation and to 
regulate pain, but are not recommended for long term use as the side effects can be 
detrimental. A regime can include several of these medications at one time. All 
medications have a degree of toxicity manifesting as adverse side effects and therefore 
are not without long term risks.  
1.3. The Mechanism of Oral Ulceration 
1.3.1. The Oral Mucosa Epithelium  
Human oral keratinocyte cells make up the majority of the outer-most layer of the oral 
mucosa epithelium, or stratified squamous epithelium, the mucosal surface barrier (Fig. 
1.3.1.1). Oral keratinocytes may or may not be keratinized (expressing the structural 
protein keratin) depending on the region of the mouth (Moharamzadeh et al., 2007); for 
instance, the buccal mucosa is made up of non-keratinized cells whereas the gingival 
epithelium is partially keratinised. Keratinocytes provide structure and barrier protection 
from the external environment. The oral buccal epithelium has an intermediate thickness 
of 40-50 cell layers and, because it lacks keratin, allows easy diffusion of serum proteins 
into the oral cavity and likewise is more permeable to extracellular components (Shojaei, 
1998). In response to external stimuli such as microbes, oral keratinocytes have been 
shown to produce IL-1α, IL-6, transforming growth factor (TGF)-β, TNF-α, basic 
fibroblast growth factors, (Formanek et al., 1999) as well as granulocyte macrophage 
colony stimulating factor (GM-CSF) (Yamamoto et al., 1994). They also produce IL-8, a 
potent inflammatory chemotatic protein which can recruit neutrophils as part of the innate 
immune response and induce the release of NE.  
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Fibroblasts, the most common cells of the connective tissue, are congregated in the 
lamina propria just below the epithelial top layer (Fig 1.3.1.1). They produce collagen 
and extracellular matrix which supports the overall tissue structure. Fibroblasts also play 
an important role in wound healing and tissue remodelling. This may be assisted by the 
collective fibroblast and keratinocyte production of secretory leukocyte protease inhibitor 
(SLPI), a protective anti-microbial and serine protease regulating protein, which has also 
been shown to help in scarless oral wound healing (Sumi et al., 2000). Fibroblasts also 
have a strong influence on keratinocyte adhesion, keratin expression, and epithelial 
phenotype depending on the original location and nature of the fibroblast (Okazaki et al., 
2003). They can be prompted to produce IL-8, IL-1α, IL-6, and IFN-γ. Fibroblasts 
synthesize keratinocyte growth factor, fibroblast growth factors (Knerer et al., 1999), 
hepatocyte growth factor, and have receptors for epidermal growth factor (EGF) (Wang et 
al., 1990). These proteins assist in keratinocyte differentiation and epithelium 
regeneration (Gron et al., 2002). It has been shown that salivary EGF is reduced in RAS 
and BD patients even when there is no ulcer present (Adisen et al., 2008). This could lead 
to mucosal damage due to a lack of natural reparative processes.   
 
Up to 10% of the oral mucosa epithelium is made up of other cell types including 
melanocytes, Merkel cells, and Langerhans cells and deeper into the submucosa there  is a 
small number of macrophages and inflammatory cells such as lymphocytes as well as 
plasma cells and mast cells (Moharamzadeh et al., 2007). Langerhan cells, a type of 
intraepithelial dendritic cell, although fewer in number than keratinocytes, act as 
important antigen presenting cells (APC) along with macrophages (Shojaei, 1998). They 
both have MHC class II molecules, as do neutrophils, which can prime naïve T helper 
cells (Barrett et al., 1996) to produce IL-2 which induces T-cell proliferation and 
cytokines such as IFN-γ, GM-CSF, IL-4, and TNF-β (Walker, 2004). 
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Fig. 1.3.1.1: Layers of the Non-Keratinised Oral Mucosa 
The apical layer of the oral mucosa is the stratified squamous epithelium. Non-keratinized 
epithelium lines the buccal mucosa, inner lips, ventral surface of the tongue, floor of the 
mouth and soft palate. Desquamation readily occurs at the surface while the basal cells 
proliferate and move upward. Below this, the lamina propria incorporates the connective 
tissue components made up of the extracellular matrix (ECM) including elastin and 
collagen as well as capillaries, fibroblasts, and inflammatory cells (macrophages, mast 
cells, and neutrophils). The submucosa is also made up of connective tissue as well as 
adipose tissue and anchors minor saliva glands. The figure is based on an illustration from 
Ireland (Ireland, 2006) which has been updated and reconfigured for this thesis.  
1.3.2. Saliva, Oral Homeostasis, and Ulceration 
A critically important component that allows cells of the oral mucosa to function 
normally is saliva. It is a complex biological fluid that provides digestive enzymes to 
breakdown food, interacts with commensal or foreign bacteria, viruses, and fungi, 
provides a medium on which immune cells and complexes travel, and maintains good oral 
health. It is also a lubricant between soft tissues and hard enamel of the teeth which 
reduces irritation (Schipper et al., 2007). Individuals who have abnormal production of 
saliva, such as dry mouth, suffer from increased tooth decay, gingivitis, and gum 
inflammation, and reoccurring oral ulcers as seen in Sjögren’s syndrome (Talacko et al., 
2010). 
 
Stratified squamous 
epithelium (made up 
of keratinocytes) 
Lamina propria  
(fibroblasts, capillaries, 
nerves and extracellular 
matrix) 
 
 
 
 
Submucosa (minor saliva 
glands, adipose tissue, 
connective tissue, muscle) 
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Three major glands contribute to the salivary content: the parotid, submandibular, and 
sublingual glands (Miller et al., 2010). In whole saliva, minor salivary glands (on the 
tongue, palate, lips, and cheeks), as well as gingival crevicular fluid (GCF), and passive 
diffusion of serum-derived molecules from capillaries adjacent to the glands contribute to 
the fluid components (Miller et al., 2010, Schipper et al., 2007). The main constituent of 
saliva is water (99.5%) followed by glycoproteins, enzymes (such as NE), peptides, 
immunoglobulins such as secretory IgA (Walker, 2004) and inorganic electrolytes (Miller 
et al., 2010). These many salivary constituents and the sloughed off cells of the lining 
layers of the mucosa such as epithelial cells on the tongue, buccal, labial, hard and soft 
palate are constantly being incorporated into saliva. Needless to say, the mouth is a very 
active environment. There is also plenty of biochemical activity from the surrounding 
cells and bacteria making saliva an ideal specimen for cell and protein research. Saliva is 
also easy to collect, non-invasive, pain-free, cost effective, and is also safer to collect than 
blood as there is a low infectivity risk to the patient and health professional (Lee and 
Wong, 2009). 
 
1.3.3. Saliva is Important for Oral Homeostasis  
Throughout an ulcer’s existence in the mouth, from its development to healing stage, it is 
bathed in saliva that is laden with proteins such as enzymes and growth factors. However, 
there is an uncertainty whether oral mucosa is behaving “normally” in individuals with 
RAS and systemic disorders like BD. It is of clinical interest to investigate what is 
occurring in the saliva and mucosa in the time between non-ulcerated tissue and an 
ulcer’s development. It is currently unknown what biochemical injuries the mucosa is 
enduring in these disorders and if it involves systemic elements from the blood vessels 
just beyond the mucosa lining, the local cells making up the mucosal epithelium or from 
the salivary gland secretions.  
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1.4. Hypothesis and Aims of the Project 
The project presupposes on the basis of the evidence presented above that NE 
dysregulation is causing oral mucosal damage in BD and RAS patients and thereby 
triggering recurrent oral ulceration. Hence, the aims of this study are to: 
 
1. Determine whether levels of inflammatory markers measured in serum are 
also reflected in saliva and whether these levels correlate to disease 
activity. Saliva may be a reliable, non-invasive clinical specimen allowing 
BD patient to be monitored. 
2. Investigate whether the enzymatic activity and levels of NE are increased 
in BD and RAS during oral ulceration. 
3. Measure the endogenous protease inhibitors, alpha1-antitrypsin (α1AT) 
and secretory leukocyte protease inhibitor (SLPI) in BD and RAS during 
active and quiescent oral ulcer episodes in order to determine whether 
levels are adequate to control NE. 
4. Determine whether BD neutrophils undergo cell death via the novel 
mechanism of NETosis in which neutrophil extracellular traps (NETs) are 
released contributing NE to the local environment. 
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2.1. Study Subjects, Specimen Collection, and Laboratory Processing 
2.1.1. Subject Recruitment 
Adults aged 18 years and above being investigated for or confirmed to have BD or RAS 
were recruited to the study with informed consent (REC number P/03/122) (See 
Appendix 1). Individuals with RAS were allocated as a disease control group. Samples 
were collected during multidisciplinary BD clinics which occurred twice a month: once at 
St Thomas Hospital and the other on-site at the Oral Medicine Clinic at the Dental 
Hospital, Royal London in Whitechapel. For the last year of the study, the local BD 
Clinic occurred fortnightly and the St Thomas site was no longer attended for sample 
collections. Patients frequently had repeat visits which enabled comparative experiments 
of the patient’s disease activity at different time points. A separate clinic at the 
Whitechapel site was allocated for RAS patients and HCs. 
 
2.1.2. Patient Information and Research Specimens 
Specimens collected for analysis consisted of whole unstimulated saliva, oral buccal 
mucosa swabs, and oral tissue biopsies. Blood was collected into 5 millilitres (ml) or 10 
ml heparin EDTA anti-coagulator vials for the isolation of plasma, PBMC, and 
neutrophils while coagulating vials were used for serum. Each participant’s personal 
information was recorded such as their name, date of birth, sex, ethnicity, the presenting 
clinical activity of their systemic disease (if applicable) as well as the absence or presence 
and severity of an oral ulcer (minor, major, or herpetiform) using a clinical activity log 
sheet that was completed by the examining clinician (See Appendix 1: Behçet’s Disease 
Clinical Activity Information Forms). For our specific study criteria, if one or more oral 
ulcers were present during specimen donation, then the patient was deemed orally active 
(a). If there was no ulcer, they were recorded as having a quiet (q) episode. Patients were 
also assessed on their systemic activity during clinic and deemed systemic active, or 
having relapsed, if they had at least three symptoms characteristic of the disease, for 
instance, oral ulcers, joint inflammation, eye or skin lesions or genital ulcers. This clinical 
assessment was based on the Criteria for Diagnosis of Behcet's Disease by the 
International Study Group for Behcet's Disease . If there were no systemic symptoms or 
complaints, they were deemed as systemically quiet. Each participant was designated a 
unique and confidential identification number and samples were labeled with this code 
and additional abbreviation of SAL, PLA, SER for saliva, plasma and serum, 
31 
 
respectively, along with the clinic date before storage at -80ºC. Recorded patient 
information and completed questionnaires were kept secure in a locked metal cabinet in a 
university building which requires ID card access. A central database was created for 
patient and specimen information and a copy supplied on an encrypted password-only 
accessible USB.  
 
2.1.3. Collection and Processing Blood 
Blood was collected for NHS clinical processing and research at the same time. 
Venepuncture was performed and blood collected directly into Vacutainers
® 
(Becton, 
Dickinson Co. UK). Blood was collected into one 5 ml tube which coagulated it in order 
to derive fibrinogen-free serum as well as two 10 ml EDTA non-coagulating purple tubes 
for plasma, PBMC, and neutrophil isolation (See NETs protocol Section 5.2.2.).  
 
For serum collection, the BD Vacutainers® were centrifuged to separate the whole blood 
from the serum at 3300 x g for 6 minutes (min) at room temperature (RT). Serum was 
aliquoted into 300 µl into a 2 ml cryovial. Freezer-proof labels were place on each vial 
with the patient’s study code number, patient group (HC, BD, or RAS), specimen type 
and the date of sample collection and clinic. Samples were stored at -80
o
C until use.  
 
2.1.4. Collection and Processing of Saliva Samples  
Patients and HC volunteers rinsed their mouth with 5 ml of water prior to collection of 
unstimulated whole saliva. Patients were asked to expectorate over a maximum period of 
5 minutes into 20 ml sterile universal tubes which were immediately placed on ice during 
clinic. The volume of saliva collected from each patient varied from 1-2 ml. Samples 
were transferred to the laboratory, centrifuged at 4
o
C for 15 minutes at 3500 x g in order 
to remove cellular debris. The saliva supernatant was then aliquoted, 200 µl per vial, 
avoiding the cellular pellet. Unless otherwise stated, when discussing a saliva sample in 
subsequent experiments, this refers to the cell-free saliva supernatant portion that was 
aliquoted. The saliva samples were placed immediately on dry ice to freeze as was the left 
over cell pellet. Samples were stored at -80
o
C until use. 
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2.1.5. Collection of Oral Buccal Mucosa Biopsies 
Patients attending BD clinic who presented with oral ulceration and which warranted 
further investigation as deemed by the oral medicine consultant were referred to a 
specialised biopsy clinic. Informed patient consent was obtained. Clinical patient details 
were recorded (Appendix 1: Oral Biopsy Clinic Patient Details Form). After the tissue 
was excised, the biopsy was placed briefly on a sterile petri dish and portioned in half -
each half keeping a portion of un-ulcerated epithelium. One half was sent for histological 
analysis by a pathologist (Prof Kim Piper) and the other half was prepared immediately as 
described below. 
2.1.5.1. Freezing Oral Biopsy Tissue 
In order to prepare the biopsy for freezing in liquid nitrogen (N2(l)), the biopsy needed to 
be orientated so that when being cut, it would give a cross section of epithelium, lamina 
propria and submucosa layers. A square glass coverslip was wedged vertically into a 
small round cork where it had been slightly perforated with a scalpel (Fig 2.1.5.1.1). A 
few drops of optimum cutting temperature (OCT) (Tissue-Tek®, Sakura® Finetek, VWR, 
UK) was placed onto the cork where the biopsy was to be embedded and the tissue was 
orientated so that the epithelium was adjacent to the coverslip. Finally, a few more drops 
of OCT were added onto the top of the biopsy and firmly holding the cork with long 
tweezers, the entire cork and tissue were submerged into N2(l) for 10 sec to freeze the 
tissue. When complete, the coverslip was removed and the cork snapped along the 
perforated area. The biopsy fixed to the cork was then placed into a cryovial labelled with 
the patient ID number and date and transported to the laboratory either in N2(l) or on dry 
ice. The tissue was stored in the -80
o
C freezer. 
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Figure 2.1.5.1.1. Orientation of biopsy for freezing. A small cork base was perforated 
with a scalpel and a glass coverslip slotted in. The biopsy was adjusted so that the 
epithelium was adjacent to the erected glass coverslip. The entire conformation was 
immersed into liquid nitrogen using long forceps. 
2.1.6. Collecting Oral Buccal Swabs  
Oral mucosa buccal swabs (OBS) were obtained from the inner cheek of patients. The 20 
mm sterile cytology brush (Deltalab, Spain) is able to collect the upper layers of the 
mucosal epithelium without damaging tissue. Each brush was swiped 10 times over an 
area of the mucosa. The cellular material on the brush was immersed into a 1.5 ml 
microcentrifuge tube with 400 µl of RLT Buffer (RNeasy Micro Kit, Qiagen, UK) which 
contains the chaotropic salt guanidine thiocyanate to disrupt cell membranes and preserve 
nucleic acid. The brush was vigorously agitated in the buffer to disperse the cells then 
discarded and using a new sterile brush a second swab was taken from the same area and 
collected into the same lysis buffer as the first swab. Approximately 50 µl of the lysis 
buffer is lost during the process of immersing the brushes to remove cells leaving 350 µl 
of sample for extraction. The procedure was then repeated on the opposite inner cheek 
with a new 400 µl aliquot of RLT Buffer. If a patient had an oral ulcer and approved, the 
swab was gently swept over the ulcer and recorded as a direct ulcerated (U) mucosal 
sample. Samples from non-ulcerated areas were recorded as (NU). Specimens were 
immediately frozen on dry ice whilst at clinic in order to preserve the RNA content. Back 
in the lab, samples were stored at -80
o
C until RNA and protein extraction could be 
completed.  
 
 Epithelium  
Coverslip 
Cork 
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2.1.7. Isolating and Purifying RNA from OBS  
2.1.7.1. Extraction and Purification of RNA  
The initial, critical step involved when defrosting the OBS cells in lysis buffer on ice, was 
the addition of 3.5 µl (1% final concentration) of beta-mercaptoethanol (β-ME) to the 350 
µl sample and vortexing to homogenize. The β-ME acts as an RNase inhibitor and 
therefore protects the RNA from degradation during subsequent procedures, especially 
those performed at room temperature. The RNeasy Micro Kit (Qiagen, UK) was utilized 
for the extractions as described by the supplier’s protocol. After the lysate was 
homogenized, 20 ng of carrier RNA supplied by the kit was added to the sample. Then, 
one volume of 70% ethanol (made up in RNase-free water, Life Technologies, UK) was 
added to the homogenised lysate and mixed. The sample solution was then pipetted into a 
MinElute spin column with 2 ml collection tube and centrifuged at 16,000 x g for 1 min at 
room temperature which bound the RNA (and residual DNA) in the sample to the silica 
column. The flow through containing DNA and protein was saved for downstream 
experiments.  
 
The nucleic acids bound to the column were washed with 350 µl of Buffer RW1 
centrifugating at the same time and speed as the previous step. An on-column DNase 
digest was then performed. For each sample, 10 µl of reconstituted DNase I (2.73 U/µl) 
and 70 µl of Buffer RDD were combined in a separate tube and then a total of 80 µl was 
added to the top centre of each column. The column was left for 15 min at room 
temperature and then washed with 350 µl of Buffer RW1 after which the column was 
centrifuged at 12,000 x g for 1 min. The flow through was discarded and the column was 
placed into a new 2 ml collection tube and 500 µl of Buffer RPE (which was pre-diluted 
with ethanol) was added to the top of the column. The column was again centrifuged at 
12,000 x g for 1 min and the flow through discarded. Another wash with 500 µl of 80% 
ethanol was added to the top of the column and centrifuged for 2 min at 12,000 x g. The 
collection tube was replaced again and the column centrifuged at 16,000 x g for 5 min. 
Afterwards, the collection tube and contents were discarded. Lastly, the spin column was 
placed into a new 1.5 ml microcentrifuge tube and 14 µl of RNase-free water was added 
to the centre of the column, left for 1 min, and centrifuged at 16,000 x g for 1 min to elute 
the RNA. 
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2.1.7.2. Initial Quality and Quantity of RNA  
The eluted RNA was immediately placed on ice.  To assess the RNA quantity and quality 
a Nanodrop™ 1000 spectrophotometer (Thermo Scientific, UK) was used to measure the 
Absorbance (A) at 260nm and 280nm wherea 260/280 ratiobetween 1.7 - 2.0 indicated a 
good purity for an RNA sample. The Nanodrop™ can accurately measure 2 – 3700 ng/µl 
of double stranded (ds)DNA and 2 – 3000 ng/µl of RNA as determined by the 
manufacturers. 
 
2.1.7.3. DNase Treatment and Reverse Transcription 
A second DNase enzyme digestion of genomic (g)DNA was performed on the RNA 
eluate before undergoing reverse transcription (RT). Degrading all residual gDNA in the 
sample was critically important in order to accurately quantify the targets. Also, the 
design of the primer sequences for all 19 reference targets were unknown (Roche 
proprietary information). They may or may not be intron-spanning regions of the gene 
and could potentially amplify a portion of the gDNA sequence.  
 
In order to degrade all gDNA, the TURBO™ DNA-free kit (Ambion, UK) was utilised. 
Each DNase reaction was composed of 5 µl of 10X TURBO buffer, 1 µl TURBO DNase 
enzyme (2 Units/µl), 11 µl of extracted OBS sample and RNase-free water to make a 
final 50 µl final reaction volume. The sample did not exceed 2 µg of nucleic acid (since 2 
Units of TURBO DNase is able to remove a maximum of 2 µg gDNA in a 50 µl 
reaction). The mixture was briefly vortexed, pulse centrifuged, and placed on a PCR heat 
block for 30 min at 37
o
C. Afterwards, samples were taken off the heat block and 5 µl of 
DNase inactivation reagent from the kit was added to each sample. This was incubated 
for 5 min at room temperature with occasional vortexing to resuspend the sediment. The 
samples were then centrifuged at 10,000 x g for 1.5 min. The clear supernatant fluid 
(purified RNA) was collected by pipette carefully avoiding the white pelleted material 
and transferred to a new clean tube and kept on ice. Approximately 48 µl of isolated RNA 
was recovered.  
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2.1.7.4. Second Quality and Quantity Assessment of gDNA-free RNA  
In order to further assess the quality and quantity of the gDNA-free RNA, 1 µl of up to 11 
RNA samples at a time were tested on the Agilent 2100 Bioanalyser using an Agilent 
RNA 6000 Pico Chip (Agilent Technologies) for measuring Eukaryote Total RNA. The 
procedure was followed as described in the manufacturer’s manual. Once the RNA 
samples were loaded, the chip was read within 5 min. Based on the results of the 
electropherograms showing the 18S and 28S rRNA peaks, the quality of the samples were 
assessed. If the RNA sample had a poor RNA integrity number (RIN) and showed major 
degradation, then the sample would be excluded from any further downstream analysis. 
2.1.7.5. Reverse Transcription 
Based on the concentration and volume of RNA available, RT was performed on ≤ 2 µg 
per 20 µl reactions with the High Capacity cDNA Reverse Transcription Kit with RNase 
Inhibitor (Applied Biosystems, Life Technolgies, UK).  In most instances, the reaction 
volume was doubled to 40 µl in order to incorporate 20 µl of sample since most RNA 
samples had low protein concentrations). Reagents from the kit were defrosted and kept 
on ice. A mastermix was created by mixing the reagents listed in Table 2.1.7.5.1. 
 
Table 2.1.7.5.1. Mastermix Components for the High Capacity cDNA Reverse 
Transcription Kit with RNase Inhibitor.  
 
The final volume was adjusted to 40 µl by adding DNase/RNase-free water. The mixture 
was vortexed and 20 µl was distributed to new 0.2 ml eppendorfs containing 20 µl of 
RNA sample. (Note that an aliquot of 2 µl of each RNA sample was kept at -80
o
C for 
assessment of gDNA contamination on the reference panel described in Chapter 6). Each 
RT reaction tube was then placed into a Veriti Thermo Cycler PCR machine (Thermo 
Scientific, UK) with the following incubation times and temperatures: 25
o
C for 10 min, 
37
o
C for 120 min, and 85
o
C for 5 min to deactivate the RT enzyme, and cooled to 4
o
C 
Reaction Component Starting Concentration 
(provided by the kit) 
Final Concentration in 
Mastermix 
Reaction Buffer 10X 1X 
deoxynucleotide 
triphosphates mix (dNTP)  
25X (100 mM) 1X (4 mM; 1000 µM each) 
RT Random Primers 10X 1X 
MultiScribe RT Enzyme 50 U/µl 2.5 U/µl 
RNase Inhibitor 20 U/µl 1 U/µl 
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until retrieved and placed on ice. The new complementary (c)DNA was aliquoted, 
labelled, and placed into a -20
o
C freezer.   
 
2.1.8. Preparing Mowiol Mounting Media 
Mowiol mounting media was prepared several days before use. Mowiol
®
4-88 was 
generously supplied to us by Dr Ann Wheeler. All other reagents were supplied by Sigma, 
UK. In order to prevent the fluorophores fading on the mounted specimen, 0.4 % of 1,4-
Diazabicyclo[2.2.2]octane (DAPCO) was also included in the preparation. To make 25 ml 
of Mowiol, 6 g of glycerol, 6 ml of sterile dH20, 12 ml of 0.2 M Tris (pH 8.5), and 0.1 g 
of DAPCO were combined with 2.4 g of Mowiol
®
 4-88 in a glass flask and mixed with a 
magnetic stirrer for between 5-7 hours and then allowed to sit for 2 hrs (the Mowiol does 
not dissolve completely). It was then incubated at 50
o
C for 10 min and centrifuged at 
5000 x g for 15 min in 2 ml eppendorf tubes or top speed in a large bench top centrifuge. 
The mixture’s supernatant was then aliquoted and frozen at -20oC until use. The Mowiol 
solution was allowed to equilibrate to room temperature before use otherwise air bubbles 
formed under the coverslip.  
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Chapter 3: 
Inflammatory Cytokines 
in Saliva and Serum 
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3.1. Introduction 
3.1.1. Cytokines and T-cells 
Lymphocytes derived from the bone marrow which develop in the thymus, otherwise 
known as T-cells, make up the fundamental cells of the cell-mediated immune response. 
A portion of these migrate through the blood to secondary lymph organs such as the 
lymph nodes, spleen, tonsils, and epithelium-associated tissue such as Peyer’s patches in 
the gastrointestinal tract, and areas of the lungs and skin. It is usually here or during 
recirculation that the T-cells are exposed to foreign proteins or polysaccharides by 
antigen-presenting cells. This process activates T-cells and a variety of cell to cell 
signalling proteins or peptides, called cytokines, modulate their recruitment to sites of 
inflammation (Alberts, 1994). 
 
Two main types of T-cells exist: cytotoxic T-cells (with CD8 co-receptor) and helper T-
cells (with a CD4 co-receptor). Cytotoxic T-cells recognise infected cells which present 
foreign antigen on a specialised protein called major histocompatibility factor (MHC) 
Class I and subsequently directly kill the cell. However, helper T-cells do not kill the 
antigen presenting cell they recognise with MHC Class II molecules outright. Instead, 
they contribute to the immune response by stimulating other white blood cells. This 
prompt is coordinated by a variety of local mediators: cytokines and chemokines.  
 
Prior to their own production and secretion of cytokines, naïve T helper cells can undergo 
differentiation into several different subtypes depending on protein signals from the 
environment (Fig  3.1.1.1.). For instance, if interferon (IFN)-γ and/or interleukin (IL)-12 
are increased in the surrounding area, they will promote the development of type 1 helper 
T cells, or Th1. These in turn continue to produce additional IL-12 and IFN-γ as well as 
IL-2, TNF-α, and TNF-β (Palmer, Weaver, 2010). One of the main duties of Th1 cells is 
to help activate macrophages, cytotoxic T-cells, and Natural Killer (NK) cells. If the 
external protein signals are predominately IL-4, this will persuade the development of 
type 2 helper T cells, or Th2. This type of T-cell will continue to produce IL-4 as well as 
IL-5, IL-6, and IL-10 mostly interacting with eosinophils, some T-cells, mast cells, and 
antibody producing B-cells leading towards humoral type immunity. 
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Figure 3.1.1.1. Cytokines mediate the immune response. Depending on which cytokine 
is dominant in the environment drives the development towards Th1, Th2, Th17, or Treg 
responses. In turn, the cells involved in these pathways release specific cytokines to help 
regulate, overcome, and resolve a pathogen or host’s immune imbalance. Figure is 
adapted from (Mesquita Jr et al., 2009).  It is important to note that these cytokines are 
mainly but not exclusively produced by CD4 T-cells. 
 
IL-2 is a Th1-type cytokine that is produced mainly by helper T-cells. IL-2 can stimulate 
self-proliferation of helper and cytotoxic T-cells and B cells and is therefore at times 
considered a type of growth factor (Alberts, 1994). Increased levels of IL-2 in the plasma 
as well as a significant increase of its receptor has been detected in lymphocytes from 
RASa patients (Sun et al., 2000).  
 
IL-12p70 is a Th1 pro-inflammatory cytokine made up of a 40 kDa and 35 kDa subunits. 
It is produced by macrophages, B-cells, and dendritic cells in response to foreign antigens 
such as LPS, intracellular microbes, or activated T-cells. IL-12 has also been known as 
the natural killer cell stimulatory factor and the cytotoxic lymphocyte maturation factor 
mediating cell killing via NK cells and T cells. It can induce IFN-γ and IL-2 production 
and helper T-cell proliferation leading towards a Th1 immune response. An increase of 
IL-12 in BD serum has been correlated with BD activity (Turan et al., 1997) and disease 
progression (Frassanito et al., 1999). 
 
IFN-γ  
IL-12 
IL-4 
IL-1, IL-6 
TGF-β 
 IL-10 
TGF-β 
41 
 
IFN-γ was originally recognised as the main constituent of the Th1 response. It is 
produced mostly by the same cells that produce IL-2 but can also be generated by cells of 
both the innate and acquired immune systems, namely NK cells and T-cells. IFN-γ targets 
B cells, macrophages, and endothelial cells activating the expression of Class II MHC 
molecules on the surface of these antigen presenting cells (APC) (Alberts, 1994). 
Although BD is often recognised as a Th1 dominant response (Frassanito et al., 1999), 
there are studies that have conflicted with the classic generation of increased IFN-γ. For 
instance, IFN-γ was measured in serum of BD active patients and was found to be lower 
than BD quiet, RAS, and HC (Aridogan et al., 2003). 
 
Tumour necrosis factor-alpha (TNF-α) is a rapidly released cytokine that can act as an 
alarm when encountering foreign or stress stimuli (Tracey et al., 1987). It is mainly 
produced by monocytes and macrophages but can also be sourced from T-cells, 
neutrophils, mast cells, and endothelial cells (Feldmann and Maini, 2001). As the name 
implies, it can induce the death of tumour cells but also has an important role of initiating 
an immune response (via chemotaxis) and can be pyrogenic (causing fever). Acute up-
regulation of the immune response is usually beneficial, however chronic exposure to 
TNF-α can impair T-cell activation as seen in in vitro studies (Cope et al., 1994).  
 
An in vitro study has shown that TNF-α was increased in unstimulated peripheral blood 
monocytes from active RAS patients than in HC (Taylor et al., 1992). Oral lesion and 
non-lesional sites from RAS patients have also been shown to have increased levels of 
TNF-α mRNA as well as IL-2 and IFN-γ mRNA compared to HC (Buno et al., 1998). 
Thalidomide (which reduces TNF-α activity) and pentoxifylline (which acts to inhibit 
TNF-α production) have been effective in RAS ulcer treatment (Revuz et al., 1990, Zabel 
et al., 1993). TNF-α has been one of the most investigated cytokines in BD (Zhou et al., 
2012). Studies continue to test this cytokine and its levels in different BD manifestations, 
for example, a recent study found that serum from BD patients with active uveitis have 
been shown to have significantly higher levels of TNF-α than those without any eye 
involvement for 3 months (Ozdamar et al., 2009). Anti-TNF-α therapy (such as 
Infliximab) has also been helpful in controlling active episodes of uveitis in BD (Hatemi 
et al., 2009) and oral and genital ulceration (Robertson and Hickling, 2001). All of these 
findings imply that TNF-α has an important role in RAS and BD pathologies. 
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Tumor necrosis factor-beta (TNF-β) is also known as lymphotoxin and is a potent 
inflammatory cytokine similar to TNF-α. It is produced by activated T and B 
lymphocytes and can be toxic to tumor cells. In cytotoxicity tests, TNF-β was more 
cytotoxic than TNF- α in a murine fibroblast cell line but less toxic against capillary 
endothelial cells (Kircheis et al., 1992). In BD, it has been found to be secreted in high 
levels by γδT cells when compared to HC (Yamashita et al., 1997) but is infrequently 
tested in the majority of BD and RAS investigations. 
 
IL-4 and IL-5 are Th2-type cytokines produced by helper T-cells. They both stimulate B 
cells to proliferate and mature. IL-5 also promotes maturation of eosinophils. IL-4 is 
considered a critical element for driving the development of Th2 immune response (Choi 
and Reiser, 1998). Neither cytokine has been well characterised in BD (Zhou et al., 2012) 
nor have they been investigated extensively in RAS. There is some data available from a 
study conducted by Aridogan, et al, (Aridogan et al., 2003) in which the IL-4 (and IL-10) 
serum levels were increased in active BD.  
 
IL-6 is produced by T-cells, B cells, and macrophages and can stimulate the proliferation 
of B cells and immunoglobulins as well as differentiate T lymphocytes (Yamakawa et al., 
1996, Hirano et al., 1986, Alberts, 1994). A naïve T-cell can be stimulated by IL-6 (and 
transforming growth factor beta (TGF-β) to become a Th17-type cell which in turn 
releases IL-17A (Shimizu et al., 2012). An increased level of IL-17A has been detected in 
BD serum (Chi et al., 2008) and several other autoimmune diseases such as rheumatoid 
arthritis (Benedetti and Miossec, 2013). It has also been found infiltrating the salivary 
glands in Sjögren’s syndrome (Alunno et al., 2013) and in the plasma from those with 
systemic lupus erythematosus (Ambrosi et al., 2012). In addition to CD4+ Th17 cells, IL-
17 (with ligand A) is produced by γδ T cells, NK cells (Raifer et al., 2012), and CD3+ 
(CD4-/CD8-) cells (Alunno et al., 2013) in response to extracellular pathogens and can 
induce the production of IL-8 thus recruiting neutrophils and contributing to 
inflammation. However when the release of IL-17A is exacerbated, this can also lead to 
the destructive tissue pathologies of inflammatory and autoimmune diseases (Mellett et 
al., 2012). Recently, BD has been investigated for production levels of IL-17. In 2008, 
Chi, et al, reported that stimulated PBMC’s from BD patients with uveitis had increased 
levels of IL-17 but this could not be detected in the patient’s serum (Chi et al., 2008).    
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IL-10 is also a key immunoregulatory cytokine produced by almost all leukocytes which 
include the innate immune cells (monocytes, macrophages, dendritic cells, mast cells, NK 
cells, eosinophils, and neutrophils) and adaptive immune cells (T-helper cells Th1 and 
Th2, CD8+ T-cells, B cells, and γδT cells) and Th17 type cells. While IL-10 can help to 
regulate the Th1/Th2 balance, it can also promote development of the Th2 type response 
by inhibiting IFN-γ being made in T-cells (Romagnani, 1995). It further promotes 
antibody production in B cells by increasing Bcl-2 expression which decreases B cell 
apoptosis (Levy and Brouet, 1994). IL-10 has been found in high levels in active BD 
patient serum (Aridogan et al., 2003) but has not necessarily been significantly increased 
in highly active BD compared to inactive or mild disease (Turan et al., 1997).  
 
IL-8 is a potent chemokine whose presence in low levels can elicit a strong immune 
response to a variety of stimuli especially for the recruitment of neutrophils and activation 
of leukocytes in response to bacterial antigens. It is produced by a multitude of cells 
including neutrophils, monocytes, macrophages, endothelial and epithelial cells. 
Neutrophils and lymphocytes express the IL-8 receptor (Murphy and Tiffany, 1991) as do 
monocytes, NK cells (Morohashi et al., 1995), human umbilical vein endothelial cells 
(HUVEC) (Murdoch et al., 1999), human lung microvascular endothelial cells 
(HMVECs), and dermal human microvascular endothelial cell lines (HMECs) 
(Schraufstatter et al., 2001). IL-8 works to enhance the adherence of circulating 
leukocytes to endothelial cells during inflammation (Sahin et al., 1996).  
 
IL-8 has been one of the main chemokines studied in BD. The serum concentration of IL-
8 has been detected in significantly high amounts in BD patients compared to HC but not 
consistently between active and inactive episodes of BD (Sahin et al., 1996). Durmazlar, 
et al, sought to differentiate BD with vascular problems and correlation with serum IL-8. 
They found that active BD with vascular involvement had a 4-5 fold increase of IL-8 over 
those without any vascular symptoms (such as thrombosis or superficial 
thrombophlebitis). IL-8 in inactive BD patients with a history of vasculitis was still 2-fold 
higher than inactive BD with no vascular association (Durmazlar et al., 2009). It has also 
been found that an increase of IL-8 mRNA was directly associated with BD serum-treated 
macrophages from HC in vitro (Alpsoy et al., 2003). Mantas, et al, suggested that 
although there was a diverse source of IL-8 from BD cells, lymphocytes were considered 
to be the major contributors (Mantas et al., 2000).   
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IL-1β is recognised as a “master cytokine” in the process of inflammation for being the 
main mediator coordinating an attack on invading microbes (Dinarello, 1996, Cauci et al., 
2003) or in response to injury. It is produced mainly by blood monocytes, but can also 
derive from macrophages, dendritic cells, and neutrophils increasing fever and 
hypotension. IL-1β can induce many chemokines, especially IL-8, and mediates systemic 
inflammation (Dinarello, 1996). It has been observed that an increase in IL-1β has a 
simultaneous increase in IL-8 as well. IL-1β has been investigated in BD, but not to the 
extent of IL-8 or TNF-α. A significant rise of the protein in the serum has been detected 
from BD active and inactive patients compared to HC (Duzgun et al., 2005). 
 
Although the main investigation of this experiment was to identify pro-inflammatory 
cytokines associated with oral and systemic disorders, some of the cytokines on the panel 
have dual roles acting as pro- and anti-inflammatory proteins to down-regulate the 
immune systems reaction. These cytokines include IL-4, IL-6, and IL-10 which also make 
up the Th2-type response and have been shown to usually be lower in concentration than 
Th1 type cytokines in the BD immune response. IL-4 and IL-10 can inhibit macrophage 
function. Some Th1 and Th2 cytokines can be cross-regulatory, such that Th1 type 
cytokines like IL-12 and IFN-γ can inhibit Th2 activation whereas IL-4, a Th2 type 
cytokine, can inhibit IFN-γ production (Elenkov, 2002) (Lucey et al., 1996). 
 
Persons with BD have had their blood plasma and serum repeatedly investigated for 
markers of inflammation in order to gain understanding of the mechanism of their 
immune response. Research conducted in many different countries including but not 
limited to Turkey (Akdeniz et al., 2004), Saudi Arabia (Sheth et al., 1995), Japan 
(Yamakawa et al., 1996), and Europe (Zouboulis et al., 2000) have measured proteins 
associated with inflammation in their patient cohort, however, the majority have relied on 
the same laboratory method of a sandwich ELISA. While this is still considered a reliable 
technique, protein levels in serum samples are often too low to be measured accurately, if 
at all (Yamakawa et al., 1996, Zouboulis et al., 2000).  
 
Cytokines in saliva have rarely been investigated in BD or RAS. As a test specimen, 
unstimulated whole saliva has many benefits. It is readily available, non-invasive, and 
hosts a mass of salivary gland and cell-derived proteins in the fluid. Granted, the mouth is 
not a sterile environment. Saliva envelopes the natural flora of the mouth and will contain 
microbial contaminants which may influence the local cellular immune response. Another 
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potential bias when using saliva as a test specimen for inflammation may be an 
individual’s overall oral health and hygiene. However, incorporating diverse group of 
healthy controls for cytokine comparisons should help to resolve any potential bias and 
result in a valid interpretation. 
 
3.1.2. Hypothesis and Aims of the Experiment 
It is believed that saliva will reflect the systemic inflammation in BD patients serum but 
not RAS patients.  In order to test this theory, this experiment aims to compare saliva and 
serum and their respective inflammatory profiles in HC, BD, and RAS to: 
1. Differentiate pro-inflammatory proteins between patients with and without 
oral ulcers 
2. Investigate if BD systemic inflammation can be detected in saliva while no 
oral ulcer is present 
3. To identify specific cytokines or chemokines that may influence the onset 
of an ulcer  
4. To investigate if there is a correlation between inflammatory markers in 
serum and saliva 
5. To validate the use of FlowCytomix™ array with saliva  
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3.2. Methods 
3.2.1. Cytokines and Chemokines in Saliva and Serum: The FlowCytomix™ 
Multiplex Array 
The FlowCytomix™ Multiplex array (Bender MedSystems, UK) is a bead based assay 
system in which microbeads of different sizes are coated with specific fluorescent 
antibodies to detect different cytokines in a sample. This allows multiple target detection 
using a low volume of sample and is compatible with various flow cytometers. An 
investigation of the inflammatory cytokines and chemokines (IL-8, IL-1β, IL-2, IL-
12p70, IFN-γ, IL-10, IL-6, IL-4, IL-5, TNF-α, TNF-β, and IL-17A) were measured in 25 
μl of the cell-free portion of neat unstimulated saliva and matched serum from BD, RAS, 
and HC participants. The protocol was followed as described in the manufacturer’s 
manual for the human Th1/Th2 kit (Bender MedSystems, eBioscience, Ltd, UK). 
 
To reconstitute the standards, a small volume of dH20 was added to the 12 individual 
analyte vials as indicated on the label. 10 µl of each standard was then added to a clean 
1.5 ml eppendorf (Standard 1) resulting in a volume of 120 µl to which 80 µl of 1X array 
buffer was added for a final volume of 200 µl, this is an initial 1:20 dilution of each 
analyte. 100 µl of array buffer was added to a further 6 eppendorf tubes (Standards 2-7) 
and then 50 µl of Standard 1 was added to Standard 2 and vortexed to mix. This 1:3 
dilution series was completed for the rest of the standards and repeated in duplicate. 25 µl 
of the duplicate Standards 1-7 were then transferred to labelled FACS tubes. An 
additional third tube for Standard 1 was also included and used for setting up the flow 
cytometer. 
 
Next, the Bead Mix was prepared. For each sample, standard, and blank, 25 µl of the bead 
mix was required. Depending on the final volume of the mixture, a final dilution of 1:20 
of each bead solution was added to the mix and vortexed. The final volume was made up 
with reagent buffer and then the mix was centrifuged for 5 min at 3000 x g in order to 
wash the beads. Supernatant was discarded and replaced with reagent dilution buffer to 
achieve the same final volume then vortexed. A solution of Biotin-Conjugate was also 
prepared by adding 50 µl per reaction (including standards, blanks, and samples) into a 
new tube for a final dilution of 1:20 in reagent buffer therefore for 12 analytes, 300 μl of 
Biotin-Conjugate was added to 2400 μl of reagent dilution buffer).        
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To new pre-labelled FACS tubes 25 µl of each sample was added and the same volume of 
assay buffer was then added to new FACS tubes for a duplicate blank reaction. The 25 μl 
pre-prepared Bead Mix was added to all tubes including blanks followed by 50 μl of the 
Biotin-Conjugate mix. Each reaction tube was gently vortexed and incubated at RT (18 – 
25
o
C) for 2 hours away from light. Meanwhile, the Streptavidin-PE solution was prepared 
for a total of 94 samples, with volume allowance, by diluting 176 μl in 5324 μl of assay 
buffer (i.e. 1:31 dilution).  
 
After the first incubation, 1 ml of the assay buffer was added to all FACS tubes using a 
repeat pipette then tubes were centrifuged for 5 min at 200 x g. To decant the supernatant, 
the FACS tube was quickly inverted only once. About 100 μl of residual fluid remained 
in the tube. This wash step was repeated again. Then 50 μl of the pre-prepared 
Streptavidin-PE solution was added to all tubes, vortexed to mix, and incubated for 1 hr at 
RT in the dark. Afterwards, the same washing procedure was repeated twice. Finally, 500 
μl of assay buffer was added to each tube and protected from light. The reactions were 
then ready to be read on the flow cytometer, however, they could be stored at 4
o
C for up 
to 24 hours. For this experiment, the reactions were stored overnight.     
 
The BD FACS Canto™ II flow cytometry instrument was used for the data collection. 
Assistance was sought from Dr Gary Warnes, (Flow Cytometry Core Facility Manager, 
QMUL), with the initial program set up. A linear dot plot window was opened for 
forward scatter (FS) (x-axis) and side scatter (SSC) (y-axis). Two more windows were 
opened for PE emission (around 575nm) and far red for our instrument which was in the 
PerCP-Cy5 channel (around 700nm). The plots were set to log mode and all 
compensation set to zero. Setup beads (supplied in the kit) were vortexed and 500 µl 
added to a new FACS tube. The FS and SSC parameters were adjusted so that the small 
and large beads could be visualised separately as demonstrated in the first plot in Fig. 
3.2.1.1. Upon selecting each bead population (A and B) and having these represented in 
the two new scatter plots, the PE voltage was adjusted so that the beads were against the 
left side of the plot (see Plot 2 in Fig 3.2.1.1). Then the PerCP-Cy5 voltage was adjusted 
to clearly separate each population parallel to each other. This set up was saved for 
subsequent experiments.  
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Fig. 3.2.1.1. Demonstration of bead populations for different sizes and emissions on 
the flow cytometer. This image shows 11 analytes from the Human Th1/Th2 11plex 
FlowCytomix Kit manual. The correct bead set up was critical in order to analyse the 
cytokines properly.   
 
While still in Set Up mode, Standard 1, with the highest analyte concentration was run on 
the flow cytometer and the PE emission was adjusted to that the bead populations were as 
far right on the plots as allowed (Fig 3.2.1.1, plots 2 and 3). Afterwards, the Setup Mode 
was switched to Acquisition Mode and 10,000 events for each standard, blank, and 
sample were collected. All standards produced a measurable cytokine range with a 
standard curve efficiency ≥ 97% except for IFN-γ which had a 94% efficiency. Analyte 
concentrations were calculated against the standard curves using the FlowCytomix™ Pro 
3.0 Software. 
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3.2.1.2. The Sample Number for Saliva and Serum from Different Patient Groups 
The 37 final saliva samples for each group consisted of: HC n=10, RASq n=5, RASa n=2, 
BDq n=11, and BDa n=9. Thirty-seven matched serum samples from the same patients 
who donated saliva on the day were also measured. The patients were kept in the same 
active or quiet category based on the presence or absence of an oral ulcer. One BDq 
serum sample was read erroneously on the flow cytometer so had to be excluded. 
Therefore the 36 final serum sample numbers for each group were: HC n=10, RASq n=5, 
RASa n=2, BDq n=10, and BDa n=9. Patient demographics are shown in Table 3.2.1.2.1. 
 
Table 3.2.1.2.1. Patient Demographics for Saliva and Serum Analysis.  n, patient 
number. a, active/oral ulcer present. q, quiet/no ulcer present. M, male. F, female. Med 
MWash, medicated mouthwash. n/a, not applicable. *serum from one BDq patient had to 
be excluded due to erroneous flow cytometer reading. 
 
 
3.2.1.3. Statistical Analysis 
Because of the relatively small sample size, the median cytokine measurements in each 
group were compared to one another using the Mann Whitney U, non-parametric 
statistical test (2 tailed) for two independent samples. Significance is indicated by 
*p<0.05, **p<0.02. Welch’s correction for small samples was also completed for the 
RASa group. 
 
Groups HC RASq BDq  RASa BDa 
n 10 5 11* 2 9 
Mean age (years) 
 
31.6 43 37.8 34.5 40.6 
Range (years) 19 - 48 25 - 59 25 - 50 26-43 21 - 57 
Sex    
5 M, 5 F 
 
3 M, 2 F 6 M, 5 F 1 M, 1F 1 M, 8 F 
Number of Patients 
Not On Any 
Medication 
10/10  
(100%) 
5/5 
(100%) 
1/11 
(0.09%) 
2/2 
(100%) 
2/9   
(22.2%) 
Number of Patients 
Taking BD-Related 
Medication 
n/a n/a 
6/11 
(54.5%) 
n/a 
7/9 
(77.8%) 
Number of Patients 
using Med MWash 
n/a n/a 
1/11 
(0.09%) 
n/a 
6/9 
(66.7%) 
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3.3. Results  
3.3.1. Pro-Inflammatory Cytokines in Saliva and Serum  
In order to directly compare the saliva and serum, the figures listed in Table 3.3.1.1. were 
generated by plotting the raw data from the FlowCytomix™. Therefore, this does not take 
into account the total protein quantity in each sample. Overall, saliva cytokines were 
more readily detectable than serum in 25 µl of a neat sample. 
 
Cytokine 
Classification 
(Predominant 
expression) 
Analyte  
 
Assay 
Sensitivity* 
(pg/ml) 
Saliva Results 
in Figure: 
Serum Results 
in Figure: 
Chemokine IL-8 0.5 Fig. 3.3.1.1 Fig. 3.3.1.1 
Th1 IL-1β 4.2 Fig. 3.3.1.1 Fig. 3.3.1.1 
Th1 TNF-α 3.2 Fig. 3.3.1.1 Fig. 3.3.1.1 
Th1 IL-2 16.4 Fig. 3.3.1.2 Fig. 3.3.1.2 
Th1 IL-12 p70 1.5 Fig. 3.3.1.2 Fig. 3.3.1.2 
Th1 IFN-γ 1.6 Fig. 3.3.1.2 Fig. 3.3.1.2 
Th1 TNF-β 2.4 Fig. 3.3.1.3 Fig. 3.3.1.3 
Th2 IL-4 20.8 Fig. 3.3.1.3 Fig. 3.3.1.3 
Th2 IL-5 1.6 Fig. 3.3.1.3 Fig. 3.3.1.3 
Th2 IL-6 1.2 Fig. 3.3.1.4 Fig. 3.3.1.4 
Th2 IL-10 1.9 Fig. 3.3.1.4 Fig. 3.3.1.4 
Th17 IL-17A 2.5 Fig. 3.3.1.4 Fig. 3.3.1.4 
 
Table 3.3.1.1. The FlowCytomix™ Th1/Th2 Analyte Panel. The classification, assay 
sensitivity, and corresponding result figures for the 12 pro-inflammatory 
cytokines/chemokines tested in 25 µl of undiluted saliva and serum from different patient 
groups using a novel flow cytometry multiple bead-bound antibody assay. *The upper 
detectable limit was 20,000 pg/ml for each analyte except for IL-8 and IL-17A whose 
upper limit was 10,000 pg/ml. 
 
Out of the 12 cytokines measured in saliva, IL-1β and IL-8 were found to be the most 
abundant across all patient groups (Fig. 3.3.1.1). The group median levels of IL-1β in HC, 
RASq, and BDq saliva were approximately 2 times higher than their IL-8 levels. BDa had 
2.5 times the concentration of salivary IL-1β than IL-8. There was one HC whose saliva 
had increased levels of IL-8 and IL-1β resulting as outlying value in both graphs. HC 
serum did not have any detectable IL-1β and only 1 out of the 5 RASq serum samples 
gave a value. Both BDa and BDq serum had elevated IL-1β and IL-8. The saliva levels of 
TNF-α were similar amongst HC, RASq, and BDq with a group median level of 40.2, 
42.2, and 42.1 pg/ml, respectively. Similarly, serum TNF-α levels were nearly equal in 
HC and RASq at 13.01 pg/ml and 13.95 pg/ml, however BDq serum levels were slightly 
raised at 37.4 pg/ml. Both patient groups with oral ulcers showed increased TNF-α. 
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Fig. 3.3.1.1. IL-8, IL-1β, and TNF-α concentration differences in saliva and serum 
from matched patients. The centre bar within each group’s dot plot indicates the group 
median concentration. The extended bars indicate maximum and minimum values. 
Graphs on the left are saliva measurements and on the right are serum. Note, saliva IL-1β 
y-axis is 10X the scale of serum. Patient groups include HC (healthy control), RAS 
(recurrent aphthous stomatitis), and BD (Behçet’s disease). q, indicates mouth quiet/no 
ulcers. a, refers specifically to active mouth ulcer(s) regardless of other systemic 
symptoms. No significant differences between patient groups were identified. 
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When evaluating the Th1 cytokine panel, there was only one significant difference 
between the groups. Serum IL-2 was significantly increased in RASa than RASq, 
although the sample size was small (n=2) (Fig. 3.3.1.2). It was readily detected in all 
saliva samples and most serums. The median group values for IL-2 in saliva were similar 
across all groups (ranged from 138 – 190 pg/ml). The serum values for HC, RASq, and 
RASa were also very similar (ranged from 101 – 133 pg/ml), however the IL-2 in BDq 
serum was 2.5 times these levels. RASq and RASa had the highest levels of IL-12p70 in 
their saliva, but was not detected in their serum at all. IFN-γ in serum was also not 
detected.  
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Fig. 3.3.1.2. IL-2, IL-12p70, and IFN-γ concentration differences in saliva and serum 
from matched patients. The centre bar within each group’s dot plot indicates the group 
median concentration. The extended bars indicate maximum and minimum values. Left, 
saliva measurements. Right serum measurements. Patient groups include HC (healthy 
control), RAS (recurrent aphthous stomatitis), and BD (Behçet’s disease). q, indicates 
mouth quiet/no ulcers. a, refers specifically to active mouth ulcer(s) regardless of other 
systemic symptoms. **p<0.02 (with Welch’s correction). 
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Amongst the Th2 cytokine measurements in saliva, the majority of patient groups showed 
group medians below 100 pg/ml, with the exception of the RASa group. TNF-β was 
infrequently detected in serum samples where as in saliva more measurements were able 
to be identified (Fig. 3.3.1.3). HC, BDq, and BDa saliva shared a similar IL-4 median 
concentration. HC IL-4 was measured having 96.6 pg/ml while BDq and BDa shared 
exactly the same quantity of 93.1 pg/ml. RASq and RASa also had similar saliva IL-4 
concentrations to each other at 67.1 and 61.2 pg/ml, respectively. 
 
IL-5 had similar median saliva concentrations among groups (77.9 pg/ml) except for 
RASa being slightly higher at 125.7 pg/ml. In serum, RASa IL-5 was relatively low, 32.8 
pg/ml, compared to the other groups which had a median of 69 pg/ml collectively. 
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Fig. 3.3.1.3. TNF-β, IL-4, and IL-5 concentration differences in saliva and serum 
from matched patients. The centre bar within each group’s dot plot indicates the group 
median concentration. The extended bars indicate maximum and minimum values. Left, 
saliva measurements. Right, serum measurements. Patient groups include HC (healthy 
control), RAS (recurrent aphthous stomatitis), and BD (Behçet’s disease). q, indicates 
mouth quiet/no ulcers. a, refers specifically to active mouth ulcer(s) regardless of other 
systemic symptoms. No significant differences between groups were identified. 
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Both saliva and serum, IL-6 had the lowest concentrations across all patient groups (Fig. 
3.3.1.4). However, significance was still able to be detected. BDa patient saliva was 
significantly higher than HC (p=0.045) and BDq (p=0.0342). The RAS patients with 
active oral ulcers also had significantly higher IL-6 levels than RAS without ulcers 
(p=0.01). 
 
IL-10 in saliva was similar in HC and RASq groups at 50.5 pg/ml and 56.0 pg/ml, 
respectively. RASa had the highest median level at 169.8 pg/ml. BDq and BDa had 
similar levels (75.7 pg/ml and 65.9 pg/ml, respectively) with one high outlier in each 
group. Serum levels in HC, RASq, and RASa groups were low or undetectable. BDq only 
had a few measurements giving a median level of 12.5 pg/ml.  
 
IL-17A was detected in the majority of saliva samples but not in serum. BDq and BDa 
IL-17A in saliva had a similar distribution and median level of 29.5 pg/ml and 27.5 
pg/ml, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.1.4. IL-17A, IL-6, IL-10 concentration differences in saliva and serum from 
matched patients. The centre bar within each group’s dot plot indicates the group 
median concentration. The extended bars indicate maximum and minimum values. Left, 
saliva measurements. Right, serum measurements. Patient groups include HC (healthy 
control), RAS (recurrent aphthous stomatitis), and BD (Behçet’s disease). q, indicates 
mouth quiet/no ulcers. a, refers specifically to active mouth ulcer(s) regardless of other 
systemic symptoms. Note that the saliva IL-6 y-axis scale is different from IL-6 serum. 
Significance indicated by *p<0.05, **p<0.02 (with Welch’s correction). 
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Due to the large variability of the saliva samples, the total protein was quantified and 
analytically normalized based on a total protein quantification of 0.5 µg/µl for each saliva 
sample. This concentration was chosen because it was the lowest total protein 
concentration quantified amongst the saliva samples. For instance, if a saliva sample’s 
total protein concentration was 1 µg/µl and its IL-8 measurement was 200 pg/ml: the 
designated baseline total protein (0.5 µg/µl) was divided by the sample’s total protein 
quantification (1 µg/µl) and then multiplied by the IL-8 result for that sample (200 
pg/ml). The portion of IL-8 measured amongst the total protein in saliva would be 100 
pg/ml. This was conducted for each saliva sample and each cytokine measurement. As a 
result, some cytokine correlations were found. 
 
The normalised saliva measurements of IL-8 and IL-1β across all patient groups had a 
correlation with linear regression of 0.789 (Fig. 3.3.1.5). Additionally, IL-12p70 and 
TNF-β measured in saliva resulted in a close correlation of 0.85 (Fig. 3.3.1.6). Finally, 
IL-5 and IL-10 detected in saliva from all patient groups showed a linear regression of 
0.694 (Fig. 3.3.1.7).  
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Fig. 3.3.1.5. Correlation of IL-8 and IL-1β measured in saliva from all patient 
groups. Linear Regression = 0.79. Lines on either side show the 95% mean confidence 
intervals. 
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Fig. 3.3.1.6. Correlation of IL-12p70 and TNF-β measured in saliva from all patient 
groups. Linear Regression = 0.85. Lines on either side show the 95% mean confidence 
intervals. 
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Fig. 3.3.1.7. Correlation of IL-5 and IL-10 measured in saliva from all patient 
groups. Linear Regression = 0.694. Lines on either side show the 95% mean confidence 
intervals. 
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3.4. Discussion 
3.4.1. Saliva and Serum Inflammatory Markers 
Originally, the FlowCytomix™ array was compared to a different method of cytokine 
measurement for saliva and plasma samples: an IL-8 ELISA (work completed by Dr 
Eleni Hagi-Pavli, data not shown). The assay measured IL-8 in BD plasma regardless of 
systemic or oral activity (BD n=50, HC n=11) and saliva supernatant samples (BD n=35, 
HC n=9). Mean IL-8 was found at low levels in plasma (BD 4.0 ± SEM 1.4 pg/ml, HC 
2.1 ±0.7 pg/ml) and high levels in saliva (BD 720.6 ±42.36 pg/ml, HC 705.7 ±68.4 
pg/ml). In our FlowCytomix™ array, the BD patients were sub-divided depending on the 
presence of oral ulceration to further assess the inflammatory components of the saliva. 
 
When measuring protein levels in saliva, it was important to analyse saliva from ulcerated 
mouths in a separate group for the reason that inflammatory cells and cytokines are highly 
likely to be at peak levels at the site of a wound. Frequently, in research studies which 
compare BD and RAS patients, the activity of the BD patients is well-defined, however 
the critical detail of whether the RAS patients were suffering an ulcer or not fails to be 
mentioned. This parameter needs to be better defined. Therefore, we analysed RAS saliva 
and serum samples from persons with (active, a) and without ulcers (quiet, q) separately 
and what was found was that RASa and RASq groups showed different inflammation 
profiles. 
 
Some cytokine levels in RASa saliva samples were lower than expected such as in IL-1β, 
but this is most likely due to the sample size being n=2. It was surprising to find that 
RASq had higher levels of salivary IL-8 and IL-1β to that of HC. This suggests that IL-8 
chemokine and IL-1β in saliva may recruit inflammatory cells in RAS patients during a 
quiescent episode. This could provoke the onset of an ulcer. Saliva could potentially be a 
reliable specimen for monitoring cytokine precursors of inflammation when the mouth is 
non-active. 
 
A study conducted in 1995 by Ozoran and his colleagues did not find any significant 
differences of the IL-8 levels in serum between BD systemically active, BD quiet, or HC 
(Ozoran, 1995). However, since then, a multitude of studies have reported significant 
findings based on ELISA assays. When the criteria for active or symptomatic systems 
were analysed separately, so that the sera from patients with oral ulcers were compared to 
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those without ulcers, IL-8 was significantly increased in individuals with oral ulcers 
(Zouboulis, 2000; Katsantonis, 2000; Durmazlar, 2009). Importantly, our study also 
found that this was the case, but in addition, also found high levels of serum IL-8 in BD 
quiet patients that were non-symptomatic.  
 
Zouboulis, et al, also reported that up to 51% of their serum samples were below 
detectable limits of their ELISA assay (10 ng/ml) so that, for example, 19 BD quiet sera 
samples were tested but only 4 samples could detect IL-8 (Zouboulis et al., 2000). Using 
the FlowCytomix™ array, we had an improved yield and only 2 out of 38 serum samples 
(5%) were below our 0.5 pg/ml IL-8 detection limit. Unfortunately, our other analyte 
targets in serum were not detected as readily as IL-8. Not including IL-8, the majority of 
undiluted serum samples were below detectable limits (28 out of 38 samples or 74%). 
However, overall, neat saliva samples showed better detection than serum. Saliva had an 
average of only 2 out of 35 saliva samples (6%) per analyte below detectable levels, the 
exception being saliva IFN-γ which had 22 missing values.  
 
The ratio of salivary IL-8 and IL-1β (average ratio of 1:2) showed a strong predictability 
that IL-1β would be nearly twice as high than IL-8 in 89% of the samples. Together, they 
showed a correlation in the collective saliva samples from all groups. However, serum 
samples did not adhere to this ratio. Katsantonis, et al, suggested using IL-8 as a 
serological marker for assessing BD activity (Katsantonis, 2000). Our assessment would 
suggest that IL-8 alone is perhaps not specific enough seeing as both RASq saliva and 
BDq serum had high measurements of this chemokine. Granted, this could be alluding to 
the onset of an ulcer or other mucosal inflammation. However, IL-8 paired with IL-1β 
measurements in saliva, could improve the validity of pre-empting an active episode. The 
IL-8 and IL-1β correlation demonstrates the reliability of saliva samples to provide 
accurate data for the potential monitoring of inflammatory markers.  
 
IFN-γ has been hailed as the classically identifiable Th1 cytokine, however detecting it 
with the FlowCytomix™ array was scarce. Only 14 out of 36 saliva samples and 1 out of 
38 serum samples were measured successfully. IFN-γ was found to be increased in the 
saliva from BD patients with active ulcers which shows that only when the oral mucosa 
was damaged did the classic IFN-γ Th1 response drive forward. Frassanito, et al, also 
found increased circulating IFN-γ from only symptomatic BD patients when compared to 
BD quiet and HCs (Frassanito et al., 1999). Another Th1-type cytokine, TNF-α, did not 
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seem to differ extensively in the saliva from most groups except for BDa patients with 
active oral ulcers which presumably was most likely beneficial in order to recruit cells to 
fight any pathogens associated with the wound. Although RAS active patients had a high 
median concentration of TNF-α in saliva, this was due to one out of the two patients 
skewing the distribution. More samples are required from this patient group for a more 
accurate assessment since it has been shown to be highly expressed in RAS oral lesions in 
a previous study (Natah et al., 2004). Chronically high levels of TNF-α (which could lead 
to an influx of neutrophils and mucosal damage) were not observed in BDq saliva, 
however, the same group showed the highest level in their serum. This result suggests that 
TNF-α may be involved in stimulating a systemic response in BD but not necessarily in 
the mouth.  
 
IL-12p70, another pro-inflammatory cytokine which is known to drive the Th1 immune 
response by inducing IFN-γ and IL-2, was found to be increased in RASq saliva, although 
this did not allude to high levels of either IL-2 or IFN-γ. Instead, it did have a correlation 
with TNF-β in saliva. In saliva, IL-12p70 and TNF-β may work in close collaboration 
with each other.  
 
IL-17A was incorporated into the array panel because it has been shown to recruit 
neutrophils whose proteases can cause detrimental damage to the mucosa. IL-17A has 
also been linked to autoimmune diseases. To date, it has not previously been measured in 
salivary fluid of BD or RAS patients, but has been investigated in chronic periodontitis in 
which it was significantly lower than HC (Ozcaka et al., 2011). A previous study was 
unable to measure IL-17A in the sera from BD patients using an ELISA method (Chi et 
al., 2008) however, we were able to detect it using the FlowCytomix
TM
. Our data suggest 
that IL-17A may be worth pursuing as a contributor to the inflammation seen in BD as 
excessive IL-17A could be a detrimental trigger for prolonged inflammation. 
 
IL-6 is an alleged partner of IL-17 since it is known to be a stimulant towards Th17 cell 
differentiation which in turn releases IL-17A. Presumably, if IL-6 increased it is thought 
that IL-17A would also increase but this was not the case in our measurements as there 
was no correlation found. Serum IL-6 was seldom detected in the groups with the 
exception of two BDq samples. In contrast, salivary IL-6 was significantly higher in 
orally active BD and RAS patients although, again, this was not reflected in their IL-17A 
saliva levels. The IL-6 in an ulcerated mouth may drive a Th2-prefered pathway 
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stimulating B cell maturation instead of Th17 cell differentiation. An unknown 
stimulatory factor other than IL-6 or in conjunction with IL-6 may increase IL-17A 
production in the circulation. Low serum IL-6 in BD patients but high individual IL-17A 
measurements could also be because IL-17A is being produced by a non-Th17 type cell 
(such as γδ T cells or NK cells) (Raifer et al., 2012) which does not depend on the IL-6 
stimulatory pathway. However, these cytokines measurements will require a larger 
number of samples to be sure that IL-17A is not dependent on IL-6 in this system. IL-6 
has previously been undetectable in BD and HC plasma using an ELISA method whose 
lower detection limit was 18 pg/ml (Yamakawa et al., 1996). The IL-6 detection limit for 
our FlowCytomix array was 1.2 pg/ml, and although evidence of the cytokine was found 
in serum, the highest average was in HC at 14.2 pg/ml. Therefore, our data coincides with 
that of other previous reports which state that serum IL-6 was absent or of particularly 
low levels in BD and HC. However, another more recent study by Curnow, et al, in 2008 
found that IL-6 was significantly increased in BD patients (grouped together regardless of 
disease activity or site of activity) compared to RAS (again, not differentiated into oral 
ulcer activity) and HC (Curnow et al., 2008). They used a similar multiplex bead assay 
but with the constraint that the samples had to be read on a specialized machine, the 
Luminex 100
TM
. Once again, as seen with our own serum samples, many were below the 
level of detection: Curnow, et al, reported that only 18 out of 79 (23%) BD serum 
samples were detected, 3 out of 15 (20%) HCs, and 0 out of 20 RAS samples. Yet, IL-6 
was still described by Curnow, et al, as one of the most abundant inflammatory cytokines 
amongst a panel of 10 detected in serum (Curnow, et al, 2008). In our study, 33 out of the 
38 serum samples did not detect any IL-6. However, IL-6 in saliva had a better outcome 
being detected in 26 out of 36 samples and showing the highest levels in the BD group 
with active oral ulcers. From the results of our data, it is implausible to support the 
previous hypothesis that IL-6 has a prominent role to play in systemic inflammation in 
BD but it does suggest that the oral mucosa inflammatory cells release IL-6 in response to 
oral ulceration.  
 
IL-2 can be influenced by IL-6 as well. IL-6 can promote T helper and cytotoxic T-cell 
proliferation by increasing their IL-2 secretion (Naka et al., 2002). In the serum samples, 
it was found that RASa had significantly higher levels of IL-2 compared to RASq 
patients. It was also measured in high levels in BDa serum possibly reflecting the ongoing 
inflammation process during oral ulceration. The IL-2 in saliva had similar levels 
detected in all groups. This indicates that locally detected IL-2 was not necessarily 
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affected by oral ulceration. The increased presence of IL-2 cytokine in the mouth seems 
unnecessarily high in HC and RASq patients without any obvious mucosal inflammation 
or ulcer to attend or react to.  
 
IL-4 is an essential component to developing a Th2-type response. In our experiment, it 
was found to be highest in the BDq group’s saliva. However in the serum, IL-4 failed to 
be detected in the majority of samples. Therefore, IL-4 may be a more prominent force 
driving the production of antibodies in the mouth other than systemically. 
 
RASq saliva may have similar levels of IL-6 and IL-10 to HC due to anti-inflammatory 
affect. An increase in IL-10 has previously been found to promote wound healing 
(Peranteau et al., 2008). However, a decreased production of IL-6 in the oral mucosa is 
also thought to differentiate rapid, scarless oral mucosal healing from skin regeneration 
(Szpaderska et al., 2003). It would be useful to investigate salivary IL-6 and IL-10 in vitro 
to see in which pro- and/or anti-inflammatory capacity the cytokines are predominantly 
working as on RAS and BD mucosal epithelial cells.  
 
IL-5 and IL-10 showed a strong correlation in all saliva samples. Interestingly, when BDq 
patients were re-categorised into a new group without any ulcers or systemic symptoms, 
they had the highest IL-5 and IL-10 concentrations in the saliva (data not shown). Both of 
these Th2-type cytokines can promote B cell proliferation and maturation leading towards 
a Th2 response. IL-10 can also inhibit T-cells from making IFN-γ (Romagnani, 1995). 
This could be the reason why non-symptomatic BD patients had their IL-10 saliva level 
as one of the highest of all groups while IFN-γ was one of the lowest. This inverse 
relationship was apparent in BD patients with ulcers as well: IL-10 and IL-5 were low 
while IFN-γ was remarkably high.   
Despite all of the BD patients who donated saliva and serum were on immunosuppressive 
medication, they still showed high levels of inflammatory cytokines in their saliva. It was 
difficult to determine the outcome of the serum analysis since so many samples were 
below the level of detection especially for IFN-γ in which 37 out of 38 serum samples 
were undetectable. The values measured showed a wide range, especially for serum 
results, but can be more accurately assessed with larger sample sizes. The 
FlowCytomix™ is an expensive array but a copious amount of data was obtained with a 
single experiment and 39 paired saliva and serum samples in order to confirm the 
inflammatory state of persons who suffer with oral ulcers and/or BD.  
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3.4.2. Conclusions:  
 
1. Saliva is a valuable, useful, and readily available specimen that can be used to 
investigate both the oral and systemic inflammation. Samples should be analysed 
separately depending on whether an ulcer is present or not. 
 
2. FlowCytomix
TM
 array is a sensitive technique which only requires a minimum of 25 µl 
of sample to obtain valuable measurements, especially when using saliva as a specimen. 
 
3. Cytokine measurements in serum are often too low to provide conclusive data.  
 
4. A high level of IL-8 and IL-1β in RAS patients’ saliva when they do not have an ulcer 
may be the inflammatory instigators of developing an ulcer. Their anti-inflammatory IL-
10 level which is similar to HCs may be overcome leading towards inflammation. 
 
5. The immune response of systemically active BD patients without an episode of oral 
involvement can still influence the inflammatory markers found in saliva. Also, 
importantly, BD patients who are orally non-symptomatic still maintain underlying 
inflammation as is evident of the high levels of inflammatory cytokines in their saliva 
which warrants further investigation. A potential monitoring system for the saliva 
cytokines could pre-empt the onset of a multi-symptomatic episode. This knowledge 
could provide an alert system for topical or systemic therapeutic interventions.  
 
6. The BD cytokine profile has shown a mixed Th1/Th2 response rather than 
predominantly Th1. 
 
 
 
 
 
 
 
 
 
 
68 
 
 
 
 
 
Chapter 4: 
Neutrophil Elastase 
and Its Protease 
Inhibitors 
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4.1. Introduction 
4.1.1. Neutrophil Elastase and its Main Protease Inhibitors: Secretory Leukocyte 
Protease Inhibitor and Alpha1-Antitrypsin 
4.1.1.1. Neutrophil Elastase 
Neutrophil elastase (NE) is a 29.5 kDa serine protease glycoprotein contained mainly 
within neutrophil primary azurophil granules. Neutrophils are the first leukocytes to 
arrive at sites of infection in order to contain and degrade microbes as a protective benefit 
to the host. Their typical behaviour is to ingest pathogens and then guide them to 
internalised compartments called phagosomes which fuse with primary azurophil 
granules containing active NE, myeloperoxidase (MPO), Cathepsin G (CatG) and 
Proteinase 3 (PR3), as well as antimicrobial peptides including alpha-defensins and 
lysozyme, and the ability to generate oxygen metabolites such as superoxide anion (O2
-
) 
(Korkmaz et al., 2008b, Witko-Sarsat et al., 2000, Faurschou and Borregaard, 2003). In 
this contained internal space, the digestive compartment, referred to as phagolysosome, 
the granule contents work simultaneously to degrade microbes.  
 
The azurophil granules, also known as the peroxidase positive granules, and their contents 
are synthesised in immature neutrophils, specifically, the bone marrow myelocytic 
progenitor cells, during the early stage of granulocyte development (Takahashi et al., 
1988) (Korkmaz et al., 2008b). This is when NE is produced. The protease is then stored 
in azurophilic granules at a high concentration of approximately 5.33 mM (Liou and 
Campbell, 1995) which equates to 0.157 pg/ml or 3-4 pg per neutrophil (Korkmaz et al., 
2008a). Damiano, et al, has shown that two different azurophil peroxidase positive 
granule subsets exist in the neutrophil. The first type contains NE, is larger in size, has a 
small amount of peroxidase activity, and makes up 26% of the azurophil population. The 
second does not contain any NE and has a strong peroxidase activity (Damiano et al., 
1988).  
4.1.1.2. Neutrophil Granules, NE and Exocytosis 
As well as acting as phagocytes to ingest and digest microbes, viable neutrophils can also 
simultaneously exocytose their granule contents under controlled conditions to further 
induce the immune response (Lacy, 2006). Necrotic neutrophils uncontrollably release all 
cell contents whereas NETosis is a programmed cell death in which neutrophils purposely 
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externalise their DNA and azurophil contents (NETosis will be explored further in 
Chapter 5). Alongside azurophils, neutrophils also contain three other granules referred 
to as specific, gelatinase, and secretory vesicles. The specific (secondary) and gelatinase 
(tertiary) granules are also called the peroxidase negative granules (Faurschou et al., 
2002, Sengelov et al., 1993). All three are synthesised at later stages of neutrophil 
development. Interestingly, the later the granules are produced, such as the secretory 
vesicles, the first they are to be released from the neutrophil. The fact that azurophils, 
containing potent proteases that could cause host tissue damage, are the last to be 
exocytosed suggests a self-regulatory mechanism. Most granules proteins have the 
capacity to be bactericidal, but can also help lead the migration of neutrophils. For 
instance, when the secretory vesicle is exocytosed, its various protein receptors 
incorporate themselves onto the neutrophil membrane. This enables the cell’s attachment 
to vascular endothelial cells and its migration through vessels and tissues towards the site 
of inflammation (Faurschou and Borregaard, 2003, Faurschou et al., 2002). Therefore, it 
is fitting that secretory vesicles are the first to be exocytosed from the neutrophil in order 
to establish contact.  
 
Depending on the type of stimulus, neutrophils can purposely exocytose a portion of their 
granules in order to instigate or propagate the immune response. For instance, an 
increased uptake of calcium (Ca
2+
) induces the orderly granule release mentioned 
previously with azurophils being mobilised last (Sengelov et al., 1993). N-formyl-
methionyl-leucyl-phenylalanine (FMLP), a bacteria wall derived chemoattractant, 
mobilises a quarter of neutrophil’s gelatinase granules but very few azurophil and specific 
granules (Kjeldsen et al., 1999). Specifically, TNF-α, IL-8, complement 5a (C5a), and 
LPS primes neutrophils and causes NE to be released (Lee and Downey, 2001).  
 
Granules are mainly reserved for the intracellular fusion with a phagosome containing an 
engulfed microorganism (Sengelov et al., 1995). However, externally shed NE 
participates in several roles as a propagator and suppressor of the immune system. NE has 
the ability to degrade various connective tissues, including extracellular matrix (ECM) 
components such as elastin, collagen, fibronectin, laminin, and proteoglycan (Roghanian 
and Sallenave, 2008a) (Heutinck et al., 2010) compromising the integrity of healthy 
tissue. Multiple studies have demonstrated the tissue damage caused by NE. These studies 
will be further reviewed later in this chapter (section 4.1.1.6). However, if regulated 
appropriately, a small amount of NE tissue degradation can encourage the regeneration of 
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new cells. NE is also able to degrade IL-1β, TNF-α (Owen et al., 1997), IL-2 (Ariel et al., 
1998), and IL-6 (Bank et al., 1999) inflammatory cytokines thereby downgrading the 
response. NE can also cleave CD14 which is the main receptor for bacterial LPS on blood 
monocytes and gingival fibroblasts (Le-Barillec et al., 1999, Nemoto et al., 2000). 
 
Despite the damage that NE can cause, neutrophils do take on a very important and 
helpful role in the reparative processes by phagocytising debris and keeping a local area 
clear so that additional neutrophils and other cellular components and pro-inflammatory 
cytokines can gain access to an infected area (Ghasemlou et al., 2010). Neutrophils are an 
essential part of this process. With a low number or absence of neutrophils, the innate 
immune response is stunted and individuals can develop severe, recurrent infections and 
may end up suffering from mouth ulcers (Bouma et al., 2010). A delicate balance of 
neutrophils and NE is paramount for normal tissue function. 
 
The life span of circulating neutrophils has been debated for many years. In 1997, 
neutrophils were estimated to have a half-life of around 6 hours (Haslett, 1997). This was 
revised in 2000 by Webb, et al, with the realisation that they could live for 24-48 hours 
(Webb et al., 2000). More recently, in 2010, Pillay, et al, showed that HC neutrophils can 
circulate in vivo for 5.4 days in peripheral blood (Pillay et al., 2010). However, when 
recruited to sites of inflammation or infection within tissues, it is believed that neutrophils 
can survive for longer periods by delaying apoptosis (Wright et al., 2010). Therefore, one 
can envisage that during chronic inflammation the presence of activated neutrophils in 
tissues may increase the risk of NE-related damage. Thus persistent, active neutrophils 
releasing NE in the oral cavity may disrupt the mucosal lining causing a type of 
pathology which manifests as an ulcer. 
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Fig. 4.1.1.2.1. The Neutrophil and Azurophil Granules. A resting neutrophil image 
taken with an electron microscope showing the azurophil granules (or primary granules, 
pg), which appear as large dark granules. Secretory granules are also indicated (sg). Other 
features that are indicated are the nucleus (N); centriole (ce); mitochondri (m). 
Reproduced with permission from Witko-Sarsat, et al, 2000 (Witko-Sarsat et al., 2000). 
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4.1.1.3. Secretory Leukocyte Protease Inhibitor 
Secretory leukocyte protease inhibitor (SLPI) is a small 11.7 kDa stable innate inhibitory 
protein which has broad spectrum anti-bacterial, anti-fungal, and anti-viral activity and 
protects mucosal epithelial tissue surfaces from endogenous proteolytic enzymes (serine 
proteases) such as trypsin, cathepsin G, and neutrophil elastase (NE) (Jacobsen et al., 
2008). SLPI has been found in various secretions including seminal plasma (Ohlsson et 
al., 1995),  cervical mucus (Moriyama et al., 1999), nasal (Lee et al., 1993), and bronchial 
secretions (Sallenave, 2000), sputum (Sallenave et al., 1997), reflex tears in the eye 
(Sathe et al., 1998), and saliva stemming from the parotid gland (Thompson and Ohlsson, 
1986). It is produced in the non-ciliated epithelial cells of the lung mucosa (De Water et 
al., 1986), cultured immortalised oral buccal mucosa epithelial cells from stillborn foetus 
(Jana et al., 2005), alveolar macrophages (Sallenave, 2000), and pancreatic B-cells (in the 
islets of Langerhan cells) (Nystrom et al., 1999).  
 
SLPI is also secreted from oral buccal epithelial cells (Nittayananta et al., 2013b) and 
salivary gland acinar cells (Ohlsson et al., 1984) and therefore is considered a local 
inhibitor of serine proteases NE and CatG in the oral cavity. SLPI can also be found in the 
specific (secondary) granules of human neutrophils (Sallenave et al., 1997, Jacobsen et 
al., 2008). It has been reported to be the primary regulatory inhibitor of human NE in 
sputum supernatants of Chronic Obstructive Pulmonary Disease (COPD) patients 
(Piccioni et al., 1992) and has been shown to contribute to oral mucosa wound healing in 
mice (Angelov et al., 2004).  
 
4.1.1.4. Alpha1-Antitrypsin Inhibitor  
Alpha1-antitrypsin (α1AT), also known as alpha1-protease inhibitor (α1-PI), is a 52 kDa 
glycoprotein which is categorised as a member of the serpin family. It is one of the best 
described NE inhibitors. Hepatocytes are the main producers of the protein which is then 
secreted into the plasma and circulated. To a lesser degree, but still important sources, 
α1AT mRNA has also been found in breast milk macrophages (Perlmutter et al., 1985), 
alveolar macrophages (Mornex et al., 1986, van 't Wout et al., 2012), blood monocytes 
(Isaacson et al., 1981, Mornex et al., 1986, Perlmutter et al., 1985), monocyte-derived 
dendritic cells (van 't Wout et al., 2012), human lung epithelial cells (Cichy et al., 1997) 
and various lung cell lines, such as the A549 cells (Morgan et al., 2009), but not in blood 
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lymphocytes (Mornex et al., 1986). α1AT has been detected in neutrophil azurophil 
granules (du Bois et al., 1991, Mason et al., 1991), and was recently found in fractionated 
portions of neutrophils’ specific granules, gelatinase granules, and secretory vesicles 
(Clemmensen et al., 2011).  
 
4.1.1.5. Oral Mucosa Inflammation, Neutrophil Elastase and Regulation  
In a normal healthy mouth, inflammation along the soft mucosal linings of the oral cavity 
is usually due to minor wounds and/or microorganisms whether they are commensal, 
opportunistic, or pathogenic (Marsh, 2012) (Walker, 2004). Bacteria is always present in 
the mouth, however if they become overgrown or invasive, the immune system increases 
its defences to keep them in balance. Microbial antigens such as lipopolysaccharide (LPS) 
can stimulate the production and release of the pro-inflammatory cytokine IL-1β by 
keratinocytes, fibroblasts, endothelial cells, and leukocytes particularly monocytes which 
have migrated through the mucosa (Tsai et al., 1995) (Sabroe and Whyte, 2007). C5a 
peptides from serum and local macrophages also promote an inflammatory response from 
neutrophils and other leukocytes (Manthey et al., 2009). Along with IL-1β, TNF-α is 
released by endothelial cells and macrophages (Feldmann and Maini, 2001). This can 
induce IL-8 chemokine production (Silva et al., 2009) in a variety of cells including 
neutrophils, macrophages, endothelial and epithelial cells. IL-8 then recruits and guides 
additional neutrophils toward the source of infection or inflammation (Kaburaki et al., 
2003). Neutrophils externalise some NE to aid in the further up-regulation of leukocytes 
and contribute to the inflammatory process by recruiting more neutrophils which also 
produce additional IL-8 and TNF-α.  
 
Excessive NE can cause epithelial tissue damage (Ginzberg et al., 2001). SLPI, generated 
from saliva glands and epithelial cells due to stimulation by bacterial LPS and human 
host’s IL-1, TNF, and NE (Sallenave, 2000), attempts to balance the protease activity. 
Serum-derived α1AT is also present having gained access to the oral cavity through the 
gingival sulcus along with neutrophils (Nakamura-Minami et al., 2003, Pederson et al., 
1995). Both endogenous SLPI and α1AT are found in neutrophil granules as well but it is 
unknown to what extent they contribute to the protease-antiprotease balance in the oral 
cavity. In certain cases, it is not always clear what is instigating the inflammation or if it 
is derived from foreign or self-antigens. Nevertheless, during chronic oral inflammation, 
there is an on-going cycle of these pro-inflammatory events. In a summarized illustration,  
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Figure 4.1.1.5.1 depicts SLPI and α1AT’s regulation of NE and their interaction with the 
oral epithelium and surrounding inflammatory response. NE itself is not necessarily an 
absolute prerequisite for initiating the inflammatory response (Hirche et al., 2004), 
however its persistence influences the cyclic nature of chronic inflammation 
(Kessenbrock et al., 2011).  
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Fig. 4.1.1.5.1. Proposed Working Model of the Oral Environment During Immune 
Up-Regulation: Summary of the Interaction of the Epithelium, Inflammatory 
Cytokines, Neutrophil Elastase, SLPI and α1AT. Microbes stimulate oral keratinocytes 
(Ker) and immune cells such as Langerhan cells (LH) to produce IL-8. IL-1β can be 
synthesised and released by local fibroblast (Fibr) or leukocytes that have travelled 
through the mucosa from the vasculature (Tsai et al., 1995). IL-1β induces further IL-8 
production (Silva et al., 2009) which is a neutrophil chemoattractant (Kaburaki et al., 
2003) and they migrate through the epithelium towards the site of infection and 
inflammation. Neutrophils phagocytose foreign entities and also release NE (and Pr3, 
CatG) into the extracellular environment due to continued bacterial stimulation, and 
presence of TNF-α, IL-8, and C5a. Neutrophil apoptose shortly after but if they become 
necrotic (or undergo NETosis), they may release additional NE. Epithelial cells and 
salivary glands produce SLPI while GCF/serum-derived α1AT help to regulate NE. 
Neutrophils also have endogenous α1AT and SLPI but the extent of their external 
inhibitory contribution is not known. In addition, macrophages (Mac) and LH cells are 
both APC’s and have MHC class II molecules. These can prime Type 1 T helper cells 
(Th1) (Barrett et al., 1996) to release IL-2 which induces further T-cell proliferation and 
additional inflammatory cytokines such as TNF-α, TNF-β, IFN-γ, and GM-CSF (Walker, 
2004). TNF-α can further stimulate IL-8 production and recruit more neutrophils. 
Activated neutrophils can release IL-8 as well. Excessive, prolonged exposure to NE can 
damage cells and the integrity of the mucosal lining possibly resulting in an ulcer. (Th2 
interactions are not depicted in the diagram but involve secretory IgA, IL-4, IL-6, and IL-
10).  
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4.1.1.6. NE, Disease, and Ulceration 
The continuous presence of NE in chronically inflamed tissue of individuals with chronic 
obstructive pulmonary disease (COPD), cystic fibrosis, and inflammatory bowel disease 
has been implicated as a cause of tissue damage (Stockley, 2002, Quinn et al., 2010, 
Heutinck et al., 2010). Excessive activity or an imbalance of NE could lead to increased 
pathology, auto-immunity, allergy, and tumour metastasis. Neutrophil degranulation can 
be triggered by various inflammatory factors such as lipopolysaccharide (LPS), TNF-α, 
G-CSF, C5a, and contact with ECM or cell surfaces (Nathan, 2006). Its increased 
presence leads to inflammation and ECM remodelling (Heutinck et al., 2010) and has 
been shown to cause apoptosis in intestinal (Ginzberg et al., 2004) and lung epithelial 
cells (Suzuki et al., 2005). Neutrophil’s externalised reactive oxygen species (ROS) are 
known to damage cells as well but a study conducted by Smedly, et al, was able to show 
that human microvascular endothelial cells co-cultured with neutrophils from a Chronic 
Granulomatous Disease (CGD) patient whose neutrophils do not have the ability to 
produce superoxide molecules were still able to cause cellular injuries similar to that of 
normal HC neutrophils. Notably, the majority of the damage was repressed by a synthetic, 
specific NE chloromethyl ketone-type inhibitor (Smedly et al., 1986) indicating that 
neutrophil NE was largely responsible for the cell destruction. 
 
Although a genetic deficiency of SLPI has not yet been reported, there are cases in which 
a single point mutation causes misfolding of the α1AT protein in liver cells causing a rare 
disease called α1AT deficiency. The misshapen protein accumulates in the hepatocytes 
instead of being released into the plasma circulation thus depleting the enzyme’s 
availability. Eventually, the accumulation of the ill-fated protein causes liver cirrhosis, 
but the condition can also lead to serious lung degeneration such as emphesyma/COPD 
due to NE in the lungs not being regulated effectively (Greene and McElvaney, 2010). 
 
The diagnostic classification for BD, a multi-systemic inflammatory disorder of unknown 
aetiology, was re-visited in 2013 by an international collaboration. They maintained that 
oral ulcers are still the most common and reoccurring feature suffered by patients 
(Davatchi et al., 2013). In 1975, Matsumara and Mizushima found that neutrophil 
chemotaxis was evident in BD (Matsumura and Mizushima, 1975) which sparked further 
neutrophil-based investigations. Neutrophil infiltration is evident in oral, ocular and 
cutaneous BD lesions and has been implicated in the disease’s progression and pathology 
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(Verity et al., 2003). In advanced eye involvement, a hypopyon, which is a pooled cluster 
of white blood cells including neutrophils, can occur in the eye and is characteristic in 
BD. Although the hypopyons usually disappear, the person is at high risk of future 
blindness (Kaklamani et al., 1998). The human leukocyte antigen (HLA) gene locus 
subtype B51 was also found to have an association with neutrophil hyperactivity (O'Duffy 
et al., 1983, Sensi et al., 1991). Since these early investigations, most studies on 
neutrophils and their association with BD have been solely based on blood samples. 
However, investigating salivary NE content may help elucidate what is occurring in these 
patients since neutrophils are the most common leukocytes normally found in saliva 
(Walker, 2004). If individuals with BD are not able to regulate the influx of neutrophils 
and the presence of extracellular NE in their oral cavity, perhaps the mucosa is 
overexposed to the proteolytic enzymes generated by neutrophils thus playing a part in 
their recurrent ulcer pathology.  
 
Recurrent aphthous oral ulcers are also a feature of numerous immune dysregulations 
such as Crohn’s Disease (Fatahzadeh et al., 2009), systemic lupus erythematosus (Munoz-
Corcuera et al., 2009), oral lichen planus (Munoz-Corcuera et al., 2009) but can also arise 
from radiation and chemotherapy (Sonis, 2004), and even severe stress. Individuals with 
recurrent aphthous stomatitis (RAS), who harbour no other obvious systemic features of 
immunopathology, are thought to endure a unique immune dysregulation which, for 
unknown reasons, manifests solely in the oral cavity (Natah et al., 2004).  
 
Ueta, et al, has suggested that individuals with RAS may harbour an immune cell 
dysfunction based on the evidence that their neutrophils had suppressed superoxide 
production compared to HCs, however, this was based on blood neutrophil investigations 
(Ueta et al., 1993). However, as is the case with BD, the majority of RAS investigations 
are based on peripheral blood neutrophils as opposed to those found in saliva. According 
to work completed by Lakschevitz, et al, even HC oral and peripheral blood neutrophils 
behave differently. Based on microarray data, they found that HC saliva neutrophils RNA 
changed their transcriptome when they migrated from the blood to the oral environment 
(Lakschevitz et al., 2013). This alteration was especially evident during increased oral 
infection or inflammation such as in periodontal disease where oral neutrophils showed 
delayed apoptosis leading to extended activity in the mouth (Lakschevitz et al., 2013). It 
has also been suggested that neutrophils are already primed by chemotactic factors such 
as IL-8 or TNF-α by the time they reach the oral cavity (Nakahara et al., 1998). Although 
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some aspects of salivary neutrophil function, such as the reduced phagocytosis during 
acute ulceration, have been explored in RAS (Lukac et al., 2003), the role of neutrophil 
elastase and its inhibitors have not yet been elucidated.  Also, many previous studies 
frequently overlook sampling from RAS patients who do not have an ulcer or in other 
words are in a “quiet/quiescent” state. However, this is a very important group to 
investigate so that their typical state of immunity can be better understood.   
 
As a disease biomarker, NE levels may lack specificity (Heutinck et al., 2010), for 
instance, increased NE is found in the lungs of individuals with COPD (Stockley, 2002), 
but can also be found in large quantities at most tissue damaged sites since neutrophils 
will attend to wounds in order to combat invading microbes. However, investigating NE 
in combination with its innate regulatory factors, SLPI and α1AT, can help to provide a 
clearer understanding of their dual role in the progression of pathology since the 
regulation of NE may be key to understanding mucosal tissue damage in BD. It has been 
shown that SLPI dominates over α1-AT concentrations in sputum (Moreau et al., 2008). 
Similarly, in saliva, α1-AT has been found in significantly lower concentrations than 
SLPI (Cox et al., 2006) therefore SLPI is thought to be the main NE inhibitor in these 
biological fluids. Also, α1-AT does not completely inhibit elastin-bound NE in vitro 
(Morrison et al., 1990). The mucosal pathology seen in BD could involve α1AT and/or 
SLPI not being able to regulate NE effectively. In this study, it is hypothesised that an 
inadequate production or availability of SLPI and/or α1AT in the mucosal membranes 
and saliva of RAS and BD patients could perpetuate NE damage contributing to recurrent 
oral ulcerations.      
 
4.1.1.7. Theories on the Mechanism by which SLPI and α1AT Regulate NE: 
Forming Complexes 
It has been suggested that SLPI-NE complexes exist in lung epithelial cells in vitro 
(Sullivan et al., 2008). Stanley, et al, have suggested that the same complex is present in 
vivo in sputum supernatants from bronchiectasis patients (Chan et al., 2003). SLPI was 
shown to completely inhibit extracellular elastin-bound NE in vitro (Morrison et al., 
1990) or ECM-bound NE but has been described as being reversible particularly in the 
lungs where it is thought that α1-AT picks up the NE from the SLPI complex (Bingle and 
Tetley, 1996). The serpin α1-AT is described as being able to disassociate (or reverse) the 
SLPI-NE formation (Gauthier et al., 1982) and in turn the larger α1-AT protein traps NE 
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into an irreversible complex (Carrell et al., 1982). A proposal that SLPI is recycled has 
also been brought forth (Bingle and Tetley, 1996). This is supported by the general 
information on canonical inhibitors (such as SLPI) which theorises that its target 
proteases (such as NE) are complexed into tight, non-covalent interactions rendering the 
protease inactive by directly blocking its substrate active site (Krowarsch et al., 2003) 
(Moreau et al., 2008). It is thought that this newly formed structure can be disassembled 
because the inhibitor (SLPI) does not undergo conformational changes whereas the 
serpin-type inhibitor (α1-AT) does (Krowarsch et al., 2003). In Koizumi, et al’s, 
structural model of NE and the active carboxyl (C-)terminal of SLPI, 6 hydrogen bonds 
were found between the enzyme and inhibitor (Koizumi et al., 2008). These hydrogen 
bonds were sufficient to inhibit NE, but hydrogen bonds are weaker than ionic or covalent 
bonds. Therefore, their experiment further supported the theory that the NE:SLPI 
complex could be reversed.  
 
As briefly mentioned, there are different sites on the SLPI protein which are specifically 
attributed to its various inhibitory interactions. For instance, the anti-microbial and anti-
inflammatory capabilities are thought to be controlled by the amino (NH2 or N-) terminal 
(Hiemstra et al., 1996) coupled with SLPI’s strong cationic nature while the carboxyl 
(COOH or C-) terminal is associated with limiting protease activity (Doumas et al., 2005) 
Although the N-terminal doesn’t seem to have any anti-protease properties, it may assist 
with stabilizing the SLPI:NE complex (Doumas et al., 2005). The exact mechanism by 
which SLPI’s inhibits is unknown. However, what has been shown is that the primary 
binding loop for NE contact and inactivation occurs between Leu72 and Met73 on the 
SLPI protein (Grutter et al., 1988, Koizumi et al., 2008) and is sensitive to oxidation 
(Carp and Janoff, 1980). SLPI:NE specificity is thought to be due to the Tyr68 residue on 
SLPI (Koizumi et al., 2008). It is speculated that simultaneous interactions (anti-microbial 
and anti-protease binding or multiple protease binding at different sites as with trypsin 
and chymotrypsin) can occur on a single SLPI protein (Grutter et al., 1988) (Fig. 
4.1.1.7.1). This makes SLPI an importantly diverse, multitasking regulator of the immune 
system. 
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Fig 4.1.1.7.1. The Structure of SLPI Protein. The simplified structure of SLPI is shown 
indicating its 2 basic domains and associated activity: *indicates the reactive sites of 
domain 1 being anti-protease and domain 2 as the anti-microbial site. Its separate active 
sites may be able to inhibit proteases and microbes simultaneously. B. A schematic 
showing the linear configuration of domain 1, also refered to as the NH2-terminal and 
domain 2, the COOH-terminal. The connecting horizontal bars indicate the four disulfide 
bonds in each WAP domain creating a very stable structure. Images reproduced with 
permission from Zani, et al, 2009 (Zani et al., 2009). 
 
 
 
 
 
 
 
 
A. 
B. 
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Alpha1-Antitrypsin has a reactive centre loop (RCL) which is located on a methionine 
residue at position 358 which is 37 residues from the C-terminus (Carrell et al., 1982, 
Dickens and Lomas, 2011). This RCL acts as a pseudosubstrate for the active site of 
proteinases, such as NE, so that there is a 1:1 bond of inhibitor and target. Once the 
protease is bound, it is moved from one end of the α1AT molecule to the opposite end by 
way of the RCL being cleaved and inserting itself amongst the β-sheets as demonstrated 
in Figure 4.1.1.7.2 thus trapping the protease in a covalent bond  (Carrell et al., 1982, 
Gavrin et al., 2012b, Korkmaz et al., 2008b). Usually, phagocytic cells then clear away 
the inactive complex. Initially, there was doubt that α1AT was a specific inhibitor for NE 
since valine or alanine are preferred elastase cleavage sites as opposed to methionine. 
However, there were two main indications for α1AT being defined as the primary 
inhibitor for NE. The first was that its rate at which it acted to inhibit NE was faster than 
all its other enzymes targets (such as chymotrypsin and Cathepsin G). Second, was the 
fact that α1AT-deficient models lost lung elasticity due to unregulated elastase (Carrell et 
al., 1982).  
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Fig. 4.1.1.7.2. The Protein Structure of α1AT and its Binding to NE. A. The stable, 
inactive α1AT with extended reactive centre loop (RCL), depicted in red, protrudes from 
the main structure attaching to the active region of the NE molecule. B. The subsequent 
movement of the RCL from upper to lower pole position permanently inactivates both 
proteins. The RCL becomes an additional strand in the beta-sheet A in green (the image 
above was reproduced with permission from Lomas, et al, (Lomas, Belorgey et al. 2005) 
which was remodelled from an original image by Gooptu, et al, (Gooptu et al., 2000) for 
which there is open permission from the Proceedings of the National Academy of 
Sciences of the USA.  
 
 
 
 
 
 
 
 
RCL 
RCL 
A. B. 
NE 
NE 
α1AT 
α1AT 
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The main mechanism of NE delivery consists of the release of primary azurophil granules 
into an internal phagolysosome where the microbe is degraded under controlled 
conditions. To a lesser degree, exocytosis of the primary azurophil granule into the 
extracellular spaces can occur (Kessenbrock et al., 2011). However, extracellular NE does 
not entirely disassociate itself from its originating cell as there is evidence that it is also 
found on the outer neutrophil surface (Korkmaz et al., 2008b) (Owen et al., 1995) (Allen 
and Tracy, 1995) where SLPI can bind and inhibit the protease (Zani et al., 2009). While 
bound to each other, SLPI and NE are thought to be cleared by phagocytic cells in vivo 
(Travis, 1988). SLPI can also help control neutrophil apoptosis and clear the leakage of 
cellular enzymes (Travis, 1988) thereby dampening the cyclic effect of inflammation. In 
lung epithelial cells, it has been shown that NE can up-regulate the expression of SLPI 
(Sallenave et al., 1994) which is able to directly assist with controlling infecting microbes 
as well as regulate excessive NE. There is strong evidence of the intracellular presence of 
active SLPI and α1AT in neutrophils; SLPI has been found in the cytosol and secondary 
granules in low concentrations (Jacobsen et al., 2008, Sallenave et al., 1997) while α1AT 
has been discovered in all neutrophil granules (Clemmensen et al., 2011). This would 
suggest that neutrophils evolved so that their potentially destructive elastase could be 
regulated from within their own cytosolic environment. SLPI and α1AT may play a 
protective role, on this occasion, within the internal neutrophil environment. A 
comprehensive list of NE, SLPI and α1AT’s characteristics and functions are summarised 
in Table 4.1.1.7.1 and Table 4.1.1.7.2.   
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Table 4.1.1.7.1.  Summary of NE Characteristics  
 
 
 
 
 
 
Details NE 
Protein Accession Number P08246 
Molecular weight, Molecular 
mass (Protein size) 
29,500 g/mol or 29.5 kDa 
Amino acids 267 (including signal, propeptide, and chain) 
Isoelectric point 10.5 (Korkmaz et al., 2008b, Heutinck et al., 
2010) or 10.8 (Travis, 1988), cationic 
Glycosolation Glycosolated (3 sites) 
Structure Single chain glycoprotein 
Disulfide bonds 4 
Protein family Serine protease, chymotrypsin family (Korkmaz et 
al., 2008b) 
Main functions Degrades  microbes; damages elastin and ECM 
components; activation of antimicrobial peptides 
(LL-37) 
Substrate Target Cleaves after small hydrophobic residues (i.e. 
valine) (Heutinck et al., 2010). Active site is 
composed of histidine (residue 70), aspartate 
(residue 117), and serine (residue 202) which are 
brought together in a tertiary structure (Korkmaz 
2008).   
Site for Inhibitors to Bind Binds to SLPI mainly between the NE amino acid 
region 214-217 (Koizumi et al., 2008) 
Inhibited by Inhibited by serum α1-AT in the lungs and 
vascular circulation (Gadek et al., 1981), SLPI and 
elafin present in salivary glands (Lee et al., 2002), 
and  α2-macroglobulin 
Cells containing the protein  Mainly neutrophils (Takahashi et al., 1988), 
monocytes (Campbell et al., 1989), mast cells, 
eosinophils (Lungarella et al., 1992) 
Cells producing mRNA  Bone marrow myelocytic 
progenitor cells (early stage of granulocyte 
development) (Takahashi et al., 1988) (Korkmaz 
et al., 2008b)  
Intracellular/ 
Extracellular 
Both intracellular (in azurophil and 
phagolysosome) and extracellular free or bound 
Location in cells Inside primary azurophilic granules (alongside 
Cathepsin G and Proteinase 3) 
Protein Homology Cathepsin G (35 %) (Hajjar et al., 2010) 
Proteinase 3 (56 %) (Hajjar et al., 2010) 
Azurocidin (Korkmaz et al., 2008b) 
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Details SLPI α1AT 
Protein Accession 
Number 
P03973 P01009 
Molecular weight, 
Molecular mass 
(Protein size) 
Native form: 11,726 g/mol or 11.7 kDa; In 
vitro epithelial cell lines, ~10-14 kDa 
(Sallenave et al., 1997) 
51 kDa (Carrell et al.), 52 kDa (Clemmensen 
et al., 2011), or 55 kDa (Gavrin et al., 
2012a) 
Amino acids 132  418  (Isoform 1 of a possible 5 being the 
most common) made up of 394 aa + 24 aa 
signal peptide (Carrell et al., 1982, Jeppsson 
and Franzen, 1982) 
Isoelectric point 11, cationic, basic 4.4 - 4.7, anionic (Jeppsson and Franzen, 
1982) 
Glycosolation Non-glycosylated N-Glycosolated (3 sites) 
Structure Hydrophobic, acid-stable, single polypeptide 
chain. Boomerang-like shape, each arm 
having 1 structurally homologous domain 
(Domain 1: NH2-terminal or Domain 2: 
COOH-terminal).  
One polypeptide chain with 3 carbohydrate 
side chains (Carrell et al.) referred to as the 
β-sheets and exposed reactive centre loop 
that can relocate  
Disulfide bonds 8 None 
Protein family Chelonianin family, Whey acidic protein 
(WAP) 
Serine proteinase inhibitor (Serpin)  
Main functions Inhibits NE and has   
anti-microbial activity.  
Irreversibly inactivates NE 
Main target and site of 
inhibition activity  
Inhibits NE by utilizing the SLPI amino acid 
region 84-132 (C-terminal). Active residue: 
Leucine position 72 and Methionine 73 
(Rudolphus et al., 1991) (Koizumi et al., 
2008)  
Reactive centre loop at position 358 (Carrell 
et al., 1982) 
Other targets to inhibit Inhibits cathepsin G, trypsin, tryptase, 
(pancreas-derived) chymotrypsin, chymase. 
Inhibits cathepsin G, proteinase 3, trypsin, 
chymotrypsin, thrombin (van 't Wout et al., 
2012) 
Cells containing the 
protein  
Mucosal and oral epithelial cells, secretory 
acinar cells in salivary glands (Ohlsson et al., 
1984), macrophages, neutrophils (Korkmaz et 
al., 2008b), tracheal & bronchial cells, lung 
monocytes (Sallenave, 2000), dermal 
keratinocytes, intestinal goblet-type epithelial 
cells (Bergenfeldt et al., 1996) 
Hepatocytes, neutrophils, monocytes 
(Mornex et al., 1986), alveolar macrophages 
(Perlmutter et al., 1985) and freely roaming 
within plasma/serum 
Cells producing 
mRNA  
Same as list above including oral buccal 
epithelial cells (Nittayananta et al., 2013a), 
tonsillar mast cells (Westin et al., 1999b), 
serous nasal glands (Westin et al., 1994), 
chondrocytes in human articular cartilage 
(Ohlsson et al., 1997) 
Hepatocytes, neutrophils, blood monocytes, 
alveolar macrophages  (Mornex et al., 1986) 
Intracellular/ 
Extracellular 
Mainly inhibits in extracellular spaces; but can 
be found intracellularly 
Mainly inhibits in extracellular spaces but 
can be found intracellularly 
Location in cells In neutrophils, inside secondary granules and 
the cytosol (Jacobsen et al., 2008) 
In neutrophils, inside azurophil, specific, and 
gelatinase granules as well as secretory 
vesicles (Clemmensen et al., 2011).  
In hepatocytes, processed by the 
endoplasmic reticulum and transported out 
to serum 
Protein Homology Elafin (42 %) Ovalbumin (30%), Antithrombin-III (29%) 
(Carrell et al., 1982) 
 
Table 4.1.1.7.2.  Summary of SLPI and α1AT Details  
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4.1.1.8. SLPI as a Potential Therapeutic Agent 
Recombinant (r)SLPI has been put forth as a potential therapeutic entity due to its proven 
in vitro anti-bacterial (Escherichia coli and Staphylococcus aureus) (Hiemstra et al., 
1996), anti-fungal (Candida albicans) (Tomee et al., 1997), and anti-viral (HIV) 
(McNeely et al., 1995) functions. SLPI regulation of excessive and potentially damaging 
NE has also made it an important protein to explore for treatment purposes (Tomee et al., 
1998). Inhaled administration of rSLPI has been shown to reduce NE and IL-8 levels in 
the inflamed lungs of cystic fibrosis sufferers (McElvaney et al., 1992) (McElvaney et al., 
1993). Aerosolised rSLPI was shown to be stable in epithelial lung fluid of sheep after 6 
hrs in vivo (Gillissen et al., 1993). If excess NE is shown to cause oral mucosal damage, 
rSLPI could be considered for use as a preventive or acute treatment for oral ulcers. Its 
known functions of influencing wound healing (Sumi et al., 2000), its anti-microbial 
ability, and its NE regulation make this protein an ideal candidate for those who suffer 
with oral ulcers.   
 
4.1.1.9. α1AT as a Potential Therapeutic Agent 
Current α1AT therapy centres either on intravenous replacement for individuals suffering 
with α1AT-deficiency affiliated COPD (Miravitlles, 2012) or inhaled α1AT protein 
dissolved in buffer for cystic fibrosis (CF) treatment (Griese et al., 2007). The inhaled 
α1AT treatment, Prolastin® (Bayer Corp, USA), significantly reduced the number of 
neutrophils in CF patients sputum along with pro-inflammatory markers such as IL-8, IL-
1β, and TNF-α (Griese et al., 2007). Again, if excess NE is shown to cause damage to the 
oral mucosa, there is potential for topical α1AT administration to prevent or treat oral 
ulcers. However, a possible disadvantage may be oxidation of the α1AT by reactive 
oxygen species generated by oral phagocytic cells and bacteria species thus rendering the 
protein ineffective (Matheson et al., 1979). An alternative human NE inhibitor, EPI-
hNE4, was specifically constructed to resist oxidation due to its lack of methionine 
residues. It was developed by Diax Corporation (Cambridge, USA) in conjunction with 
Debiopharm (Switzerland) and was successfully tested in vitro using healthy blood 
neutrophils and CF sputum for anti-NE activity, but has not yet undergone testing in vivo 
(Attucci et al., 2006). 
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Other low molecular weight NE inhibitors are already available on the market such as 
Sivelestat (market name Elaspol
®
, Ono Pharmaceutical Co., Ltd.) for acute lung damage 
due to inflammation, but is only available in Japan and South Korea (Lucas et al., 2011). 
AZD9668 (AstraZeneca, UK), another reversible NE inhibitor drug, has been trialled on 
those with CF (Elborn et al., 2012) and COPD (Vogelmeier et al., 2012), but failed to 
show significant improvement when analysing lung function. In Elborn, et al’s, clinical 
trial, the sputum neutrophil counts and elastase activity were no different in cystic fibrosis 
patients receiving the drug (Elborn et al., 2012), however the IL-6 inflammatory marker 
was significantly reduced in sputum. Recently in 2013, a small, UK-based Phase II trial 
found that bronchiectasis patients treated with AZD9668 did show improved lung 
function, but still had the same numbers of neutrophil in sputum (Stockley et al., 2013). 
The capacity for these treatments to work systemically in those with vascular 
inflammation and mouth ulcers has not been explored.        
 
4.1.1.10. SLPI Gene Expression 
Previous studies have shown increased expression of human SLPI mRNA in cultured 
primary bronchial epithelial cells (van Wetering et al., 2000), serous glands in the nasal 
mucosa (Westin et al., 1994), and saliva glands of healthy versus HIV-infected people 
(Wahl et al., 1997a) using Northern blot analysis. However, more recently, QPCR has 
been utilized to measure SLPI mRNA in different cell types. An increased expression was 
measured in inflamed tissue from human colonic biopsies (Schmid et al., 2007) and in 
cells harvested from cultured post-mortem human airway submucosal glands stimulated 
with NE (Saitoh et al., 2001). Normal gingival epithelium and immortalized foetus buccal 
mucosa have also shown upregulated SLPI mRNA when exposed to purified HIV-1 viral 
lysate (Jana et al., 2005).  
 
To date, no gene polymorphism or genetic SLPI deficiency associated with a disorder has 
been described (Vogelmeier et al., 1996). As mentioned previously, a single nucleotide 
polymorphism (SNP) of the α1-AT gene has been found to be associated with lung 
emphysema, liver disease, and anti-proteinase 3 antibody-positive vasculitis (Stoller and 
Aboussouan, 2005). SLPI has yet to be characterised or measured in BD and RAS. In this 
study, the sensitive RT-qPCR technique will measure SLPI mRNA from adult human oral 
buccal mucosa epithelial cells in normal healthy individuals and those with BD and RAS 
during and in between oral ulceration presentation. This will help to clarify if there are 
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abnormal SLPI mRNA levels present in BD or RAS patient and whether their epithelial 
cells respond to an ulcer with an upregulation of SLPI to regulate NE.  
 
4.1.1.11. Inhibitor Inactivation and Other Regulatory Factors to Consider  
Just as NE concentrations are controlled, SLPI and α1AT are also subjected to regulation. 
SLPI can be cleaved and inactivated by Cathepsins B, L, and S cysteine proteases if they 
are released from eukaryotic cell lysosomes (Taggart et al., 2001). SLPI is also 
inactivated by chymase, a serine protease, suggesting an in vivo feedback mechanism of 
regulation (Belkowski et al., 2009). Cathepsin B has been measured in saliva and gingival 
crevicular fluid (GCF) of persons with periodontitis but was found be present at a much 
lower concentration than SLPI or α1AT (Cox et al., 2006). Cathepsin L has also been 
measured in saliva (Mirzaii-Dizgah and Riahi, 2011) and can act as a potent elastase 
(Chapman et al., 1994). Similar to NE and Cathepsin B, Cathepsin L has the potential to 
degrade various ECM components (Dickinson, 2002). However, Cathepsin B and L are 
intracellular lysosomal enzymes and therefore have an optimal activity in low pH (3-6.5). 
If they are released from cells and in a neutral or alkaline pH environment, these enzymes 
are unstable and permanently deactivated (Dickinson, 2002). This would reduce their 
digestive capabilities in the oral extracellular environment which is bathed in saliva with 
a pH normally around 6-7 (Humphrey and Williamson, 2001b) creating an opportunity 
for released NE to degrade ECM instead. Cathepsin S, another SLPI inhibitor with similar 
structure to Cathepsin B and L, has been shown to be stable with 25% of its optimal 
elastase activity at pH 7-8 in vitro (Shi et al., 1994, Shi et al., 1992) so could conceivably 
contribute to both the breakdown of ECM and the inhibition of SLPI. However, the level 
of Cathepsin S in the oral cavity is unknown as it is mainly expressed by antigen 
presenting cells such as alveolar macrophages and has a high concentration in the spleen 
(Shi et al., 1994). Finally, chymase can be found in sputum as it is most likely released 
from lung and oral mast cell granules. SLPI can inhibit chymase but it has also been 
shown in vitro that chymase can cleave SLPI as if it were its substrate. With all of these 
potential salivary SLPI inhibitors, it is still not known if the cleavage of SLPI occurs with 
an unbound or complexed SLPI molecule.  
 
α1AT can be inactivated by neutrophil-derived collagenase (Michaelis et al., 1990), 
metalloproteinases (Vissers et al., 1988), and reactive oxygen species (ROS) (Rosenberg 
et al., 1984) (Vignola et al., 1998) all of which may be present extracellularly in the 
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mouth. SLPI is also susceptible to inactivation by oxidants (Heinzel-Wieland et al., 1991), 
heat (Gomez et al., 2009), and cigarette smoke (Cavarra et al., 2001). SLPI’s antibacterial 
activity can withstand an acidic pH of 4.5 (Gomez et al., 2009) but its antiprotease 
activity is not known at very low pH. α1AT’s ability to inhibit NE is severely reduced at 
low pH (Schonberg et al., 2012). 
 
α1AT can inhibit Proteinase 3 while both SLPI and α1AT can inhibit Cathepsin G. These 
proteases have similar capabilities of degrading elastin, collagen and proteoglycan as NE 
but are kinetically slower and therefore considered inefficient. It is for this reason that 
they have not been directly implicated in tissue damage (Travis, 1988, Reilly and Travis, 
1980). Thereby, Proteinase 3 and Cathepsin G were not chosen as part of the primary 
investigation to the underlying cause and reoccurrence of ulcers, but could still potentially 
play a minor role.  
 
4.1.2. Hypothesis  
The hypothesis of this study is that excessive NE in the mouth is contributing to the cyclic 
inflammation and the oral ulcerative pathology in both BD and RAS disorders. NE’s 
proteolytic activity in saliva and on the mucosal epithelium may be contributing to oral 
tissue damage leading to an ulcer. The two main NE inhibitors, SLPI and α1AT, may be 
depleted and therefore not able to regulate excessive NE effectively.  
 
4.1.2.1. Objectives: 
1. Determine the concentration of NE, SLPI, and α1AT in saliva from HC compared 
to BD and RAS patient groups with and without oral ulcers 
2. Investigate the activity of NE in saliva and its interaction with various inhibitors 
3. Investigate NE, SLPI, and α1AT protein and complexes in saliva specimens using 
western blot 
4. To identify the location of these proteins in oral mucosal tissue biopsies at the site 
of ulceration and surrounding the wound 
5. Measure the mRNA of SLPI in HC, BD, and RAS patients’ oral buccal epithelial 
cells 
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4.2. Materials and Methods 
4.2.1. Western Blots for Detecting NE, SLPI, and α1AT Proteins 
4.2.1.1. Preparation of Samples and Positive Controls for Gel Electrophoresis 
Saliva and isolated OBS protein aliquots were defrosted from the –80oC and kept on ice. 
The saliva samples had their total protein previously quantified so that the same 
concentration could be added into each well on the gel. A final volume between 10-25 µl 
would be added per well including loading and reducing buffers.  
Known concentrations of the positive control were run alongside the samples on the same 
gels. For SLPI assays, the positive control selected was an E. coli-derived (Ser26-Ala132) 
12 kDa recombinant human SLPI protein (R&D Systems, UK). The NE positive control 
consisted of the full length 29.5 kDa native, active NE protein isolated from human 
neutrophils (Abcam, UK). The α1AT positive control was an in-house preparation of the 
A549 lung carcinoma epithelial cell line protein extract.  
Saliva and OBS samples were prepared in a 1X final volume mixture with NuPage 4X 
LDS sample buffer (Life Technologies, UK) and NuPage dithiothreitol (DTT)-based 10X 
Reducing Agent (Life Technologies, UK). This sample mixture was then heated at 70
o
C 
for 10 min to reduce the proteins before loading onto the gel. Commercially purchased 
positive control proteins did not have DTT reducing buffer or heat-treatment as as this 
caused adverse degradation. The gels were NuPAGE
®
 Novex 4-12%, 10% or 12% Bis-
Tris gels, 1.5 or 1.0 mm thickness, 10 or 12 wells (Life Technologies, UK). At least one 
lane with the Full Range Rainbow Marker 12-225 kDa (GE Healthcare, UK) was always 
included on the gels. The gels were run at 70 Volts (V) for 2 hrs or 100 V for 1 hr with 
the 1X NuPage
®
 MES SDS Bis-Tris Running Buffer recommended for small MW 
proteins. The visible rainbow marker allowed the travelling proteins to be monitored 
while running the gel. 
4.2.1.2. Transference of Proteins to Western Blot Membrane 
Fifteen minutes prior to completion of the run, 2 large, shallow plastic dishes were 
arranged: one containing approximately 10 ml of 100% methanol and the other distilled 
water (dH20). Polyvinylidene difluoride (PVDF) membranes were cut taking great care 
not to touch the membrane to an average dimension of 9 x 7 cm for the protein transfer 
from the gel to the membrane. For SLPI, PVDF Immobilon-P
SQ
 membranes with a pore 
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size of 0.2 µm were used in order to capture small proteins less than 20 kDa while PVDF 
Immobilon-P membranes with a pore size of 0.45 µm (Millipore, UK) was utilized for 
NE to capture proteins greater than 20 kDa. Secondary fluorescent antibodies were tested 
as well, but PVDF Immobilon-FL membrane was used instead in order to avoid a dark 
background. For all experiments, the PVDF membrane was soaked in 100% methanol for 
15 sec to activate and then placed into the dH20 for 5 min followed by a soak in blotting 
buffer for 10 min. The blotting buffer, was also the transfer buffer, and was made up of 
0.3 % Trizma (Tris) base (Sigma, UK), 1.4 % glycine (Sigma, UK), 20 % methanol 
(VWR, UK), and dH20 made up to a 1 L final volume. Subsequently, two white 
absorbance filter paper supports were also cut to a similar size to that of the membranes 
and placed in the blotting buffer for 10 min alongside the membranes. The corners of the 
membranes were handled by clean, flat-tipped tweezers. 
When the gel run was complete, the gel cassette was removed and opened with a flat 
spatula in a shallow bath of blotting buffer. The remnants of the wells were delicately 
trimmed as well as the bottom part of the gel connecting it to the cassette. A gel-
membrane transfer sandwich was assembled from “bottom to top” starting with a plastic 
cassette (as the backbone), followed by a thick pre-soaked blotting pad, 1 of the pre-cut, 
pre-soaked filter paper inserts, then the gel and PVDF membrane laid on top without 
bubbles, and then another filter paper, blotting pad, and top half of the plastic cassette. 
These layers were clipped together and slotted tightly into a transfer tank filled with 
blotting buffer and a plastic-enclosed ice block to keep the tank from overheating. The gel 
was placed on the side closest to the negative cathode as the current passed towards the 
positive anode carrying with it the negatively-charged proteins across the membrane. 
Electrophoresis was carried out at 200 mA constant current for 1 hr.  
4.2.1.3. Blocking Buffer 
When the transfer of proteins was complete, as verified by the rainbow marker and 
loading dye transferring successfully to the membrane, the casette was disassembled and 
the PVDF membrane was removed and placed into a small clean dish containing 
approximately 10 ml of blocking buffer, enough so that the solution covered the 
membrane, consisting of 5% non-fat milk prepared from powder (for NE membranes) and 
5% goat serum (for SLPI) membranes in 1X PBS with 0.05% Tween-20 (Sigma, UK). 
Membranes were blocked overnight at 4
o
C with gentle agitation.  
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4.2.1.4. Washing Membranes  
Blocking buffer was discarded after use and the membrane was washed by gentle 
agitation for 10 min with 1 X Tris Buffer Solution (TBS) wash buffer consisting of a final 
concentration of 0.1 M Tris-HCl solution, 0.9% NaCl, 0.1% Tween-20 in dH20 adjusted 
to pH 7.5 with hydrochloric acid (HCl). The membrane wash was repeated 3 times.  
4.2.1.5. Western Blotting for SLPI 
4.2.1.5.1. Primary SLPI Antibody 
After extensive optimisation in our laboratory, the most sensitive and specific SLPI 
primary antibody (1
o
Ab) that was utilized for the western blot was a goat, anti-human 
polyclonal (R&D Systems, UK) diluted to 1:500 (equivalent to 1 ng/µl). The primary 
antibody was diluted in 3% BSA in PBS with 0.05% Tween-20. The membrane was 
incubated for an hour at room temperature. The membrane was washed 3 times with TBS 
buffer before addition of secondary antibody. 
4.2.1.5.2. Secondary SLPI Antibody 
An optimised 1:3000 dilution of the secondary antibody, a horseradish peroxidase (HRP) 
stabilized donkey, anti-goat IgG conjugate (R&D Systems, UK) was used to detect SLPI. 
The secondary antibody was prepared in the same diluent buffer as the primary, 3% BSA 
in 1X PBS with 0.05% Tween-20 and incubated with the membrane for 1 hour at room 
temperature with gentle agitation. 1X TBS buffer was used to wash the membranes 3 
times for 10 min where the wash buffer was changed in between washes.  
4.2.1.6. Western Blotting for NE 
4.2.1.6.1. Primary NE Antibody 
For the NE target, monoclonal mouse IgG1 primary antibody (Clone 265-3K1) which 
was protein G purified was directly conjugated to a HRP label using Lightening-Link® 
according to the manufacturer’s protocol. (Innova Biosciences, UK). Briefly, in a clean 
eppendorf tube, 1 µl of the LL-Modifier kit reagent was mixed with every 10 µl of 
antibody to be labelled, in this case, 10 µl of LL-Modifier to 100 µl of neat 0.1 µg/µl NE 
antibody. The total amount of antibody in the mix was 10 µg. This solution was then 
transferred to a vial with the set amount of lyophilized HRP (10 µg) with gentle mixing 
using a pipette. The final ratio was 1:1 (10 µg HRP: 10 µg Ab). After the antibody and 
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HRP solution were incubated for a minimum of 3 at RT, 1 µl of LL-Quencher was added 
for every 10 µl of antibody used therefore 10 µl of Quencher was added in our 
experiments. After 30 min at RT, the HRP-labelled antibody was ready to be utilised. To 
store it long term, aliquots were place in the -80
o
C for future experiments. 
An optimised dilution of 1:500 of NE-HRP antibody was prepared in a diluent solution 
consisting of 5% goat serum in PBS with 0.05% Tween-20 and incubated for 1 hr at room 
temperature. Afterwards, TBS wash buffer was used to wash the membranes 3 times for 
10 min each session.  
4.2.1.7. Western Blotting for Beta-Actin  
Even though the samples that were used for the westerns had their total protein 
quantified, beta(β)-actin (42 kDa) was also used as an additional loading control. Probing 
for this antigen on the same membrane was conducted after the initial target (SLPI, NE, 
α1AT) was developed, detected, and washed.  
4.2.1.7.1. Human Beta-Actin Primary Antibody 
The rabbit polyclonal β-actin antibody (Abcam, UK) was diluted 1:4000 in 3% BSA in 
PBS with 0.05% Tween-20 and incubated with the membrane for 1 hr at RT. Afterwards, 
it was washed thoroughly using the protocol described above.  
4.2.1.7.2. Beta-Actin Secondary Antibody 
The secondary antibody was a goat, anti-rabbit (Thermo Scientific, UK) diluted at 
1:1200. The membrane was gently agitated for 30 min to 1 hr at RT and then washed 
three times. The protein bands were visualised using electrochemiluminescence (ECL) 
detection as described below.  
4.2.1.8. Development and Detection Using the Dark Room ECL Method       
Solutions A and B from the ECL Plus Western Blotting Substrate kit (GE Healthcare, 
UK) were equilibrated to RT before use. The western blot membrane was drip dried from 
the corners to remove excess fluid after the last wash and laid across a 20 x 20 cm clean 
pliable plastic sheet (tear-proof). The sheet was laid out flat to create a surface area on 
which to incubate the membranes with the developing fluid. Detection solution A and B 
were combined at a 40:1 ratio into a clean universal vial. The volume added to a 9 x 7 cm 
membrane differed depending on the protein target (see Table 4.2.1.8.1).  
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Reaction 
Component 
SLPI NE β-actin 
Detection 
Solutions and  
Volume Required 
A: 1 ml 
B: 0.025 ml 
A: 1 ml 
B: 0.025 ml 
A: 2 ml 
B: 0.050 ml 
Time Incubated 2 min 3 min 5 min 
Table 4.2.1.8.1. ECL Detection Solution and Incubation Time per Membrane. The 
volume and incubation time for each protein target was optimised to produce the protein 
bands without a dark background.   
Once mixed, the detection solution was pipetted on top of the membrane ensuring that the 
entire area received full coverage. During the incubation time (detailed in Table 
4.2.1.8.1), the solution was evenly distributed on the membrane by picking up the sturdy 
plastic sheet underneath and agitating the liquid. At the end of the incubation period, a 
corner of the membrane was picked up with flat-tipped tweezers and excess reagent 
allowed to drain. Next, the membrane was placed on a new, clean plastic sheet which was 
folded over to enclose the membrane. Air bubbles were gently pressed out from between 
the plastic sheet and the membrane. The membrane enclosed in the plastic sheet was then 
fixed with tape to the inside of a development cassette. Inside the dark room a piece of the 
hyperfilm (Amersham, GE Healthcare, UK) was cut to approximately the same size as the 
membrane and placed in the cassette on top of the plastic-enclosed membrane. The 
cassette was closed and left for between 1-5 min for the image to develop. Afterwards, 
the hyperfilm was placed into the development machine after which the resulting 
hyperfilm image was laid on top of the plastic protected membrane and aligned with the 
rainbow ladder in order to mark the exact placement of each kDa band size.  
4.2.2. Enzyme-Linked Immunosorbent Assays 
4.2.2.1. Recovery Assays for SLPI, NE and α1AT ELISA’s 
The validity of each ELISA assay was completed for quality assessment and 
determination of a recoverable target protein in the presence of human saliva. This was 
completed by adding a known quantity of purified target protein from the standard 
provided by each kit such as rSLPI into the specimen being assayed. A starting dilution of 
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1:200 for saliva was spiked with 800 pg of rSLPI, 5 ng of NE, or 50 ng of α1AT. These 
spike concentrations were chosen as they were within mid-range of their ELISA’s 
standard curve. A 1:2 dilution series of the spiked sample was prepared (1:400, 1:800, 
1:1600). The saliva sample alone (without any spike) and the purified protein alone were 
measured separately and their combined concentration was compared to the spiked 
sample. According to the R&D Systems protocol, acceptable recovery should be within a 
range of 80-120%. SLPI ELISA’s recovery of the spike in saliva was within the 
acceptable range of 89-99% (average 94.1%) for all four dilutions. The a1AT ELISA 
recovery ranged from 70-127% (average 100.96%), the lower recovery being in some of 
the 1:200 dilutions which means it was perhaps too concentrated. And finally, the NE 
ELISA which was able to determine an accurate 90-99 % (average 95.5%) recovery in 
three of the four dilutions, only the 1:1600 being too dilute. 
 
4.2.2.2. The Levels of NE, SLPI, and α1AT in Saliva: ELISA Assays 
Enzyme linked immunosorbent assays (ELISA) were used to measure human SLPI, 
(Quantikine
®
 immunoassay, R&D Systems, UK), human neutrophil elastase (HyCult 
Biotech kit, The Netherlands), and human alpha1-antiTrypsin (GenWay Biotech, USA). 
Some of the saliva supernatants were completed on the same day for SLPI and NE assays. 
Also, a few patients samples were repeated (to check accuracy and stability of the assay’s 
measurements) however newly defrosted saliva aliquots were always used. Samples and 
standards were run in duplicate. Due to a high amount of protein in saliva, the samples 
were diluted 1:200 in diluent buffer specific for each kit and 100 µl added to each well. 
Blank control wells with the same diluent buffer were included to subtract absorbance 
background. The number of saliva samples tested in each patient group is summarised in 
Table 4.2.2.2.1.  
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Table 4.2.2.2.1. Patient Saliva Sample Size (n) Tested on ELISA 
 
 
 
 
Patient Group / 
Mouth Activity 
SLPI  (n) NE (n) α1AT (n) 
BDa 52 50 27 
BDq 56 57 28 
HC 49 55 17 
RASa 15 12 3 
RASq 11 10 5 
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4.2.2.2.1. Human SLPI Immunoassay 
SLPI ELISA (Quantikine
®
, R&D Systems, UK) was performed as stated in the 
manufacturer’s guide. Briefly, SLPI standard was reconstituted in 5 ml of calibrator 
diluent which provided a stock of 4000 pg/ml – the highest standard concentration on the 
plate. A 1:2 series dilution was completed down to 62.5 pg/ml. Calibrator diluent alone 
was also included. 100 µl of assay diluent was added to each well (which was pre-coated 
with capture antibody by the company) followed by 100 µl of the diluted saliva samples 
and standards. The plate was sealed with an adhesive plate cover and incubated 
undisturbed for 2 hours at room temperature (RT). Each well was then washed with 400 
µl of 1X wash buffer (supplied by the kit) using a repeat pipette dispenser. The wash 
buffer was removed by inverting the plate into a sink. This was repeated another two 
times and after the last wash, the plate was inverted and blotted against a paper towel to 
remove excess moisture and any bubbles. 200 µl of SLPI conjugate (polyclonal anti-
human antibody conjugated with horseradish peroxidase) was then added to each well, 
the plate was covered, and incubated for 2 hrs at RT. The same wash procedure was 
followed. 200 µl of substrate solution (colour reagent A, hydrogen peroxide, and B, the 
chromogen tetramethylbenzidine (TMB) previously combined in equal volumes) was 
added to each well and the plate was incubated in the dark for 20 min. 50 µl of 2N 
sulfuric acid stop solution (2N H2SO4) was then added to each well and the absorbance 
was read within 30 min at 450 nm with a secondary reading at 570 nm for wavelength 
correction using the OPTIMA Microplate Reader (BMG LabTech, Germany). The 570 
nm was subtracted from the 450 nm reading. Absorbance results from the samples and 
rSLPI standards were correlated to create a standard curve in order to interpret the sample 
protein concentrations.   
 
4.2.2.2.2. Human Elastase Kit  
Saliva samples were thawed on ice before being diluted 1:200 using the NE ELISA 
(HyCult Biotech, The Netherlands) kit’s diluent buffer. The NE standard was 
reconstituted with dH20 as specified by the manufacturer. A 1:2 standard dilution series 
was prepared for a final concentration range between 0.4 – 25 ng/ml. 100 µl of both 
standards and samples were added to the wells (which were pre-coated with capture 
antibody) in duplicate on the 96-well plate provided. Blank wells were also included with 
dilution buffer alone to subtract background absorbance. An adhesive cover was applied 
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to the plate and the plate was incubated for 1 hr at RT. After which the plate was inverted 
over a sink and the liquid decanted. Each well was washed 4 times with 200 µl 1X wash 
buffer. The plate was inverted again and blotted on paper towels and 100 µl of diluted 
tracer was added to each well, an adhesive cover applied to the plate, and incubated for 1 
hr at room temperature. The same wash procedure was completed. 100 µl of streptavidin-
peroxidase was added to each well. The plate was covered, and incubated for 1 hr at room 
temperature then washed again 4 times. 100 µl of TMB (Sigma, UK) was then added to 
each well. The plate was covered and incubated for 20 min in the dark at room 
temperature after which 100 µl of stop solution 2N H2SO4 was added. The plate was read 
within 30 min at 450 nm absorbance. All NE concentrations were determined from a 
standard curve generated by the absorbance of the dilution series. Background was 
subtracted from the standards and sample values. 
 
4.2.2.2.3. Human Alpha1-AntiTrypsin  
The capture antibody provided in the kit (GenWay Biotech Inc., San Diego, CA, USA) 
was diluted 1:1000 in 0.05 M carbonate-bicarbonate solution (pH 9.6) and 100 µl was 
added to each 96 well of a NUNC absorbent plate. After incubating overnight at 4
o
C, 
fluid was discarded and each well was washed three times by adding 300 µl wash solution 
(0.05% Tween 20 in PBS, pH 7.4) and decanting. 200 µl Blocking solution (50 mM Tris, 
0.14 M NaCl, 1% BSA, pH 8) was then added and the plate was incubated for 1 hour at 
RT followed by another wash step. Saliva samples were defrosted and diluted 1:200 in 
diluent buffer consisting of same constituents as the blocking solution but with 0.05% 
Tween-20. (Serum samples were diluted 1:100,000 since α1AT has been reported as 
having a high concentrated in serum (Mornex et al., 1986)). Standards were also prepared 
in a 1:2 dilution series from 90 – 1.4 ng/ml. Duplicate wells each with 100 µl of diluted 
sample, standards, or diluent buffer alone were added to the appropriate wells and 
incubated for 1 hr at RT. Wells were then washed 5 times. Detection antibody HRP was 
diluted 1:2500 and 100 µl was added to each well, incubated for 1 hr at RT, followed by 5 
washes. To each well, 100 µl TMB enzyme substrate was added and the plate kept in the 
dark for about 15 min. To stop the reaction, 100 μl of 2M H2SO4 was pipetted to each 
well. Subsequently, the absorbance values at 450 nm were read on the OPTIMA plate 
reader (BMG LabTech, Germany). All α1AT concentrations were determined from a 
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standard curve generated by the absorbance of the dilution series. Background was 
subtracted from the standards and sample values.  
4.2.2.2.4. Statistical Test for ELISA’s, Enzyme Activity, and qPCR Assays 
The median concentrations in each group were compared to one another using the Mann 
Whitney U, non-parametric (2 tailed) statistical test for two independent samples. A non-
parametric test was chosen for several reasons. 1) Most of the data was skewed and there 
were some outliers. To try to correct this, the data was transformed, but not all the patient 
groups could achieve a normal distribution curve. This was confirmed using the Shapiro-
Wilk test of normality. 2) Although decent sample sizes were collected from HC and BD 
patients for ELISA, not enough RAS patients could be recruited for research 
participation. Their sample number was < 20.    
4.2.3. Protein Isolation from Oral Buccal Swabs  
4.2.3.1. Initial Protein Isolation Protocol 
The initial kit that was used for the isolation of protein was the Illustra Triple Prep kit 
(GE Healthcare, UK) which isolated DNA, RNA, and protein from the same sample 
however this kit was eventually discontinued as it did not yield enough RNA for qPCR. 
However, the protein that was purified was acceptable. A lysed OBS sample was 
centrifuged through a DNA column and the flow-through containing the protein collected. 
It was then transferred to a new 1.5 ml microcentrifuge tube and 600 µl of protein 
precipitation buffer type 1 was added. After vortexing, the sample was incubated for 5 
min at room temperature in order to precipitate the proteins then centrifuged for 10 min at 
16,000 x g. Supernatant was removed by pipette and the protein pellet was washed in 1 
ml of dH20 to disperse the pellet. The sample was centrifuged at 16,000 x g for 1 min and 
supernatant was removed carefully using a pipette. The OBS protein pellet was then 
suspended in 100 µl of 2-D DIGE Buffer which consisted of a final concentration of 7 M 
urea (Sigma), 2 M thiourea (Sigma), 30 mM Tris-HCl (Sigma), and 4% CHAPS (Sigma) 
dissolved in dH20. The final pH of the 2-D DIGE Buffer was adjusted to 8.5 with 1 M 
NaOH. Aliquots of the protein were stored in the -80
o
C until used for western blots.  
4.2.3.1.1. Alternative Protein Isolation Protocol 
An alternative dual RNA and protein isolation kit, the RNeasy Micro Kit (Qiagen, UK), 
provided an improved, high quality and quantity RNA yield than the Illustra Triple Prep 
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kit and so was used for the remainder of the study. After the lysed sample passed through 
the kit’s MinElute column for the first time, the 700 µl of flow-through containing the 
protein was placed on ice and processed after the RNA was isolated (see Section 2.1.7.1). 
This was transferred to a 15 ml Falcon tube and 4 volumes, or 2.8 ml, of 100% ice cold 
acetone was added. After a gentle mixing by inversion, the sample was incubated in the 
acetone for 30 min on ice. It was then centrifuged at 3500 x g for 10 min. The supernatant 
was discarded and the protein pellet left to air dry. The buccal scrape protein pellet was 
resuspended in 100 µl of 2-D DIGE Buffer as before and kept at -80
o
C until use on a 
western blot. 
4.2.4. Measuring Total Protein Concentration in Saliva and OBS Samples 
Protein concentration was determined using the 2D-Quant Kit (GE Healthcare, UK). The 
kit included a protein precipitant, co-precipitant, working colour reagent, and copper 
solution.  The kit provided 2 µg/µl of BSA to use as a standard with a suggested range of 
0 – 50 µg per reaction.  Duplicate standard tubes were prepared with a selected quantity 
of BSA for 7 standard points (i.e. 2.5 µl of 2 µg/µl of BSA would give 5 µg, etc, up to 50 
µg). Patient samples were defrosted and 5 µl was aliquoted into a new 0.5 ml labelled 
tube. Then, 67 µl of precipitant was added to each tube of standards and samples, tubes 
were vortexed briefly to mix, and incubated for 3 min at RT. An equal volume of co-
precipitant, 67 µl, was added to each tube and vortexed. All samples were centrifuged at 
16,000 x g for 5 min to sediment the protein. The supernatant was removed carefully 
using a pipette and discarded. The tubes were pulse spun again and any remaining liquid 
was pipetted and discarded with care to avoid disturbing the protein pellet.  
The protein was then dissolved in 13.3 µl of copper solution and 54 µl of dH20 and 
vortexed to mix. The Working Colour Reagent was prepared by adding 100 parts of A to 
1 part of B. 134 µl of the working colour reagent was added to the suspended protein and 
mixed immediately by inverting the tubes several times. After transferring each 200 µl 
reaction to transparent 96 well plate and incubation time of 20 min, the absorbance at 480 
nm was read on the OPTIMA Microplate spectrophotometer (BMG LabTech, Germany). 
The data was analysed as an inverted assay where the absorbance values decrease with 
increasing of protein concentration. The protein concentrations of the samples were 
determined based on the absorbance of the standards.    
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4.2.5. Protease Enzyme Activity and Inhibition Assays 
4.2.5.1. Principle of the EnzChek® Assay  
The basic kinetics of the EnzChek
®
 Elastase Assay Kit (Molecular Probes/Life 
Technologies, UK) is that a sample containing protease (such as elastase) will digest the 
elastin substrate which has been conjugated to a quenched BODIPY
®
 FL dye (DQ
TM 
elastin) thereby releasing fluorescence. If a protease inhibitor is added, the digestion of 
the DQ
TM 
elastin by the protease in the sample should be reduced or inhibited thereby 
reducing the detectable fluorescence. However, if there is not enough inhibitor to reduce 
the protease activity, then some fluorescence may be released. Saliva samples were tested 
using this kit to measure the total protease activity as well as the specific neutrophil 
elastase enzymatic activity.  
4.2.5.2. Protease Activity Assays 
4.2.5.2.1. Total Protease Activity in Saliva Samples  
The protease activity in saliva was compared in HC (n=30), BDq (n=33), and BDa 
(n=29).  The EnzChek
®
 Elastase Assay kit’s reagents were reconstituted as described in 
the manufacturer’s guidelines. Aliquoted stock concentrations of the N-Methoxysuccinyl-
Ala-Ala-Pro-Val-chloromethyl ketone inhibitor (10 mg/ml stock, equal to 19.88 mM) and 
porcine elastase (P.Ela) (100 U/ml) were kept in the -20
o
C until use. 50 µl of each neat 
saliva sample (for a 1:4 final reaction dilution) was mixed with 100 µl of 1X reaction 
buffer (which was made up of dH20, 0.1M Tris-HCl, 0.2mM sodium azide) and 50 µl of 
100 µg/ml DQ
TM
 Elastin. An active elastase (positive) control reaction incorporated 100 
µl of 0.2 U/ml of P.Ela to give 0.1 U/ml (or 0.02 units per reaction (U/rxn)) in a final 
volume of 200 µl. 50 µl of 100 µg/ml DQ
TM
 Elastin and 50 µl of 1X reaction buffer were 
also added to the control reaction. Negative control wells with 50 µl 1X reaction buffer 
and 50 µl of 100 µg/ml DQ
TM
 elastin were included in order to deduct background 
fluorescence from the samples and controls. All reactions were tested in duplicate. The 
sample plate was placed immediately into the spectrophotometer after DQ
TM
 elastin was 
added. 
Initial fluorescence values were read by the OPTIMA FLUOStar Microplate 
spectrophotometer (BMG LabTech, Germany) at an excitation wavelength of 485 ± 10 
nm and an emission wavelength of 530 ± 15 nm. (Our microplate was able to excite at 
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480 nm and emit 520-P, where P signifies a wide band width). Gain fluorescence was 
adjusted for all reactions on the plate in order to normalise to the highest fluorescence for 
a baseline reading. The ‘intensity required’ value was set between 10-50% as a large 
fluorescent increase was expected. Fluorescence measurements were acquired every 5 
min for a total of 95 min.   
Analysis of the fluorescence results was completed using Microsoft Excel software. The 
saliva samples (which had previously had their total protein content quantified) were 
normalised to a total protein content of 1.5 µg/µl and the fluorescence adjusted according 
to the formula: 
 
  
 
A large change in fluorescence from time point zero to 95 min indicated high protease 
activity.  
 
4.2.5.3. Inhibition Assays  
4.2.5.3.1. The Inhibition of Purified NE by rSLPI (Proof of Principle) 
The ability of recombinant SLPI protein (rSLPI) (R&D Systems, UK) to inhibit active NE 
(Abcam, UK) was tested by combining different concentrations of each in a fluorescence 
assay. The N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone inhibitor, P.Ela, 
rSLPI, and/or NE were added to designated wells of a black 96 well NUNC
®
 plate from 
the working stocks described below. All reaction wells had a final reaction volume of 200 
µl and were completed in duplicate. 
In separate reaction wells, 1.08 µM or 2.14 µM of rSLPI was combined with 0.1, 0.05, or 
0.045 U/rxn of NE. Two separate reactions were set up with the 1.08 µM and 2.14 µM 
rSLPI concentrations mixed with 0.01 U/rxn of P.Ela. A combination of 0.045 U/rxn NE 
and 75 µM of N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone inhibitor, which 
is a specific inhibitor of elastase, was also used as a control reaction to confirm inhibition 
of NE activity. A complete inhibition control (referred to as the negative control) was also 
difference in fluorescence from 
time zero to end of assay (nm) 
desired total protein quantity to 
normalise all samples to (µg/µl) x 
Total protein quantification of 
sample (µg/µl) 
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tested combining a known inhibitory concentration of 75 µM of the same ketone inhibitor 
with 0.01 U/rxn of P. Ela.  
Just before measurements were taken by the spectrophotometer, 50 µl of 100 µg/ml 
DQ
TM
 Elastin with BODIPY
®
 FL conjugate (the fluorescence substrate) was pipette 
mixed into each well for a final reaction concentration of 25 µg/ml. Blank wells with only 
1X reaction buffer and 50 µl of 100 µg/ml DQ
TM
 elastin were included in order to deduct 
background fluorescence from the samples and controls. The gain adjustment and 
fluorescence readings were conducted in the same manner as described in the previous 
experiment.  
 
4.2.5.3.2. Testing the Inhibition of Endogenous NE in BDa Saliva Using Various 
Concentrations of Chloromethyl Ketone  
A -80
o
C frozen saliva sample from a BDa patient was defrosted on ice and diluted 1:4 in 
1X reaction buffer from the EnzChek
®
 Elastase Assay kit. N-Methoxysuccinyl-Ala-Ala-
Pro-Val-chloromethyl ketone was tested at different final concentrations of 25 µM, 50 
µM, 75 µM, 100 µM, 150 µM coupled with 100 µl of the diluted saliva sample to a final 
saliva dilution of 1:8. As an active elastase control, purified neutrophil elastase was added 
to 50 µl of 100 µg/ml DQ
TM
 Elastin substrate. As an inhibition control, 50 µl of 100 µM 
ketone inhibitor stock was combined with 100 µl of 0.2 U/ml P.Ela. 50 µl of 100 µg/ml 
DQ
TM
 Elastin was added to all reactions just before being read on the spectrophotometer. 
Any difference in volume was made up to 200 µl with 1X reaction buffer. All reactions 
were tested in duplicate.  The gain adjustment and fluorescence readings were conducted 
in the same manner as described in the previous experiment.   
 
4.2.5.3.3. Measuring Specific Neutrophil Elastase Activity in Saliva  
BDa n=7, BDq n=6, RASa n=5, RASq n=5, and HC n=8 saliva samples were selected for 
the measurement of specific NE enzymatic activity using the EnzChek® Elastase Assay 
kit.  Using two aliquots of the same sample, the total protease activity (without inhibitor) 
and the total protease activity with specific neutrophil elastase inhibitor was measured.  
BDq, RASq, and HC saliva samples were diluted to 1:20 in the final reaction. BDa and 
RASa were diluted to 1:40 in the final reaction because the concentration of NE was 
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predominantly higher in these samples compared to saliva from non-ulcer patients and 
would saturate the elastin too quickly.   
100 µl of each diluted saliva sample was added to 50 µl of 1X reaction buffer while in a 
different well the same volume of saliva was added to 50 µl of 800 µM of specific NE 
inhibitor, N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone, giving a final 
inhibitor concentration of 200 µM. 50 µl of 100 µg/ml DQ
TM
 Elastin was added to each 
reaction. The active elastase control consisted of 100 µl of 0.2 U/ml of P.Ela., 50 µl of 1X 
reaction buffer, and  50 µl of 100 µg/ml DQ
TM
 Elastin. The inhibitor control was prepared 
as well with 100 µl of 0.2 U/ml P.Ela, 50 µl of 100 µM Inhibitor, and 50 µl of 100 µg/ml 
DQ
TM
 Elastin. Blank wells with only 1X reaction buffer and 50 µl of 100 µg/ml DQ
TM
 
elastin were included in order to deduct background fluorescence from the samples and 
controls. All reactions were tested in duplicate. After an initial gain adjustment, 
fluorescent readings were detected on the spectrophotometer every 5 min for a total of 95 
min run at 37
o
C. An increase in fluorescence during 95 minutes indicated high protease 
activity in the sample. The saliva samples that were diluted 1:40 had their fluorescence 
values multiplied by 2 in order to directly compare the values from the 1:20 saliva 
samples.  The difference between neutrophil-specific elastase activity and total protease 
activity (i.e. with and without inhibitor) was calculated.  
4.2.6. QPCR for OBS SLPI and Reference Gene 
4.2.6.1.  Primer Design for Selected Reference Genes and Target mRNA 
Messenger RNA (mRNA) sequence from the Nucleotide PubMed database was copied 
and uploaded into the Primer3 and Roche primer design programs. From here suggested 
primers were individually adjusted using the oligonucleotide properties calculator 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) and the Sigma Design 
Centre (http://www.sigmaaldrich.com/configurator/servlet/DesignCenter) to help check 
primers for potential hairpins, secondary structures, and primer dimer. Coupled forward 
and reverse primers were also checked for melting temperature (Tm) compatibility so that 
both would anneal to their target site at the same temperature. The primer sequence was 
uploaded into the Basic Local Alignment Search Tool (BLAST) in order to check for 
organism, gene, and site specificity. An ideal design for mRNA (cDNA) target would be 
an intron-spanning primer; however, since all RNA samples were treated with a second 
genomic DNase digestion using the TURBO DNA-free™ (Ambion,/Life Technologies, 
UK), this type of primer design was not crucial.  
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All primers were designed based on human mRNA database sequences taking into 
account any multiple transcript variations (Table 4.2.6.1.1). PPIA, PGK1, and GAPDH 
sequences were selected from the RTPrimerDB public database after running a reference 
gene panel (see Chapter 6). Using mFold software, the predictive secondary structure of 
the target at a 64
o
C annealing temperature was mapped in order to see where the primer 
would bind and if the area is easily accessible.  
 
Primer Name 
 
Primer Design Sequence 
 
Primer 
Tm 
 
Product 
Size 
SLPI_F 5’ CTGTGGAAGGCTCTGGAAAG      63.9 oC  
66 bp 
SLPI_R 5’ GGCACTGGGCAGATTTCTTA         64.0 oC 
PPIA_F 5’ TCATCTGCACTGCCAAGACTG 66.6 oC  
71 bp 
PPIA_R 5’ CATGCCTTCTTTCACTTTGCC 
 
65.7
 o
C 
PGK1_F 5’ ATGGATGAGGTGGTGAAAGC 63.9 oC 
 
 
118 bp 
PGK1_R 5’ CAGTGCTCACATGGCTGACT 
 
64.3
 o
C 
GAPDH_F 5’ AGCCACATCGCTCAGACAC 
 
64.3
 o
C  
66 bp 
 GAPDH_R 5’ GCCCAATACGACCAAATCC 
 
64.0
 o
C 
 
Table 4.2.6.1.1. Primers Selected for OBS Sample Gene Analysis. DNA 
oligonucleotides primers were synthesised by Sigma, UK. F, forward primer. R, reverse 
primer. Melting temperature (Tm); refers to the degree in Celsius (
o
C) at which the primer 
will anneal to the DNA template. The expected product size is described in base pairs 
(bp). 
 
4.2.6.2. Initial Primer Testing 
The primers underwent an initial reaction with Sybr Green mastermix (Roche, UK) and at 
least 2 different cDNA OBS samples to check that they were amplifying one product. In 
order to assess this, the Tm of the amplicon was obtained and water (negative) controls 
were monitored for any amplification. Product sizes were double checked by 
electrophoresis on a 1% agarose gel.  
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4.2.6.3. Producing cDNA for Use in Standard Curves: Purification of cDNA 
Standard 
After producing the correct DNA amplicon from the primer test, this amplicon or DNA 
product was purified from all the other PCR components (such as the enzymes and 
dNTPs) in order to be used for preparation of standard curves for absolute quantification.  
Using the QIAquick PCR Purification kit (Qiagen, UK), the DNA product was collected 
and mixed with 5 times the amount of PB Buffer, which is a chaotropic salt reagent 
included in the kit. This mixture was pipetted on top of the provided spin column with 
collection tube and centrifuged at 13,000 rpm for 1 min at room temperature. This bound 
the DNA to the silica column. The flow through was discarded in a specialised hazardous 
waste container for chaotropic salts. Next, 0.75 ml of ethanol-based PE buffer was added 
to the column and centrifuged again at 13,000 rpm. The flow through was discarded and 
the column re-centrifuged to pool any residual ethanol. The collection tube was then 
discarded and replaced with a 1.5 ml microcentrifuge tube. This was followed by addition 
to the top of the column of 30 µl of either DNase free water or elution buffer provided by 
the kit was added directly to the top of the column.The column was incubated for 1 min, 
and centrifuged again for 1 min at 13,000 rpm. The solution eluted from the column 
contained the purified DNA. The quantity and quality of the DNA was assessed using a 
Nanodrop
TM
 spectrophotometer. Good quality DNA gave a value of between 1.7 – 2.0 
from the 260/280 ratio.  
In order to determine dsDNA copy number of the purified amplicon, the formula given 
below was completed which takes into account the length in base pairs (bp) and quantity 
of the DNA. First, the molecular weight (MW) was determined by multiplying the 
number of bp in the amplicon by 665 (which is the assumed average weight of a bair 
pair). The quantity of DNA (ng) was measured in 1 µl of sample using the Nanodrop and 
was incorporated into the formula below in order to determine DNA copy number. 
 
 
 
Formula: 
 ( (ng/MW)/1x10
9 
) x 6.02x10
23
 molecules/mole = number of copies (per µl) 
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The procedures involving amplified products were performed in an area of the lab 
designated for Post-PCR handling. A separate lab bench, pipettes, filter tips, racks, tubes, 
coat, gloves, vortex and centrifuge were all part of the ‘clean set up’ to minimise risk of 
PCR contamination. An ultra violet (UV) hood was utilised for qPCR mastermix set up as 
well.  
4.2.6.4. Optimisation of qPCR assay  
The assay efficiency goal is 100% or as referred to by the Roche Light-Cycler Software 
as “2.0”. This is determined by the slope of the amplification curves where Efficiency = 
(10
-1/slope
)-1. A slope of -3.32 would equal 100% amplification efficiency (Bustin, 2004). 
Therefore, considering this in terms of cycles, the best amplification efficiency would be 
generated from intervals of 3.3 quantification cycles (Cq) for a 1/10 dilution series 
standard curve.  
Since a pre-mixed 2X Sybr Green I Mastermix (Roche, UK) was used for all reactions, 
and therefore dNTPs, Taq polymerase, and MgCl2 concentrations were all pre-determined 
by the manufacturer, special consideration was spent on forward and reverse primer 
concentration as well as annealing temperature and time in order to optimise the 
individual assays.  
4.2.7. Immunohistochemistry of Oral Biopsies 
4.2.7.1. Sectioning Frozen Oral Biopsies  
Frozen biopsies were relocated to a cryostat (Bright Instruments Co Ltd, UK) to 
acclimatise to -20
o
C from -80
o
C. The base on the biopsy which sat on a small piece of 
cork was mounted onto a round metal specimen chuck with a small drop of OCT (Tissue-
Tek®, Sakura® Finetek, VWR, UK) medium. The sections were cut with Magnacut 
disposable microtome blades (Bright Instruments Co Ltd, UK) at 5 - 8 µm and collected 
onto Polysine
®
 or electrostatically charged Superfrost
®
 Plus glass microscope slides 
(Menzel-Gläser, Thermo Scientific). Each slide was labelled with the patient’s ID and 
each section was numbered consecutively. The orientation was checked after the first few 
sections with both Giemsa stain and hematoxylin and eosin (H&E) stain to make sure that 
all layers of the tissue could be seen in one section (i.e. the mucosal epithelium, lamina 
propria, and submucosa) These stains also detailed various cells and tissue components.  
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4.2.7.2. Giemsa or Hematoxylin and Eosin (H&E) Stain for Orientation 
4.2.7.2.1. Giemsa Staining  
Prior to immunocytochemical staining, the biopsies were stained with Modified Giemsa 
stain (Sigma,UK) or H&E stain in order to confirm that the biopsy tissue was being cut so 
that epithelial and submucosa could be seen in one section. For the Giemsa protocol, the 
biopsy on the slide was fixed in 70% ethanol for 10 min. It was briefly dried and a drop of 
the concentrated Giemsa solution was added on top of the section and incubated for only 
30 sec. Afterwards, it was gently rinsed twice in ddH20 and allowed to air dry (but not for 
more than 5-8 min). A drop of DPX mounting media (Sigma, UK) was added on top of 
the section and a coverslip applied immediately. After the mounting reagent had dried, 
the biopsies were able to be imaged using a light microscope (Nikon Instruments, UK). 
 
4.2.7.2.2. H&E Staining 
The cellular detail of tissue biopsies were revealed using haematoxylin with eosin counter 
stain. Briefly, samples were rinsed with sterile distilled water before incubation with alum 
haemotoxylin for 5 mins at room temperature to distinguish nuclei, followed by two 
seconds exposure to 0.3% acid alcohol to enhance contrast. The tissue was rinsed once 
more and counter stained with eosin for two minutes at room temperature to reveal 
additional tissue structures and finally the samples were allowed to dry before mounting 
onto cover slips. Imaging was conducted on a Zeiss Axioskop light microscope (Zeiss, 
UK).   
 
4.2.7.3. Fixing, Blocking, and Immunofluorescent Antibody Staining of Oral 
Biopsies 
The sections were briefly dried, a Dako Cytomation hydrophobic ink pen (DAKO, 
Denmark) was used to encircle each specimen on the slide, and 150 µl of 100% ice cold 
methanol was pipetted on top of the section for 10 min to fix the tissue. Each section was 
washed with 150 µl of 1X PBS with 0.05% Tween-20 with changing of the wash buffer 
every 5 min for a total of 15 min. The same blocking buffer as utilised for the 
immunocytochemical staining of neutrophils (5% goat serum, 0.5% saponin, and 0.05% 
Tween-20 in PBS) was added and incubated for 1 hr at RT and then removed. The 
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primary antibody was diluted according to Table 4.2.7.3.1 and 100 µl was added to the 
top of the sections which were left undisturbed overnight at 4
o
C. Isotype and secondary 
antibody-only controls were also prepared on separate sections.  
Table 4.2.7.3.1. Antibody Details for Detecting NE and SLPI in Oral Mucosal 
Biopsies. The primary and secondary antibodies used for detecting NE and SLPI in oral 
ulcer biopsies are listed above. Monoclonal (m) or polyclonal (p) NE primary antibodies 
were used interchangeably depending on the coupling of another primary antibody. 
 
The next day, the biopsies were rinsed and washed with 150 µl of PBS-T three times for 5 
min at a time. The secondary antibody was diluted as indicated in Table 4.2.7.3.1. and 
100 µl added to the sections. Sections were incubated was for 1 hr at RT while being 
protected from light. Another triple wash step was then completed. Finally, a 100 ng/ml 
solution of DAPI stain was prepared in 1X PBS. 100 µl of this solution was added to each 
section and incubated for at least 5 min before being removed. By placing the slides 
vertically for a minute allowed the left over fluid around the biopsy section to dry off. 
Target Block and 
Permeabilise 
Primary and Secondary Antibodies  Antibody 
Dilution 
Isotype 
Control 
mNE 5% goat serum 
0.5% saponin 
0.05% Tw-20 
in PBS 
1
o
 Ab: mouse monoclonal IgG1, 0.1 
mg/ml neat concentration, (HyCult 
#HM2174) 
2
o
 Ab: AF555 goat, anti-mouse IgG 
polyclonal F(ab’)2 region, 2mg/ml (Life 
Technologies, UK, Cat #A-21425) 
(visible in red channel) 
 
1: 400 
 
1:2000 
 
Mouse 
IgG1 
(DAKO) 
pNE  
 
 
 
5% goat serum 
0.5% saponin 
0.05% Tw-20 
in PBS 
1
o
 Ab: NE polyclonal rabbit, anti-human, 
whole antiserum, IgG (Abcam, UK, Cat# 
ab21595)  
2
o
 Ab: AF647 goat, anti-rabbit IgG 
polyclonal F(ab’)2 fragment, 2mg/ml 
(Life Technologies, UK) (visible in far 
red channel) 
 
1: 400 
 
1:2000 
 
Normal 
rabbit 
serum 
SLPI 5% goat 
serum, 1% 
BSA, 0.5% 
saponin, 
0.05% Tw-20 
in PBS 
1
o
 Ab: monoclonal mouse IgG1, anti-
human (R&D Systems, Cat# MAB1274) 
2
o
 Ab: AF555 goat, anti-mouse IgG 
polyclonal F(ab’)2 region, 2mg/ml (Life 
Technologies, UK) (visible in red 
channel) 
 
1:100 
1:2000 
 
Mouse 
IgG1 
(DAKO) 
DNA n/a DAPI: (Sigma, UK) (visible in blue/UV 
channel) 
Final 
conc: 100 
ng/ml 
n/a 
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Moving the slide so that it lay flat again, approximately 6 µl of mowial was pipetted on 
top of the section (mowial was pre-prepared; see section 2.1.8) and a small 13mm glass 
coverslip placed on top ensuring there were no air bubbles between the coverslip and 
specimen. This was covered with aluminum and allowed to dry for at least 1-2 hrs. A thin 
layer of nail polish was used to seal the sides of the coverslip as to protect the tissue 
specimen and mounting media from drying out. Slides were stored at 4
o
C until imaged on 
a Leica fluorescent microscope using MetaMorph software.  
 
4.3. Results 
4.3.1. Western blots: Identification of NE, SLPI, and α1AT in Oral Specimens  
Saliva samples were run on Western Blots (WB) in order to see if NE, SLPI, and α1AT 
proteins could be detected in the specimens.  Re-suspended saliva cell pellets and purified 
total protein from oral buccal swabs were also subjected to this detection process. 
Recombinant SLPI and purified NE were run alongside these specimens as positive 
controls for the correct size of the proteins and confirmation of antibody detection.  
 
4.3.1.1. Optimisation of Antibodies for Western Blot 
The optimisation of the electrophoresis, protein transfer, and western blot (WB) 
completed for NE and SLPI targets mainly consisted of variations in incubation times, 
blocking reagent, antibody types and concentrations meanwhile remaining consistent with 
the use of the same running and transfer buffers, Bis-Tris gels, PVDF-type membranes, 
and equipment.  
 
4.3.1.1.1. Issues with Non-Specific Binding of Secondary Antibodies in Oral 
Specimens 
While investigating NE and SLPI saliva proteins on western blots, there were problems 
with the specificity of several secondary HRP and fluorescent antibodies from various 
manufacturers (Table 4.3.1.1.1.1). When incubating the membrane without primary 
antibody, there was a reoccurring 31 kDa protein band consistently present (data not 
shown). This revealed that there was non-specific binding of the secondary antibodies to 
an unknown element in all samples including saliva, oral buccal protein, saliva cell 
pellets, and even human serum. In order to try to block this non-specific binding, 5% goat 
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serum was used in place of 5% milk or BSA, but this did not alter the outcome. It was 
clear that the non-specific binding was due to something in the clinical samples because 
there was no non-specific binding associated with the recombinant SLPI protein or 
purified NE both of which were isolated by their manufactures. Saliva has over 1,000 
proteins and is extremely heterogeneous (Hu et al., 2005) so it was not surprising that 
there were some conflicts with antibody specificity. These control experiments were 
paramount in assessing the specificity of the antibodies involved. After many trials, two 
successful secondary antibodies were found to have specific binding. These are listed in 
Table 4.3.1.1.1.1. 
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WB Secondary  
Antibody Details 
Supplier or 
Manufacturer 
Dilution 
Tested 
Specific 
Binding? 
Secondary Antibody (Ab), 
Goat, Anti-Mouse, IgG, 
HRP, Neat Conc: 10 µg/ml 
Thermo Scientific 
Cat# 32430 
1:1000 
& 1:4000 
 
No 
Secondary Ab, Goat, anti-
mouse, HRP  
Millipore 
 
 
1:2500 
 
No 
Secondary Ab , Rabbit, anti-
mouse, IgG, HRP 
Abcam 
 
 
1:2500 
 
No 
Secondary Ab, Polyclonal 
IgG, Goat, anti-Rat, HRP 
affinity purified 
chromatography 
Millipore/ 
Chemicon Intl. 
 
1:5000 
 
No 
Fluorescent polyclonal, (red 
IRDye680LT), Secondary 
Ab, Goat, Anti-Rabbit, Neat 
Conc: 1 mg/ml 
Licor 
Cat# 926-68021D 
 
1:15,000 
 
No 
Fluorescent polyclonal, 
(green IRDye800CW), 
Secondary Ab, Goat, anti-
mouse, Neat Conc: 1 mg/ml 
Licor 
Cat# 926-32210 
 
1:15,000 
 
No  
Secondary Ab, Goat, anti-
Rabbit, HRP, Neat Conc:  
10 µg/ml 
Thermo Scientific 
Cat#32460 
 
1:1200 
 
Yes 
Secondary Ab, polyclonal 
Donkey, anti-goat , Goat 
IgG, HRP 
R&D Systems 
Cat# HAF109 
 
1:3000 
 
Yes 
Table 4.3.1.1.1.1. Secondary Antibodies Showing Specific and Non-Specific Binding 
in Human Saliva Samples. Eight secondary antibodies were tested for target protein 
specificity on a western blot with saliva samples by replacing the primary antibody with 
buffer followed by incubating the membrane with the secondary antibody. Six out of the 
eight secondary antibodies attached to an unknown 31 kDa protein and therefore could 
not be used. Only two secondary antibodies were found to be suitable for use with saliva 
proteins. The item catalogue (Cat) number (#) is given where available. Ab, Antibody. 
Conc, Concentration. HRP, horseradish peroxidase. IgG, immunoglobulin G. WB, 
Western blot.  
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Due to its consistency, the 31 kDa unknown protein causing the non-specific binding was 
investigated further. A BDq patient saliva sample was run on a western Bis-Tris gel, 
stained with 0.1% Coomassie Brilliant Blue, destained in an acetic acid/methanol 
solution, rinsed with water, excised and sent for N-terminal protein sequencing at 
AltaBiosciences, UK. The results were only 50% accurate inclusive of residues 1-8 (data 
not shown). The sequence’s initial outcome was D-I-Q-L-T-Q-S-P which most closely 
matches human Ig kappa chain V-I region BAN. Alternative sequences with the queried 
residues were also researched on protein databases but with limited matches. The reasons 
for sequencing the protein at this location was important since NE appears around the 
same size (29.5 kDa) and the specificity of detecting NE in the samples had to be clarified 
using the antibodies that were being tested. 
 
4.3.1.1.2. Initial Monoclonal SLPI Primary Antibodies: No SLPI Detection in Saliva 
Two different primary SLPI antibodies were initially run with the saliva samples. Both 
were monoclonal mouse IgG1, anti-human, antibodies (clone 31 from Abcam, UK and 
clone 20409 from R&D systems, UK). Although rSLPI was consistently detected, SLPI 
was not detected in the saliva samples using either antibody. Only clone 20409 was able 
to detect SLPI in the concentrated saliva cell pellets. 
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4.3.1.2. SLPI Primary Polyclonal Antibody: Successful Detection of SLPI in Various 
Oral Specimens 
There was success with using a SLPI primary goat polyclonal antibody (0.5 mg/ml stock 
concentration from R&D System, UK) which was run with the donkey, anti-goat 
secondary antibody (R&D System) listed above in Table 4.3.1.1.1.1. SLPI was detected 
in several oral specimens using this antibody combination on the WB membrane seen in 
Fig 4.3.1.2.1.   
                          
Figure 4.3.1.2.1. Detecting SLPI in Different Oral Specimens with the Polyclonal 
SLPI Primary Antibody (R&D Systems). Lane 1: Full Range Rainbow Ladder (GE 
Healthcare, UK). Lane 2: BD quiet (q, no oral ulcer) saliva, 14 µg total protein. Lane 3: 
BDq saliva cell pellet (SAL PEL) resuspended in 0.5 ml PBS, 9 µg added to the well. 
Lane 4: Health control (HC) oral buccal swab (OBS) total protein extract, 33 µg. Lane 5: 
SLPI-generating lung epithelial cell line (A549) supernatant (s/n). Lane 6: Recombinant 
(r)SLPI, 1.5 µg (proved to be too concentrated). The membrane was incubated at 1:500 
dilution of polyclonal primary SLPI antibody (R&D Systems) and 1:3000 of the 
secondary donkey, anti-goat (R&D Systems). The band believed to be the SLPI protein 
was detected just above the expected 12 kDa.  
The SLPI polyclonal antibody was specific and showed one clear SLPI band evident in 
the saliva pellet, saliva, and oral buccal swab samples. There was an issue with the rSLPI 
positive control which was extremely sensitive to the new antibody and components used 
for the ECL development and will therefore needed to be retested at a lower 
concentration. Unfortunately, it was also difficult to assess whether the A549 culture 
supernatant revealed a SLPI protein band as it was completely overshadowed by the 
concentrated rSLPI in the adjacent lane. However, blocking the PVDF membrane 
12 kDa 
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overnight in 5% milk at 4
o
C improved detection of the SLPI protein in the patient 
samples as there was less background.  
4.3.1.3. The Detection of SLPI in Saliva, Saliva Cell Pellets, and Oral Buccal Swabs 
from HC and BD Patients with and without Oral Ulcers  
A full array of oral specimens which included saliva cell pellet, saliva, and oral buccal 
swabs from BDa, BDq, and HC subjects were run on the same WB. SLPI was detected 
just above the expected 12 kDa band (nearly at the 17 kDa marker) in all the oral samples 
(Fig 4.3.1.3.1). The rSLPI positive control in Lane 12a had DTT added to it (the main 
component in 10X NuPage reducing agent) which was not needed causing it to smear 
while running on the gel. This was rectified in future WB’s (Fig 4.3.1.3.1. Lane 12b). 
                           
Figure 4.3.1.3.1. SLPI Detected in a Range of Oral Specimens from Three Patient 
Groups. Lane 1: Full Range Rainbow Ladder (GE Healthcare, UK). Lane 2,3,4: 
Resuspended saliva cell pellet (SAL PEL), saliva (SAL), and oral buccal swabs (OBS) 
from one BD active patient (a, having an oral ulcer). Lane 5,6,7: Resuspended saliva cell 
pellet, saliva, and oral buccal swabs from one BD quiet patient (q, no oral ulcer). Lane 
8,9,10: Resuspended saliva cell pellet, saliva, and oral buccal swabs from one HC. Lane 
11: Empty. Lane 12a: rSLPI, 0.5 µg with dithiothreitol (DTT) reducing agent. Lane 12b: 
rSLPI, 0.5 µg without DTT. Total protein was quantified for each saliva and OBS sample 
and 10 µg added to the well. Saliva cell pellets were not quantified prior to resuspension 
in 0.5 ml PBS, so a set volume of 8 µl was added to each designated well. The membrane 
was blocked overnight with 5% milk in PBS-0.05% Tween at 4
o
C after which it was 
incubated with 1:500 dilution of primary polyclonal SLPI antibody or 1 hour at RT 
followed by 1:3000 of the secondary donkey, anti-goat for 1 hour at RT. SLPI was 
detected just above the expected 12 kDa band (nearly at the 17 kDa marker) in all the oral 
samples.  
12 kDa 
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4.3.1.4. Detection of NE in Oral Specimens 
4.3.1.4.1. Detection of NE Using HRP-Labelled Primary Antibody 
The next protein that needed to be detected in oral specimens was NE. A mouse IgG1 
primary antibody was employed for this use on western blots, however the secondary 
antibody to couple with the primary was encountering the same non-specific binding 
issue as seen before. In order to circumvent the use of secondary antibodies because of 
the non-specific binding problems in saliva samples, purified NE monoclonal primary 
antibody was directly conjugated to a HRP label using Lightening-Link® (Innova 
Biosciences, UK).  
 
 
Table 4.3.1.4.1.1. HRP Conjugated NE Primary Antibody. Details of the monoclonal 
NE primary antibody used for western blot detection of NE in oral specimens. The HRP 
(horseradish peroxidase) was chemically conjugated to the purified antibody eliminating 
the necessity of a secondary antibody. The HRP label allowed the target to be directly 
detected with electrochemical luminescence (ECL). Catalogue number (Cat #). IgG1, 
Immunoglobulin G1. 
 
The NE-HRP antibody was successfully able to detect NE at the expect protein size 29.5 
kDa in all saliva samples from BDa, BDq, and HC subjects (Figure 4.3.1.4.1.1, A, B). 
The protein bands beside the 31 kDa ladder marker on both Fig 4.3.1.4.1.1  membranes A 
and B indicate the expected NE protein size which was also in line with the upper band of 
the positive control. Just as in previous SLPI western blots, the NE purified positive 
control was negatively affected with heat and the NuPage DTT reducing agent (Life 
Technologies, UK) as seen in Fig 4.3.1.4.1.1, A, Lane 5 and so was not subjected to these 
treatments in subsequent experiments before loading onto the gels (Fig 4.3.1.4.1.1, B, 
Lane 5). Despite this precaution, the NE positive control still showed a lower band 
Target Antibody Details Supplier/ 
Manufacturer 
Dilution 
Used 
Specific 
Binding? 
Successful 
Detection 
of Target? 
NE 
  
Monoclonal primary Ab  
Mouse IgG1 
Clone 265-3K1  
Protein G purified 
Neat Concentration: 
0.1 mg/ml 
HyCult 
Biotech 
Cat # HM2174 
  
1:200 
and 
1:1000 
  
Yes 
Yes,  
with 
additional 
bands (Fig 
4.3.1.4.1.1) 
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around 12 kDa. After a consultation with the supplier, it was concluded that the NE 
protein purified from human peripheral blood neutrophlis had some naturally-occurring 
degradation. The saliva samples from all the subjects also showed this degradation 
product around the same size. This was especially apparent in saliva from BDa patient in 
Fig 4.3.1.4.1.1, A, Lane 2. The protein isolated from the blood and oral buccal swab 
samples in Fig 4.3.1.4.1.1, B showed the same size 29.5 kDa NE band as the saliva but 
seemed to be separated into two thinner bands in close proximity to each other. This 
effect was not seen in any saliva samples. 
 
In addition to this lower band, all saliva samples on also showed a thick larger protein 
band between 52 and 76 kDa. This band was seen again in the whole blood protein (Fig 
4.3.1.4.1.1, B, Lane 2) and the ulcerated oral buccal swab sample (Fig 4.3.1.4.1.1, B, 
Lane 4) but with less intensity. The saliva samples in Fig 4.3.1.4.1.1, A also had another 
band above 76 kDa. It is suspected that these bands indicated an unknown protein 
complex with NE or a contaminant with a similar NE epitope. The whole blood and oral 
buccal swab protein samples were isolated using Qiagen’s DNeasy column kit (Qiagen, 
UK) followed by an acetone protein precipitation. Therefore, any complexes or 
contaminants could have been reduced in the blood and buccal samples. This could 
explain the lack of small degradation products in these processed samples as well. 
Meanwhile, the saliva samples did not undergo any protein isolation procedures before 
being loading onto the western blot gels and could have various NE complexes. 
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Figure 4.3.1.4.1.1. A and B. NE Detected in Saliva, Blood, and Oral Buccal Swab 
Samples.  A: Saliva samples’ total protein was quantified and 10 µg added to each well. 
Membrane was blocked with 5% milk overnight at 4
o
C before adding the 1:200 HRP-NE 
conjugated monoclonal primary antibody for 1 hour incubation at RT. Lane 1: Full Range 
Rainbow Ladder (GE Healthcare). Lane 2: BDactive (a, ulcer) saliva. Lane 3: BDquiet (q, 
no ulcer) saliva. Lane 4: HC saliva. Lane 5: NE positive (+ve) control, 2 µg, with 
dithiothreitol (DTT) reducing agent. B: Membrane was blocked with 5% goat serum 
overnight before adding 1:500 NE-HRP primary antibody for 1 hour incubation at RT. 
Lane 1: Low Range Rainbow Ladder. Lane 2: 5 µg of isolated protein from whole blood 
from BDq (no ulcer, but had active folliculitis and joint pain). Lane 3: BDa saliva, 10 µg. 
4: BDa oral buccal swab (OBS) taken directly from an ulcer (U), 10 µg. 5: NE +ve 
control, 1.5 µg, no reducing agent (DTT) or heat denaturing. 
 
 
 
 
 
 
 
Lane   1      2      3     4     5   Lane  1     2      3     4      5   
29.5 kDa  
A. B. 
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4.3.1.5. Detection of α1AT in Saliva 
Saliva was also tested for the levels of α1AT in BD and RAS patients in comparison to 
HC. Previous literature indicated that α1AT in saliva from periodontitis patients could 
exceed that of NE (Pederson et al., 1995), so the saliva from our patients was diluted 
1:200 and 1:600 before being run on the western blot. The expected 52 kDa α1AT protein 
band was successfully detected in BDa, BDq, and HC saliva and was the same size as the 
positive control. The amount of α1AT in BDa saliva was still quite high causing dark 
streaks on the WB (Fig 4.3.1.5.1, Lane 2, 3), but was reduced in BDq (Lane 4, 5) and 
was not an issue in HC saliva (Lane 6, 7).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.1.5.1. α1AT Detected in Saliva Samples. Saliva samples’ total protein was 
quantified and 0.03 µg added to each well. Membrane was blocked with 5% milk 
overnight at 4
o
C before adding 1:1000 rabbit, anti-human α1AT polyclonal primary 
antibody for 1 hour incubation at RT followed by 1:1500 goat, anti-rabbit HRP secondary 
antibody. Lane 1: Full Range Rainbow Ladder. Lane 2: BDactive (a, ulcer) saliva (SAL) 
diluted 1:200. Lane 3: Same BDa saliva diluted 1:600.  Lane 4: BDquiet (q, no ulcer) 
saliva diluted 1:200. Lane 5: Same BDq saliva diluted 1:600. Lane 6: HC diluted 1:200. 
Lane 7: Same HC diluted 1:600. Lane 8: Isolated total protein from lysed A549 lung 
epithelial cell line used as α1AT positive (+ve) control, 0.15 µg.  
 
 
Lane   1        2        3              4        5               6        7         8 
52 kDa 
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4.3.2. Measurement of Salivary Levels of NE, SLPI, and Alpha-1 Antitrypsin using 
ELISA  
In order to determine quantitatively if there was an excess of NE present in BD and RAS 
patients’ saliva during quiet, non-ulcerative episodes, ELISAs were used to quantify the 
protein. Importantly, saliva NE was also tested during an active oral ulcer to see if BD 
and RAS patients would have similar levels due to their innate neutrophil response to a 
wound. These values were compared to HCs. SLPI and α1AT were also measured in all 
the same patient groups using ELISA to determine if there was a direct quantitative 
relationship between NE and its inhibitors in saliva.  The number of saliva samples tested 
in each patient group is summarised in Table 4.3.2.1.  
Patient Group NE 
n 
SLPI 
n 
α1-AT 
n 
BDa 49 52 32 
BDq 59 56 29 
HC 54 49 19 
RASq 10 11 5 
RASa 12 15 4 
Table 4.3.2.1. Patient Saliva Sample Number for Each ELISA. The number of patient 
saliva samples (n) that were measured by ELISA for each target: NE, SLPI, and α1AT.  
 
4.3.2.1. The Levels of NE, SLPI, and α1AT in Saliva from HC, BD and RAS Patients  
Statistical analysis showed that BDa saliva (1794 ng/ml, group median value) had 
significantly higher levels of NE than HC (998.9 ng/ml, p<0.01) and BDq (1111.7 ng/ml, 
p<0.05) (Fig 4.3.2.1.1). There was also a 2-tailed significant difference, p<0.05, between 
the BDa patient group and RASq (1043.4 ng/ml). RASa saliva (3080.7 ng/ml) had the 
highest NE levels which was particularly evident when compared to HC (p≤0.001), RASq 
(p<0.01), and BDq (p<0.01). HC showed the lowest levels of NE.  
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The median NE level measured in the BDq patient group was higher than HC and RASq, 
but this was not statistically significant. However, when considering the protein 
quantification range, BDq saliva had a much larger range and higher maximum value than 
either HC or RASq. The minimum NE measurement in BDq saliva was 132.7 ng/ml 
while the maximum was 10,124.1 ng/ml. Meanwhile, HC NE levels ranged from 196 - 
5,178  and RASq from 287.3 – 2,673.4 ng/ml. Table 4.3.2.3 outlines these minimum and 
maximum values as well as the 25
th
 and 75
th
 percentile range. 
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Figure 4.3.2.1.1. Salivary NE levels amongst different patient groups. The 
black centre bar in each box of the plot represents the median NE protein level 
measured for each group. The box itself represents 50% of the values in the group 
and the extended bars indicate the extent of maximum and minimum values 
therefore encompassing the range. o indicates outliers. Data is plotted on a 
logarithmic scale. HC (healthy control), RAS (recurrent aphthous stomatitis), BD 
(Behçet’s disease). q, indicates mouth quiet/no ulcers. a, refers specifically to 
active mouth ulcer(s) regardless of other systemic symptoms. The non-parametric 
Mann-Whitney U test was used to assess significant difference between two 
groups. Significance based on 2-tailed, 95% CI. *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
** 
* 
** 
*** 
* 
** 
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SLPI levels were found to be the highest in RASq (Figure 4.3.2.1.2). When comparing 
group medians, the level of SLPI was significantly higher in RASq (860.1 ng/ml) than 
BDq (198.7 ng/ml) and BDa (320.6 ng/ml) patient groups, p<0.01. The 487.3 ng/ml of 
SLPI in HC saliva was also significantly higher than BDq, p<0.05. BDq had the lowest 
levels amongst all the other groups.  
   
  
Figure 4.3.2.1.2.  Salivary SLPI levels amongst different patient groups. The 
black centre bar in each box of the plot represents the median SLPI protein level 
measured for each group. The box itself represents 50% of the values in the group 
and the extended bars indicate the extent of maximum and minimum values 
therefore encompassing the range. o indicates outliers. Data is plotted on a 
logarithmic scale. HC (healthy control), RAS (recurrent aphthous stomatitis), BD 
(Behçet’s disease). q, indicates mouth quiet/no ulcers. a, refers specifically to 
active mouth ulcer(s) regardless of other systemic symptoms. The non-parametric 
Mann-Whitney U test was used to assess significant difference between two 
groups. Significance based on 2-tailed, 95% CI. *p<0.05, **p<0.01, ***p<0.001. 
** 
** 
* 
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Since NE is also regulated by α1-AT, the levels α1-AT inhibitor was also measured 
(Figure 4.3.2.1.3). Salivary levels of α1-AT were significantly higher in BDa (14,326.1 
ng/ml) than HC (4995 ng/ml) (p<0.001) while BDq (8395.3 ng/ml) was significantly 
higher than HC (p<0.05) as well. Most of NE, SLPI and α1-AT measurements were 
carried out on the matching samples taken from each patient. An inverse relationship 
between SLPI and NE was observed when comparing the concentration of the two targets 
between patients groups (Figure 4.3.2.1.4). Analysis showed that when the concentration 
of SLPI in saliva was low, the concentration of NE was high and vice versa. For instance, 
BDa had a high NE concentration of 1794 ng/ml while SLPI resulted in a low median 
value of 320.6 ng/ml. This suggested that there is either a depletion of SLPI in saliva 
when NE is increased or that SLPI is binding to NE or another substrate thereby 
decreasing its epitope availability for antibody detection. This did not seem to be an issue 
with the ELISA measurement of NE and α1-AT as these proteins showed high 
quantitative levels and had a direct relationship with eachother (Figure 4.3.2.1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
 
     
 
Figure 4.3.2.1.3.  Salivary α1AT levels amongst different patient groups. The black 
centre bar in each box of the plot represents the median α1AT protein level measured for 
each group. The box itself represents 50% of the values in the group and the extended 
bars indicate the extent of maximum and minimum values therefore encompassing the 
range. o indicates outliers. Data is plotted on a logarithmic scale. HC (healthy control), 
RAS (recurrent aphthous stomatitis), BD (Behçet’s disease). q, indicates mouth quiet/no 
ulcers. a, refers specifically to active mouth ulcer(s) regardless of other systemic 
symptoms. The non-parametric Mann-Whitney U test was used to assess significant 
difference between 2 groups. Significance based on 2-tailed, 95% CI. *p<0.05, **p<0.01, 
***p≤0.001. 
 
It was also noteworthy that the concentration of the NE inhibitor α1-AT in the saliva far 
exceeded that of NE and SLPI which is demonstrated in Fig. 4.3.2.1.4. The medians for 
each patient group are compared in Table 4.3.2.2. 
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Figure 4.3.2.1.4. Comparison of SLPI, NE and Alpha1-Antitrypsin. An alternative 
depiction of Figures 4.3.2.1.1, 4.3.2.1.2, and 4.3.2.1.3 showing the differences in 
concentrations between NE and its inhibitors in saliva. Note that α1AT is graphed at half 
of its concentration measured by ELISA.     
Protein Target 
BD Active 
(ng/ml) 
BD Quiet 
(ng/ml) 
Healthy 
(ng/ml) 
RAS Active 
(ng/ml) 
RAS Quiet 
(ng/ml) 
SLPI  320.59 198.72 487.28 383.01 860.09 
NE  1793.95 1111.71 998.87 3080.73 1043.35 
α1AT  14326.07 8395.34 4994.96 7934.22 7118.54 
Table 4.3.2.2. Patient Groups Median Concentration Values of NE, SLPI, and α1AT 
Salivary Protein Targets Measured by ELISA. These group median values are 
demonstrated in Figures 4.3.2.1.1, 4.3.2.1.2, and 4.3.2.1.3). 
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Protein Target and 
Range Details 
Patient Group and Mouth Activity 
  
BD Active 
(ng/ml) 
BD Quiet 
(ng/ml) 
Healthy 
(ng/ml) 
RAS Active 
(ng/ml) 
RAS Quiet 
(ng/ml) 
NE 25
th
 percentile 1148.92 872.39 544.48 2194.29 566.47 
NE 75
th 
percentile 3573.57 2832.66 2800.84 3461.04 1975.79 
NE Min Value 323.59 132.77 195.98 983.64 287.32 
NE Max Value 21623.60 10124.09 5178.03 7106.02 2673.44 
 
SLPI 25
th
 percentile 83.98 92.04 117.27 185.90 512.35 
SLPI 75
th
 percentile 650.32 608.50 954.42 732.15 992.08 
SLPI Min Value 17.79 8.70 31.81 17.52 68.52 
SLPI Max Value 2616.33 2107.81 2159.66 1831.42 2404.99 
 
α1AT 25
th
 percentile 8609.95 6823.78 3017.83 6365.33 5656.08 
α1AT 75
th 
percentile 21286.10 13618.59 9810.08 11055.11 14890.83 
α1AT Min Value 1165.46 1121.41 524.77 5739.36 4448.71 
α1AT Max Value 44454.82 47313.33 22174.37 16337.12 20931.38 
 
Table 4.3.2.3. Value Range of the NE, SLPI, and α1AT Salivary Protein Targets 
Measured by ELISA. The 25
th
 and 75
th
 interquartile values as well as the minimum 
(min) and maximum (max) protein concentration values in ng/ml units are listed above. 
These values are represented in the box plots in Figures 4.3.2.1.1, 4.3.2.1.2, and 4.3.2.1.3. 
In order to confirm the very high α1AT levels found in saliva, an additional α1AT ELISA 
was conducted on patient serum which is the main constituent for delivery of α1AT to the 
tissues. These samples were diluted in PBS at 1:100, 1:10,000, and 1:100,000 and 
measured. The 1:100,000 serum dilution generated the best assessment of α1AT content 
(see Table 4.3.2.3.4). This range was compared to those in published literature (i.e. for 
the HC group since BD and RAS patients have not previously had this inhibitor measured 
in their saliva). The range of α1AT was confirmed to be within an accurate range. 
Therefore, this provided additional confirmation that the high α1AT values measured in 
the saliva samples using ELISA were accurate.  
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Patient Group and 
Oral Ulcer Activity 
n 
Group Median 
ng/ml 
Range (Min and Max) 
(ng/ml) 
HC 5 1.94 x 10
6
 1.63 x 10
6
 2.48 x 10
6
 
BDq (collective) 5 1.98 x 10
6
 1.77 x 10
6
 2.46 x 10
6
 
BDq, no symptoms 2 1.87 x 10
6
 1.77 x 10
6
 1.98 x 10
6
 
BDq, other symptoms 3 2.09 x 10
6
 1.79 x 10
6
 2.46 x 10
6
 
BDa 4 2.0 x 10
6
 6.9 x 10
5
 2.92 x 10
6
 
RASa 1 n/a n/a n/a 
RASq 2 2.32 x 10
6
 2.03 x 10
6
 2.61 x 10
6
 
 
Table 4.3.2.3.4. α1AT Levels in Serum. Serum samples were measured using the same 
α1AT ELISA as saliva samples for comparison. n, number of subjects’ serum tested. 
Min, minimum values. Max, maximum values. 
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4.3.2.2. NE, SLPI, and α1AT Saliva Concentrations From BD Patients Taking 
Colchicine 
Colchicine is one of the recommended medications for oral ulcers in BD (Sander and 
Randle, 1986). It works by reducing the migration of neutrophils (Roubille et al., 2013). 
Therefore, NE and its inhibitors’ α1AT and SLPI concentrations were assessed in saliva 
from BD patients taking colchicine and whether they had oral ulcers. 
There were significant differences when comparing the group median concentrations in 
NE. BDq patients taking colchicine still had significantly high NE in their saliva 
compared to BDq who were not on the medication (p=0.036) (Fig 4.3.2.2.1). This 
suggests that colchicine is not reducing the recruitment of oral neutrophils and therefore 
the presence of NE in the oral cavity during quiescent ulceration. The BDq group not 
taking colchicine had significantly lower NE than both BDa on colchicine (p=0.009) or 
not on colchicine (p=0.028). Taking colchicine during an active ulcer was able to reduce 
the concentration of salivary NE but not significantly.  
Although none of the α1AT and SLPI level comparisons were significant amongst BD 
patients on colchicine, there were notable trends. BDa patients on colchicine showed 
increased α1AT suggesting that colchicine may help increase the quantity of α1AT in 
saliva for protection against NE. Meanwhile, BDa patients not taking colchicine had a 
rise in SLPI concentration. This is surprising since the usual trend amongst our patient 
population was to see a decrease of SLPI during active oral ulceration.  
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Fig 4.3.2.2.1. Comparing Saliva NE, α1AT, and SLPI Concentrations from BD 
Patients Taking Colchicine. The bars graphs show the group median NE, α1AT, and 
SLPI saliva concentrations from BD Behçet’s Disease (BD) quiet (q, no oral ulcers) and 
BD active (a, oral ulcer) patients. *p<0.05. **p<0.01. 
 
 
 
* 
** 
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4.3.3. NE and SLPI in Western Blots: Comparing ELISA Measurements  
To investigate the indirect relationship seen in NE and SLPI protein levels measured by 
ELISA, some of the same saliva samples were run on western blots. This was to see if the 
quantitative ELISA measurements would coincide with the protein band intensity of NE 
and SLPI.  Fig. 4.3.3.1, A and B confirmed that the intensity of SLPI and NE protein 
bands detected on the western blots corresponded to the ELISA levels. One SLPI band is 
evident in the SLPI membrane (Fig. 4.3.3.1, A). However, the majority of saliva samples 
on the NE western blot (Fig. 4.3.3.1, B) again revealed an additional upper (52 – 76 kDa) 
and lower band (just above 12 kDa) accompanying the expected 29.5 kDa NE.  
Considering that the primary SLPI antibody used in the western blot and the ELISA 
antibodies are from the same company (R&D Systems, UK), it is possible that they are 
only binding to un-bound or “free” SLPI. This would coincide with the single protein 
band at 12 kDa on the western blot. Meanwhile, the NE antibody could be detecting all 
bound, un-bound and fragmented NE explaining the multiple protein bands.  
Human oral keratinocyte protein (purified from an ex vivo culture) was included as a 
negative control and was not expected to show any NE band at 29.5 kDa which indeed 
was absent. However, an upper band just above 52 kDa did appear at the same size as the 
large, unknown protein seen in the saliva samples strongly suggesting that this upper band 
could be a protein contaminant from the foetal calf serum used in the culture media which 
would contain NE, SLPI, or α1AT.  
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SEE FIGURE 4.3.3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3.1. SLPI and NE in Saliva. The total protein was quantified and 10 µg 
loaded per well. A. Polyclonal SLPI antibody was diluted 1:500 and incubated for 1 hr at 
RT. After washing, a donkey, anti-goat secondary antibody was diluted to 1:3000 and 
incubated with the membrane for 1 hr at RT. Lane 1: Rainbow Full Range Protein Marker 
(GE Healthcare). Lane 2: BDa (active ulcer) saliva. Lane 3: BDq (quiet, no ulcer) saliva. 
Lane 4: RASa saliva. Lane 5: RASq saliva. Lane 6: HC saliva. Lane 7 and 8: recombinant 
SLPI (rSLPI, 12-14 kDa). B. Monoclonal NE-HRP antibody was diluted 1:500 and 
incubated for 1 hr at RT. Lane 7 and 9: purified human NE, 29.5 kDa, positive control 
(NE+), no DTT added or heat treatment. Lane 8: Empty. Lane 10: Oral keratinocyte 
(Oker) isolated culture supernatant as a NE negative control. 
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4.3.4. Total Protease and Specific NE Enzyme Activity in Saliva 
Serine proteases, like NE, have the ability to cleave protein substrates after small 
hydrophobic residues (such as valine) and are characterised by an active serine amino 
acid site (Heutinck et al., 2010). Two reaction systems were utilised to assess the activity 
of both endogenous NE and purified NE. The first employed the use of the fluorometric 
EnzChek
®
 Elastase Assay kit (Molecular Probes) to prove not only that active NE was 
present in a patient saliva by its specific inhibition with N-methoxysuccinyl-Ala-Ala-Pro-
Val-chloromethyl ketone (Fig 4.3.4.2.1 to Fig 4.3.4.2.2), but also that total protease 
activity could be determined by the breakdown of fluorescent-conjugated bovine elastin. 
The second system tested the ability of purified NE (Abcam, UK) and endogenous, i.e. 
native, NE in saliva to degrade a colormetric human elastin substrate, MeOSuc-Ala-Ala-
Pro-Val-pNA (Sigma, UK), coupled with a potent specific NE inhibitor, GW311616A 
(Sigma, UK).  
 
4.3.4.1. Proof of Concept: Both Recombinant SLPI and a Chloromethyl Ketone 
Specific Inhibitor Can Prevent Purified NE from Hydrolysing Bovine Elastin 
Substrate 
Initially, a proof of concept experiment was conducted in order to show that purified NE 
could be inhibited by purified rSLPI. Enzyme and inhibitor were combined and tested at 
variable dilutions alongside a constant concentration of 25 µg/ml fluorescent-conjugated 
bovine elastin. The lower of the two rSLPI concentrations tested, 1.08 µM, was able to 
successfully inhibit the majority of 0.385 µM (0.045 U/rxn) of NE resulting in a NE:SLPI 
concentration ratio of about 1:3 (Fig. 4.3.4.1.1). The same concentration of 0.385 µM NE 
was completely inhibited by the NE specific inhibitor 75 µM of N-Methoxysuccinyl-Ala-
Ala-Pro-Val-chloromethyl ketone in a control reaction. However, when the NE 
concentration was increased to 0.424 µM (0.05 U/rxn), 1.08 µM of SLPI was not 
sufficient to inhibit the NE activity. Double the concentration of rSLPI (2.14 µM) was 
able to provide some inhibition of a larger concentration of NE (0.848 µM (0.1 U/rxn)). 
The highest NE concentration, 0.848 µM, was tested with 1.08 µM of rSLPI resulting 
with the NE in the reaction immediately digested nearly 100% of the elastin available, 
producing the largest baseline fluorescent measurement (Fig 4.3.4.1.1). When using the 
porcine pancreatic elastase, both concentrations of rSLPI were not as effective in 
inhibiting the digestion. However, the higher concentration of rSLPI was able to inhibit 
the porcine elastase more efficiently. A positive control reaction was run at the same time 
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whereby porcine elastase (0.01 U/rxn) was 100% inhibited by the ketone inhibitor (75 
µM) throughout the 95 min, 30
o
C reaction.  
The majority of the rSLPI inhibition occurred within the first 5 min of each reaction. This 
was demonstrated by either no change or a slight increase of fluorescence (Fig 4.3.4.1.1). 
Most of the elastin degradation by NE occurred between 5 and 45 min in all reactions 
since the largest fluorescence increase was seen during this period.  
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Fig. 4.3.4.1.1. The Inhibitory Activity of rSLPI on the Enzyme Activity of NE: 
Testing Purified Proteins. A validation experiment was completed to test different 
concentrations of recombinant SLPI protein (rSLPI) and its ability to inhibit both purified 
neutrophil elastase (NE) and porcine pancreatic elastase (P.Ela.) in the presence of 25 
µg/ml fluorescent-conjugated bovine elastin. All proteins were commercially purchased. 
A combination of NE and N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone 
(ketone inhib) was also used as a control for inhibiting NE activity. A negative control 
was also tested combining known inhibitory concentration of ketone inhibitor for P.Ela. A 
constant fluorescence (no change) indicates efficient inhibition. Increased fluorescence 
denotes that the reaction is not being inhibited effectively; however a small difference in 
change of fluorescence from the start of the assay to the end indicates some inhibition. 
Blank wells with only reaction buffer and fluorescence substrate were measured in order 
to deduct background fluorescence from the samples and controls. All reactions were 
tested in duplicate.        
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4.3.4.2. Total Protease Activity and Specific NE Activity in Saliva: Initial Tests 
Both experiments in Fig 4.3.4.2.1 and Fig 4.3.4.2.2 tested the same BDa saliva sample. 
After 95 minutes, the difference between 25 µM and 150 µM of inhibitor in a 1:8 saliva 
dilution showed only a 46% decrease of NE activity (Fig 4.3.4.2.1). Larger saliva 
dilutions (up to 1:40) were tested with 25 µM of inhibitor (Fig 4.3.4.2.2). It was found 
that NE activity decreased by 89% by diluting the final saliva concentration from a 1:4 to 
a 1:40 dilution. But again, 100% inhibition was not achieved in the samples. The neat 
salivary NE content, 1347 ng/ml, had previously been measured by ELISA.  At a 1:40 
dilution, the NE level would be about 33.7 ng/ml (or 5.71 µM) in the reaction. In order to 
fully inhibit the NE, either the saliva will have to be diluted 11% more or the inhibitor 
concentration will have to be increased by 11%. As a negative control, saliva alone was 
tested for auto-fluorescence, but it was confirmed saliva did not emit any fluorescence 
(data not shown). 
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Figure 4.3.4.2.1. Specific Inhibition of Endogenous NE in BDa Saliva: Testing 
Different Concentrations of Inhibitor (a Range of 25-150 µM) with a BDa Saliva 
Sample. The specific chloromethyl ketone inhibitor was added at various concentrations 
to a 1:8 saliva (SAL) dilution (this was the final dilution of saliva in the reaction). Porcine 
elastase (P.Ela., 0.02 units per reaction, U/rxn) with and without 25 µM inhibitor were 
used as controls. The digestion of bovine elastin was monitored by the release of its 
conjugated fluorescence during a 95 minute incubation. A high inhibitor concentration 
(>150 µM) was required to inhibit only part of the neutrophil elastase activity in a 1:8 
diluted saliva sample. 
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Figure 4.3.4.2.2. Specific Inhibition of Endogenous NE in BDa Saliva: Testing One 
Concentration of Inhibitor (25 µM) with One BDa Saliva Sample at a Various Final 
Dilutions (Range 1:4 to 1:40). The specific chloromethyl ketone inhibitor was added at 
25 µM to the various saliva dilutions (in the final reaction).  Porcine elastase (P.Ela., 0.02 
units per reaction, U/rxn) with and without 25 µM inhibitor were used as controls. The 
digestion of bovine elastin was monitored by the release of its conjugated fluorescence 
during a 95 minute incubation.  
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4.3.4.3. Total Protease Activity in Saliva: Comparing Different Groups  
When performing the bovine elastin based EnzChek
®
 elastase activity reaction without 
any specific NE inhibitor, various endogenous proteases including NE are present in 
saliva such as macrophage-derived elastase and gelatinase may be contributing to the 
digestion of the elastin-BODIPY
®
 compound releasing its fluorescence (Mecham et al., 
1997). The measurement of this protease activity is demonstrated in Fig 4.3.4.3.1. HC 
saliva had significantly lower levels of protease activity than BDa after 95 min at 25
o
C 
(p<0.02).  
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Figure 4.3.4.3.1. Comparing the Total Protease Activity in Saliva from Each Patient 
Group. Total protein concentration in each saliva sample was quantified and normalised 
to 1.5 mg/ml. Healthy Control (HC), n=30. BDquiet (q, no oral ulcers), n=33. BDactive 
(a, oral ulcer present), n=29. Significance determined using the Parametric Independent 
Sample T Test,*p<0.02. 
 
 
* 
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4.3.4.4. Specific NE Activity in Saliva: Comparing Groups  
The same EnzChek
®
 assay was run again to determine the total protease activity in saliva, 
but this time duplicate saliva samples were simultaneously tested with 200 µM of the 
chloromethyl ketone specific NE inhibitor added. This assay was completed in order to 
determine the definitive level of endogenous NE activity present in saliva samples from 
BD, RAS, and HC groups. The results can be seen in Fig 4.3.4.4.1. A large amount of the 
ketone inhibitor, 200 µM, was necessary to inhibit more than 77 % of NE activity in all 
the diluted saliva samples. HC saliva, which has been shown in the ELISA to have the 
least amount of NE, also showed the lowest percentage (77.2 %) of NE activity. 
Meanwhile, 87.2 % of NE activity was inhibited in RASa saliva, the same group shown to 
have the highest NE levels. BDa had 82.5 %, BDq 81.5 %, and RASq 82.8 % of their NE 
activity inhibited. This suggests that NE is the main enzyme in saliva which is capable of 
digesting elastin in all patient groups.  
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Figure 4.3.4.4.1. Specific NE Enzymatic Activity in Saliva. The total protease activity 
in saliva was measured by the digestion of fluorescent-conjugated elastin. A separate 
aliquot from the same saliva samples had 200 µM of specific NE inhibitor, N-
methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone, added. NE-specific digestion of 
elastin was also measured in these reactions simultaneously. Saliva samples were tested 
from each patient group: BDa (active oral ulcer) n=7, BDq (quiet, no ulcer) n=6, HC n=8, 
RASq n=5, RASa n=5. The bars in red show the group median values of the total protease 
activity. The blue bars are the group median values for the same saliva samples with 200 
µM of NE inhibitor. Error bars indicate the 95% Confidence Intervals. The reduction in 
elastin digestion in samples with NE inhibitor demonstrates its specific NE activity. 
Porcine elastase (P.Ela.) was used as a positive (+) control: its digestion of elastin was 
inhibited 100% by NE inhibitor.                                                            
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4.3.5. Real Time Quantitative PCR  
Due to the apparent SLPI depletion in saliva, the expression of SLPI mRNA in the oral 
cavity was investigated. Oral buccal mucosa epithelial cells were obtained from all 
patient groups and had their RNA extracted and transcribed to cDNA in order to 
determine if SLPI was up- or down-regulated during oral ulceration.  
 
4.3.5.1. Validation and Controls 
4.3.5.1.1. Bioanalyzer 
After nucleic acid extraction and digestion of remaining genomic DNA, OBS RNA 
samples were tested for RNA quality and integrity using Applied Biosystem’s Agilent 
Bioanalyzer before being used for any downstream assays. If RNA quality is 
compromised, the analysis could be unreliable.  
 
 
 
                                    
Figure 4.3.5.1.1.1. A and B. A: Electropherogram of an RNA OBS Sample. This 
graph displays a data plot of size and migration time in seconds (x-axis) as 1 µl of OBS 
RNA sample runs through a picoRNA chip electrophoresis matrix (Applied Biosciences) 
revealing the fluorescence intensity units (FU) of the RNA (y-axis). The first large peak 
represents the 18S rRNA; the second peak is the 28S rRNA. From the height and area of 
these peaks, the 18S:28S ratio, as well as the entire trace that run along the baseline, the 
quantity and purity of the RNA sample can be deduced. A RNA Integrity Number (RIN) 
is issued to grade the RNA on a scale of quality from 1 to 10 (10 being the best). B: 
Electrophoresis of an RNA OBS Sample. A second visualisation of the same RNA 
sample running through the electrophoresis matrix. The two dominant rRNA bands can 
be detected. 
 
A   B   18S   28S   
28S   
18S   
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4.3.5.1.2. Validated Reference Genes for Oral Epithelial Cells  
Roche’s 19-human reference gene panel and qBasePlus software (Biogazelle, Belgium) 
was used to analyse the most stable mRNA reference genes in oral epithelial cells in HC, 
RAS (with or without an ulcer), and BD (with or without an ulcer). The results revealed 
that the most stable gene was GAPDH followed by the next top five: PPIA, PGK1, 
ACTB, YWHAZ, and 18S rRNA (see Chapter 6). PPIA was subsequently used as a 
reference gene to normalise the data for the SLPI mRNA qPCR assays.  
 
4.3.5.1.3. Inhibition Assessment Assay 
An inhibition assay was conducted in order to test if there were PCR inhibitors in the final 
cDNA samples. PCR inhibitors are substances that can cause inefficiency of a qPCR 
reaction introduced during the multi-process procedure of preparing DNA or RNA 
(cDNA) for gene amplification. These substances include reagents that are introduced 
during the sample collection, such as heparin, or extraction procedure such as ethanol or 
phenol, or can be remnants of the RT enzyme. The spud assay, originally designed by 
Nolan, et al, (Nolan et al., 2006b) was conducted on different dilutions of OBS cDNA in 
order to see if spiking a known concentration of a foreign target (in this case, a 101 bp 
potato sequence) can be fully amplified or “recovered” in the presence of the cDNA 
sample. The quantification cycle (Cq) of the amplified target in the cDNA sample (for 
example, if the target amplifies at Cq 26) is compared with its amplification in water (the 
control) which gives Cq 24. Then it can be determined that the cDNA sample is slightly 
inhibited because it takes 2 more PCR cycles to amplify its target. This equates to a 7.7 % 
deviation from the water control. In Figure 4.3.5.1.3.1, the % of Cq deviation from the 
water control is calculated for each sample. A deviation of 0% signifies no inhibition in 
the sample while a deviation of 100% is total inhibition of amplification. As seen in 
Figure 4.3.5.1.3.1, when every neat sample was tested, the deviation percentage was 
above 9 %. This will alter the true quantification of the target gene. Any inhibitors in the 
OBS cDNA, which is most likely due to the presence of RT enzyme, are overcome with a 
1:10 dilution of cDNA. Therefore, cDNA must be diluted before commencing a qPCR 
reaction in order to ensure that the gene targets are amplified efficiently and accurately.  
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Figure 4.3.5.1.3.1. Spud Inhibition Assay Results: cDNA Must Be Diluted Before Use 
in qPCR Assays. Several samples and their dilutions had the spud amplicon added to 
them before (spud) amplification. These samples included: two oral buccal swab (OBS) 
cDNA samples, S1=cDNA Sample 1, S2=cDNA Sample 2, S3=cDNA Sample 3, and a 
water sample that underwent reverse transcription (RT+). They were added to the spud 
qPCR assay as a neat sample, diluted 1:3 or 1:10. A separate water sample spiked with 
the same spud amplicon was run as the non-inhibited control. The bars represent the 
difference between the quantitation cycle (Cq) of the non-inhibited water control and the 
spiked cDNA samples. Neat (un-diluted) samples in the qPCR assays ranged from 8% to 
100% inhibited. Therefore, diluting cDNA samples is required before being analysed 
using qPCR. 
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4.3.5.2. SLPI mRNA Expression Levels in OBS 
SLPI mRNA expression was measured in adult human oral buccal mucosa epithelial cells 
from HCs, BD and RAS patients during and in between presentation of an ulcer. There 
were several statistical differences in the OBS mRNA expression between groups (Fig. 
4.3.5.2.1). The largest significant difference was between HC and BDq (p≤0.001) which 
suggests that even when there is no ulcer present, the oral mucosal epithelial cells of BD 
patients have upregulated SLPI mRNA. RASq also showed significantly upregulated 
SLPI mRNA (p<0.05) compared to HC. BDa patients’ buccal swabs that were taken away 
from their ulcerated area (BDa, NU) showed that the SLPI mRNA was significantly 
higher than HC (p<0.05). The BDa, NU SLPI expression was also higher than the 
samples taken directly from the ulcer (BDa, U) which is probably due to necrotic tissue 
and therefore a lack of active metabolism and SLPI production. The non-ulcerated 
epithelial cells in the oral cavity may compensate for the ulcerated tissue.   
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Figure 4.3.5.2.1. OBS SLPI mRNA Expression Levels in Different Patient Groups 
and Ulcer Sites. SLPI Cq values were first normalised using the qBasePlus Biogazelle 
software against the Cq values for the PPIA reference gene. The black centre bar in each 
box of the plot represents the median SLPI mRNA expression measured for each group. 
The red box represents 50% of the values in the group and the extended bars indicate the 
extent of maximum and minimum values therefore encompassing the range. HC (healthy 
control), RAS (recurrent aphthous stomatitis), BD (Behçet’s disease). q, indicates mouth 
quiet/no ulcers. a, refers specifically to active mouth ulcer(s) regardless of other systemic 
symptoms. NU = swab taken from the buccal mucosa away from the oral ulcer. U = swab 
taken directly from the ulcer. BDa NU n=20, BDa U n=6, BDq n=27, HC n=16, RASq 
n=11, RASa NU n=4, RASa U n=2. Data assessed by PAWS/SPSS V18: Mann Whitney 
U, non-parametric statistical test comparing median values of two independent groups (2-
tailed). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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4.3.6. Oral Biopsies Histology 
4.3.6.1. NE and SLPI in Oral Ulcer Buccal Mucosa 
Expression of NE and SLPI was investigated in biopsies from BD patients and in control 
tissue using immunofluorescence.  The available clinical data and oral pathologist’s (Prof 
K. Piper) conclusions following histological examination are summarised in Table 
4.3.6.1.1.  
All biopsies were excised from the left or right buccal mucosa. The outermost edge of the 
biopsies exhibited some non-specific antibody staining due to the antibodies becoming 
trapped underneath the biopsy edge. Therefore fluorescent-stained biopsy edges were 
ignored.  
As seen in Fig 4.3.6.1.1, the oral ulcer from the control (Bx1) had minimal NE staining 
although there was some light clustered staining just below the basal cell layer of the 
epithelium and a small area of the submucosa. As expected SLPI expression was 
observed in the epithelium. Also in Bx1,SLPI staining appears in some connective tissues 
within the submucosa with no positive SLPI staining in the lamina propria.  Bx2 showed 
a minimal amount of epithelium in sections and SLPI was not detected. However, there 
was extensive NE staining throughout the lamina propria and deep submucosa (Figure 
4.3.6.1.2). 
In Bx3, a minor saliva gland and duct was unintentionally excised from the buccal 
mucosa but was instrumental in demonstrating SLPI-positive staining in the acini (Figure 
4.3.6.1.3). The inner lining of the duct adjacent to the gland also stained positive for 
SLPI. The epithelium also shows SLPI although the biopsy had partially folded in on 
itself upon cutting and mounting onto the slide. NE was not prominent in the tissue.  
Bx4 had extensive distribution of NE within the lamina propria (Fig. 4.3.6.1.4). SLPI but 
not NE was found in the epithelium. SLPI was also detected in the submucosa. It had a 
stringy, pattern which may be SLPI staining along fibres of the connective tissue. 
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Table 4.3.6.1.1. Patient Descriptions and Biopsy Details. One oral buccal epithelium 
biopsy was donated by a non-BD patient who was undergoing clinical assessment for oral 
ulcers with hyperplasia. Biopsies from three Behçet’s disease (BD) patients, 1 male (M), 
and 2 female (F), were also collected. A description of their ulcer and its duration was 
recorded whenever available, but this was not always the case (n/a). An oral medicine 
pathologist, Professor Kim Piper, provided a histology report on a portion of the same 
biopsy.   
 
 
 
 
 
 
 
 
 
Patient 
Biopsy 
Number 
Patient 
Group  
Sex Age Ulcer 
Description 
Ulcer(s) 
Duration 
Prior to 
Excision 
Histological 
Conclusion by 
Pathologist 
Bx1 Non-BD 
(control) 
M 59 Hyperplasia, 
ulcerative 
changes 
n/a hyperkeratosis and 
widespread non-
specific ulceration 
Bx2 BD F 28 Minor and 
herpetiform 
10 days Non-specific 
ulceration consistent 
with BD diagnosis 
 
Bx3 
 
BD F 30 n/a n/a Non-specific 
ulceration, non-
specific perivascular 
cuffing as seen in BD 
Bx4 
 
BD M 48 Major 6 days Non-specific 
ulceration 
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SEE BIOPSY FIGURE 4.3.6.1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.6.1.1. Oral Ulcer Biopsy from Non-BD Patient. Bx1.Clinical investigation for 
hyperplasia & ulcerative changes. Identified as Bx1. DAPI DNA (blue), NE (red), SLPI 
(green). Arrows indicate main areas of positive staining for NE and SLPI. 10X 
magnification. Scale bar 100 µm. 
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SEE BIOPSY FIGURE 4.3.6.1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.6.1.2. Oral Ulcer Biopsy from BD Patient. Bx2. Minor and herpetiform ulcers 
for 10 days. DAPI DNA (blue), NE (red), SLPI (green). Arrows indicate main areas of 
positive staining for NE and SLPI. Giemsa-stained biopsy included for orientation. 10X 
magnification.  Scale bar 100 µm. 
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SEE BIOPSY FIGURE 4.3.6.1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.6.1.3. Oral Ulcer Biopsy from BD Patient. Bx3. DAPI DNA (blue), NE (red), 
SLPI (green). Arrows indicate main areas of positive staining for SLPI. Enlarged image 
shows a minor saliva gland and duct from the buccal mucosa which stained positive for 
SLPI. Giemsa-stained biopsy was included for orientation. 10X magnification. Scale bar 
100 µm. 
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SEE BIOPSY FIGURE 4.3.6.1.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.6.1.4. Oral Ulcer Biopsy from BD Patient. Bx4. Patient had a major ulcer for 6 
days prior to excision. DAPI DNA (blue), NE (red), SLPI (green). Arrows indicate main 
areas of positive staining. Giemsa and H&E stained biopsy sections were included for 
orientation. 10X magnification.  Scale bar 100 µm. 
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4.4. Discussion 
4.4.1. Salivary NE Levels in the Presence and Absence of Oral Ulcers 
The salivary NE concentration in BD and RAS patients with oral ulcers was significantly 
higher than the same patient groups without oral ulcers. This eludes that both groups have 
the innate neutrophil response that was expected during a wound (Dovi et al., 2004). The 
ELISA assay also revealed the normal, HC baseline of NE in the mouth. The 
concentration ratio of NE:SLPI was 2:1 based on the HC group median. RASq had a 
similar ratio closer to 1:1. When an ulcer was present, the RASa saliva revealed an 8:1 
ratio. Both BDa and BDq resulted in exactly the same 6:1 ratio with NE dominating over 
SLPI. In order for a wound to heal effectively, the presence of neutrophils and 
extracellular NE needs to dissipate. The trend in our patient groups showed that NE levels 
were reduced in RASq, but not BDq patients.   
It is with concerned interest that higher levels of NE were detected in BD patients’ saliva 
without the presence of an ulcer. Neutrophils and extracellular NE can perpetuate 
inflammation, delay appropriate healing, and because of its NE’s proteolytic nature can 
destabilise various proteins of the ECM (Szpaderska et al., 2003, Yager and Nwomeh, 
1999). Circulating neutrophils and increased NE have been previously implicated in the 
systemic chronic inflammatory response in BD (Deger et al., 1995, Eksioglu-Demiralp et 
al., 2001), but until this present study, was not linked to the extracellular presence of the 
protease in saliva and its potential damage to the oral mucosa.  
Quantifying a higher NE level in BD compared to RAS patients suggests that when an 
oral ulcer is absent, RAS patients have a more subdued innate immune “resting” state 
than BD patients. RASa patients may resolve the influx of neutrophils more efficiently 
than BDa. However, RASq sample size representation was quite low in these assays 
(n=10), and additional measurements are necessary to confirm significant differences. 
Therefore, while it can be suggested that NE plays a central to the oral pathology seen in 
BD, its role in RAS ulcers is still uncertain. 
4.4.2. SLPI mRNA in Oral Buccal Epithelial Cells and Protein Level Discrepancy  
Before the results of the SLPI protein levels quantified by ELISA can be explored in 
detail, it is necessary to discuss the oral epithelial cells which contribute to producing 
local SLPI mRNA. Recently, two real time qPCR-based studies were able to collect and 
access SLPI mRNA expression in healthy oral buccal epithelium using cytobrushes 
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(Taborda et al., 2012) and punch biopsies (Nittayananta et al., 2013a). These healthy 
controls were used to compare HIV-seropositive patients SLPI expression. Unfortunately, 
both studies also failed to validate their reference gene for normalisation. Without the 
validation that the reference gene is stable in all samples and sample treatments, the 
expression results are inaccurate and therefore misinterpreted. Our study was the first to 
measure SLPI mRNA in the oral buccal epithelium from HC as well as BD and RAS 
patients during quiet and active episodes of ulceration alongside a validated, stable 
reference gene. (See Chapter 6 for more details on oral buccal epithelial cells reference 
gene validation).    
For all the individuals tested, there was no genetic deficiency associated with oral SLPI 
since mRNA was able to be quantified in each sample. Interestingly, even when oral 
ulcers were absent, the buccal mucosal epithelial cells of BD patients showed highly 
upregulated SLPI mRNA. This is probably a response to the chronic presence of 
inflammatory markers, NE, and other unknown stimulants. Unexpectedly, RAS patients 
without ulcers also showed significantly higher SLPI mRNA expression compared to HC. 
While this coincides with the RASq SLPI protein level being higher than HC, both groups 
shared similar NE levels in their saliva. Therefore, salivary NE may not be solely 
responsible for stimulating the increased epithelial SLPI mRNA expression in RAS 
patients.  
Additional RASa and BDa OBS samples are necessary to deduce significant differences 
between patients with active ulcers, especially at the direct site of the ulcer. These 
samples were difficult to obtain due to the pain of placing a brush onto the sensitive 
surface of the ulcer which would frequently aggravate the wound. Also, after testing 
several of these direct-ulcer RNA samples on the Bioanalyser, several showed low quality 
and had to be excluded from the study at this checkpoint. This created a limitation of the 
study. 
A previous study on sputum found that SLPI concentrations measured by ELISA were 
higher in COPD patients when compared to HC non-smokers (Tsoumakidou et al., 2010). 
In our study, it was predicted that the salivary SLPI concentrations would be higher in 
individuals with oral ulcers due to the fact that it is part of the inflammatory response to a 
wound (Angelov et al., 2004). However, surprisingly, when comparing the different 
patient groups, SLPI protein levels decreased significantly in BD patients whether or not 
they had ulcers present. This contradicts the mRNA results which indicate that oral 
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epithelial cells from BD patients (with or without ulcers present) have significantly 
increased expression of SLPI. Presumably this means that the cells are producing high 
quantities of SLPI protein, although this was not detected with the ELISA. The success of 
the translational process of SLPI (mRNA to protein) is unknown in this instance, 
however, our data would suggest that 1) the production, folding, or exocytosis of the 
SLPI protein is insufficient during ulceration or 2) SLPI may be “used-up” or bound 
(complexed) with NE (or other proteases and microbes) thereby causing degradation of 
the SLPI protein or masking of the SLPI antibody epitope. Unfortunately, the epitope 
information for the antibody used in the present study is not available from the 
manufacturer in order to confirm this theory.  However, we believe the latter to be the 
most likely cause of the mRNA-protein discrepancy due to the inverse relationship seen 
in NE and SLPI ELISA results.  
Similar discrepancies between SLPI mRNA and SLPI protein measurements have been 
shown in other studies (van Wetering et al., 2000) (Saitoh et al., 2001) (Jana et al., 2005). 
Van Wetering, et al, presumed their juxtaposing results were due to an increase in cell-
associated as opposed to cell-secreted SLPI after stimulation of bronchial epithelial cells 
by NE in culture. Saitoh, et al, interpreted similar results as a delay in exocytosis of SLPI 
from epithelial cells since the cells’ first contact with NE may release a large initial 
amount of stored SLPI. It has been shown that a short in vitro incubation of ex vivo 
human tracheal submucosal serous gland cells with NE can result in increased exocytosis 
of SLPI protein (Maizieres et al., 1998), but cells could be too slow to replace the protein 
(Jana et al., 2005). From our findings thus far, we can contribute that SLPI is produced 
and released into the oral cavity but that it is met with high levels of NE and α1AT. The 
levels of SLPI produced do not seem to be sufficient to regulate the consistently high 
concentrations of NE that are seen in BD. This is assuming that the levels of these three 
proteins measured in HCs are the levels that are required for homeostasis to be 
maintained in the oral mucosa. 
 A study by Sallenave, et al, showed that SLPI mRNA was up regulated when a lung 
epithelial cell line was stimulated with IL-1β and TNF (Sallenave et al., 1994). SLPI 
mRNA has also been shown to be induced in vitro by NE (Jin et al., 1997).  Therefore, 
the high up-regulation of SLPI mRNA could be directly due to the high level of NE in the 
mouth.  
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In another experiment, Saitoh, et al, combined α1AT and NE into SLPI-producing 
epithelial cell cultures (Saitoh et al., 2001) resulting in the SLPI mRNA being 
significantly reduced compared to a culture with only NE added (without α1AT anti-
protease). Therefore, if there is a relatively large amount of competitive inhibitor (α1AT) 
already present in an NE-laden environment, the induction of SLPI mRNA production 
could be reduced. In our experiments, salivary α1AT had higher protein concentrations 
than NE and SLPI. Therefore, it could be deduced that even if SLPI mRNA is 
upregulated, it still may not translate to sufficient levels of protein to regulate NE since an 
over-abundance of α1AT is present in the oral environment.  
 
4.4.3. The Inverse Relationship of NE and SLPI Protein  
A direct relationship between NE and α1AT levels was apparent in our ELISA 
measurements, however, there was an unexpected inverse relationship between NE and 
SLPI. As previously discussed, this phenomenon could be due to SLPI being degraded 
and inactivated, bound to other proteases such as CatG, or inhibiting microbes – all of 
which could cause masking of the compatible configuration necessary for antibody 
detection. The SLPI depletion could also be because not enough is being produced to 
meet the demands despite SLPI mRNA upregulation and/or once the protein is released 
from the cells, it is overwhelmed by increased NE. 
The inverse relationship between SLPI and NE protein was also previously described in 
oral fluid samples by Cox, et al, in 2006. They found increased NE and decreased SLPI in 
gingival crevicular fluid and diluted whole mouth saliva (Cox et al., 2006). Our ELISA 
data concurs with this excess of NE over SLPI in the oral environment based on protein 
concentration ratios. The low levels of measurable SLPI may be a consequence of the 
high levels of NE if the proteins have complexed and cannot be detected. This theory is 
supported by similar assays conducted by Saitoh, et al, in 2001 in which they suspected 
the epitope of their commercial SLPI monoclonal antibody coincided with the protein’s 
active inhibitory site (Saitoh et al., 2001).  
The type of physical binding of SLPI with NE has been demonstrated by Koizumi, et al, 
in 2008, but they only worked with half of the SLPI protein – the C-terminal domain that 
binds to NE (Koizumi et al., 2008). In theory, its binding with NE could block the SLPI 
detection antibody, but this clearly does not occur 100% of the time since our 
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experiments have shown that we are able to measure over 850 ng/ml of SLPI by ELISA 
as well as visualise it in the saliva and OBS as one clear protein band in Western blots at 
the 12 kDa expected size. The question remains whether our ELISA is detecting either 
complexed or unbound SLPI, or both.   
Exploring SLPI’s response to a stimulant, a study conducted by Grobmyer, et al, in 2000 
showed fluctuating SLPI measurements in plasma over 48 hrs after intravenous injection 
of LPS into healthy controls. They used the same SLPI ELISA from R&D Systems that 
we employed. After baseline measurements, SLPI levels seemed to rapidly decrease - the 
lowest occurring 3 hrs post-LPS challenge. Then, there was a rapid increase above 
baseline concentrations peaking at 12 hrs after which the levels descended and returned 
closer to baseline levels by 48 hrs. Both high and low LPS dosages experienced the same 
fluctuations although the higher dosage increased the range of maximum and minimum 
SLPI levels (Grobmyer et al., 2000b). In our experiment, patients with active ulcers were 
shown to have decreased SLPI, similar to the initial exposure of LPS. Based on patient 
group analysis, BD patients never seemed to replenish or recover their salivary SLPI 
levels signifying that a constant stimulant is present. Most insightful is when no ulcer is 
present, BD patients still have what seems to be depleted SLPI while RAS patients have 
high concentrations. This would suggest that BD patients endure a constant stimulant 
regardless of oral ulceration while RAS patients do not and are able to recover an 
immunogenic equilibrium.  
Grobmyer, et al, speculated that there could be an issue with the detection of SLPI by 
ELISA. They suggested that SLPI could be degraded by proteases (which were 
upregulated by the LPS) or that SLPI was bound to an unknown receptor. This binding 
may also mask the antigen-antibody recognition making it “invisible” to the ELISA 
(Grobmyer et al., 2000b). This technical misrepresentation was also demonstrated by two 
similar ELISA results. The first was testing an in-house ELISA developed by Westin, et 
al, in which two antibodies to human SLPI (raised in mouse and sheep in-house) were 
used to conduct a sandwich ELISA. A fixed concentration of recombinant human SLPI 
was mixed with varying NE concentrations in PBS and measured on the SLPI ELISA. 
This basic analysis revealed that when more than double the amount of NE was 
introduced to rSLPI, the SLPI concentration was reduced nearly two-fold (Westin et al., 
1999a). It is worth noting that the same result occurred with Cathepsin G but not with 
chymase. SLPI binds both of these but perhaps at different sites allowing the ELISA 
antibody to detect SLPI at one site but not another. The second example, a study 
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conducted by Sullivan, et al, sought to validate the R&D Systems’ ELISA measurements 
of SLPI. Using purified proteins, they found that increasing NE > 100:1 (NE:SLPI 
stoiceometric molar ratios) steadily decreased the successful detection of rSLPI (Sullivan 
et al., 2008). The authors of these experiments theorised that this apparent SLPI depletion 
may be due to the NE:SLPI complex configuration masking the SLPI antibody detection 
or an over-abundance of NE clouding the SLPI antibody detection. Westin, et al, 
suggested that the ELISA may be giving “false low values”. In our circumstances, a 
heterogeneous saliva sample already contains both SLPI and NE, therefore the total SLPI 
concentration may already be masked at a baseline reading since ensogenous NE 
concentration always seems be higher even in healthy controls.       
4.4.4. High Levels of Alpha-1 Anti-Trypsin in Saliva 
It was surprising to see that the α1AT in saliva, even in HCs, was at such high 
concentrations since several other studies reported lower concentrations of salivary α1AT. 
Pederson, et al, measured only 5 - 240 ng/ml of α1AT by ELISA in healthy control 
unstimulated, whole saliva (Pederson et al., 1995). In a study by Cox, et al, the α1AT 
values in whole saliva from severe chronic periodontitis patients reported a vast range of 
1,272 - 16,748 ng/ml (Cox et al., 2006) but not concentrations above 1 x 10
6
 ng/ml as our 
study had. In both previous studies, the saliva samples were diluted 1:2 with an equal 
amount of buffer. In order to confirm that our patients’ saliva samples were being 
measured by the α1AT ELISA accurately and to clarify mixed reports, stored serum 
samples from the patients and HC donors were diluted in PBS at 1:100, 1:10,000, and 
1:100,000 and measured since serum is known to carry high quantities of α1AT. The 
1:100,000 diluted serum levels showed that HC had a mean of 1.97 x 10
6
 ng/ml which 
was within previously reported ranges. For instance, Mornex, et al, revealed that α1AT in 
normal serum had a mean of 2.03 x 10
6
 ng/ml (range 1.24-3.40 x 10
6
 ng/ml) (Mornex et 
al., 1986). Another study found that the α1AT content in plasma from healthy, normal 
donors was between 1.5 x 10
6 
- 3.5 x 10
6 
ng/ml when measured by immunodiffusion 
(Dickens and Lomas, 2011)while others reported a similar range (in serum and plasma) 
from 1.2 x 10
6 – 2 x 106 ng/ml by standard nephelometry (Sun and Yang, 2004). The 
confirmation of high quantities of α1AT measured in serum both in previously studies 
and using our ELISA method helped to validate the high concentrations measured in our 
patients’ saliva. It is proposed that the saliva samples used in Cox, et al, and Pederson, et 
al,’s studies were not sufficiently diluted before being assessed by ELISA. Therefore, in 
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our study, the predominant anti-protease concentration in saliva was α1AT and not SLPI 
as was hypothesised.  
The results from our investigations showed there was a strong association between 
salivary levels of α1AT and NE. At this time it is not clear whether an increase of NE in 
saliva is actually stimulating the increased recruitment of α1AT from circulating serum 
but this could be inferred. If the α1AT:NE are irreversibly complexed, it is unknown 
whether this interferes with their concentration measurements using ELISA. In future 
experiments, it is vital to determine if the high NE levels measured by ELISA are actually 
already complexed with α1AT. If this is the case, the risk of ECM being digested by NE 
would be depleted. The western blots we conducted showing multiple NE protein bands 
suggest that antibodies could simultaneously target NE and NE bound to other proteins. A 
study by Pederson, et al, (1995) was able to measure the NE:α1AT complex in saliva 
using an ELISA assay with α1AT as the capture antibody followed by NE primary 
detection antibody (Pederson et al., 1995). It would appear that the antibody epitopes they 
used were capable of attaching to complexed proteins. When NE is complexed with 
α1AT, it is functionally inactive (Carrell et al., 1982, Gavrin et al., 2012b, Korkmaz et al., 
2008b). Again, this information is important for understanding NE’s activity and potential 
tissue damage in the oral cavity. 
From our evidence, we propose that SLPI and α1AT levels are influenced by NE and not 
necessarily by the sole presence of oral ulcers since BD patients without oral ulcers still 
have high NE. It is a cyclic relationship in which NE will perpetuate increased 
chemotaxis of additional neutrophils and NE inhibitors. In 1988, J. Travis described NE 
as a stimulus for SLPI in the lung (Travis, 1988). But perhaps SLPI levels are also 
influenced by the surprisingly high concentration of α1AT in the saliva. SLPI and α1AT 
are beneficial competitors in the sense that they have a specific affinity to inhibit the same 
potentially damaging NE enzyme. Both can be found internally in neutrophils (Amulic et 
al., 2012, Clemmensen et al., 2011, Paakko et al., 1996) presumably protecting the cell 
itself from unintentional proteolytic damage. Both are also found in gingival crevicular 
fluid, although α1AT is serum-derived and SLPI is thought to be from the gingival 
junctional epithelium (Nakamura-Minami 2003). However, since SLPI is also produced 
locally by oral epithelial cells and the salivary gland acinar cells, it was expected to be the 
main salivary inhibitor for NE, however, α1AT which is produced in liver cells and 
transferred to the serum, was more abundant. The fact that α1AT was found in such high 
quantities in saliva yet the NE present was still able to actively degrade elastin was a 
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surprising find since as a serpin, α1AT, is thought to irreversibly bind and inactivate NE 
(Korkmaz et al., 2008b). However, even with the surplus of α1AT, the NE was still 
active, even in HC. This occurrence was also found by Vignola, et al, (1998) in the 
sputum samples of asthmatic and chronic bronchitis patients (Vignola et al., 1998). They 
proposed that α1AT could be inactivated by reactive oxygen species, such as superoxide 
anions and hydrogen peroxide, or loses function when bound to neutrophil 
metalloproteinases, such as NE, and collagenase (Michaelis et al., 1990). 
The reactive centre loop on an α1AT molecule, which acts as an attractive cleavage site 
for NE, has a methionine residue which is susceptible to this oxidation (Matheson et al., 
1979). Not only are phagocytic cells such as neutrophils and macrophages capable of 
generating oxidizing agents but so are bacteria at the site of infection. Logistically, it 
would be counterproductive for NE to be immediately inhibited by α1AT since this would 
allow bacteria to overwhelm the host’s tissues. It may be the case, as Carrell, et al, 
proposed, that at the periphery of an infected site, the α1AT may better contain the 
protease activity, but at the centre of infection, the various oxidizing species from 
neutrophils, macrophages, and bacteria downgrade the α1AT inhibitor (Carrell et al., 
1982, Schonberg et al., 2012). 
Our enzymatic assays and antibody-binding stages of the ELISA’s have been carried out 
under neutral pH conditions. Patient saliva was diluted at least 1:20 and 1:200 in PBS, 
respectively, when undergoing analysis due to its high total protein content. In saliva, 
α1AT was at least 5 times the concentration of NE in HC, BDq, RASq, and BDa patient 
groups. If α1AT, a serpin-type inhibitor, binds and inactivates NE irrevocably, then this 
would most likely diminish the NE enzyme activity. However, the NE activity measured 
in BDa was still significantly higher compared to HC. This suggests that the salivary 
α1AT is not fully active in order to regulate salivary NE. This may further be explained 
by the dampened activity of α1AT in the slightly acidic pH of human saliva (Reibetanz et 
al., 2012, Schonberg et al., 2012)  which normally can range from a pH of 5.3 – 7.8 
(Humphrey and Williamson, 2001a). If neutrophils and extracellular NE are present 
especially in the absence of an oral ulcer (as seen in BDq), reactive oxygen species could 
further contribute to lowering saliva pH rendering α1AT inactive thus creating another 
protease-inhibitor imbalance. 
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 4.4.5. Target Proteins Identified by Western Blots 
The polyclonal goat SLPI antibody was useful in identifying one, clear SLPI protein band 
in various oral specimens just above the 12 kDa protein ladder. The rSLPI may be a 
slightly less cationic than the native protein as it ran a fraction slower during the 
electrophoresis process resulting in a band slightly higher than the samples. Saliva 
samples that were used on SLPI westerns were also targeted with NE antibodies. The 
expected 29.5 kDa NE protein band was detected. The protein content in these western 
blots coincided with the quantity of the saliva sample measured on the ELISA. 
Purification columns (DNeasy kit, Qiagen) with an acetone protein precipitation were 
used to isolate protein from whole blood and OBS samples, but the fluid portion of saliva 
was not filtered or purified further, therefore could have resulted in the two closely 
separated NE bands.   
It was expected that employing the use of a purified, monoclonal NE-HRP conjugated 
antibody would result in one band at the 29.5 kDa mark. Surprisingly, there were 
additional protein bands identified in the NE westerns. The three bands, with different 
degrees of intensity, showed up at approximately 12, 31, and 52 kDa in the majority of 
saliva samples. In the NE-HRP western blots, the lower band hovering just above 12 kDa 
in several saliva samples could be a component of NE. The suppliers of the purified, 
native NE derived from human blood neutrophils (Abcam, UK) suggested that the lower 
bands were probably due to some NE degradation. Finally, all samples including saliva, 
isolated protein from blood, and ulcerated oral epithelium revealed the large band just 
above 52 kDa.  
Isolated protein from the oral keratinocyte culture supernatant also revealed the 52 kDa 
band. This sample was meant to be a negative control for the 29.5 kDa NE, which was 
absent, but it was not anticipated that a larger band would be identified. It is suspected 
that this larger band was a residual NE:α1AT complex from the serum used in the 
keratinocyte culture media. As there is no further NE production released from these cells 
and α1AT is generally found in higher quantities in serum than NE, the NE was bound by 
excess α1AT and detected on the western blot. Therefore, it is a strong possibility that the 
reoccurring large band in all the other patient samples is the NE:α1AT protein complex. 
An inhibitor-enzyme complex of SLPI and NE has been previously been described 
(Koizumi et al., 2008, Sullivan et al., 2008, Morrison et al., 1990, Chan et al., 2003). If 
SLPI bound NE and formed a strong complex in saliva which was tolerant of 70
o
C and 50 
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mM DTT reduction, it was expected that this complex could be detected on the western 
blot around 41.2 kDa (11.7 kDa SLPI + 29.5 kDa NE). This was not the case in any of the 
samples or the combination of purified proteins. It could be that this complex was 
disrupted since it is believed to be reversible (Gauthier et al., 1982) during protein 
reduction (DTT or heat treatment) or sample processing (freeze-thaw).  
Saitoh, et al, proposed their antibody may also have been recognising some SLPI 
proteolytic products (Saitoh 2001), but we did not find proof of these smaller protein 
fragments on our SLPI western blots. The smaller fragments lead to an interesting 
observation also previously reported by Cox, et al, (Cox et al.) in which cleavage 
products of SLPI less than 12 kDa were detected by western blots. Degradation of SLPI 
has also been shown by Weldon, et al, using increasing concentrations of purified NE 
over SLPI (Weldon et al., 2009). Cysteine proteases such as Cathepsins B, L, and S in the 
mouth as well as chymase, a serine protease from mast cells (Belkowski et al., 2009), can 
cleave and inactivate SLPI (Cox et al., 2006) (Taggart et al., 2001). However, it has not 
been reported if cleavage can occur once SLPI is complexed with a protease. If SLPI was 
shown to be cleaved in our samples, presumably it would affect the function of the 
inhibitor and result in NE being deregulated which would be detrimental to the oral 
tissues. Low molecular weight SLPI cleavage products or fragments were not observed 
on any of our western blots, therefore we can infer that from our results this pathological 
mechanism is not occurring in our patients groups. However, the use of native, non-
reducing gels may show a better representation if the SLPI is being degraded. 
4.4.6. Salivary Proteases and NE Activity 
As a proof of principle, the ability of recombinant SLPI to inhibit purified human NE was 
demonstrated at a 1:3 ratio of NE:SLPI. An in vitro study previously reported that 
recombinant SLPI was able to inhibit free NE on a 1:1 molar ratio (Morrison et al., 1990).  
However, another study combined non-recombinant native SLPI isolated from lung 
epithelial cells with purified NE and measured SLPI by ELISA. They found that 25 times 
more SLPI was necessary to inhibit NE (Saitoh et al., 2001). In this experiment and our 
own, a larger amount of SLPI was required to inhibit NE activity. Interestingly, our 
ELISA results showed that salivary SLPI was consistently found in lower concentrations 
in comparison to NE even in HC individuals. Perhaps this represents its working ratio 
which according to the ELISA averaged 2:1 (NE:SLPI). After all, it would be detrimental 
to inhibit all NE as it has an important role in innate immunity.  
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The same recombinant SLPI from R&D systems was also tested by Pilette, et al, on 
PMA-stimulated blood neutrophil cultures, resulting in 90% inhibition of 0.05 µM NE 
activity when mixed with 2.5 µM of rSLPI (Pilette et al., 2003). Similarly in our 
experiment, 69% of 0.385 µM NE was inhibited by 1.08 µM rSLPI. 
To confirm that the NE measured in saliva was biologically active, a NE-specific 
inhibitors (N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone) was added to BD, 
RAS, and HC patients’ saliva samples. The exogenous inhibitor revealed that all groups 
had highly active NE in their saliva causing elastin cleavage. The two highest activities 
were associated with the two groups having an oral ulcer: RASa and BDa. The NE 
activity corresponded to the NE concentrations measured with total protein being 
normalised for each sample. This outcome was not altogether unexpected since the 
presence of an ulcer would usually stimulate neutrophil recruitment in order to control 
any bacteria invading the wound. However, the BDq group also had a higher NE activity 
than HCs. Individuals with BD have been described as having hyperactive neutrophils in 
their blood circulation (Verity et al., 2003, Matsumura and Mizushima, 1975). Our data 
adds to this observation that active salivary NE is also present. Furthermore, high levels 
of enzymatically active concentrations of NE in BD saliva could contribute to recurrent 
mucosal damage and ulceration associated with this disorder. The question whether 
increased NE in saliva can be regulated effectively by SLPI is therefore of important 
clinical relevance in these patients. 
The same chloromethyl ketone inhibitor, at 200 µM, was previously used to show > 90% 
inhibition of 0.05 µM of degranulated NE derived from phorbol-myrisate-acetate (PMA) 
stimulated blood neutrophil culture (Pilette et al., 2003). A similar buffer at pH 7.5 and 
reaction temperature at 37
o
C was used for our first assay with the ketone inhibitor.  
Similarly to α1AT, it is speculated that a portion of native SLPI could be deactivated in 
vivo by reactive oxygen species. Oxidation has been shown to occur at the same protease-
inhibiting site – the methionine residue (Korkmaz et al., 2008b). This could be a naturally 
occurring balance of enzyme and inhibitor. Unfortunately, native SLPI from each 
patient’s saliva sample could not be isolated in this study, therefore limiting investigation 
of the function and activity of native, human salivary SLPI (only the recombinant form is 
available commercially). It may be possible in the future to do this using chromatography 
and HPLC purification in order to use it in assays as they have done from sputum samples 
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(Hochstrasser et al., 1981), but at the moment, due to the large volume of saliva that is 
required for purification and the cost entailed, this was not a logistical consideration. 
In saliva from all patient groups tested, NE can retain its activity in saliva when handled 
according to the conditions observed for the current study which included: storing on ice 
at clinic, centrifuging at 4
o
C, aliquoting and freezing aliquots on dry ice at the lab bench, 
then transferring these immediately for long term storage to a -80
o
C freezer until use. 
 
4.4.6. Distribution of NE in Ulcerated Oral Buccal Epithelium  
4.4.6.1. Distribution of NE  
NE was found within the lamina propia and submucosa in the ulcer biopsies although 
there was extensive distribution in two biopsies from BD patients. Despite their similar 
NE expression indicating neutrophil infiltration, these patients had very different clinical 
features. One patient was experiencing an acute episode of activity. Along with the mouth 
ulcers, they also had genital ulcers, folliculitis, and CNS issues. Interestingly, this person 
was not on any medication. Quite differently, another BD patient had oral ulceration, was 
considered to be non-relapsed, and was medicated with azathioprine and betnesol 
mouthwash. The biopsy from the third BD patient showed minimal NE expression yet 
this patient was relapsed with joint and folliculitis manifestations and was reported to use 
triple mouthwash for the ulceration but was not on any systemic medication for BD. From 
this data, NE expression in ulcerated tissues does not reflect BD disease activity.  
In all four biopsies, NE expression was never directly detected in the epithelium or above 
the stratum basale layer. This was surprising as it was expected that neutrophils would 
inundate the area of an ulcer, but it is likely that other areas around the ulcer, especially if 
the epithelium was compromised or perforated, provided the chemotactic factors 
necessary to recruit neutrophils. A few CD3
+ 
T-lymphocytes were identified within the 
epithelial layers of all biopsies except for BD Bx2 since there was no epithelium present 
in the section (data not shown). Although CD3
+ 
cells were in relatively small numbers in 
the epithelium, a large congregation of CD3
+ 
cells were evident just below the stratum 
basale border inside the lamina propria in the control biopsy and more extensively in the 
same two BD biopsies with extensive NE infiltration described above. The appearance of 
CD3
+ 
T-cells which are part of the adaptive immune system is compatible with the fact 
that the mucosal tissue from these patients had been ulcerated for 6 and 10 days. The age 
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of the ulcer could also be the reason why NE expression was not found in the intact 
epithelium since neutrophils are usually the first to migrate to a wound and usually 
subside after a few days when the adaptive immune system would dominate. 
4.4.6.2. SLPI in Ulcerated Mucosa 
SLPI was identified in the epithelium of the buccal mucosa in two biopsies from BD 
patients and in the control tissue. SLPI expression was evident throughout the epithelial 
cell layer, but did not frequently present below the margin of the stratum basale into the 
lamina propria. This staining is comparable to oral mucosal staining seen in HC biopsies 
(Wen et al., 2011) and confirms its expression in oral buccal epithelial cells. SLPI was 
difficult to detect in one of the BD biopsies because there was a very limited amount of 
epithelium in the section. However, it was fortuitous that in this biopsy a minor saliva 
gland and duct from within the buccal mucosa was excised in the biopsy specimen. 
Strong positivite SLPI staining was observed all along the inner lining of the acini in the 
gland and duct cells similarly seen in Wahl, et al, (Wahl et al., 1997b). This provided 
evidence that saliva glands produce SLPI in BD patients with oral ulcers, even though 
their salivary SLPI levels are low. NE was not found around or within the gland, however 
CD3+ cells were scattered along these structures (data not shown for CD3).   
In the control and one non-relapsed BD patient biopsies, SLPI also appeared to be evident 
lining the major vessels and some connective tissue fibres. The origin of SLPI’s presence 
is probably serum-derived. 
SLPI was difficult to stain at first since fixation with 100% ice-cold methanol on these 
tissues did not allow the SLPI epitope to be detected by polyclonal or monoclonal SLPI 
antibody. It was not until fixing with 4% PFA for 10 min and combining this with the use 
of a mouse monoclonal SLPI antibody that positive identification of SLPI within the 
epithelial cells became apparent. 
Note that α1AT was targeted on the biopsies but due to time constraints and the necessary 
optimisation involved with this particular antibody, α1AT staining in these biopsies was 
inconclusive (data not included).  
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4.4.7. Conclusion 
NE was found in significantly high concentrations in saliva from RAS and BD patients 
with oral ulcers compared to HC. The NE enzymatic activity was directly proportional to 
the concentration of NE in saliva. Importantly, the NE concentration was also elevated in 
individuals with BD even in the absence of ulceration. Due to its increased presence, NE 
could play an important role in the cause of oral mucosal damage and recurrent ulceration 
in BD.  
Both NE and SLPI have anti-microbial properties and help to protect the oral mucosa 
against invading oral microbes. It was hypothesised that SLPI concentration would 
increase alongside an increase of NE during oral ulceration, but this was not the case. 
Instead what we found was an inverse relationship in which a higher NE concentration in 
saliva meant a lower SLPI concentration. Interestingly, SLPI mRNA expression was 
significantly up-regulated in BD oral mucosal epithelial cells with or without ulceration. 
It would seem that SLPI is inadequately supplied in saliva and may not be able to regulate 
high concentrations of NE. This in turn recruits various other inflammatory cells into the 
oral mucosa which continue to produce inflammatory cytokines. A chronic cycle of 
inflammation is created which may contribute towards direct mucosal injury leading to 
the manifestation of recurrent ulceration and severity of an ulcer. 
The majority of BD patients (whether experiencing an active or quiet episode) are on 
long-term medication, such as corticosteroids and colchicine, to control inflammatory 
exacerbations. However, colchicine, which has been shown to reduce neutrophil 
chemotaxis (Matsumura and Mizushima, 1975), did not reduce the high level of salivary 
NE in BD patients without ulcers. Therefore, despite being on colchicine, neutrophils 
must still gain access to the oral cavity in large quantities since the presence of NE was 
increased. This reinforces the need for local inhibition of increased NE.   
Application of topical recombinant SLPI has been shown to reduce inflammation, elastase 
activity, and the time it takes for a wound to heal (Ashcroft et al., 2000). Incorporating 
rSLPI in a mouthwash for individuals with oral ulcers may reduce the severity and 
healing time. For individuals with a systemic disorder, like BD, in which NE and pro-
inflammatory mediators are constantly up-regulated, a topical mouthwash may prevent 
the chronic reappearance of painful oral ulcers. McElvaney, et al, was able to show that 
cystic fibrosis patients who used aerosolised rSLPI had decreased NE in their lungs 
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(McElvaney et al., 1993). In 2009, Li, et al, proved that a low cost, high yield version of 
biologically active recombinant SLPI could be produced using Pichia pastoris yeast (Li et 
al., 2009) providing a more practical method of in-house preparation and supply for 
research. 
Also, a critical investigation of the native SLPI human antigen-antibody epitope 
combinations need to be identified in order to definitively analyse the levels of free and/or 
unbound SLPI protein in human specimens such as plasma and saliva. This will not only 
help us understand the mechanism of SLPI’s inhibitory properties, but also help to 
discover its true concentration as this is especially important in monitoring rSLPI-based 
medical treatments. 
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Chapter 5: 
NETosis in 
Behçet’s Disease 
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5.1. Introduction 
5.1.1. NETosis: The Discovery of an Alternative Type of Death in Neutrophils 
A histology textbook published in 1995 describes neutrophil membrane protrusions 
(Junqueira et al., 1995). About the same time, Takei, et al, reported observing an atypical 
cell death when human neutrophils were activated with phorbol 12-myristate 13-acetate 
(PMA) (Takei et al., 1996). In standard culture media (RPMI 1640 with 10% FCS) and 
common incubation conditions (37
o
C, 5% CO2, 95% humidity), the addition of PMA into 
an isolated population of neutrophils produced a unique and unusual cell death involving 
the formation of vacuoles and the nucleus morphing into a spherical shape causing it to 
“spread out.” After 3 to 4 hrs, the cell ruptured spilling its contents into the extracellular 
space. Then in 2004, Volker Brinkmann and his colleagues at Max Planck Institute in 
Berlin, published their experiments describing a similar neutrophil-specific cell death 
entailing the externalization of particular cellular constituents which they proved had 
bactericidal capabilities (Brinkmann et al., 2004). They named the ruptured cells’ 
filaments neutrophil extracellular traps, or NETs, and this new type of programmed cell 
suicide became known as NETosis (Steinberg and Grinstein, 2007).  
 
To date, many scientists have expanded the portfolio of information on NETs even 
though the exact mechanism is still unknown. However, Brinkmann, et al, were the first 
to describe some of the key elements required for neutrophils to undergo NETosis: 
neutrophil elastase (NE), myeloperoxidase (MPO), reactive oxygen species (ROS) and 
the main constituents of the NETs being DNA histones (Brinkmann et al., 2004). 
Brinkmann, et al, used PMA to induce neutrophils, but also included the biologically 
relevant stimulants IL-8 and bacterial LPS. Importantly, NETosis was found to be an 
active process requiring the cell to remain functional up until the stage at which NETs are 
released and the cell dies (Brinkmann et al., 2004). They proved that activated, live 
neutrophils were releasing NETs by using exclusion dyes, such as sytox
®
 green, which 
only penetrate the cell membrane when integrity is lost. They also found that only live, 
motile cells could produce NETs.   
 
NETosis can be differentiated from the other cell death pathways – apoptosis and 
necrosis. Apoptotic cells condense and fragment their chromatin without the 
disintegration of the nuclear envelope (Fuchs et al., 2007). Also, NETosing cells do not 
express phosphatidylserine phospholipid, the receptor for the Annexin V marker, which 
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occurs in apoptosis or when the cell membrane is compromised. Fuchs, et al, 
demonstrated the morphology of neutrophils that underwent necrosis when exposed to 
bacterial toxin in order to help distinguish this type of cell death from NETosis. They 
found that during necrosis, the cells retained their nuclear envelope and a clear separation 
of granules and nuclear components was seen (Fuchs et al., 2007). Takei, et al, also 
showed that when stimulated with PMA, none of the neutrophils showed chromatin 
agglutination which is a feature of necrosis (Takei et al., 1996).  
 
It has been shown that NETs are released in response to microbial infection (Brinkmann 
et al., 2004). More specifically, it is thought that this pathway is a response to an 
overwhelming influx of infectious organisms such as in severe infection or sepsis (Ma 
and Kubes, 2008). The launched web of decondensed chromatin has been observed by 
scanning electron microscopy (Brinkmann et al., 2004). Cellular proteins such as NE and 
MPO bind and biologically inhibit pathogens (Brinkmann et al., 2004, Fuchs, 2007 
#3576, Fuchs et al., 2007). To date, sixteen pathogens have been tested and proven to 
induce a NET response (Brinkmann and Zychlinsky, 2012). These include some common 
bacterial species, such as Staphylococcus aureus and Escherichia coli, and the yeast, 
Candida albicans. Even Aspergillus spp. fungal hyphae, which are too large to 
phagocytose, have been eliminated by NET filaments (Bianchi et al., 2009).  
 
Most of the early work on NETs involved in vitro stimulation of neutrophils with PMA, 
LPS, IL-8, or co-incubations with pathogens (Brinkmann et al., 2004, Fuchs et al., 2007). 
More recently, NETs occurring in vivo have been investigated in order to be 
morphologically described. Histological sections from a rabbit infected with shigellosis 
were able to show extracellular NE and histone fibres (Brinkmann et al., 2004). Another 
in vivo animal model with Klebsiella pneumonia determined that wild-type mice could 
produce NETs while NE-knockout mice could not (Papayannopoulos et al., 2010).    
 
5.1.2. The Role of DNA, Neutrophil Elastase and Myeloperoxidase in NETs 
As the main constituents of the fibrous chromatin NET scaffold, NE, a potent serine 
protease, and MPO, a peroxidase enzyme which makes hypochlorous acid (HOCl) in the 
presence of hydrogen peroxide (H2O2) and chloride anion, have the potential to actively 
penetrate microbial cell membranes and cleave bacterial virulence factors (Logters et al., 
2009, Papayannopoulos and Zychlinsky, 2009). In addition to their enzymatic activity, 
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both NE and MPO are cationic proteins that can inhibit bacterial growth by binding to the 
pathogen’s negatively-charged surface. MPO, a glycosolated 146 kDa dimer protein, is 
stored along with NE in the azurophil granules in abundance. MPO can also be found in 
lower concentrations in monocytes but not tissue macrophages (Malle et al., 2007). These 
two enzymes are usually released into a neutrophil’s phagolysosome to internally digest 
opsonised pathogens in a controlled, enclosed environment.  
  
MPO is itself non-oxidative, but it catalyses the oxidation of halides (such as chloride 
anion, Cl
-
) using H2O2 to create hypohalous acids (mainly the unstable oxidizing agent 
HOCl) and other highly reactive antimicrobial products. HOCl can then go on to 
participate in oxidation and halogenation reactions (Malle et al., 2007). Upstream of this 
cascade, located at the neutrophil’s phagosomal and cell membrane, nicotinamide adenine 
dinucleotide phosphate (NADPH) supplies the electrons needed to reduce oxygen to 
superoxide anions. The superoxide simultaneously reduces and oxidizes creating H2O2 
which is the substrate for the MPO-catalysed reaction. Individuals with complete MPO-
deficiency cannot make NETs (Metzler et al., 2011) which highlights the importance of 
MPO in the NETosis pathway. Also, people suffering from the severe immunodeficiency 
disorder Chronic Granulomatous Disease (CGD), have a NADPH oxidase gene defect 
and therefore cannot produce ROS. Their neutrophils also do not form NETs (Fuchs et 
al., 2007). However, by restoring NADPH oxidase via gene therapy or by adding 
exogenous H2O2, they can regain the ability to make NETs. Therefore, the molecular 
pathway involving NADPH, ROS, and MPO are important contributors to enable 
NETosis to take place.  
 
The role that NE plays in NETosis has become one of the definitive characteristics of this 
pathway. Previous experiments have shown that NE relocates from the azurophil granule 
and enters the nuclear space (Papayannopoulos et al., 2010). Here it is thought to digest 
the histones, mainly targeting H4, thereby unravelling the supercoiled DNA chromatin 
structure (Papayannopoulos et al., 2010). Histones are cationic proteins which help to 
condense DNA in the nucleus. Two of each of the core histone proteins (H2A, H2B, H3, 
and H4) are grouped together creating a cylindrical structure. Short sections of dsDNA 
wrap around these core histones creating individual nucleosomes. The DNA strands are 
secured in place by H1, a linker histone. Many millions of nucleosomes are then 
supercoiled to form the chromosome. Histones themselves have also been shown to have 
potent anti-microbial effects by promoting cell lysis (Hirsch, 1958, Kawasaki and 
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Iwamuro, 2008, Kim et al., 1996). Globular domains for H2A-H2B-DNA have been 
detected sitting among long stretches of NET fibres (Brinkmann et al., 2004) suggesting 
their involvement in the capturing and inactivating of bacteria. 
 
It is thought that the azurophil granules remain intact during NETosis. They do not enter 
the nuclear region, but individually, two of its major components (NE and MPO) have 
been identified co-localising with intracellular DNA (Papayannopoulos et al., 2010), 
however, MPO has been shown to transport separately into the nucleus at a later time 
point than NE enhancing the decondensation process (Papayannopoulos et al., 2010). 
Experiments conducted by Papayannopoulos, et al, ruled out proteinase 3 and cathepsin 
G, two proteases that are also located in the azurophil granule, in the breakdown of 
neutrophil DNA (Papayannopoulos et al., 2010).  It is not known by which mechanism 
NE and MPO are able to be selectively transported. Once NETs are released, additional 
proteases have been identified in the structure such as Cathepsin G and bactericidal 
permeability-increasing protein (BPI) from azurophils, lactoferrin and gelatinase from 
specific and tertiary granules, respectively (Brinkmann et al., 2004). No membranes are 
seen surrounding the chromatin fibres. Proteins not present in NETs included the granule 
membrane protein CD63, actin, and tubulin (Brinkmann et al., 2004). 
5.1.3. Endogenous Inhibitors of NETs 
SLPI and α1AT can both be found circulating in human plasma (Grobmyer et al., 2000a). 
Their concentrations have been reported to increase in individuals suffering from chronic 
inflammation, such as in COPD (Hollander et al., 2007). Hepatocytes are the main 
producers of α1AT while mucosal epithelial cells and salivary gland acinar cells generate 
SLPI (Ohlsson et al., 1984). Neutrophils also produce and harbour these protease 
inhibitors intracellularly. SLPI can be found in specific granules, also referred to as 
secondary or peroxidase-negative granules, while α1AT has been located in the same 
azurophil granule as NE and MPO (Mason et al., 1991). More recently, α1AT was also 
found in multiple neutrophil granules including, the specific granules, gelatinase granules, 
and secretory vesicles (Clemmensen et al., 2011). SLPI and α1AT’s involvement in the 
NETosis pathway have only been reported as extracellular components once NETs are 
expelled, however they have not yet been characterised intracellularly during this cell 
death process.  
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5.1.4. NETosis, or ETosis, in Other Granulocytes 
Thus far limited to granulocytes, the active release of DNA and cell contents with an 
antimicrobial purpose is unique. The process of inducing Extracellular Traps (ETs) in 
eosinophils (Yousefi et al., 2008) and mast cells (von Kockritz-Blickwede et al., 2008) 
has been reported. Yousefi, et al, showed that IL-5 or IFN-γ primed ex vivo human 
eosinophils to discharge DNA and cationic proteins in vitro when stimulated with LPS 
and complement factor 5a (C5a) and to a lesser degree eotaxin. Interestingly, there was no 
ETosis without priming. In the same study, intestinal biopsies from five individuals with 
Crohn’s disease were also found to have mast cell and eosinophil IL-5 expression as well 
as evidence of eosinophilic extracellular DNA throughout the tissue. Bacterial 
lipopolysaccharide (LPS) has also been shown to stimulate mast cells to release their 
contents, however this was only tested in mouse-derived or human cell line mast cells as 
opposed to isolated ex vivo human mast cells (von Kockritz-Blickwede et al., 2008).  
5.1.5. The Pathology of Neutrophil Extracellular Traps  
It is thought that NETs evolved to contain and fight the spread of infection. However, 
they have also been identified in non-infectious conditions such as in preeclampsia 
(Gupta et al., 2005) and psoriasis (Skrzeczynska-Moncznik et al., 2012). NETs may be 
partly responsible for the direct destruction of inflamed tissues due to the enzymes and 
ROS released. It is well documented that one of the main NET constituents, NE, is 
capable of cleaving various host proteins that construct the extracellular matrix such as 
elastin which leads to the degradation of connective tissue. The NE in NETs could 
therefore contribute to tissue damage. 
 
NETs can also instigate and/or perpetuate an inflammatory response. It is thought that 
they may contribute to the pathogenesis seen in autoimmune diseases with chronic 
inflammation such as in rheumatoid arthritis (RA). Recently, Khandpur, et al, found 
NETs in the skin and synovial fluid from RA patients. In addition, RA serum and 
synovial fluid could induce NETs in HC neutrophils in vitro (Khandpur et al., 2013). The 
autoimmune diseases Systemic Lupus Erythematosis (SLE) and small-vessel vasculitis 
(SVV) have elevated levels of anti-neutrophilic cytoplasmic antibodies (ANCAs) which 
have been implicated in the pathogenesis. The most common ANCAs autoantibodies 
target Proteinase 3 (PR3) and MPO, but in SLE, antibodies against DNA and histones are 
also targeted (Branzk and Papayannopoulos, 2013, Tsokos, 2011). Therefore, NETs are 
thought to be an additional extracellular source of the target antigens. Also, ANCAs 
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perpetuate the inflammatory cycle by activating neutrophil respiratory burst and 
production of ROS by binding to surface-expressed PR3 and MPO. The on-going 
inflammation causes capillary damage. Kessenbrock, et al, found that TNF-α primed 
neutrophils incubated with isolated ANCA-IgG from SVV patients could induce NET 
formation (Kessenbrock et al., 2009). Similarly, autoimmune complexes from SLE 
patients could stimulate NET production in HC neutrophils (Garcia-Romo et al., 2011).  
In both SVV and SLE, NETs were also found deposited in kidney biopsies (Villanueva et 
al., 2011, Kessenbrock et al., 2009). NETs may be implicated in the pathogenesis of BD 
vasculitis. Although auto-antibodies have not been fully described in BD to date 
(Direskeneli, 2006), it is still a possibility that one exists. There have not yet been any 
investigations on the occurrence of NETs in BD patients in their vasculature, mucosa, 
tissues, or organs. 
 
It has been shown that there are several ways in which neutrophils can be recruited into 
the oral cavity. GCF is thought to be a major route for neutrophils into the mouth (Cox et 
al., 2006). We have previously seen in section 4.3.6.1 that neither neutrophils nor 
released NE were identified in intact epithelial oral tissue above the basal cell line, but 
were recruited in large quantities when the tissue was compromised by ulceration. These 
macroscopic ulcers as well as common microscopic abrasions that occur in the mouth are 
an obvious route for blood-derived neutrophils to gain access through the mucosal lining. 
However, the question still remains why a higher concentration of NE, which is mainly 
reserved for intracellular digestion of bacteria, is found in the saliva of BD patients who 
suffer episodic ulceration regardless of the presence of an ulcer. This prompted an 
investigation to find out if BD patients harboured circulating neutrophils undergoing a 
high frequency of NETosis, and therefore extracellular NE, which could potentially reach 
the oral cavity propagating or initiating ulcers.  
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5.1.6. Aims  
Our objectives of the experiments were to investigate: 
 
1. Whether ex vivo neutrophils from BD patients undergo a higher occurrence of NETosis 
than HC. This will be determined by observing the convergence of NE and MPO with 
intracellular DNA during NETosis as well as the quantification of extracellular DNA.  
2. Upon inducing NETosis, whether neutrophils from BD patients and HCs undergo a 
similar process involving NE and MPO. 
3. To determine if NE is actively contributing to cellular NETosis by blocking it with 
synthetic NE inhibitor. Also, to see if this type of inhibition can down-regulate the 
occurrence of NETosis. 
4. And finally, where endogenous neutrophil-derived SLPI and α1AT inhibitors are 
located during NETosis and if they co-localise with NE intracellularly and/or 
extracellularly. 
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5.2. Materials and Methods 
The final experimental design for investigating NETs in vitro was arrived at following 
several initial optimisation protocols for isolating and culturing neutrophils, and for 
imaging neutrophils undergoing NETosis.  
5.2.1. Optimisation Experiments 
5.2.1.1. Initial Sytox
®
 Green Experiments and Culturing Neutrophils on Poly-D-
Lysine Coated Coverslips 
Extracellular DNA from isolated neutrophils were successfully detected using sytox
®
 
green dye while in the culture wells (Figure 5.2.1.1.1). Sytox
®
 green (Life Technologies, 
UK) does not penetrate intact cellular membranes only binding to extracellular DNA that 
is released upon cell death. While some extracellular neutrophil DNA remained within the 
immediate boundary of the cell’s outer membrane creating a cylindrical shape (Figure 
5.2.1.1.1, arrow), most of the DNA stretched across large areas attaching to and 
encompassing neighbouring cells’ DNA. These strands of DNA are thought to be the 
hallmark of NETs (Fuchs et al., 2007) and therefore observation of these web structures 
signifies that cells are undergoing NETosis. When imaged, the exposure time had to be 
increased so that both the cells and their extended DNA strands could be visualised in a 
single image. 
Initial experiments also incorporated testing different concentrations of poly-D-lysine 
used coat glass coverslips to improve neutrophil attachment for imaging. This 
methodology has been reported in several papers (Garcia-Romo et al., 2011). Glass 
coverslips were coated with 0.001% (or 10 µg/ml) of poly-D-lysine with a high molecular 
weight (150-300 kDa) to encourage cell attachment. Fibrous strands of extracellular DNA 
were evident in the unstimulated and positive control PMA-stimulated neutrophil cultures 
using a 1:15,000 sytox green dilution (final concentration in each well was 0.33 µM) as 
described by Pappayannopoulos, et al’s. Figure 5.2.1.1.2 shows neutrophils from a 
relapsed BD patient undergoing NETosis. Neutrophils from other BD patients (data not 
shown), and surprisingly also from HC subjects (data not shown), revealed similar 
reactions and therefore this unexpected result alerted us to the fact that something else 
was happening in our neutrophil cultures that was inducing NET formation. Following 
several lines of questioning we came to the conclusion that it was perhaps the poly-D-
lysine that was causing NETosis. Therefore, we hypothesised that NET formation would 
increase with increasing Poly-D-lysine concentration hence the same number of HC 
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neutrophils were seeded onto coverslips coated with increasing concentrations of Poly-D-
lysine. Indeed, the number of neutrophils NET forming increased with increasing Poly-D-
lysine concentration. Subsequently, coating glass coverslips with poly-D-lysine was 
aborted. Instead, sterile non-coated glass coverslips were used instead for all cultures 
processed for immunocytochemistry while 24-well polystyrene, flat bottom culture plates 
(Nunc, VWR, UK) were used for in-well sytox
®
 green imaging.  
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Figure 5.2.1.1.1. Initial Culturing Method: In-Well Imaging of Unstimulated 
Neutrophils from a BD Non-Relapsed Patient Cultured onto 0.001% Poly-D-Lysine 
Coated Glass Coverslips. Cells were stained with sytox
®
 green (1:15,000 dilution) and 
imaging was completed 1 hr after cells were distributed in culture. In-well imaging 
completed on inverted Nikon fluorescent microscope (GFP channel). Characteristic net-
like configurations of extracellular DNA were observed. Some cells remained cylindrical 
(arrow). X40 magnification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.2.1.1.2. Neutrophils from Relapsed BD Patient Cultured onto 0.001% Poly-
D-Lysine Coated Glass Coverslips and Mounted. Cells were either treated for 1 hr with 
(C) or without (A) PMA. Another duplicate culture was incubated for 3 hrs with (D) or 
without (B) PMA. At the specified time points, cells were stained in culture with sytox 
green and then coverslips delicately removed and inverted onto mounting medium. 
Images taken on an Epifluorescent Leica microscope, X20 magnification. Bar indicates 
10 µm.  
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5.2.2. Isolation of Neutrophils from Whole Blood for Investigation of NETs In Vitro  
Neutrophil isolation was based upon the protocol described by Brinkmann, et al, 
(Brinkmann et al., 2004) using Histopaque 1119 and percoll gradients. Therefore, 
Histopaque 1119 (Sigma, UK) was equilibrated to RT at least 2 hrs before use. Several 
days prior to conducting the procedure, the 13 mm, thickness number 1.5 non-coated 
borosilicate glass coverslips (VWR, UK) were sterilized by autoclave. 1X and 10X PBS 
was also prepared and autoclaved.  
 
All blood work was carried out in a Class II Safety Cabinet. Histopaque 1119 (Sigma, 
UK) (6 ml) was added to sterile 15 ml falcon tubes. Then carefully, 5 ml of whole blood 
was layered on top and tubes were centrifuged at RT for 20 min at 800 x g without 
braking. Using a sterile pasteur pipette, the plasma was removed from the top layer 
(Figure 5.2.2.1,  A), transferred in a separate tube, and placed in -80
o
C freezer for future 
experiments. The next layer consisting of PBMC’s was also collected separately, washed 
in PBS by centrifugation (300 x g, 10 min) to create a cell pellet to which 0.5 - 1 ml of 
RLT lysis buffer (from RNeasy Qiagen kit, UK) was added. This was stored in the -80
o
C 
for future nucleic acid extraction. 
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Figure 5.2.2.1. A, B, C.  A. The Layers of Blood after Histopaque Separation. The top 
yellow plasma layer was transferred by pipette to a new tube for freezer storage. The next 
layer containing mainly PBMCs was also collected separately and stored. Next, the pink 
layer containing neutrophils and other granulocytes was carefully collected without 
disturbing the RBC layer and transferred into a new 15 ml tube. The RBC layer was 
discarded. B. Layering the Percoll Gradients.  In a 15 ml centrifuge tube, 2 ml of the 
highest percoll concentration (76.5%) was added first followed by the careful layering of 
2 ml of the next highest concentration. Layering was continued with all subsequent 
percoll preparations. Lastly, 2 ml of the resuspended granulocyte pellet added followed by 
centrifugation at RT for 20 min at 800 x g without braking. C. Collecting Neutrophils 
within the Percoll Gradients. Approximately 4 ml of the cloudy, white layer consisting 
of neutrophils was collected and transferred to a new tube. The first 2 ml of clear fluid 
was discarded. RBC’s gathered toward the bottom layer were avoided. 
 
The lower pink mid-section of the resulting Histopaque layers contained the granulocytes 
and some RBC’s. This layer was carefully collected by pipette and transferred into new 
15 ml Falcon tubes. The bottom dark red layer containing only RBC’s was discarded. The 
collected granulocytes were washed with sterile 1X PBS and centrifuged for 10 minutes 
at 300 x g. Meanwhile, a 90% Percoll solution was prepared by mixing 18 ml of 100% 
Percoll with 2 ml of 10X PBS. Then with 1X PBS, several diluted solutions of percoll 
were prepared in separate tubes: 76.5%, 72%, 67.5%, 63%, and 58.5% (2 ml was 
prepared for each patient blood sample). 2 ml of each Percoll gradient was carefully 
layered on top of each other starting with the highest 76.5% as shown in Figure 5.2.2.1, 
B.  
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After cells were centrifuged, the supernatant was discarded and the cell pellet was 
resuspended in 2 ml of PBS. If the pellet was particularly large with abundant RBC’s, 
then the pellet was suspended in 4 ml PBS. A maximum of 2 ml of the resuspended pellet 
was then carefully layered onto the top gradient, therefore if the resuspension of cells was 
4 ml due to a large pellet, then 2 gradient preparations were required for each sample. 
This was then centrifuged for 20 min at 800 x g without braking at RT. After 
centrifugation, the top clear layer and most of the 58.5% layer (which contained a cloudy 
band of residual PBMC’s) were removed (Figure 5.2.2.1, C). The remaining interphases 
were collected into a new tube avoiding the lowest layer where the RBC’s congregated. 
Cells were washed by addition of 1X PBS and centrifuged for 10 min at 300 x g after 
which the supernatant was removed and the cells re-suspended in 2 ml of culture media. 
Culture media was prepared consisting of RPMI 1640 (Gibco/Life Technologies, UK), 10 
mM HEPES (Sigma, UK), and 5% fetal calf serum (FCS) (Gibco/Life Technologies, 
UK). Initially, a standard 10% of FBS was added to the media and then lowered to 5% 
due to its reported inhibition of NET formation (Fuchs et al 2007). The cells were then 
counted using a haemocytometer and their viability assessed using the trypan blue 
exclusion test (usually > 99% viable). 
 
5.2.3. NET Formation 
Five experimental conditions were used to study NET formation in vitro: 1) unstimulated 
(non-treated) neutrophils, 2) 100 nM of PMA-stimulated neutrophils as a positive control 
for inducing NETs, 3) neutrophils with 5 µM of NE inhibitor (NEi, type GW311616A 
from Sigma, UK) for inhibiting NET formation, 4) PMA and NEi together as an 
additional control, and finally 5) neutrophils with 0.01 U/µl DNase I from bovine 
pancreas (Sigma, UK) used as a negative control to dissolve extracellular DNA released 
by NETs. Immunocytochemistry and the quantitative sytox
®
 green experiments were run 
concurrently, however for ease, the experimental protocols are described separately. 
 
5.2.3.1. Immunocytochemical Qualitative Experiments: Antibody Staining and 
Fluorescent Confocal Microscopy 
Neutrophils were seeded into 24-well culture plates containing sterile glass coverslips at a 
concentration of 250,000-500,000 cells in 400 µl which would be added into each well of 
a  for downstream immunocytochemistry purposes. One plate was prepared for each 
patient and each time point. The glass coverslips were added to the wells. If they floated 
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on the media, they were gently pushed down with sterile tweezers so that they sat at the 
bottom of the well.  Separate working stocks of PMA (Sigma, UK), NEi, and DNase I 
were prepared in media. Immediately after the cells were added to the wells, 50 µl of a 45 
µM NEi working stock was added to 400 µl of neutrophils in each designated NEi well 
(final well volume of 450 µl). Also, 25 µl of a 90 µM NEi working stock was added to 
400 µl of neutrophils in the well for NEi+PMA reactions. Both reactions contained 5 µM 
of NEi as the final concentrations. The cells were incubated for 1 hr at 37
o
C in 5% CO2 
and allowed to settle. After settling, 50 µl of media was added to unstimulated cells and 
50 µl of 0.09U/µl DNase I working stock added to DNase reaction wells. Also, 50 µl of 
900 nM PMA working stock was added to the PMA stimulated cells while 25 µl of a 1800 
nM PMA working stock was pipetted into the NEi+PMA wells. A final volume of 450 µl 
media gave 100 nM PMA per well. Any well where 25 µl of reagent was added, another 
25ul of media was added to nbring the final volume to 450 µl.  The first time point was 2 
hours after the neutrophils were initially added to the well (this includes 2 hrs of NEi 
incubation as well) and 1 hr of stimulation by PMA or digestion by DNase. The next time 
point was 2 hrs after the first, so a total of 4 hours of neutrophil incubation with and 
without NE inhibitor and 3 hrs of PMA stimulation and DNase reaction. 
The same time points were used for the sytox green and immunocytochemistry plates. My 
supervisor Dr Eleni Hagi-Pavli assisted with the fixing and washing step for these plates 
while I conducted the sytox green imaging. Using a sterile pasteur pipette, 450 µl of 
media was removed gently and transferred to a new, identical 24-well plate set up in order 
to be stored in the -20
o
C. Then 300 µl of 4% paraformaldehyde (PFA) (w/v) was added to 
each well, incubated for 15 min (in a Class II Cabinet), removed and washed with sterile 
1X PBS by adding 1 ml to each well and leaving for 5 min then discarding. This wash 
step was repeated twice more. A final volume of 0.5 ml of PBS was added to each well, 
the plate lid was placed on top, and cling film or parafilm secured around the boarder. The 
plates were dated and kept at 4
o
C until used for immunofluorescent staining.  
PFA-fixed neutrophils were washed once with 0.5 ml of 1X PBS followed by addition of 
300 µl of blocking buffer made up of 5% goat serum (Merck Millipore, USA), the cell 
permeabilising agent 0.5% saponin (Sigma, UK), and 0.05% Tween-20 (Sigma, UK) 
diluted in PBS. They were left for 1 hour at RT. Meanwhile, the primary antibody was 
diluted in preparation for use according to the optimised dilutions outlined in Table 
5.2.3.1.1.  The same blocking buffer was used as the diluent for all the antibodies.  
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Target Block and 
Permeabilise 
Antibody Stains Antibody 
Dilution 
Isotype 
Control 
mNE 5% goat serum 
0.5% saponin 
0.05% Tw-20 
in PBS 
1
o
 Ab: mouse monoclonal IgG1, 0.1 
mg/ml neat concentration, (HyCult 
#HM2174) 
2
o
 Ab: AF555 goat, anti-mouse IgG 
polyclonal F(ab’)2 region, 2mg/ml (Life 
Technologies, UK, Cat #A-21425) 
(visible in red channel) 
 
1: 400 
 
1:2000 
 
Mouse 
IgG1 
(DAKO) 
pNE  
 
 
 
5% goat serum 
0.5% saponin 
0.05% Tw-20 
in PBS 
1
o
 Ab: NE polyclonal rabbit, anti-human, 
whole antiserum, IgG (Abcam, UK, Cat# 
ab21595)  
2
o
 Ab: AF647 goat, anti-rabbit IgG 
polyclonal F(ab’)2 fragment, 2mg/ml 
(Life Technologies, UK) (visible in far 
red channel) 
 
1: 400 
 
1:2000 
 
Normal 
rabbit 
serum 
MPO 5% goat serum 
0.5% saponin 
0.05% Tw-20 
in PBS 
1
o
 Ab: polyclonal rabbit IgG, anti-human, 
(DAKO #A0398) 
2
o
 Ab: AF647 goat, anti-rabbit IgG 
polyclonal F(ab’)2 fragment, 2mg/ml 
(Life Technologies, UK) (visible in far 
red channel) 
 
1:400 
 
1:2000 
 
Normal 
rabbit 
serum 
SLPI 5% goat 
serum, 1% 
BSA, 0.5% 
saponin, 
0.05% Tw-20 
in PBS 
1
o
 Ab: monoclonal mouse IgG1, anti-
human (R&D Systems, UK,               
Cat# MAB1274) 
2
o
 Ab: AF555 goat, anti-mouse IgG 
polyclonal F(ab’)2 region, 2mg/ml (Life 
Technologies, UK) (visible in red 
channel) 
 
1:100 
1:2000 
 
Mouse 
IgG1 
(DAKO) 
α1AT 5% goat serum 
0.5% saponin 
0.05% Tw-20 
in PBS 
1
o
 Ab: polyclonal rabbit, anti-human, 
(Novocastra #NCL-A1Ap) (Leica 
Microsystems, UK)  
2
o
 Ab: AF647 goat, anti-rabbit IgG 
polyclonal F(ab’)2 fragment, 2mg/ml 
(Life Technologies, UK) (visible in far 
red channel) 
 
1:500 
 
1:2000 
 
Normal 
rabbit 
serum  
DNA n/a DAPI: (Sigma, UK) (visible in blue/UV 
channel) 
Final 
conc: 100 
ng/ml 
n/a 
Table 5.2.3.1.1. Optimised Target Antibody Details, Blocking and Permeabilising 
Buffers, and Isotype Controls for PFA-Fixed Neutrophil NETs. 
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Once the blocking step was complete, the buffer was removed from each well and 
discarded and then replaced with 250 µl of the diluted primary antibody and left to 
incubate overnight at 4
oC. NE and SLPI or NE and MPO or NE and α1AT primaries were 
tested together and could be used to stain the cells as a dual reaction in one well (as they 
also used different secondary antibody fluorophores). Note that a polyclonal NE primary 
antibody was used for dual staining with SLPI. Meanwhile, monoclonal NE was coupled 
with MPO or α1AT since the polyclonal NE antibody was produced in the same animal as 
those from MPO and α1AT and therefore would not be differentiated by the secondary 
antibody. Isotype controls were also used in place of primary antibodies for each target to 
check for specificity Table 5.2.3.1.1. These isotypes were diluted to the same 
concentration as the primary antibodies. Other wells were also allocated as controls to 
check for secondary antibody non-specific binding whereby only the secondary antibody 
was added, so during the primary antibody incubation stage, these controls would have 
250 µl of only the diluent/blocking buffer added. They were all incubated overnight at 
4
o
C without disturbance. 
 
After the primary antibody incubation, coverslips were washed with 1 ml PBS-T, for 5 
min. after which PBS-T was removed and discarded. This wash step was repeated 3 times 
for all wells. Before the last wash, the secondary antibody was prepared. Depending on 
the primary species and target, the secondary antibody was either polyclonal Alexa-
Fluor
® 
555 goat, anti-mouse or Alexa-Fluor
® 
647 goat, anti-rabbit (Molecular Probes/Life 
Technologies, UK). Both had F(ab’)2 fragments with a neat concentration of 2 mg/ml. 
Secondary antibodies were diluted as indicated in Table 5.2.3.1.1 using the same 
blocking buffer/diluent described above. Each well containing the coverslip-bound 
neutrophils received 250 µl of the diluted secondary antibodyand incubated for 1 hr at RT 
in the dark. Afterwards, each well was washed as described above.   
 
A 100 ng/ml solution of DAPI nuclear stain (Sigma, UK) was prepared in 1X PBS and 
250 µl of DAPI solution was added to each well which wereincubated for 5 min. 
Following staining, coverslips were carefully lifted out with the help of sharp, long 
curved precision tweezers (Ideal-Tek 7.S Swiss Mode). The coverslip was inverted and 
placed directly onto a 5 µl drop of Mowiol that had been added onto a glass microscope 
slide. (See Mowiol preparation in General Methods in Section 2.1.8.). The slides were 
protected from light and left to dry.  After the mounted coverslip edges were sealed with 
nail varnish, the neutrophils were observed using an upright 710-Z2 Zeiss Confocal 
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microscope utilizing the 405 nm, 561 nm, and 633 nm lasers for the DAPI, red, and far 
red channels, respectively. Dr Ann Wheeler assisted in the initial set up with the confocal 
microscope.  Images were captured using a high powered, X40 oil objective with a 1.30 
numerical aperture (na) (DIC M27, EC Plan-Neofluar). Zen 2012 software Version 8 was 
then used to analyse the images.  
5.2.3.2. Quantification of Sytox Positive Neutrophils Preparing Neutrophils in 
Culture 
Parallel to the experiments described above, 400 µl of 100,000 cells per well was added 
to separate 24-well plates for the quantification of sytox
®
 green extracellular, 
decondensed DNA using an fluorescent Timelapse microscope. Just as before, several 
different treatments were prepared. Neutrophils were 1) unstimulated (non-treated), or 
had the addition of 2) 100 nM of PMA-stimulated neutrophils as a positive control 3) 5 
µM of NE inhibitor, 4) 100 nM PMA and 5 µM NEi together as an additional control, and 
lastly 5) 0.01 U/µl DNase I as a negative control to dissolve extracellular DNA. Duplicate 
wells were prepared for all reactions, A mixture of sytox
®
 green and Hoechst 33342 dyes 
(Life Technologies, UK) as prepared by adding 2 µl of neat (5 mM) sytox green (and 15 
µl of neat (10 mg/ml) of the Hoechst 33342 into 14,983 µl of culture media. 450 µl of the 
mixture was added to the culture well’s 450 µl volume giving a final dilution of 1:15,000 
of sytox
®
 green (equivalent to 0.33 µM) and 1:2000 for the Hoechst 33342 (or 5 µg/ml).   
 
5.2.3.2.1. The Quantification of Sytox Positive Neutrophils in Live Cultures 
In-well images were taken of the neutrophils immediately after the addition of the sytox
®
 
green and Hoechst 33342 mixed using an inverted, epifluorescent Timelapse microscope 
paired with MetaMorph software (Version 7.7.3.0). The cells were visualised using the 
X20 air objective. Simultaneous images were captured in each in the DAPI and green 
fluorescent protein (GFP) channel for at least 3 separate fields of vision.. The images 
were further analysed using FIJI/ImageJ free software (Schindelin et al., 2012). The 
number of neutrophils staining positive for sytox
®
 green (extracellular DNA) and positive 
for Hoechst 33342 (live cell nuclear stain) were counted for each individual image. The 
number of sytox positive cells ≥ 100 µm2 area were tallied and divided by the total 
number of neutrophils (Papayannopoulos et al., 2010). Each image was processed 
individually and the average percentage (%) of sytox positive (sytox
+
) cells were 
determined for at least three images of the same treatment and time point for each patient 
or HC. 
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In order to count the number of sytox
+
 neutrophils and the total cell number, a threshold 
was set to automatic pick up grey intensities emanating from the cells so that operator 
bias was reduced to a minimum (Fig 5.2.3.2.1.1). However, any features in the images 
such as floating cells or light reflection were excluded by manual adjustment to reduce 
the threshold slightly in order to include cells and exclude imaging anomalies.  
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SEE FIGURE 5.2.3.2.1.1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.2.3.2.1.1. Simultaneous Images in GFP and DAPI Channels. Sytox
® 
green 
attaches exclusively to extracellular DNA while Hoechst 33342 is able to penetrate the 
nuclear membrane and stain intracellular, intact DNA. Using FIJI/ImageJ software, 
minimum thresholds would be automatically set to recognise positively stained cells in 
each channel. Triplicate images were tallied to determine the mean percentage of sytox
+
 
cells for each culture treatment. X20 magnification using air objective on Timelapse 
microscope. Scale bar 25 µm. 
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5.2.4. Patients Included in the Study 
BD patients who were experiencing relapsed BD symptoms (n=7) and those in remission 
(n=3) were included in the study. Four HCs were also included. Table 5.2.4.1. provides 
patient participants’ details in the NETs Experiments. 
 
Table 5.2.4.1. Patient Demographics for PFA-Fixed NETs Analysis. Symptom abbreviations: 
Gen, genital ulcer. Jnt, joints. EN, erythema nodosum. Fol, Folliculitis. Vas, vascular. CNS, 
central nervous system. Medication abbreviations: Aza, Azathioprine. Colc, Colchicine. C.std 
inhaler, Corticosteroids. Doxy, Doxycycline. MMF, Mycophenolate mofetil. NSAID, non-
steroidal anti-inflammatory drug. Ome, Omeprazole. Pred, Prednisone. Thal, Thalidomide. 
Other: Neutro, neutrophil count from clinic (normal range 2-7.5x10
9
/L (Waugh et al., 2006)). 
Some blood counts were not completed (n/a). M, male. F, female. +, active symptoms. -, no 
symptoms.  *HC4 did not have enough neutrophils for all staining protocols/culture conditions 
however sytox green and MPO/NE staining analysis completed. 
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5.3. Results 
5.3.1. Investigating Neutrophil Extracellular Traps in Behçet’s Disease: Sytox® 
Green Extracellular DNA Analysis 
5.3.1.1. Immediate versus Next Day Imaging  
Once sytox
®
 green was added, images were immediately taken of the neutrophils while 
they were still in the culture wells. In order to ease time pressure and improve the 
practicality of having more time to take images of the cells in culture, images were 
repeated the next day within 17-24 hours. It was found that there was a significant 
increase (p<0.034) of the mean percentage of sytox
+
 neutrophils in the PMA-stimulated 
cultures when the images were taken up to 24 hrs after sytox
®
 green was added (Fig. 
5.3.1.1.1). This presented a problem for the accurate interpretation of sytox
+ 
neutrophils. 
Based on the evidence that PMA-stimulated neutrophils showed an increase in sytox
+ 
cells, it was decided that all images should be taken immediately after set time points as 
opposed to delaying until the next day. 
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SEE FIGURE 5.3.1.1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.1.1.1. A. and B. Representative Results of Increased Sytox
+
 Neutrophils 
During Next Day Imaging of the Same 1 hr PMA-Stimulated HC Neutrophil 
Culture. A. Top images are of the culture 1 hr after cells were stimulated with 100 nM 
PMA. Images were taken within 1 hr of adding sytox
®
 green and Hoechst DNA stains to 
the culture media with live neutrophils. Bottom images were taken from the same HC 
PMA-stimulated culture within 24 hrs. B. The Mean Difference Between Sytox
+
 HC 
Neutrophils when Imaging the Same Culture at Different Times. Error bars represent 
±SEM of the mean percentage of sytox positive cells (≥ 100 µm2) from multiple images 
of biological replicates. Mann Whitney U, 2-tailed, non-parametric test, *p<0.05. 
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The unstimulated neutrophils seemed to absorb more Hoechst nuclear stain during the 
long incubation overnight as the fluorophore was more intense the next day (Fig 
5.3.1.1.2,  A) but this did not alter the ability to accurately detect and count the cells. 
Because unstimulated HC neutrophils showed similar sytox green results with a 
difference of only 0.14% between immediate and next day imaging (Fig 5.3.1.1.2, B) the 
data for this group and culture condition was included in the subsequent analysis. 
However, all other HC and BD patient neutrophil culture treatments were assessed 
immediately.  
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SEE FIGURE 5.3.1.1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.1.1.2, A. and B. An Example of Increased Sytox
+
 Neutrophils During Next 
Day Imaging of the Same Unstimulated HC Neutrophil Culture. A. Top images were 
taken within 1 hr of adding Sytox green and Hoechst stains to the culture media with live 
neutrophils. Bottom images were taken from the same HC culture within 24 hours. B. 
The Mean Difference Between Sytox
+
 HC Neutrophils when Imaging the Same 
Culture at Different Times. Error bars represent ±SEM of mean percentage of sytox 
positive cells (≥ 100 µm2) from multiple images of biological replicates. 
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5.3.1.2. Sytox® Green Analysis in Different Culture Conditions  
5.3.1.2.1. Positive Control Experiments: Inducing Neutrophils Extracellular Traps 
using PMA Stimulant  
The first experiment was to determine how many neutrophils were stimulated using PMA 
to produce NETs in HC and BD patients’ neutrophils. The neutrophils from each patient 
were subjected to a positive control experiment in which 100 nM of PMA was added to 
the cultures in duplicate after an hour of being settled in the media. All patients’ cultures 
were able to induce NETs, as determined by the extracellular DNA staining with sytox
®
 
green. NET production increased by 13.4% (median value) in BD relapsed patients’ 
neutrophils when subjected to PMA stimulation (Fig 5.3.1.2.1.1). This was nearly triple 
the difference seen in non-relapsed patients whose incidence of NETosis rose only by 
4.6%. The smallest difference was observed in HC neutrophils in which unstimulated 
cells showed 0.36% of the cells undergoing NETosis rising to 2.5% with PMA 
stimulation.  
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Fig 5.3.1.2.1.1. Inducing NETosis In Vitro using PMA: A Positive Control 
Experiment. Comparing the median group value of the mean percentage (%) of sytox
+
 
neutrophils in unstimulated and PMA-stimulated cultures. The data in this figure stems 
from images taken immediately after adding sytox
®
 green to the cultures. Both time 
points are included. 
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When comparing the post-PMA stimulation time points, it was determined that the 
production of NETs increased by 27.2% (median group value) in BD Relapsed patients 
from the first to second time point. The non-relapsed BD patients only increased 9.21% 
while the HC showed the lowest increase at 2.68% between time points (Fig  5.3.1.2.1.2). 
 
            
Fig 5.3.1.2.1.2. The Difference in Time Points when Inducing NETosis In Vitro using 
PMA. Comparing the median group value of the mean percentage of sytox
+
 neutrophils 
PMA-stimulated cultures at the first (1 hr post-stimulation) and second time point (3 hrs 
post-stimulation). The data in this figure stems from images taken immediately after 
adding sytox
®
 green to the cultures.  
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5.3.1.2.2. Comparing Unstimulated Sytox+ Neutrophils from Different Patient 
Groups in Vitro 
Unstimulated cultures refer to neutrophils which were not exposed to any known artificial 
chemical or pathogenic stimulant in the culture wells. In these unstimulated cultures, 
there was a significant increase in the detection of extracellular DNA due to the formation 
of NETs in the BD patient group, regardless of whether they were experiencing disease 
relapse or not, compared to HC, p=0.02 (Fig  5.3.1.2.2.1). With the exception of one 
measurement, all HC neutrophil cultures had < 1% sytox
+
 (Mean, SEM; 0.5, ±0.12). 
Meanwhile, collectively, BD patients had an average of 1.5% (±0.32) which was triple the 
HC average. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig  5.3.1.2.2.1. The Mean Percentage of Sytox Positive Neutrophils in HC and BD 
patients. Data includes two time point measurements (2 hrs and 4 hrs in culture) from 
unstimulated cultures and HC images that were taken immediately. Subjects tested: 
HC n=4, BD n=10. Total number of mean % sytox
+
 cell measurements: HC=14, 
BD=20. Mann Whitney U non-parametric analysis; * indicates p≤0.05.  Error bars 
represent ± 1 SE.  
* 
198 
 
BD patients who were considered to have a clinically defined relapse of symptoms 
showed significantly higher sytox
+
 cells than HC (p=0.032) (Fig 5.3.1.2.2.2.). BD 
relapsed patients also showed a higher percentage of sytox
+
 cells than non-relapsed 
patients but was not significant (p=0.149). Although the non-relapsed BD group had a 
higher mean percentage of sytox
+
 cells than HC, the difference was also not significantly 
(p=0.069).  
 
 
 
 
Fig 5.3.1.2.2.2. The Mean Percentage of Sytox Positive Neutrophils in Clinically 
Relapsed and Non-Relapsed BD Patients Compared to HC. Data combines two time 
point measurements (2 hrs and 4 hrs in culture) from unstimulated cultures. Number of 
subjects tested: BD Relapsed n=3, BD Non-Relapsed n=7, HC n=4. Number of mean % 
sytox
+
 cell measurements in the data analysis: BD Relapsed=6, BD Non-Relapsed=14, 
HC=14. Mann Whitney U non-parametric analysis; * indicates p≤0.05.  Error bars 
represent ± 1 SE.  
 
 
 
 
* 
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All BD patients on azathioprine (Aza) medication for the treatment of their symptoms 
revealed a higher group median of the mean percentage of sytox
+
 cells than patients not 
taking the drug, however the differences were not significant (p=0.083). BD relapsed 
patients taking Aza had a group median of 3.44% (of the mean percentage of sytox
+
 cells) 
while those with the same status not taking Aza were more than half the value at 1.56%. 
(p=0.36) (Fig 5.3.1.2.2.3). Similarly, comparing the median values of the non-relapsed 
patient on Aza (1.77%) to non-relapsed patients not taking the medication (0.61%) was 
again reduced by more than half the median value (p=0.20). Only two out of 10 BD 
patients were on colchicine and therefore were not assessed.   
      
Fig 5.3.1.2.2.3. The Mean Percentage of Sytox
+
 Neutrophils: Comparing Patients On 
Azathioprine Medication. The box plot shows the median group values of the mean 
percentage of sytox
+
 neutrophils of patients who were on Azathioprine (Aza) at the time 
blood was donated. The data includes two time point measurements from unstimulated 
cultures (2 hrs and 4 hrs). The box itself represents 50% of the values in the group and the 
extended bars indicate maximum and minimum values. Circles indicate outliers. Number 
of subjects (n) and mean % sytox
+
 measurements represented in the data: BD Relapsed on 
Aza, n=2, sytox
+
=4; BD Relapsed not on Aza n=1, sytox
+
=2; BD Non-Relapsed on Aza 
n=1, sytox
+
=2; BD Non-Relapsed not on Aza n=6, sytox
+
=12. HC not taking any 
medication, n=4, sytox
+
=14. Mann Whitney U, non-parametric analysis. 
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Data from the first and second time points represent duplicate neutrophil cultures that had 
been incubated at 37
o
C with 5% CO2 for a total of 2 and 4 hrs, respectively. BD Relapsed 
patients showed a high variation of the mean % of sytox
+
 neutrophils after the first 2 hrs 
in culture (ranging from 0.23 to 4.16%) (Fig 5.3.1.2.2.4). This produced a low median 
group value of 0.48%. However, after 4 hrs in culture, the median group value for the 
relapsed patients increased to 2.85%. Due to the 2 hr time point data variability and low 
number of BD relapsed patients, this resulted in no significant difference between 2 and 4 
hrs (p=0.51). Similar medians were determined for both time points in the BD Non-
Relapsed patients group. After 2 hrs in culture, the group’s median (of the mean % of 
sytox
+
 neutrophils) was 0.65%. After 4 hrs in culture, this occurrence was sustained 
resulting in a similar median value of 0.61%, however it did show greater variability. 
Lastly, after 2 hrs in culture, neutrophils from the HC group resulted in a median value of 
0.41% (of the mean % of sytox
+
 neutrophils). The median increased only slightly to 
0.44% after 4 hrs. The only significant difference found between median values were the 
4 hr cultures from BD Relapsed and HC groups (p=0.016) (Fig 5.3.1.2.2.4). In general the 
data showed that after a longer incubation in unstimulated culture, there was an increase 
in the mean % of sytox
+
 neutrophils in BD patient groups.  
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Fig 5.3.1.2.2.4. Comparing the Mean Percentage of Sytox
+
 Neutrophils in 
Unstimulated Cultures at Two Different Time Points. The median group values of the 
mean percentage of sytox
+
 neutrophils were determined for both time points (2 hrs and 4 
hrs after initial plating) when the cultures were stained with sytox
®
 green and Hoechst 
and immediately imaged. The bar in the centre of each box indicates the median group 
value. The box itself represents 50% of the values in the group and the extended bars 
indicate maximum and minimum values. Circles indicate outliers. Number of subjects 
included: BD Relapsed n=3, BD Non-Relapsed n=7, HC n=4. Number of mean % sytox
+
 
cell measurements for both time points: BD Relapsed=6, BD Non-Relapsed=14, HC=14. 
Mann Whitney U non-parametric analysis; * indicates p≤0.05. 
 
 
 
 
 
 
 
* 
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5.3.1.2.3. The Effect of NEi on Neutrophils 
When comparing PMA-stimulated cultures with and without NEi, after 1 hr there were no 
significant changes between any of the patient group medians (of the mean % of sytox
+ 
neutrophils). However, cultures with NEi that were exposed to 3 hrs of PMA-stimulation 
showed significant decreases compared to PMA-only cultures in two patient groups: BD 
Relapsed (p≤0.05) and Non-Relapsed (p<0.02) (Fig 5.3.1.2.3.1). This indicated that NEi 
had the desired affect to inhibit the occurrence of NETosing neutrophils thus lowering the 
number of sytox
+ 
neutrophils after a longer time in vitro. BD Relapsed patients’ showed 
the largest decrease between PMA-only and PMA with NEi cultures at 23.3% followed 
by 8.5% for the BD Non-Relapsed group. The group median in PMA-stimulated HC 
cultures also decreased by 2.1% when NEi was included but this was not a significant 
reduction. (Note that the total time in culture was 2 hrs with 1 hr of PMA-stimulation and 
4 hrs with 3 hrs of PMA). 
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Fig 5.3.1.2.3.1. Comparing the Mean Percentage of Sytox
+
 Neutrophils in 1 hr and 3 
hrs PMA-Stimulated Cultures with and without Neutrophil Elastase Inhibitor (NEi) 
in Different Patient Groups. The median group values of the mean percentage (%) of 
sytox
+
 neutrophils were determined for PMA-stimulated cultures with and without 5 µM 
of NEi. The 1 hr and 3 hrs indicate the time the cultures were stimulated with PMA. The 
bar in the centre of each box indicates the median group value. The box itself represents 
50% of the values in the group and the extended bars indicate maximum and minimum 
values. Circles indicate outliers. Number of subjects included: BD Relapsed n=3, BD 
Non-Relapsed n=6, HC n=3. Data are expressed on a log scale. Mann Whitney U, 2-
tailed, non-parametric test, *p≤0.05, **p<0.02. 
 
 
 
 
 
 
 
 
 
* 
** 
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Both HC and BD non-relapsed patient neutrophil cultures with NEi had slightly higher 
group median (of the mean % of sytox
+
 cells) than the unstimulated cultures at the same 
time point. The only group that showed a reduction in sytox
+
 neutrophils with the addition 
of NEi was the relapsed BD patients after 4 hrs in culture. No statistical differences were 
found when comparing group medians (Fig 5.3.1.2.3.2). 
 
           
 
Fig 5.3.1.2.3.2. Comparing the Mean Percentage of Sytox
+
 Neutrophils in 
Unstimulated and Neutrophil Elastase Inhibitor (NEi) Treated Cultures in Different 
Patient Groups. The median group values of the mean percentage of sytox
+
 neutrophils 
were determined for both time points of unstimulated and NEi cultures. The bar in the 
centre of each box indicates the median group value. The box itself represents 50% of the 
values in the group and the extended bars indicate maximum and minimum values. 
Circles indicate outliers. Number of subjects included: BD Relapsed n=3, BD Non-
Relapsed n=6, HC n=3. Mann Whitney U, non-parametric analysis. 
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5.3.2. NETosis with and without PMA-Stimulation: Observation of Neutrophil 
Elastase In Vitro Using Immunocytochemistry 
Neutrophil elastase (NE) has been recognised as a key enzyme involved in the NETosis 
cell death pathway. Characteristically, NE is seen to translocate from its azurophil 
granules located throughout the cytoplasm and enter the nucleus due to the loss of nuclear 
membrane integrity. NE then mixes with the cell’s nuclear material unravelling the coiled 
nucleosome’s DNA and histone complex that configure compact chromatin. In order to 
demonstrate the phases of NETosis, Fig 5.3.2.1 is a collection of images from our study 
showing PMA-stimulated neutrophils undergoing NETosis in vitro similar to how it has 
been reported in previous publications.  
 
For this study, the images in Fig 5.3.2.1 were categorised as three separate stages of the 
NETosis process: early, intermediate, and advanced. But to begin with, in Fig 5.3.2.1, 
panel 1 shows the classic multi-lobed, hypersegmented, round-bodied neutrophil. There 
is a clear separation of the NE in the cytoplasm (contained in its azurophil granules) and 
the DNA in the nuclear envelope. NE defines the early NETosis process by leaving its 
granules and gaining entry to the nucleus where it breaks down DNA-histone complex 
causing enlargement of the nuclear area. Meanwhile, the granules seem to become more 
concentrated as the staining is more pronounced throughout the cytoplasm (Fig 5.3.2.1, 
panel  2). A few prominently stained NE granules remained in the cytoplasm (Fig 5.3.2.1, 
panel, 3). As the cell entered the intermediate stage of NETosis, the hypersegmented 
structure of the neutrophil’s nucleus completely dissipates (Fig 5.3.2.1, panel 4). 
Vacuoles appear within the remaining nuclear material and the cytoplasm, however, the 
cell’s plasma membrane is still intact (Fig 5.3.2.1, panel 5). Finally, in the advanced 
stage, the cell’s membrane loses its integrity and the internal contents disperse into the 
external space (Fig 5.3.2.1, panel 6). 
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Fig 5.3.2.1. Positive Control: Neutrophils Undergoing NETosis in a PMA-Stimulated 
Culture. Panels show the typical neutrophils morphologies undergoing NETosing 
following PMA stimulation. Panel 1 shows a normal, hypersegmented neutrophil. Panels 
2 and 3 show early NETosis in which granules became more pronounced. This stage is 
defined by the initial translocation of NE (red) into the nucleus (DNA, green). This co-
localisation creates a yellow hue. DNA decondensation takes place. Panels 4 and 5 show 
neutrophils undergoing the intermediate stage in which the nucleus continues to swell and 
vacuoles develop. Panel 6 shows the advanced stage of NETosis in which cells have 
erupted and cast out NETs. Confocal 710, X40 oil magnification. Bar indicated 10 µm. 
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Blood neutrophils from HC (n=3 for SLPI staining, n=4 for MPO staining), non-relapsed 
BD (n=7), and relapsed BD patients (n=3) were investigated in vitro to determine whether 
they would naturally undergo NETosis without PMA-stimulation. Observations of the 
different stages of NETosis displayed in Fig 5.3.2.2 were assessed by confocal 
microscopy after immunocytochemical staining. The naturally occurring NETosis had 
some distinguishing features that were different from the PMA-stimulated process. In 
early NETosis, NE was seen to mix with the cell’s DNA while maintaining some of the 
hypersegmented morphology, however the azurophil granules were not as prominent in 
the cytoplasm as they were with PMA (Fig 5.3.2.2, panel 1 and 2). This was evident for 
both HC and BD patients. In fact, NE was seen to frequently co-localise with the entire 
nucleus (panel 2) leaving no evidence of NE remaining in the cytoplasm. Some of the 
nuclei were seen to enlarge but not as much as the PMA-induced cells. Total 
decondensation of the DNA took place during the intermediate stage (Fig 5.3.2.2, panel 
3). Similarly to PMA, vacuoles could be seen through-out the cell while the plasma 
membrane remained intact (Fig 5.3.2.2, panel 4). Finally, expulsion of the cell contents 
marked the advanced stage of NETosis (Fig 5.3.2.2, panel 5 and 6). The majority of NE 
and DNA fibres were cast into the immediate surroundings without any predictive 
formation, however some of the extracellular fibres were distinctively different compared 
to the PMA-induced NETs (Fig 5.3.2.2, panel 5). The NET itself looked highly 
structured with a thick mesh, fan-like structure. This occurred in two different BD 
patients’ unstimulated cultures.  
A histone antibody targeting one of the core proteins, H3, was included in some initial 
staining. However, the staining was discontinued because H3 and DNA staining were 
identical (data not shown) and it was concluded that the DAPI DNA stain was sufficient 
for the detail required in these experiments.  
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Fig 5.3.2.2. BD Patients’ Neutrophils Undergoing NETosis in Unstimulated Culture. 
The panels show the various morphologies of NETosing neutrophils. The co-localisation 
of NE (red) and DNA (green) created a yellow hue. Incubations in culture media were up 
to 4 hours. Images taken on Confocal 710, X40 oil magnification. Bar indicated 10 µm. 
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5.3.2.1. NE Inhibitors and NETosis 
5.3.2.1.1. NE and its Synthetic Inhibitor 
After initially observing NE’s role during induced and naturally occurring NETosis, it 
was important to further investigate the same cultures with NE inhibitor (NEi). This was 
conducted in order to determine whether: 1) NE was an integral element in NETosis and 
if so, 2) whether HC and BD patients’ neutrophils undergoing NETosis could be 
repressed with NEi. The inhibited NETosis reaction expected due to the introduction of 
NEi is demonstrated in Fig 5.3.2.1.1. In the unstimulated cultures, it was hypothesised 
that pre-activated isolated blood neutrophils would undergo NETosis, but with the 
addition of NEi, the process would be inhibited. The same dampening of NETosis cell 
death was expected in the PMA-stimulated cultures with NEi. Eight out of 14 (57.1 %) 
individuals showed this anticipated reaction to 5 µM of NEi in at least one of their time 
point incubations. These included 2 out of 4 HCs, 2 out of 3 BD Relapsed patients, and 4 
out of 7 BD Non-Relapsed patients. All of these cultures were observed almost 
exclusively during the later time point which was after 4 hrs of normal incubation 
conditions or 3 hrs of PMA exposure. The only one that showed this hypothesised 
reaction after 2 hrs of incubation (or 1 hr of PMA-stimulation) was a BD Relapsed 
patient.   
 
As shown in Fig 5.3.2.1.1, NETosing neutrophils in the unstimulated culture (first panel) 
changed when NEi was added (second panel) - NEi inhibited the NETosis cell death 
pathway. The neutrophils maintained their lobulated nuclei, the cell did not enlarge, and 
NE from the granules did not move into the nucleus. Again this is demonstrated in the 
third and fourth panels which show PMA-induced NETosis and the NEi inhibited 
reaction, respectively. Although there was some swelling of the neutrophils and the NE 
seems more granular in the cytoplasm, the NE did not translocate to the nucleus which 
remained hypersegmented.   
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Fig 5.3.2.1.1. The Hypothesized Reaction to NE Inhibitor in Unstimulated and PMA-
Stimulated NETosis. The panels show the expected neutrophil reactions in different 
culture conditions: with or without PMA-stimulation and NEi. The images are neutrophils 
from a BD patient. The co-localisation of NE (red) and DNA (green) created a yellow 
hue. Images taken on Confocal 710, X40 oil magnification. Bar indicated 10 µm. 
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5.3.2.1.2. Endogenous Neutrophil-Derived SLPI During NETosis  
In addition to targeting NE to investigate its role in NETosis, the neutrophil’s endogenous 
inhibitor, SLPI, was also observed for any interactions with NE. Each patient group was 
assessed separately. The neutrophil images in the following panels are a collection of 
representative cultures from HC or BD patients. 
5.3.2.1.2.1. NE and SLPI in Unstimulated Cultures 
5.3.2.1.2.1.1. Unstimulated HC Blood Neutrophils In Vitro 
Very few PFA-fixed, antibody stained neutrophils were seen using confocal microscopy 
in the cultures from 3 out of 4 HC subjects whose original culture started with 1-4x10
5
 
cells. In fact, only 0-2 cells were observed per frame at X40 magnification which is 
represented by HC1 in Fig 5.3.2.1.2.1.1, Panel 1. (The dimensions of each imaged frame 
on the confocal microscope’s X40 objective was 212 µm x 212 µm.)  Only one HC 
subject’s neutrophils had an average of 7 cells per frame (Fig 5.3.2.1.2.1.1, Panel 1, 
HC2). 
Typical, hypersegmented neutrophils were infrequently detected from HCs probably due 
to a lack of cell priming (i.e. surface ligand activity) and would therefore not adhere as 
well to the plain glass coverslips. Thus it was presumed that the majority of neutrophils 
that did not adhere did not encounter a stimulus in vivo or in vitro (Smith et al., 1979) 
(Webster et al., 1986). In Fig 5.3.2.1.2.1.1, Panel 1 HC neutrophils labelled a are some 
of the few hypersegmented neutrophils seen. In particular, these neutrophils showed small 
blebbing projections from the main body of the cell which signifies that the cells were 
either undergoing early apoptosis and/or actively travelling using their pseudopodia-like 
projections. Apoptosing neutrophils (Panel 1, label b) were occasionally observed in the 
unstimulated cultures. They were identified by condensed nuclei which was no longer 
hypersegmented and the cell diameter was less than 10 µm. NE and SLPI could be 
detected in the cytoplasm separate from DNA.  
After 2 hrs of culture, very few HC cells were detected undergoing NETosis as is evident 
in Fig 5.3.2.1.2.1.1, Panel 1 (c, d). A higher intensity of the NE antibody stain was 
observed on the border of the still hypersegmented nuclei in early NETosis (arrow, c). 
SLPI coincided with the NE stain and the overlap of all three NE, SLPI, and DNA 
fluorescent antibodies created a bright pink-white tinge. Advanced NETosis in 
unstimulated HC neutrophils was rare (d). Finally, there were a few non-NETosing 
SLPI
+
/NE
- 
eosinophils (e) identified in the cultures as well. 
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SEE FIGURE 5.3.2.1.2.1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.1.1. Unstimulated HC Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in Unstimulated Cultures. Neutrophils were cultured in 24-
well plates on non-coated glass coverslips. The cells were all incubated for a total of 2 hrs 
(Panel 1) and 4 hrs (Panel 2) in culture media without NE inhibitor before being fixed in 
4% PFA. The cells were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). 
X40 oil magnification, Confocal 710. Bar indicates 10 µm.  
 
 
213 
 
After 4 hrs in culture, there were very few cells from HC subjects that remained attached 
to the coverslips. Some of the cells that did attach were hypersegmented (Fig 
5.3.2.1.2.1.1, Panel 2, HC1) although these were frequently located closer to the 
coverslip edge where they were probably agitated. Other cells included a few small 
neutrophils with condensed DNA that were thought to be apoptosing (Fig 5.3.2.1.2.1.1, 
Panel 2, HC2). Two neutrophils were detected undergoing the early stage of NETosis 
(Fig 5.3.2.1.2.1.1, yellow arrows) in which NE mixed with the DNA with some initial 
decondensation. In some cells, the NE seemed more concentrated along the periphery of 
the nucleus. However, even after 4 hrs in culture, the advanced eruption stage of NETosis 
was only observed once among the unstimulated HC cultures.  
 
SLPI was detected in all cultured neutrophils. In hypersegmented and apoptosing cells, 
SLPI remained in the cytoplasm. However, unstimulated HC neutrophils undergoing 
NETosis revealed that SLPI co-localised with the NE in the nucleus (Fig 5.3.2.1.2.1.1, 
Panel 2, HC2). The erupted neutrophil showed an overlapping pattern of all three targets 
(DNA, NE, and SLPI) (Panel 1, HC2, d). In all cases, SLPI seemed to stain with more of 
a grainy appearance than NE. 
5.3.2.1.2.1.2. Unstimulated Non-Relapsed BD Patients’ Blood Neutrophils In Vitro 
BD patients that were considered to be clinically non-relapsed had their blood neutrophils 
subjected to the same culture conditions as HC subjects. Compared to HCs, there were 
more neutrophils attached to the uncoated, glass coverslips in 5 out of 7 (71.4%) patients’ 
untreated cultures. In unstimulated cultures from either time point, 5 out of 7 (71.4%) 
non-relapsed BD patients’ neutrophils also showed a clear indication that they were 
undergoing early NETosis (Fig 5.3.2.1.2.1.2, yellow arrows) by exhibiting a dense 
accumulation of NE (red) converging with DNA (green) within the nucleus. The same 
percentage of BD non-relapsed subjects’ neutrophil cultures showed evidence of 
advanced NETosis identified by the spilling of internal contents into the extracellular 
environment (Fig 5.3.2.1.2.1.2, Panel 1, BD3 and Panel 2, BD2). 
 
However, some neutrophils in the cultures showed a variety of unexpected morphologies 
which were quite different to HCs (Fig 5.3.2.1.2.1.2, Panel 1 and 2). There were 
neutrophils with large vacuoles (Panel 1, BD2) from one non-relapsed BD patient while 
another patient’s neutrophils showed atypical formations with fan-like projections (Panel 
2, BD1). No intact cells were identified in one patient’s culture after 2 hrs incubation; 
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only cellular debris staining positive for DNA was found on the coverslips (data not 
shown).  
 
During both time points, SLPI was seen to co-localise with the internal DNA/NE complex 
when the neutrophil was undergoing NETosis in unstimulated cultures. This is best 
demonstrated in Fig 5.3.2.1.2.1.2, Panel 2, BD3. SLPI was always found to stain within 
the region of externalised NETs. 
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SEE FIGURE 5.3.2.1.2.1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.1.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in an Unstimulated Culture. Neutrophils were cultured in 24-
well plates on non-coated glass coverslips. The cells were incubated for a total of 2 hrs 
(Panel 1) and 4 hrs (Panel 2) in culture media. Cells were then fixed in 4% PFA. The 
neutrophils were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). Yellow 
arrows indicate definitive stages of NETosis. X40 oil magnification, Confocal 710. Bar 
indicates 10 µm.  
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5.3.2.1.2.1.3. Unstimulated Relapsed BD Patients’ Blood Neutrophils In Vitro 
Clinically relapsed BD patients neutrophils were subjected to the same culture conditions 
as non-relapsed patients and HCs. Fig 5.3.2.1.2.1.3 represents the neutrophils in 
unstimulated conditions in vitro originating from these relapsed BD patients (n=3). After 
2 hrs in culture, 2 out of the 3 (66.7%) patients had a low number of neutrophils attaching 
to the coverslips (an average of 2 per frame). These cells showed evidence of early and 
intermediate NETosis with the convergence of NE and DNA. Their nuclear material had 
also decondensation and enlarged Fig 5.3.2.1.2.1.3, Panel 1, BD1. After 4 hrs in culture 
without any external chemical stimulation, both of these patient cultures showed evidence 
of advanced NETosis in which nearly all the cells released their contents (Fig 
5.3.2.1.2.1.3, Panel 2, BD1, BD2).  
 
The third patient had an increased number of neutrophils attached to the coverslips (an 
average of 25 cells per frame) after 2 hrs incubation. These neutrophils showed a variety 
of active stages: normal hypersegmented as well as early and late NETosis (Fig 
5.3.2.1.2.1.3, Panel 1, BD2). Interestingly, after 4 hrs, the intermediate stage of NETosis 
(decondensed nuclei and swollen cells) predominated amongst the cells.  
 
SLPI co-localised with the NE/DNA complex in 2 out of 3 BD relapsed patients’ 
unstimulated neutrophil cultures in intact cells undergoing ‘naturally occurring’ NETosis.  
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SEE FIGURE 5.3.2.1.2.1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.1.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in an Unstimulated Culture. Neutrophils incubated for a total 
of 2 hrs (Panel 1) and 4 hrs (Panel 2) in culture media. Cells were then fixed in 4% PFA. 
The neutrophils were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). 
X40 oil magnification, Confocal 710. Bar indicates 10 µm.  
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5.3.2.1.2.2. Unstimulated Neutrophil Cultures with NEi 
5.3.2.1.2.2.1. HC Blood Neutrophils In Vitro with NEi 
When incubating the HC neutrophils for 2 hrs with NE inhibitor (NEi), no NETosing 
cells were detected in any culture. The neutrophils remained hypersegmented (Fig 
5.3.2.1.2.2.1, Panel 3, HC1) or were small, round apoptosing cells with condensed DNA 
and cytoplasmic contents (Panel 3, HC2). A few bi-lobed eosinophils (SLPI
+
/NE
-
) were 
also detected. After 4 hrs in culture, despite the NEi, a few neutrophils did progress to 
early (Panel 4, HC1) and intermediate NETosis (HC2).  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.2.1. Unstimulated HC Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in Unstimulated Cultures with NE Inhibitor. Neutrophils 
were incubated for a total of 2 hrs (Panel 3) and 4 hrs (Panel 4) in culture media with NEi 
before being fixed in 4% PFA. The cells were stained for NE (red), SLPI (blue), and 
DNA (DAPI) (green). Co-localisation of all three targets resulted as pink areas. Yellow 
arrows indicate various stages of NETosis. X40 oil magnification, Confocal 710. Bar 
indicates 10 µm.  
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5.3.2.1.2.2.2. Non-Relapsed BD Patients’ Blood Neutrophils In Vitro with NEi 
With the addition of 5 µM of NEi during the 2 hr incubation, 4 out of 7 (57.1%) BD non-
relapsed patients’ neutrophils showed fewer cells undergoing NETosis (Fig 5.3.2.1.2.2.2, 
Panel 3, BD1, arrow) compared to their unstimulated counterpart without NEi. After 4 
hrs, 6 out of 7 (85.7%) cultures did not show any signs of NETosing cells except for BD3 
in Fig 5.3.2.1.2.2.2, Panel 4 (arrow).   
 
Some of the other cell characteristics that were detected in cultures with NEi are 
represented in Fig 5.3.2.1.2.2.2, Panel 3 and 4. Eight out of 14 (57.1%) cultures 
regardless of their incubation time of 2 or 4 hrs showed some normal, hypersegmented 
nuclei (Panel 3: BD2; Panel 4: BD1, BD2). However, similar to the unstimulated 
cultures, some neutrophils had an atypical morphology. For instance, the cell in Panel 3 
from BD1 had decondensed DNA and blebbing without co-localising NE. There were 
cells that seemed to be spilling their contents (Panel 3, BD2) and neutrophils thought to 
be undergoing apoptosis (Panel 3, BD3). 
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SEE FIGURE 5.3.2.1.2.2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.2.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in an Unstimulated Culture with NE Inhibitor. Neutrophils 
were cultured in 24-well plates on non-coated glass coverslips. The cells were incubated 
for a total of 2 hrs (Panel 3) and 4 hrs (Panel 4) in culture media with NEi. Cells were 
then fixed in 4% PFA. The neutrophils were stained for NE (red) and SLPI (blue) and 
DNA (DAPI) (green). Yellow arrows indicate definitive stages of NETosis. X40 oil 
magnification, Confocal 710. Bar indicates 10 µm.  
 
221 
 
5.3.2.1.2.2.3. Relapsed BD Patients’ Blood Neutrophils In Vitro with NEi 
The addition of NEi dramatically reduced the occurrence of NETosis in the BD relapsed 
patients’ neutrophils. Two out of the 3 patients whose cells showed evidence of NETosis 
in their unstimulated cultures, now showed normal, hypersegmented neutrophils after 2 
hrs incubation (Fig 5.3.2.1.2.2.3, Panel 3,  BD1). Only one patients showed evidence of 
NETosing cells in the presence of NEi (Panel 3, BD2). Following the 4 hr incubation 
with NEi, none of the 3 patients’ neutrophils had progressed toward cell death via the 
NETosis pathway (Panel 4, BD1, BD2). Neutrophils with this normal morphology 
retained NE and SLPI in the cytoplasm.  
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SEE FIGURE 5.3.2.1.2.2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.2.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in an Unstimulated Culture with NE Inhibitor. Neutrophils 
were incubated for a total of 2 hrs (Panel 1) and 4 hrs (Panel 2) with NEi in culture media. 
Cells were then fixed in 4% PFA. The neutrophils were stained for NE (red) and SLPI 
(blue) and DNA (DAPI) (green). X40 oil magnification, Confocal 710. Bar indicates 10 
µm.  
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5.3.2.1.2.3. PMA-Stimulated Neutrophil Cultures  
5.3.2.1.2.3.1. PMA-Stimulated HC Blood Neutrophils In Vitro  
The next experiment was to use PMA to induce NETosis in HC neutrophils as a positive 
control. The results are shown in Fig 5.3.2.1.2.3.1. The most obvious observation was 
that the activated neutrophils had readily attached  to the glass coverslips. The neutrophils 
from 3 out of 4 (75%) HC subjects reacted to the PMA after 1 hr of stimulation (Panel 5, 
HC1). Only 1 HC subject’s cells remained unaffected (Panel 5, HC2). After 3 hrs of 
PMA-stimulation (and a total of 4 hrs in culture) (5.3.2.1.2.3.1, Panel 6), many of the HC 
subjects’ neutrophils had reacted with a few showing the end stage of NETosis in which 
the cell contents  were cast out into the local environment (Panel 6, HC1). SLPI was not 
seen to co-localise with the NE/DNA complex in PMA-induced HC neutrophils until 
expelled from the cell in a NET. In all the cultures, the eosinophils, identified by their 
SLPI
+
/NE
-
 staining and bi-lobed nucleus, were never seen to undergo NETosis with or 
without PMA-stimulation. 
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SEE FIGURE 5.3.2.1.2.3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.3.1. HC Neutrophils In Vitro: Investigating the Occurrence of NETosis 
in a PMA-Stimulated Culture. Neutrophils were cultured in 24-well plates on non-
coated glass coverslips. The cells were all incubated for a total of 2 hrs (Panel 5) and 4 
hrs (Panel 6)  in culture media without NEi. 100 nM of PMA was added after the first 
hour of incubation. Cells were then fixed in 4% PFA. The cells were stained for NE (red) 
and SLPI (blue) and DNA (DAPI) (green). Yellow arrows indicate various stages of 
NETosis. X40 oil magnification, Confocal 710. Bar indicates 10 µm. 
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5.3.2.1.2.3.2. PMA-Stimulated Non-Relapsed BD Patients’ Blood Neutrophils In 
Vitro  
When non-relapsed BD patient neutrophils were exposed to PMA in culture, within 1 hr, 
4 out of 7 (57.1%) samples showed evidence of advanced progression of NETosis. The 
classic characteristics included the expulsion of cell contents which is demonstrated in 
Fig 5.3.2.1.2.3.2, Panel 5, BD3. In fact, two of these samples only showed cellular debris 
left on the coverslip. Two out of 7 (28.6%) samples showed the convergence of NE with 
DNA and the beginning of nuclear decondensation indicative of early NETosis (Panel 5, 
BD2). Only one sample had not yet reacted to the PMA (Panel 5, BD1).  
After 3 hrs of PMA-stimulation (a total of 4 hrs in culture), all 7 (100%) non-relapsed BD 
subjects’ cultures had reacted to the stimulant. All the cultures showed intermediate or 
advanced NETosis. The intermediate stage of NETosis was observed in 4 out of 7 
(57.1%) cultures including cytoplasm and nuclear vacuolization as well as cell swelling 
and decondensing of nuclear DNA (Fig 5.3.2.1.2.3.2, Panel 6, BD1). The casting out of 
cellular contents is the final act in advanced NETosis. This was observed in 3 out of the 
remaining 7 cultures (Panel 6, BD2, BD3).  
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SEE FIGURE 5.3.2.1.2.3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.3.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in a PMA-Stimulated Culture. Neutrophils were cultured in 
24-well plates on non-coated glass coverslips. The cells were all incubated for a total of 2 
hrs (Panel 5) and 4 hrs (Panel 6) in culture media without NEi. 100 nM of PMA was 
added after the first hour of incubation. Cells were then fixed in 4% PFA. The cells were 
stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). X40 oil magnification, 
Confocal 710. Bar indicates 10 µm. 
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5.3.2.1.2.3.3. PMA-Stimulated Relapsed BD Patients’ Blood Neutrophils In Vitro  
When stimulating the relapsed BD patients’ neutrophils with 100 nM of PMA, all of the 
cells in culture reacted after only 1 hr of exposure. One patients’ neutrophils showed 
decondensation of the nuclear material and swelling indicative of the intermediate stage 
of NETosis (Fig 5.3.2.1.2.3.3, Panel 5, BD1). Meanwhile, the other two patients’ cell 
cultures were undergoing advanced NETosis with the expulsion of cell contents into the 
surrounding environment as seen in Fig 5.3.2.1.2.3.3, Panel 5, BD2. After 3 hrs of PMA-
stimulation, all the cells from all 3 relapsed BD patients had undergone advanced 
NETosis (Panel 6).  
 
SLPI was not observed to co-localise with the NE/DNA complex in intact, PMA-induced 
neutrophils but this was probably because most of the cells’ contents had already been 
expelled. Among the NETs, SLPI stained in a similar but not exact pattern of the 
externalised NE and DNA. 
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SEE FIGURE 5.3.2.1.2.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.3.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in a PMA-Stimulated Culture. Neutrophils were incubated for 
a total of 2 hrs (Panel 5) and 4 hrs (Panel 6) in culture media without NEi. 100 nM of 
PMA was added after the first hour of incubation. Cells were then fixed in 4% PFA. The 
cells were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). X40 oil 
magnification, Confocal 710. Bar indicates 10 µm.  
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5.3.2.1.2.4. PMA-Stimulated Neutrophil Cultures with NEi 
5.3.2.1.2.4.1. PMA-Stimulated HC Blood Neutrophils In Vitro with NEi 
Despite the addition of NEi, most PMA-stimulated HC neutrophils continued to undergo 
early NETosis as indicated by the arrows in Fig 5.3.2.1.2.4.1, Panel 7 and 8, however, 
advanced NETosis was observed in only one HC culture. One other culture showed no 
progression towards NETosis at all (Panel 7, HC2); NE remained separated from the 
DNA. Therefore, NEi probably inhibited or delayed these HC neutrophils from 
undergoing NETosis.  
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SEE FIGURE 5.3.2.1.2.4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.4.1. HC Neutrophils In Vitro: Investigating the Occurrence of NETosis 
in a PMA-Stimulated Culture with NE Inhibitor. Neutrophils were cultured in 24-well 
plates on non-coated glass coverslips. The cells were all incubated for a total of 2 hrs 
(Panel 7) and 4 hrs (Panel 8) in culture media with NEi. 100 nM of PMA was added after 
the first hour of incubation. Cells were then fixed in 4% PFA. The neutrophils were 
stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). Yellow arrows indicate 
various stages of NETosis.  X40 oil magnification, Confocal 710. Bar indicates 10 µm. 
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5.3.2.1.2.4.2. PMA-Stimulated Non-Relapsed BD Patients’ Blood Neutrophils In 
Vitro with NEi 
Incorporating 5 µM of NEi before the PMA was added to the cultures seemed to hinder 
progression of induced NETosis in a total of 9 out of 14 cultures (64.3%): 3 out of 7 
(42.9%) cultures after 1 hr of PMA-stimulation and 5 out of 7 (71.4%) cultures after 3 hrs 
of stimulation. Cultures showed a mix of hypersegmented, normal neutrophils as well as 
cells undergoing the convergence of their NE into the DNA (Fig 5.3.2.1.2.4.2, Panel 7, 
BD1) signifying early NETosis which was still apparent after 3 hrs of PMA-stimulation 
(Panel 8). SLPI was not observed to co-localise with the NE/DNA complex while the 
PMA-stimulated, BD non-relapsed patient neutrophils remained intact.  
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SEE FIGURE 5.3.2.1.2.4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.4.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in a PMA-Stimulated Culture with NE Inhibitor. Neutrophils 
were incubated for a total of 2 hrs (Panel 7) and 4 hrs (Panel 8) in culture media with NEi. 
100 nM of PMA was added after the first hour of incubation. Cells were then fixed in 4% 
PFA. The cells were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). X40 
oil magnification, Confocal 710. Bar indicates 10 µm. 
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5.3.2.1.2.4.3. PMA-Stimulated Relapsed BD Patients’ Blood Neutrophils In Vitro 
with NEi 
Despite NEi in the culture, an hour of PMA-stimulation showed that neutrophils from 2 
out of the 3 BD relapsed patients underwent advanced NETosis (Fig 5.3.2.1.2.4.3, Panel 
7, BD2). This remained evident after 3 hrs (Panel 8, BD2). However, it was worth noting 
that some of the cells in these cultures still had DNA that was lobular without NE and 
DNA mixing.  Also after 3 hrs of PMA exposure, the third relapsed BD patient whose 
neutrophils retained normal, hypersegmented nuclei after 1 hour’s stimulation began to 
show cellular swelling and DNA decondensation (Panel 8, BD1).  
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SEE FIGURE 5.3.2.1.2.4.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.4.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in a PMA-Stimulated Culture with NEi. Neutrophils were 
incubated for 2 hrs (Panel 7) and 4 hrs (Panel 8) in culture media with NEi. 100 nM of 
PMA was added after the first hour of incubation. Cells were then fixed in 4% PFA. The 
cells were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). X40 oil 
magnification, Confocal 710. Bar indicates 10 µm.  
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Despite 1 hr of PMA-stimulation, by including NEi in the initial culture, one of the 
relapsed BD patients’ neutrophils was able to retain normal morphology (Fig XIII, Panel 
7, BD1). Previously, with PMA alone, this patient showed intermediate stage of NETosis. 
NEi was able to inhibit NE from converging with the DNA and thus preserving the 
hypersegmentation in the relapsed BD patients’ cultures.  
5.3.2.1.2.5. Unidentified Cell Death 
A few of the unstimulated cultures had a small selection of neutrophils that were 
undergoing cell death, but the type of process could not be identified solely with the 
protein targets that were used. A selection of these cells is demonstrated in Fig 
5.3.2.1.2.5.1. The top panel shows a HC neutrophil in which the nuclear DNA has been 
disrupted and fills up the entire space within the cell’s borders. However it maintains a 
compact, round morphology (possibly attributed to apoptosis) with NE on the periphery 
while SLPI is distributed throughout the cell. The middle panel shows a BD patient’s 
neutrophil whose nucleus was still hypersegmented with some infiltration of NE 
indicative of NETosis, but seemed as if its cytoplasm ruptured before the process could 
finish. The last panel again shows a neutrophil from a different BD patient. The DNA was 
broken down and had expanded through-out the cell. SLPI had a similar distribution 
contained within an irregular cell border.  A small patch of NE existed in the cell centre. 
The expansion of the cell larger than 10 µm could be a sign of secondary necrosis. 
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Fig 5.3.2.1.2.5.1. HC and Non-Relapsed BD Patients’ Neutrophils In Vitro: 
Undefined Cell Death Processes in Unstimulated Cultures. Neutrophils were 
incubated for 2 and 4 hrs in culture media. Cells were then fixed in 4% PFA. The cells 
were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). X40 oil 
magnification, Confocal 710. Bar indicates 10 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.1.3. MPO and NETosis 
After NE’s movement to the nucleus, its azurophil co-inhabitor, MPO, is selectively 
translocated from the granule to the nucleus during NETosis (Papayannopoulos et al., 
2010). To observe this event, the cultured, fixed neutrophils from all patient groups 
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underwent immunofluorescent antibody staining with MPO. A demonstration of MPO’s 
observed behaviour during PMA-induced NETosis can be seen in Fig 5.3.2.1.3.1. When 
induced with PMA, the cells enlarged and vacuoles were more prevalent than 
unstimulated cultures.  
It was difficult to capture the event of MPO mixing with the DNA in unstimulated 
cultures from BD non-relapsed patients (Fig 5.3.2.1.3.3) and especially HCs (Fig 
5.3.2.1.3.2). This could be because the ex vivo neutrophils were all different ages and 
therefore undergoing NETosis at different stages, if at all. It was suspected that BD 
relapsed patients had a higher prevalence of primed neutrophils resulting in a larger 
collection of cells to observe (Fig 5.3.2.1.3.4). In these patients’ cultures, there was more 
evidence of intermediate and advanced stage NETosis thus capturing the MPO’s 
involvement. All patient cells that released NETs showed a conglomerate of 
NE/MPO/DNA co-localised fibres without any particular, recognisable pattern. 
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Fig 5.3.2.1.3.1. Positive Control: Neutrophils Undergoing NETosis in a PMA-
Stimulated Culture. Demonstrated in the panels above are the typical morphologies of 
NETosing HC and BD neutrophils when they were induced with PMA. The main MPO 
activity occurred in the intermediate stage of NETosis after NE had translocated into the 
nucleus, therefore the first image shows this integration of MPO (blue) into the nucleus. 
The second and third panels show progressed intermediate stages in which MPO granules 
in the cytoplasm become more concentrated and pronounced, decondensation of DNA 
(green) takes place, and the cell continues to swell and vacuoles may develop both in the 
cytoplasm and nucleus. The final panel shows the advanced stage of NETosis in which 
cells erupts and casts out NETs. The asterisk marked panels signify the commonly 
observed progression of NETosis from decondensed nuclei to advanced NETosis. 
Confocal 710, X40 oil magnification. Bar indicated 10 µm. 
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SEE FIGURE 5.3.2.1.3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.2.1.3.2. Unstimulated and PMA-Stimulated HC Neutrophils In Vitro: 
Observation of MPO. Neutrophils were cultured in 24-well plates on non-coated glass 
coverslips. The cells were all incubated for a total of 2 hrs and 4 hrs in culture media 
before being fixed in 4% PFA. The cells were stained for NE (red), MPO (blue) and DNA 
(green). Co-localisation of all three targets produced pink regions. X40 oil magnification, 
Confocal 710. Bar indicates 10 µm. 
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SEE FIGURE 5.3.2.1.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.2.1.3.3. Unstimulated and PMA-Stimulated Non-Relapsed BD Neutrophils 
In Vitro: Observation of MPO. Neutrophils were incubated for a total of 2 and 4 hrs in 
culture media before being fixed in 4% PFA. The cells were stained for NE (red), MPO 
(blue) and DNA (green). Co-localisation of all three targets produced pink regions. X40 
oil magnification, Confocal 710. Bar indicates 10 µm. 
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SEE FIGURE 5.3.2.1.3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.3.4. Unstimulated and PMA-Stimulated Relapsed BD Neutrophils In 
Vitro: Observation of MPO. Neutrophils were incubated for a total of 2 and 4 hrs in 
culture media before being fixed in 4% PFA. The cells were stained for NE (red), MPO 
(blue) and DNA (green). Co-localisation of all three targets produced pink regions. X40 
oil magnification, Confocal 710. Bar indicates 10 µm. 
5.3.2.1.4. The Role of Endogenous Alpha-1 Antitrypsin During NETosis 
Neutrophils also harbour another endogenous NE inhibitor, alpha-1 antitrypsin (α1AT), 
which is stored in the azurophil granules alongside NE (Mason et al., 1991). The cultured 
PFA-fixed neutrophils were subjected to staining with NE and α1AT antibodies in order to 
242 
 
observe if co-localisation occurred between serine protease and serpin inhibitor 
intracellularly while undergoing NETosis or after the event of casting out. 
 
In Fig 5.3.2.1.4.1, unstimulated HC neutrophils stained positive for NE, α1AT, and DNA. 
The neutrophils underwent early NETosis as NE began to mix with the DNA acting to 
deconstruct its histone and chromatin assembly. A higher concentration of NE can be seen 
on the periphery of the lobed nuclei which can be seen in the first panel. Meanwhile, the 
α1AT (in purple) seems to remain in spotted granules throughout the cytoplasm. There 
does not seem to be any overlap of α1AT with either the NE or diffused DNA staining. To 
compare α1AT’s cytoplasmic location in HCs, additional staining was completed on BD 
patients’ neutrophils for all the experimental culture conditions including unstimulated 
and PMA-stimulated NETosis with or without NEi. A representative panel of the results 
can be seen in Fig 5.3.2.1.4.1. 
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SEE FIGURE 5.3.2.1.4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.4.1. Alpha-1Antitrypsin during NETosis In Vitro. HC, BD non-relapsed 
and relapsed patients’ neutrophils were incubated with and without PMA then PFA-fixed 
and stained for NE (red), α1AT (purple), DNA (green). X40 oil magnification, Confocal 
710. Bar indicates 10 µm.  
As seen previously, NE co-localised with DNA during all stages of NETosis regardless of 
donor or culture treatment (with or without PMA). However, the α1AT appeared 
exclusively within the cytoplasm – presumably still packaged in the azurophil granules. It 
was only upon the release of NETs that α1AT would speckle-coat the area around NE and 
DNA as seen in Fig 5.3.2.1.4.1. The addition of NEi did not seem to have any effect on 
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changing the location of α1AT in the cytoplasm. This was evident in both unstimulated 
and induced NETosis with NEi (data not shown).  
 
5.3.3. Summary of Key Results 
The key results from the immunofluorescent staining of fixed neutrophils from HC and 
BD patient cultures are listed in the Table 5.3.3.1.  below. 
Key Results  Number of Patients (%) in at 
Least 1 Culture Time Point 
Advanced NETosis occurring in 
unstimulated cultures 
2/4 (50% ) HC  
5/7 (71.4%) BD Non-Relapsed* 
3/3 (100%) BD Relapsed* 
NEi reduced the progression of NETosis 
compared to unstimulated cultures without 
NEi at the same time point* 
3/3 (100%) HC  
4/7 (57.1 %) BD Non-Relapsed 
2/3 (66.7%) BD Relapsed 
SLPI but not α1AT was seen to co-localise 
with NE/DNA in intact cells in unstimulated 
cultures 
2/3 (66.7% ) HC  
5/7 (71.4%) BD Non-Relapsed 
2/3 (66.7%) BD Relapsed 
Advanced NETosis occurring after 1 hr of 
PMA-stimulation* 
1/4 (25%) HC  
3/7 (42.9%) BD Non-Relapsed 
2/3 (66.7%) BD Relapsed 
Table 5.3.3.1. Summary of Key Results *based on SLPI/NE staining data 
 
 
 
 
 
 
 
 
 
Differences  Similarities 
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 Neutrophils did not swell in unstimulated 
cultures as much as with PMA 
 Intact cells were 9-10 µm in diameter 
whereas PMA-stimulated neutrophils 
could be seen swelling in excess of 15 µm  
 In unstimulated cultures, decondensed 
DNA did not enlarge as much as PMA-
induced cells  
 Vacuoles were rarely seen in cells 
undergoing NETosis in unstimulated 
cultures (only seen in 1 BD patient) 
 SLPI co-localised with the NE/DNA 
complex in the nuclear region of intact 
neutrophils in unstimulated cultures but 
not when PMA was included 
 Unique morphologies with distinct 
DNA/NE/SLPI-coated  extracellular 
fibres seen in BD patients 
 was repressed by NEi 
 In most cases, the number neutrophils that 
adhered to coverslips increased when 
exposed to PMA 
 NE re-located to the nucleus and co-
localised with DNA 
 MPO entered and co-localised with 
the NE and DNA at a late-stage of 
NETosis 
 NEi could inhibit the progression of 
NETosis 
 The released NET DNA fibres were 
coated with NE, MPO, SLPI, and 
α1AT 
 When externalised, DNA, NE, MPO, 
SLPI, and α1AT adhered to the glass 
coverslips 
 
Table 5.3.3.2. Differences and Similarities Collectively Observed When Comparing 
PMA-Stimulated and Non-Stimulated Neutrophils from All Patient Groups In Vitro.  
 
 
 
 
 
 
 
5.4. Discussion 
5.4.1. Challenges of Working with Neutrophils in the Lab 
5.4.1.1. Time Schedule Constraints 
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Neutrophils in the peripheral circulation live a relatively short time compared to other 
leukocytes (Haslett, 1997, Webb et al., 2000). They are terminally senescent cells and 
therefore will not replicate. When conducting experiments with ex vivo human 
neutrophils, time is constrained. The in vitro experimental treatments and sytox
®
 green 
NETs quantification conducted for this study had to be completed in one day. The cells 
cultured on glass coverslips were able to be PFA-fixed and immunofluorescent stained at 
a later date. 
 
5.4.1.2. Avoiding Neutrophil Priming or Activation  
One of the most vital issues with assessing NETs from human blood was the possible 
activation of the neutrophils during purification and handling. Neutrophils exist in the 
peripheral blood in three states: quiescent, primed, or active (Hallett and Lloyds, 1995). A 
primed neutrophil differs from an active one because it has recognised a stimulus via a 
cell receptor but has not yet triggered an oxidase response (Hallett and Lloyds, 1995). 
Neutrophils can generate a superoxide respiratory burst upon adherence to plastics (Ginis 
and Tauber, 1990) or with other protocol reagents such as gelatin (Stie and Jesaitis, 
2007). We were aware that these may potentially create a situation where the risk of 
generating false positive results was increased. Due to this potential limitation, blood 
from HCs underwent the same procedures as BD patients’ blood and had their production 
of NETs assessed under the same conditions in parallel. 
 
Several difficulties were overcome during neutrophils isolation. Firstly, the Histopaque 
1119 density separation reagent and blood samples had to be at RT otherwise the blood 
did not filter through the gradient to isolate red blood cells from PBMC’s and 
granulocytes. Several patients’ blood samples were unfortunately unusable for 
downstream analysis due to the inability to filter properly. Also, if the donor was 
anaemic, the blood would not separate properly which was the case with one HC where 
only a few cultures could be prepared due to the poor neutrophil isolation. Secondly, it 
was found that Brinkmann, et al, (Brinkmann et al., 2004) description of percoll gradients 
was misleading. In their published protocol, the first step in diluting the neat percoll was 
to create a 90% solution in PBS. However, confusingly, they refer to this first dilution as 
“100%” solution and instruct the reader to create a 65, 70, 75, 80 and 85% solution from 
it, but is actually 58.5, 63, 67.5, 72, and 76.5%, respectively. This was initially 
misconstrued and could have been better described. Also, the use of RBC lysis solution 
had been included by nearly all previous NET protocols (Skrzeczynska-Moncznik et al., 
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2012, O'Donoghue et al., 2013), but there were warnings about this procedure because of 
the high risk of activating the neutrophils and so RBC lysis reagents were avoided.  
 
5.4.1.3. Neutrophil Adherence to Non-Coated Glass Coverslips 
Glass coverslips were initially coated with poly-D-lysine, however it was later discovered 
that the synthetic polymer may also have activated the neutrophils and disrupted the DNA 
making NETs. Poly-D-Lysine, a polyamino acid, increases the electrostatic interaction 
and binding between cations on surface materials used for culturing and cell membrane 
anions. A high molecular weight (150-300k) poly-D-lysine was chosen for these 
experiments in order to encourage neutrophils to attach to the glass coverslips as 
neutrophils are notoriously difficult to attach without stimulation. Whilst we do not know 
for certain how poly-D-lysine triggered NET formation, it could be due to the interaction 
of negatively charged extracellular DNA and positively charged polymer. 
Culturing neutrophils on non-coated glass coverslips had its challenges. A large number 
of neutrophils (1x10
5
-5x10
5 
cells per well) were required for the cultures destined for 
PFA-fixing and antibody staining due to repetitive wash procedures which depleted the 
number of neutrophils as they easily lifted off of the non-coated coverslips. This was the 
case especially with unstimulated cultures from HC and two BD non-relapsed patients. It 
also became apparent that non-stimulated neutrophils showed a reduced ability to adhere 
to the glass coverslips. Previous studies have shown similar occurrences when culturing 
human neutrophils for purposes other than observing NETs. Smith, et al, (Smith et al., 
1979) exposed HC neutrophils in vitro to various chemotactic factors including zymosan 
yeast activated serum, E.coli bacterial extract, the proinflammatory complement fragment 
C5a, and synthetic peptide N-formyl-L-methionyl-L-phenylalanine (FMLP). They found 
that each chemotactic factors tested caused a significant increase in the number of 
neutrophils that were able to attach to glass compared to those without any chemotactic 
factors exposure. The cell shape was altered from spherical to polarised (bipolar) as well. 
They also showed that pre-coating the glass with BSA or 5% serum reduced the 
attachment of round-shaped neutrophils but not of polarised neutrophils. Webster, et al, 
(Webster et al., 1986) found that PMA, a non-chemotactic stimulus, also increased 
neutrophil adherence in a concentration dependent manner. In our study, we also found 
that PMA-stimulated neutrophils attached readily to the coverslips. Therefore, neutrophils 
that were not PMA-stimulated but were potentially exposed to circulating chemotactic 
factors in vivo (as is possible in BD patients) may have promoted cell attachment in vitro. 
248 
 
Lastly, very few intact, non-stimulated neutrophils could be located on the slides when 
NEi was added to unstimulated cultures. NEi inhibits NE activity and as a consequence 
appeared also to have reduced the neutrophils’ adhesion to the coverslips.    
5.4.1.4. The Different Morphology of NETs Created by Laboratory Handling 
When neutrophils were cultured in order to determine whether they are undergoing 
NETosis, we found that there were two morphological states that the neutrophil could be 
visualised depending on the operator’s handling and manipulation. First, if they were 
cultured on glass coverslips, stained with sytox and then lifted, inverted and mounted 
onto slides, the neutrophils which underwent NETosis showed vivid and characteristic 
DNA net-like protrusions. This formation made it difficult to accurately quantify the 
number of NETosing cells. The second option was to culture the cells directly onto semi-
adherent culture wells, add sytox green to the media, and view them under an inverted 
timelapse fluorescent microscope with minimum mechanical disruption to the cells as 
previously described by Papayannopoulos, et al, (Papayannopoulos et al., 2010) and 
Brinkmann and Zychlinsky (Brinkmann et al., 2012). This technique provided a clearer 
image in order to determine the number of NETosing cells. Granted, it can be argued that 
a stationary culture of neutrophils does not necessarily reflect their non-static nature in 
vivo, but for the purpose of initially determining the quantification of the cells, the 
stationary culture is currently the best option.  
5.4.1.5. Immediate Imaging is Necessary for Accurate Sytox Quantification 
Imaging the same unstimulated HC neutrophil cultures the next day resulted in a small, 
non-significant increase in sytox
+
 cells. However, when re-imaging PMA-stimulated HC 
cells, there was a dramatic increase in sytox
+
 cells the next day. This is most likely due to 
the prolonged chemical stimulation in culture overnight. Therefore, imaging was carried 
out for all sytox experiments. 
5.4.1.6. Quantification of NETs 
Quantifying extracellular DNA from NETs using sytox
®
 green and Hoechst provided the 
first evidence that BD patients had a higher incidence of NETosing cells than HCs. In 
particular, the average percent of sytox
+
 neutrophils were from BD patients experiencing 
a clinical relapse. Further analysis revealed the increase of sytox
+
 cells after 4 hrs in 
unstimulated cultures from BD patients but not HCs. This data suggests that BD patients’ 
neutrophils were producing more NETs than HCs. BD relapse patients’ neutrophils also 
produced more sytox
+
 cells after 3 hrs of incubation with PMA than either BD non-
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relapsed patients or HCs further supporting our hypothesis that their cells had been 
primed or activated by an unknown factor in vivo.  
5.4.2. HC and Behçet’s Disease Patients NETs   
We have shown that blood neutrophils from HC and BD patients are capable of producing 
NETs in standard culture conditions without the addition of an exogenous chemical 
stimulant or pathogen. However, NETs were more abundant in BD patients’ unstimulated 
cultures, especially if the individuals were clinically relapsed. This evidence suggests that 
BD patients harbour a high number of primed or activated circulating neutrophils and 
there may be an activating factor in the peripheral blood inducing NETosis. We also 
found that the longer the neutrophils from BD relapsed patients were incubated, the more 
cells were seen to be undergoing NETosis compared to HCs. Interestingly, the 
components that were targeted – NE, MPO, SLPI, α1AT, and DNA – showed similar 
staining patterns in both unstimulated neutrophil cultures from HC and BD patients. 
However, in some BD patients cultures, the cell morphology was unique exhibiting fan-
like projections of the cell membrane with co-localised NE, DNA, and some SLPI whilst 
still having polymorph nuclei.    
Similar to Papayannopoulo’s, et al, findings, in our PMA-stimulated experiments NE was 
detected both in the cytoplasm and with the nuclear DNA (Papayannopoulos et al., 2010). 
However, during NETosis in both HC and BD patients’ unstimulated cultures, NE was not 
often observed in the cytoplasm. If cytoplasmic NE was observed, its intensely staining 
was low. This suggests that the translocation of NE induced by PMA may be via a 
different mechanism from that which occurrs in unstimulated HC and BD neutrophils. In 
addition, the PMA pathway may require a lower internal concentration of NE to 
destabilise the chromatin and therefore NE granules can still be detected in the cytoplasm.  
When targeting MPO, it was observed in the cytoplasm at the late-stage of NETosis when 
the nucleus had already decondensed and lost its lobular formation, but with the cell 
membrane still intact. It has been reported that in PMA-stimulated neutrophils, MPO is 
transported to the nucleus separately and at a later time point than NE (Papayannopoulos 
et al., 2010) even though they are stored in the same granule. We observed the same 
occurrence in both PMA and non-stimulated cultures from both HC and BD groups.  This 
suggests that MPO has a similar role during NETosis under these conditions. 
Individuals with the immunodeficiency condition CGD suffer recurrent infections due to 
their inability to produce ROS and are defective in making NETs (Fuchs et al., 2007). BD 
patients, on the other hand, suffer from a hyperimmune state in which an increased 
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number of active neutrophils are circulating (Matsumura and Mizushima, 1975, Verity et 
al., 2003), and according to our sytox
® 
green quantification and immunofluorescence 
imaging data, producing NETs. However, this profusion of NETs in BD may be 
detrimental and contribute to an over-reactivity to foreign or self-antigens. 
 
A study conducted by Nakahara, et al, in 1998 showed that HC oral polymorphonuclear 
leukocytes are primed and spontaneously generate a slew of ROS by an unknown 
superoxide dismutase sensitive mechanism releasing MPO (Nakahara et al., 1998). They 
may have been describing NETosis in oral neutrophils before it was formally identified as 
a cell-death pathway. To date, no experiments have been conducted on the occurrence of 
NETs in saliva although they have been identified in CF sputum (Papayannopoulos et al., 
2011). NETs have also been identified in cultured neutrophils from bronchoalveolar 
lavage fluid after treating mice lungs with LPS (Saffarzadeh et al., 2012). Therefore, it 
can be speculated that neutrophils in the upper airway and oral cavity that are perpetually 
exposed to various microbes probably have a high incidence of NETs.     
 
Streptococcus sanguinis bacteria has been shown to have an increased association with 
the oral flora of BD patients (Hatemi and Yazici, 2011). Several studies have also found 
that poor periodontal indices and overall oral health are associated with disease severity 
(Akman et al., 2007, Arabaci et al., 2009, Mumcu, 2004). Oral ulcers also correlated with 
an impaired periodontal state (Mumcu, 2004). Recently, Vitkov, et al, found abundant 
NETs in purulent exudate from the gingival crevice of those with periodontitis (Vitkov et 
al., 2009). It is conceivable that BD patients, especially those with active ulcers, would 
have a high number of NETosing neutrophils in their oral cavity. This would also help to 
explain the high levels of NE we found in their saliva (Section 4.3.2.1).  
 
BD patients also have a continuously high levels of circulating IL-8 (Durmazlar et al., 
2009) which our data in Chapter 3.3.1 confirmed in saliva. It has been demonstrated that 
at high IL-8 concentrations neutrophil azurophil degranulation occurs (Ley, 2002) 
(Baggiolini et al., 1989). IL-8 has also been shown to induce NETosis (Brinkmann et al., 
2004, Gupta et al., 2005) although there is some debate whether IL-8 can prime the 
neutrophil but cannot trigger NETs (Branzk, 2013). The increased levels of IL-8 in BD 
patients could therefore be driving neutrophils towards the NETosis cell-death pathway 
instead of apoptosis.  
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The release of NETs in the vasculature could be contributing to the inflammation and 
pathology of BD. Recently, Fuchs, et al, confirmed that when stimulated neutrophils 
created NETs, platelets and RBCs accumulated and aggregated on the DNA/histone fibres 
(Fuchs et al., 2010). Consequently, the scaffolding of a thrombus formed which was 
demonstrated in 3D flow chambers. Fibrinogen, fibronectin, and von Willebrand factor 
were also immobilised on the NETs. In vitro, NETs were able to be dismantled with 
DNase and heparin (Fuchs et al., 2010). About 40% of the individuals with BD have 
vascular involvement of various forms including deep vein thrombosis and aneurysms 
(Seyahi and Yurdakul, 2011). NETs may be contributing to these events.  
 
As mentioned previously, NETs induced by PMA in vitro are inhibited by high serum 
content (Fuchs et al., 2007). In a normal human circulatory system, plasma (which has 
clotting factors) makes up 55% of the blood, therefore in theory should reduce the 
quantity of NETs produced in vivo with the exception of those in tissue. Also, 
extracellular chromatin from necrotic cells is usually degraded by serum endonucleases 
such as DNase I (Napirei et al., 2004) and HC serum has been shown to degrade NETs 
(Hakkim et al., 2010).  
 
A recent study demonstrated the cytotoxic damage NETs can cause by culturing NET-
derived components with A549 human lung epithelial cells as well as pulmonary artery 
and umbilical vein endothelial cells (Saffarzadeh et al., 2012). They PMA-stimulated HC 
neutrophils in vitro for 4 hrs, washed the cells, agitated the culture to release the NET 
material and after a very gentle centrifugation, collected the supernatant containing the 
NET material. This was then treated with micrococcal nuclease (MNase), DNase, or left 
undigested. They showed that the cytotoxicity of NET material on A549 cells (based on 
decreased confluence and increased multicaspase activity) increased with all 3 treatments. 
The pulmonary artery and umbilical vein endothelial cell cultures also showed similar 
results. Therefore, the authors concluded that DNA was not responsible for altering cell 
growth or cell death and that purified histones and MPO were partially responsible for 
cytotoxic effects. They also showed that NE was active in the NET material and increased 
significantly when the DNA-component in NETs was digested with DNase or MNase. 
This suggests that DNA-bound NE partially reduces NE activity, but when NE is released 
from the bond DNA, ensues increased activity. Even though A549 lung epithelial cells 
are known to produce both SLPI and α1AT (Sallenave et al., 1994, Venembre et al., 
1994), the cytotoxicity to A549 cells remained high despite the use of NE inhibitor. This 
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lead to the belief that damage to the cells is not solely due to NE. These are progressive 
and important findings of the damage NETs can cause. However, it is important to note 
that PMA was used as the stimulant in these experiments and since the NETosis 
mechanism seems to differ depending on the stimulant as alluded to by Parker, et al, 
(Parker et al., 2012), it could have affected the components bound to the NETs. 
 
The various periodic symptoms that are endured by BD patients include joint 
inflammation and pain similar to arthritis. In a comparison to psoriatic arthritis, BD 
synovial fluid and biopsies have a higher number of neutrophils despite having similar 
IL-8 levels (Canete et al., 2009). Although NETs have not been investigated in BD joints, 
people with Rheumatoid Arthritis (RA) have also been found to harbour NETs in their 
synovial fluid (Khandpur et al., 2013). A positive pathergy test is included as part of the 
diagnostic criteria, although 100% of BD do not have a positive result, however 
histologically skin biopsies show infiltrating neutrophils and T-lymphocytes (Ergun et al., 
1998). Recently, NETs have been detected in psoriatic skin biopsies (Skrzeczynska-
Moncznik et al., 2012). It would be helpful to conduct further investigations of any NETs 
involvement with BD skin.  
5.4.2.1. BD Patients’ Neutrophils React Quickly to PMA Producing Enlarged Cells 
and Expansive NETs 
NETs result when PMA activates the NADPH oxidase enzyme complex at cell and 
phagosomal membranes by directly stimulating the enzyme protein kinase C-β isotype 
(Gray et al., 2013, Dekker et al., 2000, Brinkmann and Zychlinsky, 2012). Although 
PMA is synthetic and not produced de novo, it was chosen due to its ability to produce 
large quantities of superoxide and H2O2 (DeChatelet et al., 1976) and has been the main 
stimulant employed for the majority of published NET experiments. PMA has been 
described as producing a similar effect to phagocytosis (DeChatelet et al., 1976). This 
was confirmed by Takei, et al, (Takei et al., 1996) who showed that PMA-induced 
neutrophils could still phagocytose opsonised particles.  
 
We found that BD patients’ neutrophils were more susceptible to producing NETs after 
stimulation with PMA than HCs. In the majority of BD patient cultures, NETs were 
readily observed after only 1 hour with PMA-stimulation. The effect of PMA on HC 
neutrophils was not as potent. When induced, not all HC cells in the culture were 
affected; many retained the typical neutrophil features: condensed, multi-lobed nucleus 
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and a rounded cell less than or equal to 10 µm in diameter. Intact, PMA-stimulated 
neutrophils were nearly double the size of the cells undergoing NETosis in unstimulated 
cultures and resulted in a large expanse of NETs. This was true for stimulated neutrophils 
from both HC and BD patients.   
 
BD patients’ neutrophils showed this prompt reaction to PMA probably due to their 
hyperimmune state (Eksioglu-Demiralp et al., 2001). Furthermore, our in vitro results 
showing higher incidence of NETosis in BD could explain why BD patients have been 
previously reported as having high levels of extracellular NE in their circulation (Deger et 
al., 1995) and in their saliva as we have reported in this study. Activated neutrophils 
recruited to the mouth due to ongoing inflammation and/or microbial antigens, or 
neutrophils that passively gain access to the mouth via GCF or small cuts, may have a 
tendency to undergo NETosis rather than an alternative cell death. Once in the oral cavity, 
they contribute high levels of NE, histones, and ROS products in the surroundings of 
delicate oral tissues. Since it has been shown that NETs can directly kill epithelial and 
endothelial cells (Saffarzadeh et al., 2012), it is important to verify the contribution of 
NETosing neutrophils during oral ulceration.  
 
5.4.2.2. NE Inhibitor Can Stop the Progression of NETosis in Vitro 
Active NE is required to carry out NETosis (Papayannopoulos et al., 2010). A previous 
study showed that a synthetic NE-specific inhibitor blocked NE’s ability to decondense 
chromatin which is one of the main occurrences needed for making NETs 
(Papayannopoulos et al., 2010). We employed the same inhibitor in our experiments as 
confirmation that not only was NE an integral part of both PMA-stimulated and 
unstimulated NETosis but that it could reduce the incidence of this cell death pathway. 
 
The classic characteristic of early NET formation involves the intracellular translocation 
of NE from the azurophil granule to the nucleus (Fuchs et al., 2007). This was confirmed 
by the co-localisation of the DNA and NE antibody targets in our experiments. However, 
this observation was greatly reduced when NEi was used in cultures. The longer 
incubations with NEi (maximum 4 hrs) showed more frequent observations that the 
inhibitor was dampening NETosis. Another indication that the inhibitor was dampening 
neutrophil activity was the fact that very few cells were able to adhere to the glass 
coverslips. This was most evident in HC cultures. The most remarkable observable 
254 
 
difference between unstimulated cultures with or without NEi occurred in cells from BD 
patients. For example, one BD patient whose untreated neutrophils showed atypical 
morphology reminiscent of advanced NETosis exhibited rounded cells with 
hypersegmented nuclei after the addition of NEi. Collectively, the data confirms that 
unstimulated and PMA-induced NETosis in neutrophils from HC and BD patients 
involves endogenous NE which can be inhibited. 
 
Artificially reducing the occurrence or progression of NETosis may help individuals with 
chronic inflammation or autoimmune diseases. In these cases, neutrophils and other 
immune cells congregate to rid its host of a foreign or host-derived antigen. An 
abundance of NETs can become destructive to host tissue, if not regulated, therefore, 
incorporating exogenous NE inhibitors as a form of treatment could help to dampen the 
NETosis pathway. 
5.4.2.3. The Role of Neutrophil-Derived α1AT and SLPI  
5.4.2.3.1. Intracellular Participation of SLPI but not α1AT 
Alpha1-antitrypsin was not seen to co-localise with NE or DNA in intact neutrophils 
while in unstimulated or PMA-induced cultures. This suggests that α1AT does not have 
active involvement during the NETosis process. However, in order to prove its lack of 
participation, a specific inhibitor for α1AT would have to be employed. To our 
knowledge, this is the first time the locale of α1AT has been described while NETosis is 
taking place. It was not until the NETs were released that the α1AT could be detected 
localising with the NE/DNA similar to Frenzel’s, et al, in vitro findings (Frenzel et al., 
2012) suggesting α1AT could be binding to and inhibiting NE when externalised.  
 
NE and α1AT have been described as having “one of the highest known physiological 
associations” by Janoff (Janoff, 1972). It has been shown that when α1AT binds to NE the 
association cannot be reversed due to a change in α1AT conformation rendering both 
proteins inactive (Carrell et al., 1982, Dickens and Lomas, 2011). If α1AT were to bind to 
the NE intracellularly, NETosis would probably never take place due to their irreversible 
binding. NE’s ability to break down the histones in the chromatin would be inhibited. 
Interestingly, endogenous α1AT is stored in the same azurophil granule as NE (Mason et 
al., 1991). Since azurophil granules are not believed to fuse with the nuclear membrane 
during NETosis (Papayannopoulos et al., 2010), this further demonstrates the selective 
process of NE’s translocation from the azurophil to the nucleus. Also, the glycosylated 
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α1AT isoform in the azurophil granule is thought to be different from the 52 kDa isoform 
found in human plasma and the other neutrophil granules including the specific, 
gelatinase, and secretory vesicles (Clemmensen et al., 2011). Western blots of subcellular 
neutrophil fractions have revealed a doublet band of α1AT at 37 and 44 kDa from 
azurophil granules (Clemmensen et al., 2011). This suggests that the two isoforms from 
different granules may behave differently.  
 
While α1AT was observed exclusively in the cytoplasm up until NETs were produced 
regardless of culture treatment, the intracellular co-localisation of SLPI with the NE/DNA 
complex occurred in unstimulated cultures as opposed to those with PMA. Unlike α1AT, 
SLPI does not bind irreversibly to NE (Krowarsch et al., 2003), is stored in separate 
specific (secondary) granules (Jacobsen et al., 2008), and is a smaller protein than α1AT 
to transport (12 kDa compared to 52 kDa). Its size and flexible interaction with NE could 
be the evolutionary reason SLPI accompanies it into the nucleus during NETosis as 
opposed to α1AT.  
5.4.2.3.2. Extracellular Co-Localisation of SLPI and α1AT with NE 
Although externalised NE in NETs was shown to be active (Saffarzadeh et al., 2012), it is 
not clear to what extent and whether they remain active when bound to DNA. The NE 
found as globular regions on NETs is enzymatically active or whether its anti-microbial 
property is due to the high cationic charge restraining microbes. Determining NE’s 
activity is central to determining the potential damage it can cause to the surrounding host 
tissues. Recently, NE was reported to provide the majority of proteolytic activity on 
NETs when compared to PR3 and CatG (O'Donoghue et al., 2013). However, this 
information was based solely on three HC donors’ neutrophils which were induced with 
PMA.  Therefore, the enzymatic activity of externalised NE due to naturally-occurring 
NETosis still needs further exploration. 
 
In our study, after externalisation of the neutrophil contents, SLPI and α1AT can be seen 
to speckle-coat the NE and MPO as well as DNA fibres. However, the extent of each 
inhibitor’s contribution to inactivate NE is not yet known. Sallenave, et al, reported 
neutrophil-derived SLPI as a major inhibitor of NE in a model of upper airway 
inflammation despite neutrophils also producing α1AT and elafin (Sallenave et al., 1997). 
It has been theorised that when SLPI is bound to NE, the combined charge of the 
aggregated proteins is highly cationic (Sullivan et al., 2008). Bacteria with a negatively 
256 
 
charged cell surface could then be trapped to the SLPI/NE complex. Also, to note, 
negatively charged DNA could also bind to this complex (Belorgey and Bieth, 1995). 
 
The fate of α1AT in the company of MPO has been demonstrated in other studies. MPO 
produces hypochlorous acid which acts to inhibit α1AT’s ability to bind to elastase 
(Borregaard et al., 1987). Reactive oxygen species (ROS) (Vignola et al., 1998) as well as 
neutrophil-derived collagenase (Michaelis et al., 1990) and metalloproteinases (Vissers et 
al., 1988) can inactivate α1AT. Likewise, plasma-derived α1AT has also been shown to 
inhibit neutrophil superoxide production (Bucurenci et al., 1992). SLPI is also susceptible 
to inactivation by oxidants (Boudier and Bieth, 1994). Depending on the location, oxidase 
levels, and interactions, α1AT and SLPI could be at risk of being inactivated 
extracellularly. 
 
A study by Skrzeczynska-Moncznik, et al, showed differences in the location of SLPI 
staining on NETs and the type of stimulation (PMA versus psoriatic serum) 
(Skrzeczynska-Moncznik et al., 2012). Firstly, all in vitro resting neutrophils showed 
SLPI as a granular stain similar to our images. Secondly, in their cultures, PMA-
stimulated NETs from HC and psoriasis patients showed only partial staining for 
extracellular SLPI. Meanwhile, HC neutrophils stimulated with psoriatic serum showed 
SLPI co-localise with NE and DNA in the majority of NETs. Their latter observation 
could have been due to their previous intracellular co-localisation of SLPI with NE/DNA 
during NETosis as was seen in our unstimulated culture experiments. Presumably, as 
neutrophils release NETs, SLPI remains attached to the NE/DNA complex. In our study, 
PMA-induced neutrophils did not incorporate SLPI into the nucleus alongside the DNA 
during NETosis, therefore perhaps it was also partially disassociated from the external NE 
and DNA as seen by Skrzeczynska-Moncznik, et al. SLPI was also seen to co-localise 
with extracellular NE and DNA in psoriatic skin biopsies.  
 
A demonstration of the impact that extracellular SLPI/NE/DNA complexes have on the 
immune system was also explored in Skrzeczynska-Moncznik, et al’s, study 
(Skrzeczynska-Moncznik et al., 2012). The production of Type I IFN-α by blood-derived 
plasmacytoid dendritic cells was measured in vitro using a combination of rSLPI, isolated 
human NE, and DNA as stimulants. Type I IFN-α is known to induce autoimmunity in 
psoriasis but usually responds to viral DNA to inhibit pathogen replication. Alone or with 
various coupling, SLPI, NE, and/or DNA did not elicit a response, however the combined 
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use of all three triggered a significant increase of Type I IFN-α. Replacing SLPI with 
α1AT failed to show an increase above baseline as did inactivating NE in the combined 
trio. This demonstrates that the SLPI/NE/DNA complex that results from NETs can 
induce a strong immune reaction. Since BD patients’ neutrophils have shown evidence of 
the extracellular co-location of these elements, it would be worth exploring the 
SLPI/NE/DNA complex in vitro with BD epithelial and endothelial cells in order to 
measure various immunological cell responses and its potential contribution to BD 
pathology. 
 
A multitude of NET-associated proteins have been identified by mass spectrometry such 
as CatG and β-actin (O'Donoghue et al., 2013, Saffarzadeh et al., 2012, Urban et al., 
2009), however neither SLPI nor α1AT have been detected. This may be due to the fact 
that the analysis has solely been on PMA-induced NETs from HC neutrophils. Other 
factors that may have affected the mass spectrometry analysis could have been the 
extensive preparation techniques including washing the NETs, digesting them with DNase 
or MNase and exposure to various reagents in preparation for peptide sequencing.  
 
Some of the proteins identified in NETs are also targets for SLPI and α1AT such as CatG 
and PR3. Therefore, the inhibitors could only partially be involved in regulating NE. 
Depending on the in vivo location, such as the circulation, tissue, or oral cavity, an influx 
of endogenous, non-neutrophil derived SLPI and α1AT could also contribute to the 
protease inhibition. It is imperative to know if NE from NETs is being appropriately 
regulated in BD.  
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5.4.3. The Current Model of NETosis: NE, MPO, SLPI, and a1AT 
From our collective findings, NETosing neutrophils appear to undergoing a different 
pathway when in unstimulated cultures compared to PMA-induced NETosis. Fig 5.4.3.1.  
demonstrates our proposed unstimulated NETosis pathway in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.3.1. Suggested in vitro model of unstimulated, sterile NETosis observed in 
our experimental system. 1. Active neutrophils are free floating in the culture media. 
They are usually round and have a multi-lobed nucleus (green). Some cells attach to 
surfaces. Azurophilic granules with NE (red), MPO (blue), and α1AT (pink) are located in 
the cytoplasm along with specific granules containing SLPI (yellow). Note, that α1AT 
may be found in all neutrophil granules (Clemmensen et al., 2011) but is only depicted in 
the azurophil granule in this diagram. Granules within the cytoplasm outline the nucleus. 
2. When NETosis ensues, cells readily attach to non-coated glass surface. The periphery 
of the nucleus has the highest concentration of NE in early NETosis then diffuses 
throughout the DNA. Some NE granules remain in the cytoplasm (in PMA-stimulated 
cells, these granules appear more prominent). 3. The supercoiled DNA unravels and the 
nucleus begins to lose its lobular structure. SLPI can be seen to co-localise with the NE in 
the nucleus (not seen in the PMA-induced pathway). α1AT remains in the cytoplasm. At a 
late stage, MPO can be found co-localising with the NE and DNA. 4. Mixed material co-
localises and fills the cell. α1AT still remains in the cytoplasm. 5. NETs are expelled. 
Filaments of DNA with NE, MPO, SLPI, and α1AT attached are muddled together in a 
web. (loosely based on a schematic by Brinkmann and Zychlinsky (Brinkmann and 
Zychlinsky, 2012) which has been updated to represent our observations).  
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5.4.4. Eosinophils Did Not Undergo NETosis 
The co-precipitation of a low number of eosinophils during the blood neutrophil isolation 
was non-intentional. But despite a few eosinophils being observed in the cultures, they 
were never seen to undergo ETosis naturally or with PMA stimulation. Their appearance 
was easily identified having bi-lobed nucleus and staining positive for SLPI (and α1AT) 
but not for NE. Eosinophils in patients’ cultures the number of which depended on the 
individual were observed to have attached to the non-coated coverslips despite 
neutrophils having perished via NETosis or other cell death process or not having 
attached at all. As a secondary observation, it was interesting to see that the eosinophils 
present did not participate in ETosis. In a study by Yousefi, et al, (Yousefi et al., 2008), 
they showed that human eosinophils primed by IL-5 and IFN-γ and stimulated by LPS, 
C5a, and eotaxin in vitro produced ETs. They also showed evidence of ETosis in Crohn’s 
disease patient colon tissue samples. However, our observations would exclude 
eosinophil’s participation in ETosis.  
5.4.5. Unidentified Death 
In unstimulated cultures, there were a few neutrophils which did not undergo NETosis but 
expired via an alternative pathway. Apoptosis, spontaneous death, autophagy, or 
secondary necrosis could have been the cause. Primary necrosis was unlikely as its 
occurrence usually involves a harsh environment such as high osmotic pressure or a toxic 
element such as endotoxin and often occurs in groups of cells. Autophagy was also 
unlikely to occur in the experiment’s enriched culture conditions as this pathway is up 
regulated in nutrient deprivation. Apoptosis and secondary necrosis (Silva, 2010) were 
thought to be the two main alternative cell death pathways seen in our cultures. Typically 
in apoptosis the neutrophils undergo blebbing, as was seen in some cultures, where their 
DNA would degrade, condense, and the cell itself become small and round. If apoptosing 
neutrophils are not engulfed and removed by scavenger cells such as macrophages, then 
secondary necrosis may take place. This is commonly seen in isolated cultures (Silva, 
2010). However, the occurrence of these processes are currently speculative since without 
additional investigations, such as using Annexin V, Propidum iodide, and CD16 markers, 
it is difficult to categorise all the terminal pathways taking place. However, the critical 
assessment was whether or not the destructive cellular enzymes, such as NE, were being 
externalised and to examine the attendance of endogenous regulators. 
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5.4.6. Conclusions  
The evidence that BD patients’ neutrophils readily undergo NETosis in unstimulated, 
sterile culture conditions implicates its occurrence in vivo. NETs are also thought to be a 
natural and beneficial part of the innate immune system since HC neutrophils have been 
seen to manifest NETs in a small portion of their neutrophil population. The lack of NET 
production can severely hinder the control of infections as is the case in CGD. However, 
an overabundance of NETs may lack purpose in a sterile environment. Unfortunately, the 
increase of extracellular components, especially NE, may be causing direct detrimental 
effects to the integrity of the host’s vasculature and connective tissues. Therefore, NETs 
may be partially responsible for the chronic inflammation and pathology associated with 
BD, but it is imperative to deduce to what extent in order to know what treatment strategy 
to adapt. Also, gaining a better understanding of the roles that endogenous NE inhibitors 
play during both the NETosis pathway and in the extracellular environment is also 
important to define. Based on our investigations, it is believed that SLPI but not α1AT 
coincides intracellularly with NE and DNA during non-PMA induced NETosis. The role 
these components play is still unclear. However, in the extracellular environment, the 
extent of involvement of SLPI, α1AT, and other protease inhibitors will dictate the 
balance or imbalance of proteolytic activity.   
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6.1. Introduction  
6.1.2. Reference Genes in RT-qPCR 
Reference genes are also referred to as internal controls or housekeeping genes. They 
constitute conserved genes that are present in most, if not all, cells from various species at 
different expression levels depending on the cell or tissue type. In order to utilise these 
genes to help normalise the quantity and quality of messenger (m)RNA in a given cellular 
lysate, the reference genes must retain a relatively continuous expression across 
comparative cells, experimental treatments, or disease states. In other words, they should 
not be influenced and therefore fluctuate their expression levels due to these conditions. 
Validation of reference gene stability in samples being compared for their gene 
expression is paramount to represent a true and significant outcome for the gene of 
interest (GOI) after normalisation. The less stable the reference gene, the larger the fold-
change needed in order to measure a significant difference (Bustin, 2004).  
An internal control is also essential to correct for any error introduced during the entire 
experimental procedure starting with the collection of the specimens to be tested, for 
instance, whether they are frozen, lyzed immediately, or paraffin-embedded. The 
specimen itself will have biological variations as well such as its transcriptional activity. 
There is a dependency or assumption that all chemical reactions will be identical, 
however enzymes such as endogenous RNase, exogenous DNase for degrading genomic 
DNA, reverse transcriptase, and polymerase will have slightly varied reactions depending 
on the starting material, batch differences, or external laboratory circumstances. Despite 
optimising the assay, primer efficiency can very slightly as can Sybr green fluorescent 
dsDNA attachment. Error can also be introduced by the operator as perfect repetition is 
impossible. Other mechanical differences such as the retention of RNA in extraction 
columns, centrifuge speeds, the temperatures of heat blocks, or the running of the RT-
PCR instruments are heavily relied upon for 100% performance but again are relying on 
all of the experimental reactions and preparations to be as similar as possible. Measuring 
a gene in the same RNA sample that has been subjected to all the same errors which can 
then be measured alongside the gene of interest is an important element to control for all 
these potential variations (Huggett et al., 2005).  
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Using more than one reference gene can be useful for normalisation especially if the 
reference genes have different biological cell functions. In this way, one can be sure that 
the genes are not co-regulated. Vandesompele, et al, recommends using three reference 
genes to improve the accuracy of expression levels (2002). However, there are practical 
considerations which may override this suggestion such as having a low amount of RNA 
per sample or if several of the reference genes show the same stability.  
It is also advised that a reference gene should amplify around the same cycle 
quantification (Cq) as the GOI so as to avoid large variability. This can also provide a 
better representation of the gene integrity and site availability. Therefore, ribosomal 
(r)RNA is a debatable reference target since it is often highly abundant in comparison to 
mRNA (Overbergh et al., 2003). To add to this, rRNA cannot be used when the RT step 
incorporates only oligo(dT) primers because rRNA lacks poly-A tails.  
The 5’-3’ assay which assesses the integrity of mRNA was developed by Nolan, et al, in 
2006 (Nolan et al., 2006a) and was modified and incorporated by Roche, UK on the 
human reference gene panel. Their modification incorporated a 5’, middle, and 3’ primer 
pairs for an unknown target. The principle of the assay was to measure the expression of a 
gDNA gene (a sequence which includes the intron sequence as opposed to just exon 
regions for mRNA) using these 3 different target sites on the same sequence. If the 
mRNA was intact and the sequence continual (during the RT reaction), then the 3 targets 
will result in similar amplification results. An acceptable difference between the 3 
resulting Cq’s is ≤ 1 as deemed by Roche’s protocol. 
On the panel, two reaction wells per sample were also included as RT negative (-) 
controls. This means that RNA, whether it has been DNase treated or not, is not subjected 
to an RT reaction (no cDNA is produced) thus there should be no amplification. Instead, a 
small aliquot is set aside for an amplification test to see if residual gDNA still exists in 
the sample. Again, the target of these reactions is Roche’s proprietary information. 
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6.1.3. The History of Using RNA from Oral Buccal Epithelium for Molecular 
Investigations 
Oral buccal epithelial cell RNA has been previously investigated but centres around 
studies associated with oral squamous cell carcinoma (OSCC). The majority of 
publications do not mention validation of their reference genes for their studies. One 
recent investigation by Rentoft, et al, in 2010 recognised this necessary verification by 
testing 8 potential reference genes in formalin-fixed paraffin-embedded oral biopsies 
(OSCC and normal tissue) from various sites which are known to have fragmented RNA 
(Rentoft et al., 2010). However, much more frequently, RT-qPCR studies have employed 
default reference genes such as GAPDH, HPRT1, 18S rRNA, and β-actin without 
verifying the expression of these particular genes with their unique experiments (Bar et 
al., 2009). Historically, these genes were used as controls for non- or semi-quantitative 
methods such as northern blot or early RT-PCR; however due to the highly sensitive 
nature of qPCR, they have been found to be irregularly expressed amongst the various 
experimental protocols and samples.   
Two years after the initial publication of Vandesompele et al’s geNorm as a solution to 
years of qPCR experts’ urgency for the need of proper reference gene validation and 
qPCR normalisation (Vandesompele et al., 2002), Spivack, et al, employed the use of 
GAPDH, β-actin, and 36B4 reference genes for the normalisation of carcinogen targets in 
OBS without any prior stability tests (Spivack et al., 2004). Also, instead of calculating a 
mean Cq of the three reference genes in order to normalise the GOI collectively, the ratio 
of their target was assessed separately to only one or two of the mentioned reference 
genes (Spivack et al., 2004). Many others have chosen GAPDH or β-actin as default 
internal controls without validation for qPCR experiments when measuring gene 
expression in OBS OSCC and inflammatory lesions (Driemel et al., 2007) or oral lichen 
planus biopsy tissue (Ding et al., 2010). The random selection and use of a literature-
accepted reference gene was again demonstrated by Toyoshima, et al, in 2009 when 
OSCC patients with different cancer progressions had their buccal swabs assessed for 
cytokeratin expression alongside a head/neck SCC cell line and a normal oral mucosa cell 
line (Toyoshima et al., 2009a). With so many different sample types, the assessment of 
their randomly selected reference gene, GAPDH, should have been more carefully 
investigated before concluding their findings.  
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Around the same time, Campos, et al, finally recognised the fact that there was a lack of 
reference gene validation when using qPCR to analyse gene expression in OSCC clinical 
samples and cell lines (Campos et al., 2009). They set about to find the stable genes in 
immortalised oral cell lines, but more importantly addressed an important issue that many 
were by-passing. To date, there have been no reports of stable RNA reference genes 
investigated for OBS samples from HC, BD and RAS patients with and without oral 
ulcers.  
6.1.4. Applying and Interpreting geNorm Analysis using qBasePLUS 
GeNorm is an analytic algorithm developed by Jo Vandesompele, et al, in 2002 to 
determine the most stable gene amongst various samples in an experiment 
(Vandesompele, 2002, Genome Biology). GeNorm has been incorporated into the 
qBasePLUS software (Biogazelle, Belgium) for ease of use. The software applications, 
formulas, and analysis are described in detail in Hellemans, et al’s, paper in 2007 
(Hellemans et al., 2007). In summary, after using qPCR to amplifying multiple candidate 
reference genes in the cDNA samples that are going to be used for a gene expression 
study, the duplicate or triplicate Cq results are uploaded into the qBasePLUS software. 
The geNorm program performs automatic computations to first transform the average of 
these Cq’s into non-normalised values using the 2∆Cq method where 2 is the assumed 
100% assay efficiency raised to the power of delta (∆) Cq. ∆Cq is the difference between 
the lowest Cq and a Cq from the same gene in a different sample. This new value is called 
the relative quantity (RQ).  
In order to determine which reference gene is most stable, the geNorm program uses an 
extensive algorithm which ranks the genes by applying a step by step elimination of the 
least stable gene (Vandesompele et al., 2002). The principle lies in the fact that if a ratio 
between two Cq values is calculated and the Cq values were the same, the ratio would be 
equal to 1 and there would be no variability. However, in a real scenario, there are 
differences in Cq results and an increase in their ratio dissimilarity decreases gene 
expression stability. Each candidate reference gene generates an average expression 
stability measure, M. The lower the M value, the more stable the gene expression. An 
acceptable M value for homogeneous samples is < 0.5. A typical set up for these samples 
would be comparing the same cell culture for experimental treatment and control. For 
heterogeneous samples, such as human clinical specimens, an M value < 1.0 is generally 
accepted for the reference gene stability.  
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After establishing which reference genes are stable, qBasePlus can also normalise these 
reference gene Cq results to those of the target gene. The exact assay efficiency for each 
target can be input instead of assuming 100% allowing more accurate results. A 
normalization factor is generated for each sample by calculating the geometric mean of 
the RQ values for each stable reference gene measured in that one sample. The gene of 
interest RQ values can also be determined, but in order to obtain the normalised GOI 
results relative to the reference gene expression, the GOI RQ is divided by the geomean 
(normalisation factor) of the reference gene for each sample. 
The reference genes remain valid for use unless the experimental conditions are altered, 
such as how the RNA samples are preserved or if a cell culture component is adjusted. If 
conditions are changed, then reference genes needs to be re-tested on geNorm to see if 
they are still stable.  
 
6.1.5. Experiment Objectives 
 
1. To determine appropriate, stable mRNA reference genes from ulcerated and 
non-ulcerated oral buccal mucosa swabs obtained from HCs as well as BD and 
RAS patients. 
2. To determine whether the Roche Human Reference Gene Panel can provide 
suitable reference genes options out of the panel’s 19 different genes being tested. 
3. Test whether the in-built RNA Integrity Assay on the Roche Human Reference 
Gene Panel can be used to analyse the RNA quality of the OBS samples. 
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6.2. Materials and Methods 
6.2.1. QPCR Roche Human Reference Gene Panel  
The RealTime ready Human Reference Gene 384-well Panel (Roche, Germany) was 
chosen for the analysis of 19 different stable reference genes in cDNA from oral buccal 
mucosa swabs. Thirty-seven cDNA samples were analysed from three donor groups: HC, 
RAS, and BD. These were further categorised by the type of oral mucosa sampled, i.e., 
whether or not the swab was taken directly from an ulcer (U) or non-ulcerated area (NU). 
The samples run on the reference gene panel are listed in Table 6.2.1.1. 
 
 
 
 
 
 
 
 
Table 6.2.1.1. Details of the OBS from Different Patient Groups, the Area Swabbed, 
and Sample Number (n) Tested on the Human Reference Gene Panel. HC (healthy 
control), RAS (recurrent aphthous stomatitis), BD (Behçet’s disease). q, indicates mouth 
quiet/no ulcers. a, refers specifically to active mouth ulcer(s) regardless of other systemic 
symptoms. NU = swab taken from the buccal mucosa away from the oral ulcer. U = swab 
taken directly from the ulcer. 
 
The protocol recommended by the manufacturer using between 50 pg to 50 ng total RNA 
per reaction well. Also, they suggest that a cDNA sample should not make up over 4% of 
the total reaction volume otherwise there is a risk of inhibiting the reaction. 
 
 
Patient Group 
and Oral Ulcer 
Activity 
Area being 
swabbed 
Sample 
number 
(n) 
HC NU 7 
RASq NU 6 
RASa NU 3 
RASa U 2 
BDq NU 10 
BDa NU 5 
BDa U 4 
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For each cDNA sample, a mastermix was prepared in combination with the 2X 
LightCycler
®
 480 Probes Master reaction mix (Table 6.2.1.2).  Extra volume was allowed 
to accommodate for loss from repetitive pipetting therefore for each well, 5 µl of a 1:10 
dilution of cDNA was added along with 5 µl of the probes mastermix which resulted in a 
final dilution of 1:20 or 5% cDNA in each reaction well. This was mixed thoroughly by 
pipette and 10 µl of each cDNA mastermix was then added to each well in row A, column 
1 – 23 (Fig 6.2.1.3). Column 24 (the RT negative (-) control) had 1 µl of previously set 
aside non-transcribed OBS RNA samples, 4 µl of water, and 5 µl of the 2X LightCycler
®
 
480 Probes Master reaction mix. 
 
 
 
 
 
 
 
 
 
Table 6.2.1.2. Preparing the cDNA Sample Mastermix for each OBS sample to be 
run on the Human Reference Gene Panel.  
Sample or Reagent x 1 reaction 
well 
x 25 reaction 
wells 
1:10 diluted cDNA 
 
5 µl 
 
125 µl 
 
2X LightCycler
®
 480 
Probes Master reaction mix 
 
5 µl 125 µl 
Total Volume 10 µl 
 
250 µl 
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In order to avoid cross-contamination while adding the sample reaction mix to one row, 
the rows on either side were covered temporarily with plate seals. When complete, the 
plate was covered with LightCycler
®
 480 Sealing Foil and centrifuged for 2 min at 1,500 
x g in order to pull any liquid down into the wells.  
The panel was run on the LightCycler
®
 480 System I instrument (Roche) by uploading a 
pre-set, kit-specific macros program provided by Roche. The reaction volume was set to 
10 µl and detection format was a monocolour hydrolysis probe on dynamic mode with the 
FAM 483-533 filter (acquisition in the green channel). The program involved a pre-
incubation step at 95
o
C for 10 min followed by 45 cycles of denaturing at 95
o
C, 10s; 
primer annealing at 60
o
C, 30s; and extension at 72
o
C, 1s. The last 30 s of the programme 
cooled the reaction plate to 40
o
C. The data were analysed on qBasePlus software V2.1 
(Biogazelle, Belgium).  
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SEE FIGURE 6.2.1.3. 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.2.1.3. The RealTime Ready Human Reference Gene 384-well plate. 10 µl of 
each cDNA OBS sample mastermix was added to each row from wells 1 – 22. Each 
column contained a different pre-absorbed specific primers for each reference gene target. 
Untranscribed RNA from the same OBS sample, previously set aside after the extraction, 
was added to wells 23-24. This consisted of 1 µl of the RNA, 4 µl of RNase free H20, and 
5 µl of the 2X LightCycler
®
 480 Probes Master reaction mix. 
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6.3. Results 
6.3.1. Most Stable Reference Genes in Oral Buccal Epithelial Cells 
Three 384-well 19 reference genes panels were used to assess the most stable reference 
genes for 37 OBS cDNA samples from RAS and BD patients with and without oral ulcers 
alongside HC. Two samples, a HC and BDa,U, had several missing Cq values in the 
assay and therefore were excluded from the reference gene analysis leaving a total of 35 
OBS to collectively assess. The amplified reference genes were excluded if their Cq value 
was > 40 (since this indicated that there was not enough sample to be amplified and/or the 
gene had a low stability). 
 
 
 
Fig 6.3.1.1. Average Expression Stability of Reference Gene Targets. The most stable 
gene across all samples has the lowest M value (GAPDH). The least stable of the top six 
reference genes tested was 18S rRNA. 
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To demonstrate the ranking of the candidate reference genes stability, the M value was 
calculated using qBasePLUS software. The M value was within the acceptable 
heterogeneous M value less than 1.0 for GAPDH, PGK1, and PPIA (Fig 6.3.1.2). The 
next three reference genes, β-actin, YWHAZ, and 18S rRNA, had a lower stability 
demonstrated by the M value being above 1.0. This is likely due to analysing clinical 
specimens in which the biological variability is much greater than cultured cell lines.   
 
 
 
 
Fig 6.3.1.2. The Stability of GAPDH in BD and RAS patients with and without oral 
ulcers and HC as demonstrated on a qBasePLUS software bar graph. Y-axis 
constitutes arbitrary units (A.U.) The histogram shows a similar range (minimum and 
maximum) of GAPDH expression for each patient group.   
 
The most stable of the reference genes for our OBS patient samples was GAPDH. This 
shows that despite the oral epithelium being ulcerated, the relative expression of this gene 
was unwavering. The next acceptable stable reference genes were PPIA and PGK1 and 
were also below the M recommended value of 1.0.  
 
BDa               BDq            HC        RASa        RASq 
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The least stable reference gene out of all 19 on the panel was hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) which encodes the gene for the enzyme transferase 
(data not shown). It is important for creating purine nucleotides via the purine salvage 
pathway. Most of the samples failed to amplify the HPRT1 gene at all.  
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Fig. 6.3.1.3. Box Plot of Reference Gene Cq Results for all 7 Different Patient Group 
OBS Samples. The bar in the centre of each box indicates the median Cq (cycle 
quantification). The box itself represents 50% of the Cq values and the extended bars 
encompass maximum and minimum values. o indicates outliers. 
 
 
 
  
 
 
Table 6.3.1.4. The Mean Cq, Standard Deviation, and Standard Error Mean of the 
Six Most Stable Reference Genes in OBS.  
6.3.2. The RNA Integrity Assay 
 The results were varied when analysing the integrity assay which was incorporated into 3 
separate reaction wells of the plate to amplify the 5’, middle, 3’ sections of an unknown 
gene in each cDNA sample. For example, one of the cDNA samples resulted in a Cq of 
Reference gene Mean Cq STDEV SEM 
GAPDH 32.6 2.58 0.44 
PGK1 31.8 2.35 0.40 
PPIA 33.0 2.71 0.46 
β-Actin 29.4 2.88 0.49 
YWHAZ 31.9 2.87 0.48 
18S rRNA 16.1 3.91 0.66 
C
q
 
Most Stable Reference Genes 
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32.6 for the 5’ end, 33.3 for the middle, and 33.6 for the 3’ end (Fig 6.3.2.1, A). The 
calculated difference between the 5’ end and the middle was 0.7 Cq’s. For the middle and 
3’ end, the difference equated to 0.3 while the difference between the 5’ and 3’ was 1. 
According to Roche’s definition, the similarity in Cq ≤ 1 amongst the 3 different sites of 
the same gene suggests that this particular site of RNA that was transcribed during the RT 
process was intact and therefore can deduce that the RNA is of good quality.  Fig 6.3.2.1, 
B shows another sample that amplified its 5’, middle, and 3’ end at 37.1, 36.2 and 40 Cq, 
respectively. The differences in Cq were 0.9, 3.8, and 2.9. This suggests that the RNA 
may have been slightly degraded before RT. 
 
 
                                      
Fig 6.3.2.1. Demonstration of two different cDNA samples tested on the human 
reference gene panel for the continuous and equal reverse transcription of its RNA. 
A. One cDNA sample with similar amplification Cq’s for all 3 sections (5’, middle, 3’ 
end) of one gene. B. A different cDNA sample showing the Cq’s for the discontinuous 
sections of one gene.  
 
 
 
 
B. A. 
5’ 
3’ 
mid 
5’ 
3’ 
mid 
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Table 6.3.2.1. The 5’, middle, and 3’ amplification results for all 35 cDNA samples 
included in the human reference gene panel.  
 
When assessing all of the cDNA samples (Table 6.3.2.1), the majority of them (18/35 or 
51.4%) had all 3 site amplification differences ≤ 1 Cq. At least 11.4% (4/35) of the 
samples had all three Cq results that were in close proximity during amplification but still 
had one result that was above a difference of 1. Just over a quarter of the samples, 28.6% 
(10/35), could only equate a difference ≤ 1 Cq in one out of the three Cq comparisons. 
Finally, only 3 out of 36 samples (8.6%) showed all 5’, middle, and 3’ Cq results had a 
difference greater than 1 when compared to each other.   
None of the RT- RNA samples amplified and were therefore concluded to be clear of any 
gDNA contamination.  
 
 
 
 
 
 
Resulting Differences in Cq of the 
5’, middle, and 3’ qPCR Reactions 
for Each cDNA Sample 
Number of cDNA samples 
 
Percentage 
of all 
samples 
All 3 Cq's show a difference > 1 3 out of 35 
8.6% 
 
Only one difference amongst all 3 
Cq’s was ≤ 1 
10 out of 35 28.6% 
2 Cq's have a difference ≤ 1 
 
4 out of 35 11.4% 
All 3 Cq's have a difference ≤ 1 
 
18 out of 35 51.4% 
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6.4. Discussion 
The investment in three of these commercial reference gene panels was necessary to gain 
as much information as possible from our OBS samples which had low RNA to start with 
and also had never been tested on ulcerated mucosa cells in these patient groups. Ideally, 
10 OBS samples from each group would have been used as recommend by Derveaux, et 
al, (Derveaux et al., 2010) but this was hindered by three major issues: 1) obtaining 
consent from study participants for an OBS taken directly from an ulcer which was 
painful at times due to the pressure required to collect enough epithelial cells for the 
assay, 2) the high cost of the reference gene panels, and 3) no guarantee that the sample 
would not be excluded from the panel due to late Cq (> 40) or lack of gene amplification.   
 
When an ulcer was swabbed, the RNA recovered was frequently either of poor quality 
and/or very low quantity due to not being able to apply the same pressure on the wound 
compared to an area of non-ulcerated tissue. The Micro RNeasy RNA extraction kit 
(Qiagen, UK) was used instead of the Illustra TriplePrep Kit (GE Healthcare, UK) in 
order to try to obtain concentrated RNA from each OBS. A small volume of 20 ng of 
carrier poly-A RNA (provided by the Qiagen kit) was added to each lysate prior to 
loading the sample on the column in order to improve the total RNA recovery. Despite 
these efforts, the average RNA quantity measured on the Nanodrop™ just after RNA 
extraction (prior to the DNase digest) was higher in the BDa non-ulcerated samples at 
65.5 ng/µl compared to 38.1 ng/µl for those collected directly from ulcers. The RASa 
patients showed a similar result with non-ulcerated swabs having an average of 29.8 ng/µl 
and the ulcerated sample being only 11.3 ng/µl. After residual gDNA was eliminated, 
which incorporated another dilution of the RNA, the samples were checked on the 
Bioanalyzer and several direct ulcer samples had to be reconsidered for downstream 
analysis due to either extremely low quantity or dubious quality. Other studies 
experienced the same limitations of OBS RNA collection when attempting to gather cells 
from an oral wound (Spira et al., 2004).  
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OSCC samples, the basis for most oral RNA qPCR investigations, have been reported to 
have a high frequency of unusable samples. For instance, Toyoshima, et al, reported that 
14 out of 66 (21.2%) exfoliated oral epithelial samples had to be excluded due to poor 
quality (Toyoshima et al., 2009b).  Another study conducted by Driemel, et al, reported 
that out of 28 OSCC OBS patient samples, only 5 (17.9%) were suitable for use when 
assessed for RNA integrity. Also, they were only able to incorporate 10 out of 22 (45.5%) 
OBS from inflamed or hyperproliferative lesions. Meanwhile, 100% (5 out of 5) of HC 
OBS samples were acceptable (Driemel et al., 2007). Driemel, et al, attributed this loss of 
RNA integrity to a high volume of oral bacterial RNase in the samples, although this 
seems unlikely as RNase would indiscriminately destroy the RNA in both OSCC and HC 
samples alike. Nevertheless, these studies were still able to find significant differences in 
gene expression after eliminating poor quality OBS samples. 
 
Despite the low quantity of RNA from ulcerated mucosa, six reference genes were still 
able to be found to have similarly stable expressions in the various samples. GAPDH, 
PGK1, and PPIA were regarded as the top three most stable. While β-actin, YWHAZ, and 
18S rRNA could potentially be used as additional reference genes, the need to include 
them in normalisation assessment was not immediately necessary. However, seeing as 
how 18S rRNA was overly abundant in the OBS samples resulting in amplification 
between 9.7 and 24 Cq, using it for normalisation would not be appropriate unless a target 
gene was also found within the same range.   
 
Similar to the diversity of our patient sample type (HC, BD, RAS, normal tissue or 
ulcerated site), Rentoft’s, et al, study tested only a small number of oral biopsies for 
reference gene stability by geNorm in wax embedded oral tissue (Rentoft et al., 2010). 
The 10 OSCC and 10 control samples they analysed were further sub-divided by tissue 
type consisting of gingiva, tongue, hard palate, and buccal mucosa. Nonetheless, they 
were able to successfully categorise the best and worst reference genes for their samples. 
The most stable across all tissue types and malignancies was tubulin alpha-6 chain and 
the ribosomal protein S13 and the least being HPRT1 which was infrequently amplified 
(the latter being similar to our results).   
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There has been some controversy surrounding the use of GAPDH as a reference gene for 
normalisation. However, this has been due to the fact that either the gene has not been 
tested for its stable expression before use in normalisation, or following an investigation, 
has been deemed inappropriate for certain experiments using such samples as normal 
colon epithelium (Bustin, 2000). GAPDH has also shown an upregulation in human 
prostate cancer (Ripple and Wilding, 1995). We did not find that this was the case in our 
patient groups with intact or ulcerated oral buccal epithelium, therefore, we are confident 
that GAPDH can be used as an appropriate reference gene for RT-qPCR normalisation.    
 
Similar in function to GAPDH, the protein encoded by the phosphoglycerate kinase 1 
(PGK1) gene, the second most stable reference gene for our experiments, is an enzyme 
involved toward the end of the glycolysis pathway which catalyses the conversion of 1,3-
diphosphoglycerate to 3-phosphoglycerate. The third most stable gene was peptidylprolyl 
isomerase A, (PPIA) otherwise known as cyclophilin A, which encodes for proteins 
folding. The combined use of this gene plus either GAPDH or PGK1 could be useful in 
normalising future targets of interest in the oral buccal samples. 
 
A recent reference gene stability profile conducted by Riemer, et al, investigated 2 
normal and 6 HPV-immortalized keratinocyte cell lines with and without IFN-γ stimulus. 
Interestingly, almost identical to our findings, they found that GAPDH, PGK1, PPIA, and 
18S were among the most stable of 16 different reference genes tested (Riemer et al., 
2012). Naturally, their M values in geNorm assessment was much lower than ours seeing 
as they were working with established cell lines as opposed to a variety of clinical 
samples, however, is still an intriguing similarity due to the cell type and potential pro-
inflammatory stimulus. 
 
There was an issue addressed in the Spivack, et al, study in which they regarded the 
further dilution of precious RNA by applying a DNase reaction as unnecessary if primers 
are designed across exons (excluding introns) (Spivack et al., 2004). However, although 
this seems like a good suggestion, not knowing the design of the primer sequences in the 
ready-to-use commercial reference gene panel, we could not take the chance of 
inappropriate amplification of gDNA and therefore would always DNase-treat the RNA. 
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Also, seeing as we were using the same OBS samples in addition to new samples for 
measuring our GOI in subsequent assays, we needed to keep the treatment of the RNA 
sample the same in order to lower the risk of variability.  
 
The 5’-middle-3’ assay (well reactions 20, 21, 22) aimed to amplify 3 different sections 
of the same gene in our samples (the gene on the panel was undisclosed due to proprietary 
information). Ideally, the use of Oligo(dT) primers during the reverse transcription (RT) 
step is important for the assay’s interpretation because it would show the continuous 
polyA-tail 3’ end of the mRNA transcribed without interruption towards the 5’ end. If the 
physical integrity of the RNA was completely intact, then the assay would result in 3 
similar Cq’s for all 3 targets of the same gene. However, because we solely employed the 
use of random primers in the RT step (anticipating some degree of RNA degradation), the 
resulting Cq of the 3 targets on the same gene showed greater variability due to the fact 
that the random primers could have started the transcription at indiscriminate and 
different areas. Therefore, our results from this assay on the panel was helpful but could 
not provide a definitive estimate of our OBS RNA quality and integrity. For this, we 
relied on pre-RT RNA Bioanalyzer data. In future experiments, it would be advised for 
others to use a mix of Oligo(dT) and random primers prior to using the Roche reference 
gene panels if they wanted to use this feature as an additional assessment of RNA 
integrity. On a different quality assessment, the RT- test on non-RT treated RNA was 
negative for any amplification. Therefore, no residual gDNA existed in any of the 
samples.  
6.4.1. Conclusions 
Oral buccal epithelial cells collected using a cytological brush, can provide a decent 
quality and quantity of RNA from which the mRNA expression of reference genes can be 
reliably assessed. A large number of OBS samples should be collected from areas of 
ulcerated tissue to improve the number of samples with enough RNA that can 
successfully be included in multiple qPCR assays. By checking the stability of a wide 
range of 19 different reference genes in OBS samples from BD and RAS patients with 
and without oral ulcers as well as HC, we are able to apply the recommended qPCR 
normalisation technique comparing the most stable reference genes with our target genes 
and report significant findings with confidence.  
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7.1. Final Discussion  
Neutrophils are an important and vital cellular component of the innate immune system 
providing rapid protection against microbial invasion. As phagocytes and antigen 
presenting cells, they are recruited to the sites of injury or inflammation by IL-8, TNF-α, 
C5a, or bacterial LPS and work with a multitude of other host cells and additional signal 
proteins to fight infection and then regain a state of system equilibrium. Their 
contribution to the complex network of the immune system’s up regulation, sustaining, 
and subsequent down regulation is a normal occurrence in healthy individuals.  
Maintaining this balance is essential, as neutrophils contain potent proteolytic enzymes 
and the potential to produce ROS which can, if exposed to the local environment, cause 
cellular destruction indiscriminate of pathogen or host. When released extracellularly or if 
it is surface-bound to neutrophils, the azurophil granule component, NE, contributes to 
neutrophil chemotaxis. However, NE also has an affinity for ECM as a substrate with the 
ability to cleave elastin, collagen, fibronectin, and laminin all of which compose the 
host’s connective tissue (Roghanian and Sallenave, 2008b, Heutinck et al., 2010). 
Therefore, an overabundance of NE can breakdown the tissue.  
Endogenous specific inhibitors of NE, such as SLPI and α1AT, are present within human 
plasma as well as neutrophils themselves (Clemmensen et al., 2011). These protease 
inhibitors interact with exposed NE by physically attaching to it in a 1:1 stoichiometric 
configuration. By doing so, they immobilise and, at least partially, inactivate NE 
(Morrison et al., 1990) depending on the local environmental factors such as pH and 
presence of oxidants which are known to enable SLPI and α1AT. This 
protease/antiprotease complex is then cleared by phagocytic macrophages. If there is 
excessive NE, the inhibitors may struggle to control it incidentally allowing damage to 
take place. 
Individuals with BD have been shown to have hyperchemotaxis of neutrophils 
(Matsumura and Mizushima, 1975) (Neves et al., 2009), have an increased expression of 
HLA-B51 antigen which has been linked to neutrophil over-activity (O'Duffy et al., 1983) 
(Sensi et al., 1991), and specifically, the increase of circulating NE during disease relapse 
and remission (Deger et al., 1995). We also identified for the first time that BD patients 
have a high incidence of NETs in vitro which may contribute to the externalisation and 
increase of NE in vivo. Since oral ulcers are a key manifestation in BD, it is thought that 
if the reoccurrence of ulceration can be controlled, then the other symptoms may dampen 
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as well. The concentration of NE into the mouth during quiescent episodes had not 
previously been investigated. If excessive NE is shed into the oral cavity and its protease 
inhibitors are unable to maintain a balanced NE concentration and activity, the integrity 
of the oral mucosal epithelium may be compromised leading to an ulcer. 
The research elucidated from this study has provided evidence of an increased presence 
of NE in saliva from persons who suffer from BD. In addition, these high levels of NE 
were still detected in BD patients on medication to dampen their immune system. The 
reoccurrence of BD oral ulcers indeed may be due to an overabundance of NE and its 
proteolytic activity despite the fact that BDq patients’ saliva simultaneously carries at 
least seven times the concentration of the endogenous inhibitor α1AT which is thought to 
permanently inactivate NE when bound (Korkmaz, Moreau et al. 2008). Furthermore, 
SLPI, locally released from the saliva glands and mucosa epithelial cells, appears to be 
reduced in BD patients without oral ulcers. In fact, whenever NE was high, SLPI was low 
across all patient groups tested, including RAS. To add to the matter, we found that oral 
epithelial cells from non-ulcerated mucosa in BD and RAS patients had significantly 
upregulated expression of SLPI mRNA. This suggests that either the production of SLPI 
cannot meet the demand or that salivary SLPI protein is quickly depleted by the increased 
presence of NE in these patients. 
The single SLPI protein band on our western blots supports the theory that SLPI is only 
being detected when it is unbound. If SLPI and NE are complexed, it was not apparent 
using detection antibodies in either NE or SLPI western blots. In saliva, NE:SLPI 
complexed configuration may still convey protection as an anti-microbial agent due to the 
dual cationic charge that can disrupt bacterial membranes. The complex should also 
decrease the enzymatic activity of NE. However, according to shared theories by 
Gauthier, et al, and Krowarsch, et al, , SLPI may have reversible inhibition with NE 
where they can detach from each other without conformational or functional alterations 
(Krowarsch et al., 2003) (Gauthier et al., 1982). Although NE is an important component 
of the innate immune system to kill bacteria and resolve infection (Belaaouaj, 2002), it is 
a concern that neither α1AT nor SLPI are able to regulate active NE when its 
concentration increases in BD patient saliva without the accompaniment of infection or 
ulceration. This may be due to the deactivation of α1AT and SLPI by oxidants present in 
saliva (Carp and Janoff, 1980) (Matheson et al., 1979). 
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The presence of intracellular SLPI was detected in oral buccal epithelial cells adjacent to 
a BD ulcer. This helps to support our finding that SLPI mRNA is expressed in these cells 
and SLPI protein is being produced. It was also confirmed that minor buccal saliva gland 
was producing SLPI during a BD oral ulcer. Thus in these patients, SLPI does not seem to 
be deficient or depleted until it reaches the saliva which even in BDq patients is inundated 
with NE. Although NE infiltration was frequently seen in the submucosa of non-relapsed 
BD with oral ulcers, it was not seen above the intact basal cell barrier. However, our 
biopsy interpretations are based on ulcers that had manifested several days prior to the 
excision. The distribution of NE within the mucosa during quiescent BD could be more 
informative by revealing the immune cells and any extracellular proteases that are present 
which may be contributing to epithelial inflammation and erosion.  
There are several possibilities why SLPI protein levels are depleted in BD saliva. The 
first possibility is that BD patients are deficient in SLPI which is made more evident 
during oral ulceration. Having ruled out oral epithelial cells’ SLPI mRNA dysfunction, 
our data would suggest that there may still be post-translational modifications following 
the synthesis of SLPI such as abnormal protein folding or decreased accessory proteins to 
aid the intracellular production and transport. Exocytosis of the SLPI protein may be 
naturally slow, or during incidences where increased NE is present, may be reduced since 
both BD and RAS patients with ulcers had decreased salivary SLPI.  
 
Another possibility is that SLPI may be complexed with excessive oral NE as well as 
other proteases such as CatG. SLPI may also be binding to oral commensal bacteria 
depleting its usefulness as an anti-protease. Upon binding, this may hide the SLPI 
antibody epitope. This would be the best scenario since potentially a different antibody 
can be produced with an alternative site. However, the SLPI antibody we used 
successfully detected SLPI co-localising with NE in neutrophils during NETosis and in 
extracellular NETs. Of course, co-localising does not necessarily mean they are bound to 
each other but it is a possibility. If antibody binding is not an issue and SLPI is genuinely 
deficient in BD, then patients may benefit from topical rSLPI as a replacement therapy. 
This could remedy the cycle of inflammation and reduce reoccurring ulceration.  
 
It is important to investigate the role that neutrophils and their proteases have in 
producing the symptoms of BD, but it is equally important to explore the site of 
chemotactic activity, such as the oral cavity, where a discrepancy has been identified 
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between the high concentration of inflammatory cytokines and chemokines in saliva 
compared to serum. Gaining a better understanding the role of NE and its inhibitors in BD 
and RAS saliva can help elucidate the mechanism of oral ulceration and its involvement 
in systemic disease.  
 
7.2. Final Conclusions  
From our research, we conclude that the constant presence and excessive NE activity in 
the oral cavity is contributing to mucosal epithelium proteolytic damage thereby 
encouraging the development of oral ulcers. The depletion of its protease inhibitor, SLPI, 
and possible inactivation of a second specific inhibitor α1AT in saliva may trump the 
dysregulation of NE. This study is the first to report the levels of NE and its inhibitors, 
SLPI and α1AT, in BD and RAS saliva. BD patients’ taking colchicine to suppress 
neutrophil chemotaxis did not lower the high levels of NE or pro-inflammatory cytokines 
detected their saliva and therefore may benefit from using an oral, topical NE 
suppressant. Saliva is a useful, non-invasive specimen in which to monitor NE levels and 
inflammatory cytokines.   
This study also established appropriate reference genes for assessment of SLPI mRNA in 
oral buccal epithelial cells from BD and RAS patients compared to HCs. To date, no 
reference genes had been validated for use from BD and RAS patients’ buccal mucosa 
with and without ulcers. Completing the reference gene panel facilitated an accurate 
assessment of BD patients’ increased SLPI mRNA expression during period of remission. 
Oral buccal swabs are a useful, non-invasive technique that can potentially be used for 
molecular investigations in a variety of disorders with oral manifestations.  
This is also the first study to detect NETs in BD which may be contributing to their 
systemic pathology. Also, during the production of NETs, our novel observation that 
intracellular SLPI but not α1AT co-localised with NE suggests an intracellular regulatory 
role.  
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7.3. Future Work 
With the recent update of international guidelines for diagnosing BD (Davatchi et al., 
2013) and contributions from clinical and laboratory BD research with improved 
technology, revisiting the immunological aspects of BD is imperative as improved 
treatment strategies are needed. Identifying NETs in BD has provided evidence 
supporting the theory of neutrophil-derived pathology. Further investigations on NETs in 
BD are vital to assess the extent of NETosis occuring in vivo and if oral neutrophils are 
also releasing NETs thus exposing the oral environment to NE. The first critical and 
straightforward experiment to perform would be to expose neutrophils from HC to BD 
patient serum to see if there are serum components triggering NETs. It would also be 
helpful to know to what extent NE is active when released from NETs or bound to SLPI. 
Since current long-term BD medications can be detrimental, a better comprehension of 
the NETosis mechanism in BD can open the door for developing therapeutic 
interventions. 
 
In order to further explore the imbalance of NE inhibitors in saliva, it would be 
advantageous to isolate and purify native SLPI from the saliva samples instead of using 
recombinant SLPI to access inhibition of NE. The same should be assessed with 
endogenous α1AT to test its inhibitory activity in saliva and reveal if it is functionally 
active or oxidised. Also, it would be informative to look at the inflammatory markers 
from RAS and BD patient biopsies during a quiescent episode to further investigate how 
the ulcers develop.  
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Appendix 2.1. Antibody Staining Controls  
Isotype controls, primary-only and secondary-only antibodies were tested on both 
neutrophils and oral biopsies for any non-specific fluorescence. The optimised blocking 
and staining protocols successfully eliminated any non-specific antibody binding. The 
autofluorescence of tissues and cells was also tested and found to be negative. Two 
biopsies that underwent isotype control staining and primary antibody-only tests are 
demonstrated below in Fig. Appendix 2.1.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. Appendix 2.1. Negative Control Tests. A. Secondary-Only Antibodies and B. 
Isotype Controls. Panel A shows a biopsy section with no primary antibody (blocking 
buffer was used instead) with the two secondary antibodies used in conjunction with SLPI 
and NE antibodies: polyclonal AF555 goat, anti-mouse IgG and polyclonal AF647 goat, 
anti-rabbit IgG, respectively. After various exposures and gain adjustments, neither 
antibody was detected. DAPI DNA dye is the only dye that could be seen. Panel B 
demonstrates the Mouse IgG1 (at the same concentration that was used for SLPI primary 
antibody) coupled with the optimised concentration of AF647 secondary antibody. Again, 
DAPI was identified but no non-specific binding was detected in the Cy5 far red channel. 
 
AF647                                              DAPI                                            AF 555       
AF647                                                                    DAPI                                             
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Figure 4.3.3.1. SLPI and NE in Saliva. The total protein was quantified and 10 µg 
loaded per well. A. Polyclonal SLPI antibody was diluted 1:500 and incubated for 1 hr at 
RT. After washing, a donkey, anti-goat secondary antibody was diluted to 1:3000 and 
incubated with the membrane for 1 hr at RT. Lane 1: Rainbow Full Range Protein Marker 
(GE Healthcare). Lane 2: BDa (active ulcer) saliva. Lane 3: BDq (quiet, no ulcer) saliva. 
Lane 4: RASa saliva. Lane 5: RASq saliva. Lane 6: HC saliva. Lane 7 and 8: recombinant 
SLPI (rSLPI, 12-14 kDa). B. Monoclonal NE-HRP antibody was diluted 1:500 and 
incubated for 1 hr at RT. Lane 7 and 9: purified human NE, 29.5 kDa, positive control 
(NE+), no DTT added or heat treatment. Lane 8: Empty. Lane 10: Oral keratinocyte 
(Oker) isolated culture supernatant as a NE negative control. 
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Fig. 4.3.6.1.1. Oral Ulcer Biopsy from Non-BD Patient. Bx1.Clinical investigation for 
hyperplasia & ulcerative changes. Identified as Bx1. DAPI DNA (blue), NE (red), SLPI 
(green). Arrows indicate main areas of positive staining for NE and SLPI. 10X 
magnification. Scale bar 100 µm. 
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Fig. 4.3.6.1.2. Oral Ulcer Biopsy from BD Patient. Bx2. Minor and herpetiform ulcers 
for 10 days. DAPI DNA (blue), NE (red), SLPI (green). Arrows indicate main areas of 
positive staining for NE and SLPI. Giemsa-stained biopsy included for orientation. 10X 
magnification.  Scale bar 100 µm. 
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Fig. 4.3.6.1.3. Oral Ulcer Biopsy from BD Patient. Bx3. DAPI DNA (blue), NE (red), 
SLPI (green). Arrows indicate main areas of positive staining for SLPI. Enlarged image 
shows a minor saliva gland and duct from the buccal mucosa which stained positive for 
SLPI. Giemsa-stained biopsy was included for orientation. 10X magnification. Scale bar 
100 µm. 
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Fig. 4.3.6.1.4. Oral Ulcer Biopsy from BD Patient. Bx4. Patient had a major ulcer for 6 
days prior to excision. DAPI DNA (blue), NE (red), SLPI (green). Arrows indicate main 
areas of positive staining. Giemsa and H&E stained biopsy sections were included for 
orientation. 10X magnification.  Scale bar 100 µm. 
 
DNA NE 
Merged SLPI  
H&E Giemsa 
153 
          Original Image         Threshold                Mask 
 
 
 
 
 
 
 
 
 
Fig 5.2.3.2.1.1. Simultaneous Images in GFP and DAPI Channels. Sytox
® 
green 
attaches exclusively to extracellular DNA while Hoechst 33342 is able to penetrate the 
nuclear membrane and stain intracellular, intact DNA. Using FIJI/ImageJ software, 
minimum thresholds would be automatically set to recognise positively stained cells in 
each channel. Triplicate images were tallied to determine the mean percentage of sytox
+
 
cells for each culture treatment. X20 magnification using air objective on Timelapse 
microscope. Scale bar 25 µm. 
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Fig. 5.3.1.1.1. A. and B. Representative Results of Increased Sytox
+
 Neutrophils 
During Next Day Imaging of the Same 1 hr PMA-Stimulated HC Neutrophil 
Culture. A. Top images are of the culture 1 hr after cells were stimulated with 100 nM 
PMA. Images were taken within 1 hr of adding sytox
®
 green and Hoechst DNA stains to 
the culture media with live neutrophils. Bottom images were taken from the same HC 
PMA-stimulated culture within 24 hrs. B. The Mean Difference Between Sytox
+
 HC 
Neutrophils when Imaging the Same Culture at Different Times. Error bars represent 
±SEM of the mean percentage of sytox positive cells (≥ 100 µm2) from multiple images 
of biological replicates. Mann Whitney U, 2-tailed, non-parametric test, *p<0.05. 
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Fig. 5.3.1.1.2, A. and B. An Example of Increased Sytox
+
 Neutrophils During Next 
Day Imaging of the Same Unstimulated HC Neutrophil Culture. A. Top images were 
taken within 1 hr of adding Sytox green and Hoechst stains to the culture media with live 
neutrophils. Bottom images were taken from the same HC culture within 24 hours. B. 
The Mean Difference Between Sytox
+
 HC Neutrophils when Imaging the Same 
Culture at Different Times. Error bars represent ±SEM of mean percentage of sytox 
positive cells (≥ 100 µm2) from multiple images of biological replicates. 
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Fig. 5.3.2.1.2.1.1. Unstimulated HC Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in Unstimulated Cultures. Neutrophils were cultured in 
24-well plates on non-coated glass coverslips. The cells were all incubated for a 
total of 2 hrs (Panel 1) and 4 hrs (Panel 2) in culture media without NE inhibitor 
before being fixed in 4% PFA. The cells were stained for NE (red) and SLPI 
(blue) and DNA (DAPI) (green). X40 oil magnification, Confocal 710. Bar 
indicates 10 µm.  
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Fig 5.3.2.1.2.1.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: 
Investigating the Occurrence of NETosis in an Unstimulated Culture. 
Neutrophils were cultured in 24-well plates on non-coated glass coverslips. The 
cells were incubated for a total of 2 hrs (Panel 1) and 4 hrs (Panel 2) in culture 
media. Cells were then fixed in 4% PFA. The neutrophils were stained for NE 
(red) and SLPI (blue) and DNA (DAPI) (green). Yellow arrows indicate definitive 
stages of NETosis. X40 oil magnification, Confocal 710. Bar indicates 10 µm.   
 
Panel 1 
B
D
 1
 
B
D
 2
 
U
n
st
im
u
la
te
d
  
4
 h
r 
C
u
lt
u
re
 
B
D
 3
 
Panel 2 
DNA   SLPI   NE          Merged 
B
D
 1
 
B
D
 2
 
U
n
st
im
u
la
te
d
  
2
 h
r 
C
u
lt
u
re
 
B
D
 3
 
215 
  
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.2.1.2.1.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in an Unstimulated Culture. Neutrophils incubated for a total 
of 2 hrs (Panel 1) and 4 hrs (Panel 2) in culture media. Cells were then fixed in 4% PFA. 
The neutrophils were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). 
X40 oil magnification, Confocal 710. Bar indicates 10 µm.  
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Fig 5.3.2.1.2.2.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in an Unstimulated Culture with NE Inhibitor. Neutrophils 
were cultured in 24-well plates on non-coated glass coverslips. The cells were incubated 
for a total of 2 hrs (Panel 3) and 4 hrs (Panel 4) in culture media with NEi. Cells were 
then fixed in 4% PFA. The neutrophils were stained for NE (red) and SLPI (blue) and 
DNA (DAPI) (green). Yellow arrows indicate definitive stages of NETosis. X40 oil 
magnification, Confocal 710. Bar indicates 10 µm.  
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Fig 5.3.2.1.2.2.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating 
the Occurrence of NETosis in an Unstimulated Culture with NE Inhibitor. 
Neutrophils were incubated for a total of 2 hrs (Panel 1) and 4 hrs (Panel 2) with 
NEi in culture media. Cells were then fixed in 4% PFA. The neutrophils were 
stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). X40 oil 
magnification, Confocal 710. Bar indicates 10 µm.  
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Fig 5.3.2.1.2.3.1. HC Neutrophils In Vitro: Investigating the Occurrence of 
NETosis in a PMA-Stimulated Culture. Neutrophils were cultured in 24-well 
plates on non-coated glass coverslips. The cells were all incubated for a total of 2 
hrs (Panel 5) and 4 hrs (Panel 6)  in culture media without NEi. 100 nM of PMA 
was added after the first hour of incubation. Cells were then fixed in 4% PFA. The 
cells were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). Yellow 
arrows indicate various stages of NETosis. X40 oil magnification, Confocal 710. 
Bar indicates 10 µm. 
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Fig. 5.3.2.1.2.3.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: 
Investigating the Occurrence of NETosis in a PMA-Stimulated Culture. 
Neutrophils were cultured in 24-well plates on non-coated glass coverslips. The 
cells were all incubated for a total of 2 hrs (Panel 5) and 4 hrs (Panel 6) in culture 
media without NEi. 100 nM of PMA was added after the first hour of incubation. 
Cells were then fixed in 4% PFA. The cells were stained for NE (red) and SLPI 
(blue) and DNA (DAPI) (green). X40 oil magnification, Confocal 710. Bar 
indicates 10 µm. 
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Fig 5.3.2.1.2.3.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating 
the Occurrence of NETosis in a PMA-Stimulated Culture. Neutrophils were 
incubated for a total of 2 hrs (Panel 5) and 4 hrs (Panel 6) in culture media without 
NEi. 100 nM of PMA was added after the first hour of incubation. Cells were then 
fixed in 4% PFA. The cells were stained for NE (red) and SLPI (blue) and DNA 
(DAPI) (green). X40 oil magnification, Confocal 710. Bar indicates 10 µm.  
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Fig 5.3.2.1.2.4.1. HC Neutrophils In Vitro: Investigating the Occurrence of 
NETosis in a PMA-Stimulated Culture with NE Inhibitor. Neutrophils were 
cultured in 24-well plates on non-coated glass coverslips. The cells were all 
incubated for a total of 2 hrs (Panel 7) and 4 hrs (Panel 8) in culture media with 
NEi. 100 nM of PMA was added after the first hour of incubation. Cells were then 
fixed in 4% PFA. The neutrophils were stained for NE (red) and SLPI (blue) and 
DNA (DAPI) (green). Yellow arrows indicate various stages of NETosis.  X40 oil 
magnification, Confocal 710. Bar indicates 10 µm. 
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Fig 5.3.2.1.2.4.2. Non-Relapsed BD Patients’ Neutrophils In Vitro: Investigating the 
Occurrence of NETosis in a PMA-Stimulated Culture with NE Inhibitor. Neutrophils 
were incubated for a total of 2 hrs (Panel 7) and 4 hrs (Panel 8) in culture media with NEi. 
100 nM of PMA was added after the first hour of incubation. Cells were then fixed in 4% 
PFA. The cells were stained for NE (red) and SLPI (blue) and DNA (DAPI) (green). X40 
oil magnification, Confocal 710. Bar indicates 10 µm. 
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Fig 5.3.2.1.2.4.3. Relapsed BD Patients’ Neutrophils In Vitro: Investigating 
the Occurrence of NETosis in a PMA-Stimulated Culture with NEi. 
Neutrophils were incubated for 2 hrs (Panel 7) and 4 hrs (Panel 8) in culture 
media with NEi. 100 nM of PMA was added after the first hour of incubation. 
Cells were then fixed in 4% PFA. The cells were stained for NE (red) and SLPI 
(blue) and DNA (DAPI) (green). X40 oil magnification, Confocal 710. Bar 
indicates 10 µm.  
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Fig 5.3.2.1.3.1. Positive Control: Neutrophils Undergoing NETosis in a PMA-
Stimulated Culture. Demonstrated in the panels above are the typical morphologies of 
NETosing HC and BD neutrophils when they were induced with PMA. The main MPO 
activity occurred in the intermediate stage of NETosis after NE had translocated into the 
nucleus, therefore the first image shows this integration of MPO (blue) into the nucleus. 
The second and third panels show progressed intermediate stages in which MPO granules 
in the cytoplasm become more concentrated and pronounced, decondensation of DNA 
(green) takes place, and the cell continues to swell and vacuoles may develop both in the 
cytoplasm and nucleus. The final panel shows the advanced stage of NETosis in which 
cells erupts and casts out NETs. The asterisk marked panels signify the commonly 
observed progression of NETosis from decondensed nuclei to advanced NETosis. 
Confocal 710, X40 oil magnification. Bar indicated 10 µm. 
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Fig 5.3.2.1.3.2. Unstimulated and PMA-Stimulated HC Neutrophils In Vitro: 
Observation of MPO. Neutrophils were cultured in 24-well plates on non-coated glass 
coverslips. The cells were all incubated for a total of 2 hrs and 4 hrs in culture media 
before being fixed in 4% PFA. The cells were stained for NE (red), MPO (blue) and DNA 
(green). Co-localisation of all three targets produced pink regions. X40 oil magnification, 
Confocal 710. Bar indicates 10 µm. 
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Fig. 5.3.2.1.3.3. Unstimulated and PMA-Stimulated Non-Relapsed BD 
Neutrophils In Vitro: Observation of MPO. Neutrophils were incubated for a 
total of 2 and 4 hrs in culture media before being fixed in 4% PFA. The cells were 
stained for NE (red), MPO (blue) and DNA (green). Co-localisation of all three 
targets produced pink regions. X40 oil magnification, Confocal 710. Bar indicates 
10 µm. 
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Fig 5.3.2.1.3.4. Unstimulated and PMA-Stimulated Relapsed BD Neutrophils 
In Vitro: Observation of MPO. Neutrophils were incubated for a total of 2 and 4 
hrs in culture media before being fixed in 4% PFA. The cells were stained for NE 
(red), MPO (blue) and DNA (green). Co-localisation of all three targets produced 
pink regions. X40 oil magnification, Confocal 710. Bar indicates 10 µm. 
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Fig. 5.3.2.1.4.1. Alpha-1Antitrypsin during NETosis In Vitro. HC, BD non-
relapsed and relapsed patients’ neutrophils were incubated with and without PMA 
then PFA-fixed and stained for NE (red), α1AT (purple), DNA (green). X40 oil 
magnification, Confocal 710. Bar indicates 10 µm.  
 
DNA               NE            α1AT         Merged 
 
U
n
st
im
u
la
te
d
  
P
M
A
 
H
C
 
U
n
st
im
u
la
te
d
  
P
M
A
 
B
D
 N
o
n
-R
el
a
p
se
d
 
U
n
st
im
u
la
te
d
  
P
M
A
 B
D
 R
el
a
p
se
d
 
243 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.2.1.3. The RealTime Ready Human Reference Gene 384-well plate. 10 µl of 
each cDNA OBS sample mastermix was added to each row from wells 1 – 22. Each 
column contained a different pre-absorbed specific primers for each reference gene target. 
Untranscribed RNA from the same OBS sample, previously set aside after the extraction, 
was added to wells 23-24. This consisted of 1 µl of the RNA, 4 µl of RNase free H20, and 
5 µl of the 2X LightCycler
®
 480 Probes Master reaction mix. 
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